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Abstract
Understanding how phenotypes evolve through natural selection is a fundamental
question of biology. Microbial evolution studies provide the rare opportunity to experimentally
elucidate the changes that allow an organism to adapt to novel conditions. In an in vitro
experimental evolution system, cells evolve in response to a lab-controlled selective
environment. In such experiments, the evolved strains may have no fitness-gain in non-stressed
conditions, but outperform their progenitors in the selective growth conditions. A
complementary in vivo system is monitoring the evolution of drug resistance in microbial
pathogens.
Identifying the mutations underlying such evolved phenotypes have typically been
limited to the identification of regions of interest by low-resolution techniques such as classical
genetics or microarray mapping followed by sequencing, and many relevant genes may remain
undetected. The recent development of technologies for cost-effective whole-genome re-
sequencing offers the opportunity to comprehensively study evolution in action.
Here, I present a combined experimental and computational strategy to detect and study
recurrent genetic aberrations accompanying adaptive evolution in Saccharomyces cerevisiae and
Candida albicans by whole-genome re-sequencing of evolved strains using Illumina technology.
We sequence parental and evolved strains from multiple evolutionary trajectories under the same
selective pressure. Our computational approach focuses on the detection of recurrent aberrations
- ranging from SNPs to larger variations. We remove variants present in parental strains as
background and catalogue subsequent aberrations that persist and co-occur with phenotypic
changes. Likely functional changes are identified by recurrence across independent evolutionary
time courses.
In S. cerevisiae we identify those mutations that are responsible for evolved, adaptive
phenotypes, as well as demonstrate that independently arising adaptive alleles, when in the same
genetic background, reduce hybrid viability. In C. albicans, we show both large and small
recurrent variations that are highly associated with acquisition of fluconazole resistance. Our
approach elucidates the function and evolution of key systems in a key model organism and an
human pathogen. More generally, our methodology is applicable to a broad range of species,
allowing us to trace phenotypic evolution from bacteria to human cancers.
Thesis Supervisor: Aviv Regev
Title: Associate Professor of Biology
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Introduction
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Overview
In his paper, Nothing in Biology Makes Sense Except in the Light of Evolution,
Theodosius Dobzhanksy wrote, "in the light of evolution, biology is, perhaps, intellectually the
most satisfying and inspiring science. Without that light it becomes a pile of sundry facts some
of them interesting or curious but making no meaningful picture as a whole." [1] From
understanding the nature of microbial antibiotic resistance[2-4], to the clonal origin of metastatic
malignancy[5-8], to understanding more about ourselves and the biological diversity of our
world[9, 10], the dynamics of evolution are core to furthering our understanding of biology.
There are two approaches by which we can study evolutionary processes. In the first
approach, we can characterize extant species or populations and infer their evolutionary history.
In the second approach, we monitor a starting population and trace evolution as it occurs. The
latter approach is termed "forward evolution", and it is often coupled to a response to stress
serving as the known selective pressure. Forward evolution can occur in the laboratory (i.e. in
vitro), such as the case of Escherichia coli grown under nutrient limitation. For example,
whereas E. coli is defined by its inability to metabolize citrate under oxic conditions[ 1], Blount
et al. show de novo evolution of the ability to metabolize it as a carbon source[12]. Similarly,
we can monitor forward evolution in applications of human health (i.e. in vivo), such as
resistance to chemotherapy arising between primary and recurring cancer[13].
Historically, experimental forward evolution was largely conducted by fly
geneticists[14], but during the 1980's it gained more widespread popularity among
microbiologists[15, 16]. Advantages for using model organisms in experimental forward
evolution include[14]: (1) populations that are easy to grow and enumerate for particular traits;
(2) short doubling times, allowing experiments to be run for many generations; (3) in microbial
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evolution, a progenitor population and intermediates that may be retained by frozen suspension
for direct comparison at a later date; and (4) in vitro conditions that are easy to control and
guarantee clonally derived progeny. These experiments help to elucidate which mutations are
adaptive or how they occur, or allow one to compare the relative fitness of a trait mutation to
many others[17-19].
Forward-evolution experiments require follow-up characterization in order identify the
genetic changes underlying the evolved trait. Historically, mapping experiments for identifying
the mutations underlying these evolved phenotypes have been limited to the identification of
regions of interest by low-resolution methods such as classical genetics or microarray mapping
followed by sequencing of selected regions[20, 21]. Most studies have focused on large-scale
aberrations[22, 23] or candidate genes[24] and do not provide a comprehensive view of the
genetic basis of evolved phenotypes. Thus, many relevant regions may remain undetected. With
the advent and development of sequencing[25-28] and profiling technologies[20, 29, 30], the
landscape for how these experiments could be conducted and analyzed has changed.
In this thesis, I present our contribution to the identification of mutations for species of
fungi grown in both in vivo and in vitro settings under conditions of strong selection and the
resulting biology we learn in the process. First, I describe a system in which a single strain of
Saccharomyces cerevisiae was evolved for 500 generations in parallel in high salinity or low
glucose conditions[3 1]. I demonstrate how we use sequencing and expression profiling data to
identify the genes responsible for evolved phenotypes and, likely, for early speciation events.
Next, I describe how I use this methodology to trace evolutionary trajectories of drug resistance
in in vivo time series collections of the pathogen Candida albicans. And finally, I describe the
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infrastructure developed for rapid, customizable, and parallelizable analysis of genomic sequence
data.
To provide context, I begin by briefly reviewing the relevant concepts of population
genetics and evolution, spanning from predictive arguments made prior to current knowledge of
heritability as it relates to DNA to current theory and application. Next, I discuss the progression
of sequencing methodology, highlighting how progression in this arena facilitates a broader
understanding of evolution and populations genetics. Finally, I present the specific contributions
of this thesis, integrating current sequencing and profiling technologies in a way that uniquely
lends insights into evolving systems.
Evolution: Selection and Speciation
Darwin and Selection
In The Origin of Species, Darwin says, "I have called this principle, by which each slight
variation, if useful, is preserved, by the term Natural Selection."[32] Hartl and Clark distill
Darwin's definition as follows[33]:
1. More offspring are produced than can survive to procreate.
2. At least part of why individuals do not survive or procreate is due to genetic variation.
3. Genotypes associated with survival and reproduction are over-represented at time of
reproduction.
Thus, while genetics concerns itself with Mendelian laws of inheritance, population genetics
concerns itself with inheritance of traits across populations of organisms, and the governing force
is selection. The degree to which a genotype affects survivability or fecundity is measured by
fitness. Fitness can either be measured in absolute or relative terms, whereby the former is a
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measure of the difference in members having a trait before and after selection, and the latter is a
measure of the difference in ratios between two genotypes before and after selection[17]. While
typically these observations are considered within the context of Mendelian genetics in a
sexually reproductive species, they also apply to haploid, asexual organisms and those with non-
Mendelian inheritance patterns. When all members of the population become carriers of a
particular allele, the trait is "fixed". If selection is strong, fixation can happen in comparatively
few generations; this type of selection is termed "purifying"[33]. However, selection may also
be "diversifying" - keeping the number of traits diverse and preventing any one trait from
fixing[33]. Further, genetic drift may also cause a trait to fix, wherein purely stochastic events
cause a neutral or deleterious trait to fix within a population, even though it has no, or negative,
effect on fitness, respectively. Further nuances exist within these frameworks, such as genetic
draft, wherein an allele for a gene that is physically close to a different allele under selection will
"hitchhike" off that selected gene. This can happen even when that gene is selectively neutral or
deleterious. Selection can also be artificially applied within the context of a laboratory to test
hypotheses about how evolution functions in the wild. Some examples of selective conditions
commonly applied in lab settings include thermal[34-36], nutritional[12, 37] or high salt[38].
The selective conditions can mimic harsh, naturally occurring environments.
Speciation
Selection is one of many possible mechanisms that can give rise to speciation[39].
Speciation is the evolutionary process by which one group of individuals becomes reproductively
isolated from another[40]. This can be due to geographical isolation (allopatry)[41], changes in
behavior or selection that isolate different groups within a population (sympatry)[41], or
variations therein[41]. Due to reproductive isolation, the lack of gene flow gives rise to genomic
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changes that will ultimately cause one species to diverge from another. This reproductive
isolation is generally classified as prezygotic and postzygotic[41]. Prezygotic barriers might
include behavioral differences that would prevent two individuals from mating, or mechanical
barriers in the organisms themselves that cause physiological incompatibility. Postzygotic
barriers might include hybrid sterility, where mating might be successful, but the resulting
offspring cannot reproduce, or hybrid inviability altogether. JBS Haldane noted of interspecies
crosses that, "When in the F, offspring of a cross between two animal species or races one sex is
absent, rare, or sterile, that sex is always the heterozygous sex."[42] This phenomenon is
observed in animals as well as plants[43], though the mechanism underlying this observation
varies.
Of particular interest in this thesis (Chapter 1) are the events that occur early in the
process of speciation. It has been referred to as Darwin's Paradox[44]: "how could something as
patently maladaptive as the evolution of sterility or inviability be allowed by natural selection?"
Orr demonstrates this as follows[44]: for a given gene, if one population has a genotype of AA,
and another population has a genotype of aa, and if the heterozygous genotype for this gene, Aa,
is infertile, how could these populations have shared a common ancestor? At some point, there
would have had to be a heterozygous genotype from the ancestral genotype, and that individual
would have been infertile, and, thus, unable to reproduce and propagate the new allele. The
solution to this problem, as proposed by Dobzhansky[45], is that instead of a single locus, at
least two loci are required. The corollary to the previous example would then look as follows
(Figure 1): a starting population has a genotype aabb. The first population acquires the A allele,
and individuals would then be either Aabb or AAbb, both of which are fertile. A may be either
selectively neutral or adaptive. In a second population, the opposite occurs; B evolves such that
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Figure 1. The Dobzhansky-Muller models of speciation
Both models assert that incompatibility must arise from at least two genes, although it may be
more. In Dobzhansky's model (top), the alleles arising in the progeny are incompatible with
each other, and will lead to increased reproductive isolation between the two populations. In the
Muller model (bottom), the progenitor population does not change, but some progeny, forming
their own population, become reproductively isolated from the progenitor.
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individuals are either aaBb or aaBB. Both of these individuals are fertile, and B may be either
selectively neutral or adaptive, as well. If the A and B alleles are incompatible within the same
individual, then a model for speciation that incorporates hybrid sterility is resolved, thus serving
as a solution to Darwin's Paradox. Muller further refined Dobzhansky's hypothesis by
contributing that all of the substitutions necessary towards inviability can occur in the same
lineage as opposed to two[44], and related this phenomenon to linkage to the X chromosome (in
XY species), thus also addressing Haldane's Rule. Dobzhansky-Muller incompatibilities have
been identified principally in Drosophila[46], with much work remaining to be characterized in
other species; this is an area of open inquiry.
Forward experimental evolution
Experimental evolution begins with a known set of genotypes and then follows a
genotypic and phenotypic trajectory with respect to time[47] often during the application of
selective pressure. This approach directly elucidates the dynamics of evolving adaptive
mechanisms. An asset to in vitro approaches is the ability to replicate experiments and control
parameters such as mutation rate[48-50], selection strength[50], population size[50] and genetic
recombination[50]. This is especially true in microbial populations because of their large
population sizes and short generation times.
Early work in this field includes the seminal experiment of Luria and Delbraick[51],
which demonstrated that natural selection acts on genetic mutations that arise spontaneously in a
population and then are selected, rather than mutations arising in response to stress. Also
conducted in E. coli is classic work in forward evolution by Richard Lenski[18, 52, 53]. In his
earlier work, Lenski showed that E. coli strains grown at a continued, elevated temperature stress
for 200 generations acquired mutations that gave rise to an increase in fitness. It is important to
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note that these mutations do not arise because of stress, but rather, they are rapidly selected for
once they occur. Lenski's work also includes longitudinal studies, in which he has grown E. coli
in nutrient (glucose) limiting conditions for many (recently, 50,000) generations[18, 54, 55].
These studies have yielded insights in convergent evolution, the uniformity of acquisition of
advantageous mutations and the variable acquisition of neutral mutations, as well as the
acquisition of new metabolic abilities that were strongly selected for in glucose limitation.
Experimental evolution is not limited to work in bacteria. Fungi, unicellular yeasts in
particular, are excellent model organisms for experimental evolution for the same reasons
described of bacteria, namely large population sizes and rapid generation cycles. Further, as
eukaryotes, and having diverse genomic states such as both haploid and diploid members, yeast
can offer different insights into evolutionary processes. For example, in conditions similar as
those described for Lenski's work, Ferea et al. evolved Saccharomyces cerevisiae in glucose
limiting conditions[56]. This work showed not only amplification of genes associated with
hexose transport[57], which allowed strains to more effectively acquire glucose from the
environment, but also that there were similar genomic rearrangements that occurred in parallel in
response to persistent selection[58]. This approach has also been used to study other diverse
phenotypes, such as mating selection preference[59] and divergent evolution[31], both as a
means to study the progression of speciation, as well as a means to monitor evolutionary
dynamics in competing populations[60-62].
Evolution of drug resistance
The efficiency with which selection gives rise to individuals adapted to their environment
has some unfortunate implications for human health. Classic examples of this include penicillin
and chloroquin. Penicillin, identified by Alexander Fleming in 1928[63], is the most broadly-
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used class of antibacterials[64]; by 1947, the first resistant strains emerged in the clinic[65].
Similarly, chloroquine was identified[66] as an alternative anti-malarial to quinine. The World
Health Organization attempted to eradicate malaria from 1955-1969 [66], and by the late 1950s,
chloroquin resistant strains of Plasmodium falciparum were present in Asia and South
America[67]. Drug resistance is also a model system to trace evolution in action. Very recently,
such studies have begun in prokaryotes[68, 69].
The trend toward rapid drug resistance is also true of the dimorphic fungal pathogen,
Candida albicans. C. albicans exists as part of normal human flora as a commensal and is not
found in environmental reservoirs[70]; however, it is opportunistic and can be pathogenic.
Candidemia is the fourth most common cause of nosocomial bloodstream infections in the
United States[71], with C. albicans accounting for nearly 65%[72, 73] of candida infections.
Systemic infection is associated with a mortality rate as high as 50%[74]. Resistance arises
during long-term prophylactic treatment regimes[75, 76] that are sometimes indicated in
immuncompromised patients (BMT[77], HIV[78]). There are several classes of antifungals,
including: polyenes, azoles, and allylamines, which target ergosterol or its synthesis[47]; and
echinocandins and nikkomycins, which affect cell wall integrity via inhibiting glucan[79] and
chitin[80] synthesis, respectively. Azoles are typically favored for their low occurrence of host
toxicity[8 1].
Both in vitro and in vivo systems are used to study C. albicans resistance because they
provide an extensive trace of the evolutionary process by way of sampled strains throughout the
evolutionary time course. In an in vitro experimental evolution system, 12 strains of C. albicans
were evolved from a single drug-sensitive cell via daily serial transfer for 330 generations; six
regularly exposed to twice their minimal inhibitory concentration of fluconazole as the selective
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pressure, and six without any fluconazole exposure[82]. The six populations that were exposed
to fluconazole all evolved resistance to the drug, whereas the six that were not exposed remained
sensitive. Expression analysis of these populations indicated that genes known to be involved
with resistance were induced[82]. While studies such as this one help to shed light on
mechanisms of resistance, and while parameters can be tightly controlled in vitro, the laboratory
environment in which resistance evolves is not a perfect proxy for how resistance evolves in a
human patient. Thus, in vivo patient sampling methods are used to augment understanding of
drug resistance acquisiton.
There are many reasons to sample clinical isolates from patients. Sampling patients over
time and/or with respect to different regions can be used to document emergence of resistance, or
document changes in sensitivity with patient compliance to therapy[47]. Serial isolation of C.
albicans from patients over the course of drug treatment, in particular, can be helpful in
identifying mechanisms for increasing resistance[76, 83-85]. While quantities like mutation rate,
selection intensity, and effective population cannot be known from these systems, the value of
the "wild" environment and its effect on drug resistance evolution cannot be ignored. Previous
studies of resistant strains have shown that this is mediated by multiple mechanisms including
segmental aneuploidy[86], increased expression of drug pump genes[87], loss of heterozygosity
(LOH) across chromosomes or regions of chromosomes[87, 88], mutations in ergosterol
biosynthetic genes[89], and deviations facilitated by the heat shock protein Hsp90[90].
However, previous studies were also limited by their assumed clonality of sample strains as well
as their limited ability to survey genomic changes.
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Illumina Sequencing
The first major innovation made in sequencing was by Fred Sanger[25, 91]; Sanger's
"first-generation" dideoxy-sequencing dominated sequencing throughout the 1990's[92, 93].
Sanger sequencing would serve as the inspiration for massively parallel sequencing technologies
such as Solexa/Illumina. Illumina sequencing (Figure 2) uses deoxynucleotide triphosphates
(dNTPs) with reversible termination and fluorophores that distinguish one base from
another[94]. DNA preparation consists of shearing, size selection, and ligation of adapters that
will serve as templates for DNA polymerase as well as promote binding onto a glass flowcell
(Figure 2a). The DNA is separated into single strands and annealed to the flowcell. The first
round of DNA replication copies the reverse complement of the annealed strand onto a
covalently attached adaptor. The annealed strand is then removed, and subsequent rounds of
PCR replication are termed "bridge-amplification." Bridge amplification creates a clonal "patch"
of DNA on the flowcell in proximity to the first attached DNA strand (figure 2b) by folding over
(i.e. forming a "bridge") and annealing to another covalently attached adaptor. PCR templates
off of that adaptor and copies the DNA strand's reverse complement onto the new adaptor. In a
given round of bridge amplification, each single strand of DNA will act as a template for its own
reverse complement. After several rounds of replication, the result is a clonal patch of DNA
localized to the initial annealed single strand of DNA. Because the adaptors are not reverse
complements of each other, sequencing can preferentially target one strand in a patch (single-
end) or both strands in a patch, though as distinct cycles of sequencing (paired-end). The actual
sequencing then occurs by serially incorporating DNA via PCR with dNTPs that have reversible
terminators in the 3' position. Fluorescent imaging is conducted, where each patch is read as one
of 4 different fluorophores. The fluorophore and reversible terminator are then cleaved. This
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Figure 2. Ilumina DNA sequencing
A. Genomic DNA preparation for Iliumina sequencing. DNA is first sheared via nebulizer to
fragments less than 800 base-pairs. The DNA fragments are end repaired to form blunt ends
using T4 DNA polymerase and E. coli DNA Polymerase I Klenow fragment. An adenine is
added to the blunt phosphorylated DNA fragments via the Klenow fragment's polymerase
activity; this facilitates adapter ligation, which have a thymine overhang at the 3' end. Gel
purification for size selection is followed with PCR amplification with both sets of primers such
that only those constructs with both sets of adaptors undergo exponential amplification. The
DNA is then melted to single-stranded DNA to anneal to the covalently linked adaptor-
complements embedded in the flowcell.
B. Bridge amplification. ssDNA genomic constructs are allowed to anneal to the flowcell,
where they may undergo bridge amplification. The result is clustered clonal DNA patches on the
flowcell, with about 10 million clusters per lane, with eight lanes per flowcell.
C. Sequencing. Following bridge-amplification, sequence-by-synthesis reactions are carried out
between 30-100 iterations. Modified bases with reversible terminators and unique fluorophores
are incorporated. After laser recording of the base, the fluorophore and terminator are cleaved
and the next iteration of base incorporation is catalyzed.
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process is then repeated (current approaches may go for upwards of 120 iterations). Each patch's
"color" sequence represents the DNA sequence. It is at the completion of the first round of
sequencing that paired-end sequencing can occur; the process is repeated for the reverse
complement of the strand that was previously sequenced.
Both because of the increase in throughput in massively parallel sequencing approaches,
and also because of the relatively large size differences in some organisms, it may be
advantageous to put more than one sample in a single lane of a flowcell. Thus, it is important to
have the ability to deconvolute sequence data from these sources. One such method is indexing,
which adds a sample-specific barcode during sample preparation[95]. The first few sequenced
nucleotides in such a sequencing reaction are the barcode, and these reads can be binned,
accordingly.
Genome Re-Sequencing using Illumina
While massively parallel sequencing can be used for de novo assembly, most high-
throughput sequencing approaches are intended for re-sequencing. Re-sequencing uses large
numbers of short reads by way of alignment to a reference genome. Re-sequencing is both
cheaper and faster than de novo reconstruction[96] while allowing detection of variants. Both
alignment and variant detection rely on a quality metric; a method to determine both the quality
of individual bases, as well as a measure for how well short-reads map to particular locations
along the genome. Thus, we can summarize the challenges associated with re-sequencing as (1)
quality scoring, (2) read mapping, and then (3) variant discovery.
Quality scoring is defined in relation to the probability of error of a particular base being
mis-called or a read being mis-aligned. Specifically, the relationship is defined as Q =-10logioP
where Q is the quality score and P is the probability of error[97, 98]. Quality measures for re-
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sequencing data are not new to second generation sequencing platforms; they are a borrowed
concept from Sanger sequencing[97]. Quality scoring is determined in a chemistry/platform-
specific manner (usually in real-time by the sequencer). A related concept to base quality is
mapping quality; an assessment of how well a read is aligned to a reference genome. This score
integrates raw base quality as well as the degree of mismatching and gapping needed to allow a
read to map to a particular location. Reads that cannot be aligned uniquely are either not mapped
at all, or they are aligned at random with a mapping quality of 0. Both base quality and mapping
quality are required for most methods of variant detection[99].
There are many different approaches with which one can align short reads: the two most
common methods are indexing short reads[100, 101] or performing a Burrows-Wheeler
transformation on the genome[102-104] for rapid read alignment. Short read indexing aligners,
such as MAQ, index input reads and scan the reference genome, retaining the best hits and
reporting their quality[101]. By contrast to indexed short read aligners, Burrows-Wheeler
aligners require a pre-processing step on the reference genome creating a database. Once the
reference genome is indexed, short reads are hashed against the database, and their best hits are
retained. Similarly, if a read cannot be mapped uniquely, it will be assigned a mapping quality
of zero.
Once reads are aligned to a reference genome, there are many methods that can be
applied to detect variants. Methods to discover single nucleotide polymorphisms (SNPs) and
small insertions and deletions (indels)[105], structural variants[106], and copy-number variations
(CNVs)[107, 108] integrate base quality, mapping quality, and the frequency of repeated events
in order to accurately indicate the existence of variations. Discovery of these variations can then
be coupled to phenotypic variations for further analysis.
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Contributions of this thesis
In this thesis, we leverage massively parallel sequencing to study in vivo and in vitro
evolutionary time courses with at unprecedented detail. Having arrived on this scene relatively
early, our goals were to use existing technology and innovate around challenges as necessary.
Chapter 1 describes how we used this technology to explore experimentally evolved
lineages of S. cerevisiae, all arising from a single clone. In this chapter we (1) map and identify
new mutations arising from parallel experimentally evolved lines; (2) characterize the effects of
mutation on relative fitness and transcriptional phenotypes; and (3) integrate these data and
demonstrate the Dobzhansky-Muller interaction that could be a cause of incipient speciation.
In Chapter 2, we extend our approach to in vivo forward evolution by studying clinically
derived time series of C. albicans. In this chapter, we demonstrate that: (1) persistent loss of
heterozygosity on the right arm of chromosome 3 or the left arm of chromosome 5 occur
simultaneously with strains acquiring resistance to fluconazole within time series; (2) polyploidy
and isochromosome formation, while observed, do not seem to associate with increased drug
resistance, nor are they retained within the time series we sequenced; (3) correlation structure,
both positive and negative, exists in highly recurrent, persistent mutations that suggest that some
mutations are likely to co-occur or preclude some subset of mutations from occurring; and (4)
while the majority of previously isolated clinical isolates are clonally derived, this is not
uniformly true, which affects previous understanding of time series data and reinforces the need
for NGS-resolution data.
Finally, in Chapter 3, I present a general description of the procedures undertaken in both
the in vivo and in vitro projects described in subsequent chapters. These procedures include
alignment and refinement of alignment, variant detection and filtration, and novel approaches for
26
variant annotation.
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Chapter 1: Determinants of divergent adaptation and Dobzhanksy-
Muller interaction in experimental yeast populations
We use functional genomics to investigate the incipient speciation of experimentally evolved
yeast populations. We identify the underlying strain-specific mutations; assess their
contributions to growth, fitness, and expression phenotypes; and ultimately demonstrate that the
mechanism with which hybrid fitness is reduced is via a Dobzhansky-Muller incompatibility.
Reprinted with modifications from Current Biology, Vol 20, James B. Anderson*, Jason Funt*,
Dawn Anne Thompson, Snehit Prabhu, Amanda Socha, Caroline Sirjusingh, Jeremy R. Dettman,
Lucas Parreiras, David S. Guttman, Aviv Regev**, and Linda M. Kohn*, Determinants of
divergent adaptation and Dobzhanksy-Muller interaction in experimental yeast populations, pp.
1383-1388, Copyright 2010, with permission from Elsevier
*These authors contributed equally to this work.
**These authors contributed equally to this work.
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Abstract
Divergent adaptation can be associated with reproductive isolation in the process of
speciation[1]. We recently demonstrated the link between divergent adaptation and the onset of
reproductive isolation in experimental populations of the yeast Saccharomyces cerevisiae
evolved from a single progenitor in either a high-salt or a low-glucose environment[2]. Here, we
used whole-genome re-sequencing of representatives of three populations to identify 17
candidate mutations, six of which explained the adaptive increases in mitotic fitness in the two
environments. In two populations evolved in high salt, two different mutations occurred in the
proton efflux pump gene PMA1 and the global transcriptional repressor gene CYC8; the ENA
genes encoding sodium efflux pumps were over-expressed once through expansion of this gene
cluster and once due to mutation in the regulator CYC8. In the population from low glucose, one
mutation occurred in MDS3, which modulates growth at high pH, and one in MKT1, a global
regulator of mRNAs encoding mitochondrial proteins, the latter recapitulating a naturally-
occurring variant. A Dobzhansky-Muller (DM) incompatibility between the evolved alleles of
PMAJ and MKT1 strongly depressed fitness in the low-glucose environment. This DM
interaction is the first reported between experimentally evolved alleles of known genes and
shows how reproductive isolation can arise rapidly when divergent selection is strong.
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Introduction
Speciation is one of the most fundamental problems of biology, as it is the process by
which biodiversity is generated[3]. Fungi are excellent models for the study of eukaryotic
speciation[4] and divergent adaptation is one such method by which this may occur. Divergent
adaptation of populations may be associated with the evolution of reproductive isolation in two
different ways: ecological isolation[5, 6] and Dobzhansky-Muller (DM) interaction[7] (Figure 1).
Under ecological isolation, populations adapt to divergent environments through the
accumulation of genetic changes that result in increased fitness. If formed, hybrid populations
are genotypically intermediate and therefore sub-optimally matched to any environment in which
adaptation occurred. Reduced fitness in hybrids retards, if not prevents, gene flow between
populations, contributing to speciation. With DM interaction, there is negative interaction in
hybrids among alleles that have never been tested together by natural selection.
Among fully-fledged species, the majority of genes identified as components of DM
interactions are unrelated to adaptation[8]. An exception is the DM interaction between a
nuclear gene AEP2 in Saccharomyces bayanus and a mitochondrial gene OLIJ in S.
cerevisiae[9]. It is unknown whether any of the DM incompatibilities identified to date among
existing species drove the ancient speciation events.
To separate initial events from subsequent evolutionary change in extant species, we
focused on the earliest mutations conferring adaptation and reproductive isolation in
experimental populations of yeast under strongly divergent selection. In a previous work,
Dettman et al. studied experimental populations of S. cerevisiae that evolved from a single
progenitor (P) in either a high-salt (S) or a low-glucose (M) environment [2]. These populations
were propagated as batch-transferred cultures with population size fluctuating daily between 106
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Gene B - mutated in blue
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Figure 1. Fitness effects due to purely ecological isolation compared to DM interaction.
(A) Starting from a founding population, sub-populations are evolved separately in disparate
selective conditions. These evolved populations will be adapted to the selective condition in
which they are grown. These adaptations may be deleterious in the alternate selective condition
(B, top) independently (ecological isolation), or there may be a negative interaction between the
evolved alleles that causes fitness deficits in the selective condition (B, bottom) (Dobzhansky-
Muller interaction).
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('bottleneck size') and 108 individuals. After 500 generations, each of the evolved populations
had adapted to their selective environment compared to the progenitor as assessed by relative
fitness. This adaptation was environment-specific, as the evolved strains did not show increased
fitness in either the permissive or alternate selective environments. Consistent with this
observation, the S/P and M/P hybrids showed reduced fitness relative to the S and P populations
in their respective selective environments but not the permissive environment. While this was
also true of the S/M hybrids, the S/M hybrids presented an even lower fitness than the progenitor
hybrids (S/P and M/P) in their selective environments. Dettman et al. concluded that the fitness
reduction in hybrids was due to both ecological isolation and a DM interaction. The short time
frame of this study was in contrast to other studies of genes involved in speciation [7-12] and of
isolating mechanisms among extant species [13-15].
In this work, we wanted to determine the genetic and molecular basis of both the
adaptation and the reproductive isolation observed among these different yeast populations. Our
first objective was to identify which mutations arose in each line. We sequenced the haploid
progenitor (P), and haploid cells representing two of the populations evolved in high salt (S2 and
S6) and one of the populations evolved in low glucose (M8). In order to identify the causes for
ecological adaptation, we mated the evolved strains to the progenitor (S2XP, S6XP, M8XP) and
genotyped their segregrants as well as compared their fitness to the progenitor and evolved
strains. We then profiled the expression of each strain in permissive and selective environments
to identify the molecular relationship between the genotypes and evolved phenotypes. Finally,
to evaluate the cause of the DM interaction, we measured the fitness of S2XM8 segregants
carrying the adaptive alleles from S2, M8, or both.
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Results
Illumina sequencing of progenitor and evolved strains identifies seventeen candidate
mutations
To identify the evolved mutations, we conducted whole-genome re-sequencing of single
haploid representatives from two populations evolved in high salt (S2 and S6), one population
evolved in low glucose (M8), and their common progenitor (P). The three evolved strains had
increased fitness in the respective environments in which they evolved (Figure 2). We mapped
all sequenced reads to the finished S. cerevisiae S288C genome, and located mutations unique to
each evolved strain (Experimental Procedures).
Seventeen candidate mutations were confirmed by PCR, conventional sequencing, and
comparative genome hybridization analysis (Tables Sl and S2). These included: in S2, non-
synonymous point mutations in the coding sequence of PMA1, GCD2, MET3, and LAP2, a point
mutation in the intergenic region 3' to SEC13 and PNPJ, and an expansion of the ENA gene
cluster; in S6, non-synonymous point mutations in the PMA1 and CYC8 coding sequences, point
mutations in the YBP2 and CAB3 promoters, and a contraction of the ASP3 gene cluster; and in
M8, non-synonymous mutations in the coding sequences of TIM11, RPH1, MDS3, MKT1, and
SGT1, and a synonymous mutation in UBI4. We note that two other studies have identified
mutations in genome-wide screens from experimental yeast populations[16, 17].
Assessing the contribution of each evolved allele to fitness in the adaptive environment
To assess the contribution of these mutations to adaptation, we measured the fitness
effects of each of the mutations unique to S2, S6, and M8 (Tables SI and S3-S7) by monitoring
culture density during growth (Experimental Procedures). We compared the fitness of the
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Figure 2. Growth of the progenitor and evolved haploid strains and average fitness effects
of variant loci.
(A - C) Three haploid strains were isolated from evolved populations (S2, S6 from high salt, and
M8 from low-glucose) and one haploid strain was isolated from the progenitor (P) for whole
genome sequencing and fitness assays. S2 and S6 have a fitness advantage in high salt (C); M8
has an advantage in low glucose (B); S6 has a general growth defect in YPD (A) and low-
glucose (B). (D - G) Shown are fitness measurements (OD6oo, mean and standard error,
normalized to the progenitor value) for 96 progeny - fully genotyped for all coding alleles
identified by sequencing - from each of the crosses S2 X M8 (A, C, 10 loci) and S6 X M8 (B,
D, 8 loci) in high salt (A, B) and low glucose (C, D). Data are aggregated by specific alleles, as
marked. Full genotypic and fitness data appear in Tables S3-S7 and P-values of all statistical
tests appear in Table S8. Light gray bars, ancestral alleles; dark bars, evolved alleles. Fitness of
evolved parent is shown at the upper right corner. Note that values in (C) average well below
the progenitor (at 1.0). This was in part due to the high-salt evolved allele of MET3, which
confers complete absence of growth in low glucose. Note also that the values in (D) average
below that of the progenitor; here this was due to the salt-evolved allele of PM41-2, which
confers a severe growth deficiency in low glucose.
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progenitor (P) and evolved (S2, S6, and M8) strains, in both high-salt and low-glucose
environments, to that of progeny genotyped for all the identified mutations from crosses with the
progenitor (S2 X P, S6 X P, Figure 3, and M8 X P, Figure 4), and between the evolved strains
(S2 X M8 and S6 X M8, Figures 2 and 5, see Tables S3-S7 for all genotypes and fitness
measurements). To control for variation between experiments, we normalized each
measurement by the fitness of the progenitor as a reference (the fitness value of the progenitor is
1.0 in all graphs). We used 2-way ANOVA (linear, additive model) to test for the fitness effect
of each evolved and ancestral allele and for interactions between every pair of alleles (P<0.05,
Bonferroni multiple hypothesis correction; Experimental Procedures, Table S8). Since several of
the candidate SNPs involved regulatory genes (the general transcription factor CYC8 in S6 and
the chromatin modifier RPH1 and the RNA regulatory protein MKT1 in M8), we also profiled
the expression of each of the progenitor and evolved strains in YPD, high-salt and low-glucose
(Figure 6).
Recurrent mutations in PMA1, and phenocopy mutations in ENA and CYC8 contribute the
majority of the observed fitness effects in high salt
Analysis of the 48 S2 X P progeny showed that the main adaptive determinants for the
higher fitness of S2 in salt are the ENA gene-cluster expansion (mean fitness relative to
progenitor: ENA~e segregants - 2.35, ENAla segregants - 1.54, P<0.008) and the evolved allele
of PMA1 (mean fitness relative to progenitor: PMA~e segregants - 3.03 ENAla segregants -
1.16, P<10-4), with the PMA1 allele having a more pronounced effect (Figure 3A and Table S3).
PMAJ encodes an essential ATP-driven proton pump responsible for maintaining the pH
gradient across the cell membrane[18], and the ENA genes encode three paralogous ATP-driven
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Figure 3. Contribution of S2 and S6 evolved alleles to fitness In high salt
Shown are fitness measurements (OD 0 0 , mean and standard error, normalized to the progenitor
value) for 48 offspring fully genotyped for all coding alleles identified by sequencing - from
each of the crosses S2 X P (A, C, 5 loci) and S6 X P (B, D, 3 loci). Data are aggregated by
specific alleles as marked (in each marked category, e.g. "PMAJ-2", the other alleles are
segregating). Full data (including intergenic loci) are available in Tables S3 and S4. (A, B).
The bars represent the average fitness effect of each variant across all offspring. Light gray bars,
ancestral alleles; dark bars, evolved alleles. Fitness of evolved parent is shown at the upper right
corner. Significant differences are noted with P-value. (C, D) Average pair-wise effects of the
two most advantageous mutations in each strain. Shown are the same data as in A and B, but
averaged for two-locus genotypes showing positive interaction. Superscript a = ancestral allele;
superscript e = evolved allele. Interaction was tested by ANOVA; all P values appear in Table
S8.
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Figure 4. Contribution of M8 evolved alleles to fitness in low glucose
(A, B) Average fitness effect of each variant across the segregant offspring at log-phase (20h)
and post-diauxic shift (30h) during growth in low-glucose. Shown are fitness measurements
(OD6oo, mean and standard error, normalized to the progenitor value) for 48 progeny from an M8
X P cross - fully genotyped for all five coding loci identified by sequencing, at 20h (A) and 30h
(B) of growth on glucose. Data are aggregated by specific alleles, as marked (in each marked
category, e.g. "MKT1", the other alleles are segregating). Full data are available in Table S5.
Light gray bars, ancestral alleles; dark bars, evolved alleles. Fitness of evolved parent is shown at
the upper right corner. Significant differences are noted with P-value. All P values appear in
Table S8. (C) Evolved alleles of MDS3 and MKT1 (MDS3e and MKTe) account for the M8
phenotype. Shown are growth curves (OD 6oo) from three tetrads from each of two independent
crosses segregating for MDS3 and MKT1, and no other evolved alleles (based on full
genotyping). The number of replicates for each time course varied between four and eight,
reflecting independent assortment. The evolved allele of MDS3 (green) confers a benefit early,
while that of MKT1 (blue) confers a benefit late in the growth cycle, relative to the ancestral
genotype (black). Together these two alleles produce a phenotype (red) that matches that of the
M8 strain (dashed).
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Figure 5. Average fitness effects In low glucose of each variant across segregants from the
S2XM8 cross that had the ancestral MET3 allele for prototrophy
Shown are fitness measurements (ODoo, mean and standard error, normalized to the progenitor)
in low glucose for 48 fully genotyped progeny from the crosses S2 X M8 that had the ancestral
AET3 allele for prototrophy. Data are aggregated by specific alleles, as marked. Full genotypic
and fitness data appear in Tables S3-S7 and P-values of all statistical tests appear in Table S8.
Light gray bars, ancestral alleles; dark bars, evolved alleles. Fitness of evolved parent is shown at
the upper right corner. (A) 20h; (B) 24h; (C) 30h.
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sodium efflux pumps [19] (a similar ENA gene-cluster expansion has been observed previously
[20] with adaptation to high salt). ENA and PMAJ also had the only significant additive
interaction (ANOVA, P<104 , Figure 3C), although this interaction was only marginally
significant on a logarithmic scale (ANOVA of log(fitness), P<0.07). Nevertheless, the
individual effects of the evolved alleles of ENA and PMA1 in increasing fitness act in an
unreduced (non-interfering) manner when together in the same haploid genotype. This is
consistent with a reduction of H+ efflux associated with the evolved allele of PMA1, and a
greater Na+ efflux by the expanded ENA gene cluster. Together, the evolved allele of PMA1 and
the ENA expansion conferred nearly the full fitness increase of the S2 haploid over the
progenitor. Subsidiary minor effects of other mutations are summarized in Table S L..
S6 revealed a pattern of adaptation remarkably parallel to that of S2 (Figure 3B and Table
S4). A mutation in PMAJ distinct from that in S2 and another in CYC8, a general transcriptional
repressor that acts together with TUP1, each conferred large gains in fitness (mean fitness
relative to progenitor: PMA~e segregants - 2.40; PMAla segregants - 1.64, P<0.002; CYC8e
segregants - 2.68; CYC8a segregants - 1.39, P<104). A pairwise interaction between PMAJ and
CYC8 (Figure 4D), was positive and marginally significant on an additive scale (ANOVA,
P<0.0074, significance threshold of P=0.0083 with 6 comparisons), but not on a logarithmic
scale (P<0.023, significance threshold of P=0.0083 with 6 comparisons). The fitness effects of
the evolved alleles of PMAJ and CYC8 are non-interfering when together in the same haploid
genotype. The growth defect of S6 (Figure 2A and B) was due to the mutation in PMAJ; all
genotyped strains with the evolved allele grew poorly in YPD and in low glucose (Figure 2G).
The cluster of genes whose expression is specifically induced in S6 (Figure 6B) is
enriched for targets of the Tupl-Cyc8 complex (140 common genes between 837 Tupl-Cyc8
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targets and 240 genes in the S6 up-regulated cluster, out of 5728 genes in array, P<l.5x 1058),
suggesting that the evolved CYC8 allele encodes a less potent transcriptional repressor than the
ancestral allele. Furthermore, these genes - repressed by Tupl-Cyc8 in YPD [21] and
specifically induced in S6 - are enriched for known genes induced in the osmotic stress response
[22] (53 common genes between 259 OSR genes and 240 genes in the S6 up-regulated cluster
out of 5728 genes in array, P<1.52X10 2 3 ). Among the Tupl-Cyc8 target genes that are de-
repressed in S6 are the glycerol biosynthesis enzyme HOR2 (important for high salt tolerance)
and the ENA1 and ENA2 genes, phenocopying the effect of the genetic expansion of the ENA
cluster in S2.
Mutations in MKT1 and MDS3 contribute to increased fitness in distinct growth phases in
low-glucose
The contribution of the M8 evolved alleles to increased fitness and reproductive isolation
in low-glucose depended on growth phase (Figure 4 and Table S5). At 20 h, when the cultures
were growing exponentially by fermentation, only the MDS3 allele conferred a significant fitness
advantage (mean fitness relative to progenitor: MDS3e segregants - 1.3; MDS3a segregants -
0.99, P<0.003) among the M8 X P offspring (Figure 4A), and there were no significant allele
interactions. MDS3 is necessary for growth under alkaline conditions [23], consistent with the
fitness benefit it conferred when culture pH was highest (near neutrality). In contrast, the
evolved allele of MKT] - a major regulator of the mRNAs encoding mitochondrial proteins [24]
- conferred a fitness disadvantage at this phase (mean fitness relative to progenitor: MKTle
segregants - 0.83; MKT~a segregants - 1.36, P<10~4). The effect of each of these alleles was
reversed after the diauxic shift from fermentation to respiration (30h, Figure 4B), when the
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evolved MDS3 allele conferred a fitness disadvantage (mean fitness relative to progenitor:
MDS3e segregants - 0.82; MDS3a segregants - 1.12, P<104 ) and the evolved MKT1 allele was
nearly neutral (mean fitness relative to progenitor: MKT~e segregants - 1.00; MKT~a - 0.97).
To explore the stage-dependent effects of MDS3 and MKT1, we used 24 genotyped
offspring of two crosses (three tetrads from each cross) segregating only for the evolved and
ancestral alleles of MDS3 and MKT1 and for no other evolved SNPs. The evolved allele of
MKT1 alone showed no deficit relative to the progenitor in early time points (Figure 4C), but had
a strong increase in fitness late in the growth cycle. This is in contrast to the aggregate effect of
MKT1 in the presence of other segregating SNPs (Figures 4A and B), where we found a fitness
deficit early and near neutrality late. Nevertheless, in both experiments, the effect of MKT~e had
the same directionality: it performs better late in the growth cycle than early. The evolved allele
of MDS3 showed the opposite directionality, performing better early than late. Importantly,
genotypes carrying only the evolved alleles of both MDS3 and MKT1 closely approximated the
growth curve of the M8 haploid strain, accounting for the adaptation observed in low glucose
(Figure 4C).
A competitive fitness assay over a 24 h period provided a third, independent, measure of
the individual fitness effects in low glucose of the evolved alleles of MDS3 and MKT1. This
period matched the daily batch-culture regimen in the original 500 generation experiment [2],
which included both fermentative and respirative energy production. Each mutation conferred a
fitness advantage over the progenitor alleles (MDS3, 1.25 + 0.1 SE n= 9 and MKT1 1.10 + 0.2
SE n= 6). We conclude that our experimental regimen selected for alleles conferring advantages
at distinct phases of the yeast growth cycle.
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Finally, the evolved alleles of the mitochondrial protein TIM11 and the chromatin
modifier gene RPH1 conferred smaller, non-significant growth increases at 30h (post-shift,
Figure 4B, Tables S5 and S8). This effect is consistent with the role of the RPH1 paralog in
regulating gene expression post-diauxic shift [25]. However, the evolved RPH1 allele was not
essential to reconstitute the full M8 phenotype.
The MKT1 allele reverted to a wild allele during experimental evolution
The evolved MKT1 allele of M8 is identical to the allele (89G) observed in strains of S.
cerevisiae of diverse environmental origin and of S. paradoxus [26], leading to a non-
conservative amino acid change from aspartate (P) to glycine (M8). MKT1 encodes a major
component in the interaction between Puf3, a sequence-specific RNA binding protein targeting
mRNAs involved in mitochondrial function, and P-bodies, which control sequestration and
expression of certain mRNAs [24]. The cluster of genes of elevated expression in M8 strains
(Figure 6C) is highly enriched for mitochondrial genes (62 common genes between 588
mitochondrial genes and 90 genes in the M8 upregulated cluster out of 5728 genes in array,
P<2.7x 10~4), including aerobic respiration genes (10 common genes between 64 aerobic
respiration genes and 90 genes in the M8 upregulated cluster out of 5728 genes in array,
P<4.2x10~8 ), and in particular known Puf3 targets (59 common genes between 137 Puf3 target
genes and 90 genes in the M8 upregulated cluster out of 5728 genes in array, P<9.7x 10-79).
Furthermore, the M8 cluster includes genes more highly expressed in the vineyard strain RM- 11
than the lab strain BY (Figure 6C, bottom). The eQTLs for these genes were previously found to
be closely linked to the MKT1 allele that segregates in the BY X RM- 11 cross [24].
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Figure 6. Global expression changes In evolved strains associated with the adaptive genetic
changes
(A) Genome wide expression profiles from P, S2, S6, and M8 strains grown in YPD, low
glucose (LG), and high salt (HS) environments. Red - induced compared to mean of all strains in
that condition; green - repressed compared to mean of all strains in that condition. (B) Genes
with high expression specific to S6 across all conditions are enriched for Cyc8-Tupl targets and
for osmotic response genes. Shown is a zoomed in cluster from (A). Yellow bar - genes whose
expression is induced in a deletion of the TUP1 gene [19]; purple bar - genes whose expression
is induced during the Osmotic Stress Response (OSR) to high salt [20]. Genes are re-ordered by
the TUP1 and OSR annotations. (C) Genes with high expression specific to M8 across all
conditions are induced in the RM-1 1 wine strain and enriched for Puf3 targets. Top panel -
zoomed in cluster from (A). Bottom panel - expression of the same genes in the laboratory strain
BY and in the wild wine strain RM. Blue bar - genes in the Puf3 module [22], whose eQTL in a
cross between BY and RM has been linked to the same genetic change in MKT1 found also in
the M8 strain. Genes are re-ordered by membership in the Puf3 module.
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Taken together, the data suggest a past mutation from the allele (89G) uniformly present
in wild strains to that of the laboratory standard (89A), carried by our P strain, followed by an
exact reversion of that mutation at some point during the 500 generations of evolution from P to
M8. Thus, the progenitor (P) laboratory reference strain carries a less potent form of MKT1,
with lower expression of target genes, strongly selected for in lab experiments focusing on early
or mid-log phase cells in which the wild allele (here the "evolved MKTJ") confers a growth
disadvantage. In contrast, the low-glucose selection regimen on a 24h batch-transfer cycle used
in this study may more closely approximate natural conditions in which growth more often
approaches stasis, a condition that would favor the reversion to the naturally-occurring 89G
allele, and corresponding higher expression of gene targets.
A DM Interaction between PMAJ and MKT1
We next tested for the presence of DM interactions, defined as genetic incompatibilities
between alleles independently evolved in the two environments. We measured the fitness, in the
two selective environments, of 96 offspring from 24 tetrads from the S2 X M8 and S6 X M8
crosses (Figures 2 and 5). All progeny were fully genotyped for all segregating SNPs, gene-
cluster size alterations, and mating type, all of which segregated -1:1 in tetrads (Tables S6 and
S7). As before, we tested each pairwise combination of loci for interaction by means of
ANOVA (Table S8).
Among the offspring of the S2 X M8 cross in the low-glucose environment at 24 hours
(Figure 5A and Supplemental Table 6), we found only one marginal P-value of 0.015 for a
PMAle-MKTle negative fitness interaction (in the presence of other segregating alleles). Since
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the initial value was marginal, we tested this preliminary evidence for an interaction in two
additional independent experiments.
In the first, we measured the fitness of 24 genotyped offspring of two crosses (three
tetrads from each cross), that segregated at only the two SNP sites in PMAJ and MKT1 (no other
evolved alleles were present in the cross). Here, we found that the fitness of offspring carrying
both evolved alleles was depressed over the entire growth cycle in low glucose (Figure 7B), most
prominently at the 21 and 24h time points (the same time point as in Figure 7A). At 24h, an
overall ANOVA of additive variation over the four genotypes was statistically significant
(P<0.016, one test only) and a Tukey-Kramer HSD test indicated that the only difference was
between the PMAla MKT~e and PMA~e MKT~e genotypes. The reduction in the PMA~e
MKT~e genotype is therefore due to the presence of the PMA~e allele, which is otherwise nearly
neutral in the low-glucose environment and closely tracks the progenitor over the entire growth
cycle. We further confirmed this result in three additional replicate experiments with the same
strains at 24h, finding a significant interaction between the PMAJ and MKT1 alleles, when fitting
a linear mixed model treating strain as a random effect and tested against a null model of no
interaction between PMA1 and MKT1 (PMAlaMKTla: 0.69 ± 0.02, PMAlaMKTle: 0.70 ± 0.02,
PMAleMKT~a: 0.66 ± 0.01, PMA~eMKTle: 0.46 ± 0.03, P<10-4). This interaction is also
significant on log scale (P<4X10-5 ). This fulfills the criterion for a DM interaction [2]. Similar
assays with offspring segregating for MDS3 and PMA showed no such negative interaction
(Figure 7C).
We independently confirmed the negative interaction between the PM41 and MKT1
genotypes in competition experiments in the low-glucose environment at an early time point
(1 7h under conditions matching those in Figure 7B), showing a negative reduction in the number
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Figure 7. DM interactions between the evolved alleles of PMA1 and MKT1
(A) DM interaction between the evolved alleles of PMAJ and MKTJ at 24h in low-glucose.
Shown are the fitness measurements (OD00, mean and standard error, normalized to the
progenitor value) of 96 offspring of a cross between S2 and M8 in the low-glucose environment
at 24h grouped by their two-locus genotypes for PMA1 and MKT1 (e - evolved allele; a -
ancestral allele); note the depressed fitness of the genotype carrying both evolved alleles of these
genes. ANOVA: evolved allele of PMA1, P < 10~4; evolved allele of MKTJ, P < 10 4; and
interaction of the evolved alleles of PMAJ and MKT1, P < 0.015. Full data are available in
Table S6 and all P values of all tests are listed in Table S8. (B) DM interaction between the
evolved alleles of PMAJ and MKT1 along the growth curve. Shown are growth curves from
three tetrads from each of two independent crosses segregating for PMAJ and MKT1, and
carrying no other evolved alleles (based on full genotyping). The number of replicates for each
time course varied between four and eight, reflecting independent assortment. The genotype
carrying the evolved alleles of PMA1 and MKT1 (red) shows poor growth at all time points (up
to 27h) relative to the other genotypes. The other genotypes are marked as PMA~e (green);
MKT~e (blue); ancestral (PMAla MKT~a, black); and M8 (dashed). (C) Absence of an
interaction between PMAJ and MDS3; analysis as in B: PMA~e (green); MDS3e (blue), PMAle
MDS3e (red); ancestral (PMA]a MDS3a, black); and M8 (dashed).
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of doublings in the PMAe MKT~e genotype strain (MKT~e, 0.87 + 0.01 SE (n=3); PMAle, 0.89
+ 0.02 SE (n=3); PMA~e MKTle, 0.7 + .07 SE (n=3) all relative to the doublings by the
progenitor). As a control, we confirmed the expected beneficial effect of MDS3e in the
competition assay (1.28 + 0.01 SE (n=2)). The difference in fitness among the genotypes fell
just short of significant (P<0.061, one-way ANOVA, linear scale), likely reflecting the smaller
sample size and the earlier (17h) time point. Nevertheless, each of these three experiments
supported the conclusion of negative interaction between the evolved alleles of PMA1 and
MKT1, most notably at 24h. In contrast, there was no evidence for a DM interaction in the S2 X
M8 and S6 X M8 offspring in high salt and the S6 X M8 offspring in low glucose (Supplemental
S7 and S8), where all adaptive determinants had effects similar to those in crosses of the evolved
strains and the progenitor (Figures 2A and B).
Discussion
In this study we used whole-genome sequencing of progenitor and evolved strains, along
with genotyping, fitness assays, and mRNA profiling to identify and characterize the genetic and
molecular basis of early events associated with divergent selection in experimental yeast
populations. We found six key determinants, each of which contributes to ecological isolation in
which genotypically mixed hybrids are not as well matched to either environment as the pure
evolved strains.
The DM interaction between PMA1 and MKT1 is the first reported between evolved
alleles of known genes in experimental populations derived from a common ancestor. Although
it is tempting to speculate on how such an incompatibility might affect natural yeast populations,
our study was limited to haploid effects. One possibility is that a DM incompatibility like that
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reported here would quickly be eliminated with recombination. Conversely, such a DM
interaction might present a strong reproductive isolation mechanism in nature under the low rate
of outcrossing in S. cerevisiae [27]; in such a case the incompatibility would persist in hybrid
populations. These possibilities remain to be investigated.
No consistent functional theme has yet emerged among the known "speciation genes"
implicated in DM interactions among species in nature [7-12]. Here, we show that the adaptive
mechanisms evolved in response to strong directional selection in two environments have
substantial effects on gene regulation and phenotype and that at least two of the adaptive
determinants produce an intrinsic clash resulting in a fitness reduction characteristic of a DM
interaction. In extant species examined to date, the majority of DM incompatibilities occur in
genes unrelated to ecological adaptation [8]. Our study, in which we experimentally set the
conditions thought to foster incipient speciation, documents a counter example in which
divergent adaptive changes themselves confer a DM incompatibility. It is possible that newly
evolved adaptive mechanisms under other conditions will have similarly far-reaching
consequences, with potential for DM incompatibility. We propose that the potential pool of
speciation genes includes genes conveying adaptation under strong selection in the earliest stages
of speciation - that functional diversity in speciation genes could reflect the diversity of adaptive
mechanisms.
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Experimental Procedures
Strains
We used haploid strains that were derived from the diploid experimental populations described
by Dettman et al.[5]. Each strain was marked by replacement of the URA3 open reading frame
with either the NATr or G418r cassette flanked by two unique barcodes. Populations S2
(G418'), S6 (NATr), and M8 (NAT) were allowed to sporulate and four complete tetrads were
dissected from each. The S2 and S6 haploid offspring were assayed for fitness (see below) in
high salt (YPD with 1.0 M NaCi), and those from M8 in low glucose (Yeast Nitrogen Base with
2.5 g of glucose per L, rather than the standard 20 g). Strains with the highest values in the
fitness test were selected as the representatives from each population. The progenitor P (G418')
was strain Sce3044. In array experiments we also used the standard laboratory strain BY4741
and the wine strain RM- 11 a.
Illumina sequencing
We prepared genomic DNA from the progenitor (P) and evolved strains (S2, S6, and M8) and
sequenced the DNA using single-end Illumina sequencing[28]. In the progenitor, we generated
843 Mb from 36-mer sequence reads. In the evolved strains, we generated an average of 688 Mb
from 51-mer sequence reads. We then mapped the sequence data to the S288C reference
genome (Saccharomyces Genome Database ftp://ftp.yeastgenome.org/yeast/) using the Maq
alignment tool[29]; 622 Mb of the progenitor was mapped for a coverage of -52x coverage, and
an average of 447 Mb of the evolved strains was mapped for an average coverage of -37x
(Supplemental Table 2). Primary data are available at:
http://www.broadinstitute.org/regev/webdata/Anderson/.
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Identification of SNPs
SNP calling was also conducted via Maq using default parameters. There are 554 SNP loci
called in at least one strain (including the progenitor). We classified these SNPs given their
location; 182 were noncoding, 81 were synonymous nucleotide substitutions, and 291 were non-
synonymous nucleotide substitutions. From the total of 554 SNPs identified (Supplemental
Table 2), 539 were interpreted as present in the ancestor and all four derived haploid strains.
These SNPs represent mutations that occurred before the experimental evolution described by
Dettman et al. [5] and were not relevant to this study. The 15 SNPs interpreted as unique to S2,
S6, and M8 included 12 coding, non-synonymous SNPs (four in S2, two in S6, six in M8) and
three noncoding (one in S2 and two in S6) SNPs. Each of these SNPs was confirmed by
conventional PCR and Sanger sequencing, and were evaluated for their fitness effects.
SNP assays
PCR amplicons ranging from 300 - 500 base pairs in size were transferred to nylon membranes
and hybridized with 15 base oligonucleotide probes 5' end labeled with 32P. In each probe, the
site of potential base mismatch was in the center. The hybridizations were done 2 - 4 C above
the predicted Tm to ensure specificity. This method follows that described by Cowen et al.[30].
Comparative genome hybridization (CGH)
Genomic DNA was prepared according to the protocol available at http://genome-
www.stanford.edu/rearrangements/aCGH1.html. Genomic DNA (40-50 pg) was sonicated to
obtain DNA fragments of roughly 100 basepairs to 10 kilobases and purified with a QlAquick
PCR Purification Kit (Qiagen). The two DNA samples to be compared were labeled with Cy3 or
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Cy5 using the Mirus Label IT@ Nucleic Acid Labeling Kit (Mirus, Madison, Wisconsin, United
States), according to the manufacturer's protocol with the following modification: half-sized
reactions were used. The labeled genomic DNA was co-hybridized to S. cerevisiae microarrays
obtained from the University Health Network Microarray Centre (Toronto, Ontario, Canada). A
pre-soak for background reduction used the Pronto Background Reduction Kit (Coming)
according to the manufacturer's instructions. QuantArray (PerkinElmer) was used to quantify
the relative fluorescence of Cy3 and Cy5 for each spot on the array.
Confirmation of copy number changes
In subsequent experiments, specific copy number variants were assayed by digesting genomic
DNA with EcoRI, followed by electrophoresis and capillary transfer to a nylon membrane. The
blots were probed with PCR products representing most of the open reading frame of the gene.
Hybridization signal was quantified exactly as described by Anderson et al. [30]. This signal
was normalized by hybridizing with a gene (YEF3) not showing copy-number variation, to
correct for variation in the amount of genomic DNA loaded per lane.
Fitness measurements
The measure of fitness for each strain was culture density after set periods of time following
introduction of a standard volume of inoculum of an overnight culture (10 PL for high-salt
environment or 2 pL for low-glucose environment) to 10 ml of fresh medium. The P, S2, and
M8 haploid strains were included as controls. The fitness values of genotypes were highly
consistent within experiments, but the overall scale of variation differed among experiments.
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Statistical significance of allele effects and interactions
We used 2-way ANOVA to test for the fitness effect of each evolved and ancestral allele and for
interactions between every pair of alleles, and 3-way ANOVA to test for 3-allele interactions
(only one significant interaction was found). We confirmed that each dataset was generally
normally distributed based on Rankit (QQ plot), but for the lowest values (e.g., MET3e in Figure
2C) likely due to spectrophotometer error. For each test, we used a linear, fixed-effects, additive
model, with a least squares fit, as implemented in JMP, The Statistical Discovery Software,
version 5.1 (SAS Institute, Inc.). For each interaction test, there were three factors, one locus,
the other locus, and their interaction. P values for the interactions are available in Supplemental
Table 4. For each cross (S2XP, S6XP, M8XP, S2XM8, S6XM8), we used a significance
threshold of 0.05/N (Bonferroni correction), where N is the number of tests made.
Competition experiments
Equal numbers of strains carrying evolved and ancestral alleles were mixed and followed over
13.2 generations (for MDS3 and MKT] genotypes) or over 7-8 generations (PMAJ and MKTJ
genotypes) as described by Anderson et al.[31] except that SNP frequencies, rather than bar
codes, were monitored directly. For calibration standards, different strains were mixed to give
allele frequencies of: 1.0, 0.98, 0.97, 0.94, 0.88, 0.75, 0.5, 0.25, 0.13, 0.64, 0.03, and 0.02; the
correlation between pixel volumes on the phosphor screen after hybridization of PCR amplicons
on Nylon membranes with allele-specific probes were always highly correlated with the known
allele frequencies (R2 > 0.99)
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Effects of SNPs and ENA gene-cluster expansion on fitness
For measuring the association of evolved alleles with fitness effects, four crosses were made: i)
the MA Ta S2 haploid X a MA Ta P; ii) the MA Ta M8 haploid X a MA Ta P strain; iii) the MA Ta
S2 haploid X the M4Ta M8; and iv) the MATa S6 X a the MATa M8. Diploids were recovered
by simultaneous selection with NAT and G418. Sporulation and tetrad dissection were
standard 7 .
RNA preparation, genomic DNA preparation and labeling
Total RNA was isolated using the RNeasy Midi or Mini Kits (Qiagen) according to the provided
instructions for mechanical lysis. Samples were quality controlled with the RNA 6000 Nano 11
kit for the Bioanalyzer 2100 (Agilent). Genomic DNA was isolated using Genomic-tip 500/G
(Qiagen) using the provided protocol for yeast. Progenitor DNA samples were sheared using
Covaris sonicator to 500-1000 bp fragments, as verified using DNA kit for the Bioanalyzer 2100
(Agilent). Total RNA samples were reverse transcribed and then labeled with Cy3 (cyanine
fluorescent dyes) and genomic DNA samples were labeled with Cy5 using a modification of the
protocol developed by Joe Derisi (UCSF) and Rosetta Inpharmatics (Kirkland, WA) that can be
obtained at www.microarrays.org.
Microarray hybridizations
Each Cy3 labeled cDNA biological replicate was mixed with a reference Cy5 labeled genomic
DNA sample and hybridized on commercial S. cerevisiae two-color Agilent oligo-arrays in the
4x44K format (4-5 probes per target gene). Labeled genomic DNA was denatured at 95*C for 3
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minutes, then snap-cooled on ice for 5 minutes prior to being combined with an RNA sample.
After hybridization and washing per Agilent instructions, arrays were scanned using an Agilent
scanner and analyzed with Agilent's feature extraction software version 10.5.1.1, excluding final
normalization (below).
Microarray data processing
For each probe, the median signal intensities were background-subtracted for both channels and
combined by taking the log2 of their ratio. To estimate the absolute expression values for each
gene, we took the median of the log2 ratios across all probes. Data was combined using quantile
normalization to estimate the absolute expression level per gene. Finally, each gene's expression
in each sample was normalized by subtracting its mean expression across all strains in the same
condition (YPD, low glucose, or salt). The processed data was clustered using hierarchical
agglomerative clustering. Functional enrichment was assessed by comparing to previously
collected gene sets[32] and estimated using a hypergeometric test, as previously described [32].
Micro-array data are available at: http://www.ncbi.nlm.nih.gov/geo/query under accession
number GSE20943.
Supplemental data
Supplemental tables can be found on the journal's cite:
http://www.sciencedirect.com/science/article/pii/S0960982210007670#appd002
Supplemental tables can be found in Appendix 1 or at:
http://www.broadinstitute.org/regev/webdata/Anderson/
Gene Expression Omnibus Record is GSE20943.
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Chapter 2: The mutational landscape of gradual acquisition of drug
resistance in clinical samples of Candida albicans
We use whole genome re-sequencing and phenotypic characterization of strains of Candida
albicans derived from HIV patients with oropharyngeal candidiasis. We confirm the progression
of the drug resistant phenotype and couple to recurrent, persistent changes in the genome
sequence. We observe that increase in drug resistance can also be coupled to other phenotypes,
and ultimately describe those changes.
Jason M. Funt, Darren Abbey, Luca Issi, Brian G. Oliver, Theodore C. White, Reeta Prusty-Rao,
Judith Berman, Dawn A. Thompson, and Aviv Regev
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Abstract
Candida albicans is both part of the healthy human microbiome and a major pathogen in
immunocompromised individuals [1]. Infections are most commonly treated with azole
inhibitors of ergosterol biosynthesis. Prophylactic treatment in immuncompromised patients [2,
3] often leads to the development of drug resistance. Since C. albicans is diploid and lacks a
complete sexual cycle, conventional genetic analysis is challenging [4]. An alternative approach
is to study the mutations that arise naturally during the evolution of drug resistance in vivo, using
strains sampled consecutively from the same patient. Studies in evolved strains have implicated
multiple mechanisms in drug resistance, but have focused on large-scale aberrations or candidate
genes, and do not comprehensively chart the genetic basis of adaptation [5]. Here, we leverage
massively parallel DNA sequencing to systematically analyze 43 strains serially collected from
11 oral candidiasis patients, ranging from two to 16 time points per patient. We find that most
infections are clonal, allowing us to detect newly acquired mutations, including SNPs, copy-
number variations and LOHs. Focusing on mutations that are both persistent within a patient and
recurrent across patients, we identify an important and under-reported LOH event that co-occurs
with increases in drug resistance and identify both well-known drug-related genes as well as
poorly characterized, highly recurrent genes which may be functionally significant. Our work
sheds new light on the molecular mechanisms underlying the evolution of drug resistance and
host adaptation.
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Introduction
The dimorphic yeast Candida albicans is one of the most studied fungal pathogens. C.
albicans is part of the healthy human microbiome as a commensal and is not found in
environmental reservoirs[6], however it also exists as a major pathogen in immunocompromised
individuals[1]. Candidemia is the fourth most common cause of nosocomial bloodstream
infections in the United States[7], with C. albicans accounting for nearly 65%[8, 9] of Candida
infections. Systemic infection is associated with a mortality rate as high as 50%[1]. Resistance
arises during long-term prophylactic treatment regimes[10, 11] that are sometimes indicated in
immuncompromised patients (e.g. bone marrow transplant[2] or HIV[3]). Previous studies of
resistant strains have shown that this is mediated by multiple (possibly inter-dependent)
mechanisms including segmental aneuploidy[12], increased expression of drug pump genes[13],
loss of heterozygosity (LOH) across chromosomes or regions of chromosomes[13, 14],
mutations in ergosterol biosynthetic genes[15], and deviations facilitated by the heat shock
protein Hsp90[16]. Because C. albicans is diploid and lacks a complete sexual cycle,
conventional genetic analysis is simply not possible, and has been a barrier for study despite its
medical significance[4].
Both in vitro and in vivo systems provide an extensive trace of the evolutionary process,
in the form of sampled strains throughout the evolutionary time course. Thus, they hold the
promise of unocvering the evolutionary mechanism of stressor adaptation. However, previous
studies have focused predominantly on large-scale aberrations or candidate genes, but not both,
and therefore do not provide a comprehensive view of the genetic changes underlying
adaptation[5]. The development and decreasing costs of high-throughput sequencing makes it
possible to follow the genomic evolution of pathogens, but a challenge remains in distinguishing
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between selection and drift when looking at variations. In the laboratory, this difficulty has been
addressed by following several populations grown in parallel cultures under identical conditions;
the adaptive nature of mutations is indicated by their recurrence in replicate experiments. In
natural and clinical environments, such studies are more difficult and are only now are being
broached via genomic inquiry in prokaryotes[17].
In this work, we aimed to determine the entire mutational landscape of clinically derived
strains of C. albicans that acquire drug resistance. We sequenced 43 strains from 11 HIV
patients with oropharyngeal candidiasis; from each patient, there were two or more isolates. Our
first objective was to determine whether each series was clonally derived. Following
establishment of clonality, and removing non-clonal isolates, we identified and catalogued each
mutation in each series, focusing particularly on newly arising mutations. Using recurrence
between patients as an indicator of functional significance, we find both large, genome-level
events as well as small, single base-pair substitutions that are likely players in drug resistance.
Finally, we explore relating other changing phenotypes to genomic level events.
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Results
Sequencing of in vivo isolates during evolution of drug resistance
To study the in vivo evolution of azole resistance in C. albicans, we analyzed 43 strains
from 11 HIV-infected patients with oropharyngeal candidiasis[ 18, 19] (Table 1). The strains
from each patient were isolated during incidences of infection and form a time series (Figure 1,
Figure 2a). The first strain (progenitor) was isolated prior to any treatment with azole anti-
fungals; the remaining strains were isolated at later, typically consecutive time points,
culminating in the final 'endpoint' strain (Table 1). The progenitors are more sensitive to
fluconazole than subsequent isolates, as defined by the minimum inhibitory concentration (MIC)
(Table 1, Methods). Previous studies in some of these strains identified several mechanisms that
may contribute to drug resistance, including segmental aneuploidy[12], increased expression of
drug efflux genes[13], loss of heterozygosity (LOH) across large chromosomal segments[13, 14],
mutations in ergosterol biosynthetic genes[15], and facilitation by the chaperone heat shock
protein 90 (Hsp90)[16].
We sequenced the genomic DNA of each of the strains (and the C. albicans lab strain,
SC5314), using Illumina sequencing (Methods, Table 1), identified point mutations and larger
aberrations that occurred after the progenitor, and determined for each if it is persistent within a
patient and recurrent across patients (Figure 1, Supplementary Table 1). All mutations were
detected relative to SC5314, the C. albicans genome reference strain. Background mutations are
common to all strains in the series (including the progenitor, Figure 1, purple). Persistent
mutations are not present in the progenitor, but present consecutively from the isolate in which
they arose throughout the remainder of the time course (Figure 1, yellow), presumably selected
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Publication Dose E-test MIC Depth of Fraction
Name Patient Strain Entry Date Drug Treatment (mg/day) (ug/mi) Coverage Reads Aligned
White, T.C. 1 1 9/10/90 Fluconazole 100 0.25 19.2192 4,957,416 87.0215%
2 12/14/90 Fluconazole 100 1 38.7477 9,575,398 95.4372%
3 12/21/90 Fluconazole 100 4 20.9735 5,379,156 87.8439%
4 12/31/90 Fluconazole 100 3 25.7020 6,613,910 88.4204%
5 2/8/91 Fluconazole 100 4 25.5055 6,591,818 88.4265%
6 2/22/91 Fluconazole 100 4 24.5343 6,347,882 88.1557%
7 3/25/91 Fluconazole 100 4 30.1535 7,742,300 88.4035%
8 4/8/91 Fluconazole 100 4 19.5445 5,114,968 85.4924%
9 6/4/91 Fluconazole 100 4 17.2656 4,642,144 85.1604%
11 7/15/91 Fluconazole 100 4 20.8076 5,321,510 88.4235%
12 11/26/91 Fluconazole 200 4 34.0561 8,438,948 95.4677%
13 12/13/91 Fluconazole 400 32 34.9395 8,593,718 95.1638%
14 1/28/92 Fluconazole 400 24 20.5015 5,385,134 88.5430%
15 2/21/92 Clotriminazole 50 24 17.6284 4,679,970 85.7060%
16 4/1/92 Fluconazole 400 96 17.6442 4,473,684 89.0691%
17 8/25/92 Fluconazole 800 96 16.3827 4.598.094 81.9933%
Perea, S. et al. 7 412 2/15/95 Fluconazole 0 0.25 24.2606 6,393,874 87.4389%
2307 11/22(95 Fluconazole 400 0.75 17.8088 4.946.180 84.7707%
Perea, S. et al. 9 1002 4/20/95 Fluconazole 100 0.125 23.7446 5,989,852 93.2972%
2823 4/6/96 Fluconazole 800 22.9543 5,692,258 92.1211%
3795 2/26/97 Fluconazole 800 128 15.4739 5.806,668 69.2547%
Perea, S. et al. 14 580 3/13/95 Fluconazole 0 1.5 23.5691 6,419,866 84.7974%
2440 1/3/96 Fluconazole 800 1.5 27.5816 7,466,482 85.0403%
2501* 1/4/96 Fluconazole 800 96 22.6987 6.065.350 84.6670%
Perea, S. et al. 15 945 4/14/95 Fluconazole 300 4 17.8029 4,600,706 85.6004%
1619 7/11/95 Ruconazole 500 64 11.1846 3,969.036 67.7042%
Perea, S. et al. 16 3107 6/5/96 Fluconazole 800 4 20.1296 5,464,854 84.8738%
3119 6/5/96 Fluconazole 800 96 21.6383 5,725,352 85.2416%
3120 6/5/96 Fluconazole 800 96 22.1763 5,623,852 92.7914%
3184 7/1/96 Fluconazole 800 23.6035 5,846,818 91.0434%
3281 7/16/96 Fluconazole 800 19.4486 5.416.974 83.7257%
Perea, S. et al. 30 5106 1/7/98 Fluconazole 800 0.5 20.8939 5,685,762 83.1623%
5108 1/7/98 Fluconazole 800 0.75 25.0948 6,601,396 85.1954%
Perea, S. et al. 42 1691 8/3/95 Fluconazole 100 24.1965 6,262,036 87.6899%
3731 12/27/96 Fluconazole 400 256 22.4400 5,759,330 87.7794%
3733 12/27/96 Ruconazole 400 256 23.1056 6.167,930 87.2610%
Perea, S. et al. 43 1649 7/19/95 Ruconazole 0 0.125 22.2856 6,177,754 85.2690%
3034 5/15/96 Fluconazole 400 0.75 19.8168 5,504,546 82.0859%
Perea, S. et al. 59 3917 2/19/97 Ruconazole 800 2 26.6637 6,766,766 88.3911%
4617 8/28/97 Fluconazole 400 64 16.0395 4,088,796 88.2887%
4639 9/2/97 Fluconazole 400 128 27.4587 6.922.062 88.8073%
Perea, S. et al. 64 4018 4/2/97 Fluconazole 200 22.8235 6,055,484 85.2527%
4380 7/14/97 Fluconazole 200 N/A 9.104,318 13.8548%
Not clonally derived from progenitor
* isolated on same day from same patient as previously published strain, 2500
Table 1. Strain history and sequence summary
Originating lab, clinical history, MIC, and sequence statistics are summarized for each strain.
Non-clonal strains are marked in red, and were not phenotyped for resistance. Isolate 2501 was
not included in the original publication, but was isolated from the same patient on the same day.
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Figure 1. Persistent and recurrent mutations are likely significant for changing phenotype
A. Mutations that are persistent (yellow) are newly acquired compared to the progenitor and
retained in all subsequent isolates. Mutations common to all isolates in a series are background
(purple) and removed from consideration. Mutations that flow in an out of a series are
transient (pink), and are removed from consideration. Recurrence (black boxes) are
considered for functional significance across changing phenotypes (grayscale, right).
B. Isolates are sampled from a particular patient during different episodes of infection. As a
result, each isolate is related to another, though potentially not linearly. As a result, mutations
that arise in a particular sample may not be present in a population following a selective sweet
(i.e. clonal interference or bottleneck event).
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for via selective sweep. (We consider the special case of a mutation only in the endpoint strain
as persistent as well, since several of the time courses consist of only 2 or 3 isolates.) Recurrent
mutations are persistent in more than one series (Figure 1, black boxes). We reasoned that
recurrent mutations are the most likely to be adaptive, but that some adaptive mutations may be
persistent in only one patient. Transient mutations (Figure la, pink) may be the result of
evolutionary dead-ends (Figure 1b) or could be the result of sequencing errors.
Most time courses are clonal
Analyzing the background SNP mutations, we first determined that most time courses are
largely clonal, and hence likely sampled continuous evolutionary trajectories (Figures 2 and 3).
To distinguish between a clonal trajectory and repeated, independent infections (Figure 2a, top
and bottom, respectively), we determined the distance between each two strains from their SNP
profile, and used neighbor-joining to construct phylogenetic trees, with the reference strain
SC5314 as an outgroup (Methods, Figure 2b, Figure 3). All but one (10/11) of the series are
predominantly clonal, with an occasional isolate that is not. For example, all 16 strains from
Patient 1 are clonal (Figure 3a), as are the three strains from Patient 59 (Figure 2b). Conversely,
only 2 of 3 strains (strains 1002 and 3795) from Patient 9 are clonal, with the other isolate (2823)
not related to either of them (Figure 2b, bottom). In one case (Patient 64) we found that one
isolate (4380) was not Candida albicans, but likely another Candida species. We removed all
non-clonal samples from further consideration, and focused in all subsequent analyses on the 22
samples from the 10 patients with at least two clonal isolates.
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Figure 2. SNPs as a method for identifying clonally derived strains.
There are two models of infection from serial isolation of clinical isolates (a); a clonal model
where each isolate is derived from the previous (a, top) and a non-clonal model where
consecutive isolates derive from new colonization (a, bottom). An example of a clonal series is
patient 59 (b, top); a phylogenetic tree is constructed from a distance matrix based on genotype
(b, top left). These data are also visualized via a heterozygosity diagram (b, top right) where
each locus contains a SNP from at least one isolate. Each genotype is color-coded; red -
homozygous SNP, white - heterozygous SNP, and blue - homozygous for reference. Patient 9
(b, bottom) contains at least one non-clonal isolate, 2823 (distance > than 22,000, b, bottom
left). This is confirmed visually by heterozygosity diagram (b, bottom right). Clonal patient
series heterozygosity diagrams are of post-filtration SNP calls, non-clonal are of pre-filtration.
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Figure 3. Clonality in patient series.
Multi-sample SNP calling (including reference strain SC5314) is used to construct phylogentic
trees via Neighbor-Joining (A-H, left). Patients 16 and 42 (E and G) both contain non-clonal
isolates. This effect can be observed visually via heterozygosity diagram (A-H, right), where
each locus that contains at least one variant in the series contains a color entry reflecting
genotype; a homozygous SNP is red; a heterozygous SNP is white, and a locus homozygous for
the reference base is blue. Clonal patient series heterozygosity diagrams are of post-filtration
SNP calls, non-clonal are of pre-filtration.
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Ploidy varies but such variations are not generally adaptive
While we observed ploidy changes in samples from 7 of the 10 patients (Methods), most
variations were transient and not generally associated with adaptive changes in drug resistance
(Figure 4, 5). For example, in Patient 1 (Figure 4a) isolate 6 is trisomic for chromosome 3,
isolate 8 is trisomic for chromosome 6, and isolate 13 is a triploid with disomies in chromosomes
4, 6, and 7 (Figure 4a). All of these changes are transient, and only isolate 13 corresponds to a
gain in MIC. Some of the variants do recur (transiently) in other strains, most notably a
chromosome 5 trisomy (in patient 1, 15, 16, 30, 42, and 43, Figures 4a and 5d-h). However,
these changes do not correspond to a consistent change in resistance. Thus, we concluded that
most ploidy changes are likely not related to drug resistance in these strains.
Common LOH events that persist generally associated with changes in drug resistance
Conversely, we found LOH changes in almost all (9/10) series, which are often
persistent, recurrent and associated with increased drug resistance (Figure 4, 5) and are copy-
neutral. For example, there are four LOH events in Patient 1, three of which are persistent and
corresponding to an increase in MIC (isolate 3, right arm of chromosome 3; isolate 13, left arm
of chromosome 5, and isolate 16, the left arm of chromosome 5, Figure 4a). Two of these events
also recur in additional time courses, persistently and/or consistent with increase in MIC: an
LOH in the right arm of chromosome 3 in Patients 9, 14, 16, 30, and 59 (Figures 4a,b, and 5b,c)
and an LOH in the left arm of chromosome 5 in Patients 14, 15, 16, and 43 (Figures 4a, and 5c,
h). In another example, we found a persistent LOH in the right arm of chromosome 1 in Patient
59 (Figure 4b) and Patient 9 (Figure 5b), corresponding to a change in MIC. (A similar ChrlR
LOH in Patient 30 did not however associate with a significant difference in MIC (Figure 5f)).
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Figure 4. Genome level variations: persistence and transience
Persistent and transient LOHs and highlighted trisomies are visible. Patient 1 (a), has four LOH
events, 1 transient (isolate 2, chromosome R, red), and three persisent LOHs (isolate 3,
chromosome 3; isolate 13, chromosome 5; and isolate 16, chromosome 5, blue). Each of these
LOH events co-occurs with an increase in the MIC phenotype (grayscale boxes at right). Some
of these changes are recurrent, as Patient 59 (b) shows LOH on the right arm of chromosome 3
as well (isolate 4639, blue). Patient 59 also has a persistent LOH on the right arm of
chromosome 1 (isolate 4617, blue). Again, each of these LOH events co-occurs with an increase
in MIC. Recurrences of LOH in chromosome 1 (Supplemental Figure 2(b)) and right arm of
chromosome 3 (Supplemental Figure 2(b, c, e, f)) are also observed. While many LOH events
appear to be persistent, we see ploidy variants (green) in Patient 1, isolates 6, 8 and 13; none of
which are persistent.
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Figure 5. Persistent and transient large-scale genoe variations
As in figure 4, the remaining 8 patient series are displayed with transient and persistent
LOHs(red and blue, respectively), as well as large trisomies (green). Patients 9, 14, 16 and 30
have persistent LOHs on the right arm of chromosome 3 (b, c, e, f) as did both Patients 1 and 59
(figure 3). Except for patient 30, all of these co-occur with increases in MIC (grayscale, right).
LOH also occurs frequently in the left arm of chromosome 5, as well as chromosome 1. We also
observe i5L in patients 16, isolate 3120(e), and patient 30, isolate 5106 (f), but neither co-occur
with increases in MIC. LOH on chromosome 5 also occurs in high frequency (c, d, h and figure
3a) but this does not always accompany increase in MIC (c).
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LOH events are accompanied by homozygosity changes in genes that are known players in
drug resistance
The persistence and recurrence of LOH events suggest that they have been positively
selected. To identify potential drivers in these regions, we focused on those coding mutations
that switched from one homozygous state in the progenitor to a different homozygous state at the
LOH, and persisted in this evolved state thereafter. There are 26 such mutations from 7 LOH
regions in 7 patients whose progenitor, intermediate(s), and terminal isolate were collected on
separate days (Supplementary Table 2, Table 1). Some of the mutations encode genes that are
key players in drug resistance. For example, there is a non-synonymous homozygous change in
the fluconazole drug target ERG 1 associated with the formation of the persistent LOH on the
left arm of chromosome 5 in Patient 1. In another example, the persistent and recurrent LOH on
the right arm of chromosome 3 in Patient 9 is associated with the appearance of a homozygous
mutation in MRR1, a regulator of MDR1 expression. Other mutations are in genes not
previously related to fluconazole resistance, including telomere function (TEL1 and CAS1), cell
wall biosynthesis (CHS4 and ROT2), autophagy (Orfl9.6020), and mitochondrial function
(orfl9.6790, orfl9.6979, orfl9.6061).
Many genes mutate in these in vivo series, some are under selection, but there is also a clear
signature of drift
In addition to the mutations introduced by LOH, 1,915 genes have persistent non-
synonymous coding SNP mutations in at least one time course, the vast majority of them
(1,805/1,915) corresponding to changes in MIC (Supplementary Table 3). 155 of the 1,805
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genes have persistent non-synonymous SNPs in 3 or more time courses, and are thus stronger
functional candidates (Supplementary Table 3). Notably, we cannot fully rule out the
possibility that some of the recurrently mutated genes are neutral, since the 155 genes are longer
than the other 1,650 persistent genes (mean size: 2.45 ± 1.84kb vs. 1.81 ± 1.24kb, p < 1.9*10-6, t_
test).
Nevertheless, among these 155 recurrently mutated genes are key genes associated with
the drug response (e.g. TACl, DEFI), filamentous growth (e.g. FGR23 and FGR28), biofilm
formation (e.g. SRB8, POL5), and cell wall and adhesion (e.g. IFF4, HWP2, MP65), likely
reflecting the complex selective pressure in the human host. Notably, the drug target Erg 1 is
mutated in 2 time courses in addition to the LOH-coupled event above (Supplementary Table
2): a heterozygous point mutation in Patient 59 and a homozygous mutation in Patient 9.
Interestingly, little is known about many of the most recurrently mutated genes. For
example, seven of the ten most recurrent genes (mutated in at least 5 of 7 patients) are not well-
characterized. These include SRB8, a gene induced early in biofilm formation; orfl9.1606, a
target of PLC 1, an important filamentation factor; and orfl 9.7029, a putative guanine deaminase,
previously implicated in sensitivity to toxic ergosterol analogs[20]. These suggest new genes that
may be implicated not only in drug resistance per se, but more broadly in host adaptation during
Candida infections.
Significant co-occurrence of mutated genes associate with filamentation
The 155 recurrently mutated genes can be partitioned based on the correlation in their
occurrence patterns into four 'co-occurrence clusters' (Figure 6). The correlations we observe
are significantly higher than those expected in a null model (KS test, P< 2.2* 10-126, permutation
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test). Of the clusters, Cluster 4 is significantly enriched for fungal-type cell wall and cell surface
genes (p < 0.006 and p <0.042, respectively, Benjamini-Hochberg corrected).
Additional phenotypes suggest complex adaptive landscapes
Since many of the recurrently mutated genes are known to play a role in biofilm
formation, filamentation and/or adhesion, we reasoned that some of the mutations might reflect
adaptations to the host, possibly independent of the specific selective pressure of the drug. To
explore this possibility, we measured four additional phenotypes for each strain (Methods) -
filamentation, adhesion, and virulence in a worm model of infection (for some strains).
For each phenotype, there are indications of other evolved phenotypes besides drug
resistance, either correlated with or independent of change in MIC. First, MIC increases are
typically accompanied by a decrease in fitness in the absence of drug (patient 1, isolates 2-4, 13,
15 and 16, Patients 9, 14, 15 16, and 59, Figure 7), often followed by a subsequent increase in
fitness without further changes in MIC (e.g., patient 1, isolates 5-7, Fig. 7). This trajectory is
consistent with previous observations in bacteria[21] that drug resistance initially confers a
fitness cost in the absence of the drug, which is restored by subsequent compensatory mutations.
In several cases, the decrease in fitness may stem from concomitant aneuploidies, known to
confer proliferative disadvantage[22] (e.g. Figure 4a, isolate 13 and Figure 7, Patient 1),
mark). Conversely, loss of trisomies that pre-existed in the progenitor is associated with increase
in fitness in Patient 43 (Figure 5h and Figure 7). Second, some fitness increases occur
independently of drug selection or ploidy changes (e.g. Patient 1 isolates 12 and 15, Patient 59
isolate 2, Patient 43 isolate 2), and may reflect host adaptations. Finally, four of the time courses
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showed a consistent increase in filamentation with time (Supplementary Table 5), and three
show increased adhesion. All are accompanied by an in vitro fitness increase (without ploidy
changes), and some by a change in MIC.
For example, in Patient 59, there are persistent non-synonymous substitutions in the
hyphal genes UEC 1 and VAC8 in the intermediate isolate (4617), and mutations in the hyphal
genes RSV162, PST1 and OP4 in the terminal isolate (4639), corresponding to the gradual
increase in filamentation in these isolates, compared to the progenitor. These phenotypic
changes are also reflected by changes in adhesion and with decrease in survival in a C. elegans
survival assay (p<0.01, Methods), suggesting a role for these mutations in pathogenesis in vivo,
independent of drug resistance. We cannot rule out that these changes are independent or in
parallel.
Discussion
In conclusion, our genomic sequencing and analysis of C. albicans clinical series yields
novel insights into the evolution of drug resistance and host adaptation in vivo. By comparing
'consecutive' strains from one patient, we confidently exclude non-clonal samples, and identify
persistent mutations; by comparing mutations between series, we identify recurrent events.
Combining these two approaches, and associating mutations with relevant phenotypes, such as
MIC, we show that LOH is a common event, that likely sweeps through a population and recurs
across populations. Notably, some of the recurrent LOH events we find may have been difficult
to detect on SNP arrays, due to the relative paucity of SNPs in those regions in the reference
strain, SC5413, itself a clinical isolate. Furthermore, we find a substantial number of persistent
mutations that recur between patients and implicate genes from a broad range of processes,
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suggesting that some of the observed mutations are likely a result of additional complex selective
pressures in the host. Consistently, we show that the strains have evolved additional phenotypes
based on fitness, filamentation, adhesion and virulence assays. Finally, our data and, provide a
rich resource for other Candida researchers and a host of candidates for further functional
studies.
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Materials and Methods
Strains
Strains were isolated from HIV-infected patients with oropharyngeal candidiasis, as previously
described[18, 19]. The patients were not on azole anti-fungal treatment at time of enrollment;
subsequent samples were collected during recurrence of infection. The strains and are detailed in
Table 1.
Drug susceptibility
Minimal inhibitory concentrations (MIC) were determined for each strain using fluconazole E-
test strips (0.016-256 pg/ml, Biomerieux) on RPMI 1640-agar plates (Remel). Overnight YPD
cultures were diluted in sterile 0.85% NaCl to an OD600 of 0.01 and 250 uL was plated using
beads. After a 30-minute pre-incubation, 2-3 E-test strips were applied and plates were incubated
at 35*C for 48 hours. The susceptibility endpoint was read at the first growth-inhibition ellipse,
and the median value is reported here.
Illumina sequencing
Genomic DNA was prepared from different clinical time courses via a Qiagen Maxiprep kit and
sequenced using 76bp paired-end Illumina sequencing[23]. Library preparation included
barcoding with an 8 base barcode[24] for 43 samples from 11 patients sequenced in pooled
samples. Read sizes after removal of barcodes are 68 bp. All reads were mapped to the SC5314
reference genome (Candida Genome Database, gff downloaded on January 4, 2010) using the
BWA alignment tool[25]; the reads were indel-realigned using GATK[26]. Coverage for each
86
strain is reported in Table 1. Coverage was defined as the total number of bases with mapping
quality greater than 10 divided by the total number of sites in the nuclear genome.
SNP identification and clonality testing
SNP calling was performed with GATK[26] with the SC5314 alignment used as a reference
sequence. After removing non-clonal strains (below), SNP calls were performed again for the
remaining clonal isolates in each time course and unreliable SNPs were removed in each time
series based on: (1) the RMS of mapping quality (removing SNPs that were 2 standard
deviations below the mean); (2) depth of coverage (removing SNPs with coverage that was two
standard deviations above the mean); and (3) quality-by-depth (removing SNPs with a QD less
than 5).
Determination of clonality
All (unfiltered) multi-sample SNP calls relative to SC5314 were used to construct a
distance matrix between every pair of isolates within each time course and between every isolate
and SC5314. Two different homozygous genotypes counted as a distance of 1.0, a heterozygous
and homozygous genotype as 0.5. We then used neighbor-joining (as implemented in
PHYLIP[27]), a bottom-up clustering method, to construct a phylogenetic tree for each time
course, and rooted it with SC5314 as an outgroup. We define isolates with a branch distance of
greater than 22,000 as non-clonal.
Copy-number determination
For each strain, we calculated a per-locus depth-of-coverage using GATK[26], with a
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minimal mapping quality of 10. The number of reads aligning to each 5 kb window across the
nuclear genome was calculated and then normalized to the genome median. Each bin was then
multiplied to the ploidy for the majority of the genome as determined by FACS assay (below).
We then applied a sliding window across each bin, defining a potential CNV if 70% of 10
consecutive bins had a normalized count > 2.5x. Regional/chromosome copy-number variants
(e.g. trisomy) are identified if > 15% of the chromosome is identified as having a CNV.
Boundaries are confirmed by visual inspection in the Integrative Genome Viewer[28].
High-resolution ploidy analysis by flow cytometry
C. albicans were grown to log phase. 200pl of culture was centrifuged in a round bottom
microtiter plate and pellets were resuspended in 20pl of 50mM Tris pH8 / 50mM EDTA (50/50
TE). 180ptl of 95% ethanol was added and suspensions were stored overnight at 4*C. Cells were
centrifuged and pellets washed twice with 200ptl of 50/50 TE, then resuspended in 50pl of
RNAse A at lmg/ml in 50/50TE and incubated 1 hour at 37*C. Cells were centrifuged and
pellets resuspended in 50pl of Proteinase K at 5mg/ml in 50/50 TE for 30 minutes at 37*C. Cells
were washed in 50/50 TE and pellets resuspended in 50pl of a 1:85 dilution SYBR Green I
(Invitrogen, Carlsbad, CA) in 50/50 TE and incubated overnight in the dark at 4*C. Cells were
centrifuged and pellets were resuspended in 700pl 50/50 TE and read on a FACScaliber flow
cytometer (BD Biosciences, San Jose, CA). Flow data was fitted with a multi-Gaussian cell
cycle model to produce estimates for whole genome ploidy.
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LOH Determination
For each time course, we assembled the high quality SNPs (post-filtering, above) from multi-
sample calling into the columns of a matrix, ordered by genome position, with the isolates in
rows, ordered temporally. The genetic state of each locus in each sample was coded to
distinguish loci homozygous for the haploid reference (-1), heterozygous SNPs (0), and
homozygous SNPs for the non-reference state (1). We then applied a sliding window method
across each chromosome, only looking at sites in which a SNP call was made in at least one
isolate. An LOH event was defined as occurring if (1) at least one isolate had a heterozygosity
content > 40%, and (2) at least one other isolate had a heterozygosity content < 5%. Window
sizes were of length 500. Boundaries were trimmed such that if a window terminated in a
heterozygous site in the isolate for which the LOH occurred, it was trimmed back until it was
homozygous. If two 500+ windows were within 7 KB of each, the region was assessed to
determine if the event was actually one event and merged if the heteryzgous sites in the inter-
window space had homozygosed. If two isolates had LOHs that overlapped but did not have
precisely identical boundaries, the LOH regions were combined such that the LOH interval for
both isolates was the same. All LOH regions were confirmed by visual inspection and are listed
in Supplementary Table 1.
Classification of SNPs
For each time course, each SNP was classified for its position in the genome (Supplementary
Table 1). If the SNP fell within an ORF, the reference and altered SNPs were reported. If the
SNP fell outside of an ORF, the distance to the closest flanking ORFs was reported, as well as
the SNP's orientation with respect to these ORFs. SNP genotypes that are common to all
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isolates (including the 'progenitor') were classified as background mutations. Genotypes not
present in the progenitor or evolved strain, but that occur in one or more intermediate strain were
classified as transient. Finally, genotypes that occur after the progenitor, and persist through the
terminally evolved time point, are classified as persistent.
Analysis of co-occurring mutations
For co-occurrence analysis we focused only on these that (1) had persistent non-synonymous
coding SNPs that did not occur in LOH regions; (2) recurred in three or more time courses (two
or more, in the case of filamentation); and (3) where the mutation emerged (became persistent) at
the same time as a change in the relevant phenotype (MIC, filamentation, etc). We generated for
each such gene a binary patient vector, and created a gene-by-gene Pearson correlation matrix.
We used NMF[29] clustering to identify the optimal number of clusters, based on local maximas.
We then tested each of the co-occurrence gene clusters for functional enrichment (below). To
determine if the degree of co-occurrence would have arisen by chance, we ran 1,000 iterations of
one million edge-pair swaps from the original binary matrix, calculating a Pearson correlation
matrix for each of the 1,000 iterations. We compared the distribution of Pearson correlations on
the real and permuted vectors using a two-sample Kolmogorov-Smirnov (KS) test.
Functional enrichment
We calculated the overlap of each co-occurring cluster with Gene Ontology gene sets
(downloaded from Candida Genome Database on March 22, 2010) and estimated the
significance of the overlap using a hypergeometric test as previously described[30]. Nominal,
Benjamini-Hochberg adjusted, and Bonferronni adjusted P-values are reported (Supplementary
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Table 4).
Competition assay to assess fitness
We measured the relative fitness of the progenitor and evolved lines in RPMI medium,
competing them against a reference strain, expressing ENO 1::YFP. Strains stored at -80 0C were
revived on rich media petri plates and then grown overnight in 3 ml cultures of minimal media in
a roller drum at 35 *C. An aliquot of cells in each culture was removed, sonicated in a Branson
450 sonifier, and the concentration of cells was determined using a Cellometer M1O
(Nexelocom). The reference strain and experimental competitors were added to fresh RPMI
medium in a 1:1 ratio and a final cell concentration of 1 x 107 cells/ml. The cultures were grown
for 24 hours in a roller drum at 35 *C. Cells were then counted as above, and 3 x 106 cells were
transferred to fresh RPMI medium grown for 24 hours in a roller drum at 35 *C (transfer cycle
1). This procedure was repeated (transfer cycle 2). This protocol represents 5-10 generations of
growth, depending on the strain genotype. The ratio of the two competitors was quantified at the
initial and final time points by flow cytometry (Accuri). Three to six independent replicates for
each fitness measurement were performed. The selective advantage, s, or disadvantage of the
In( E ( )-in
evolved population was calculated as s = ' , where E and R are the numbers of
T
evolved and reference cells in the final (/) and initial (i) populations, and T is the number of
generations that reference cells have proliferated during the competition.
C. elegans survival assay
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A C. elegans survival assay was performed as previously described[3 1]. Briefly, E. coli OP50
and the different C. albicans clinical isolates were grown overnight respectively in LB at 37*C
and YPD at 30*C. E. coli was then centrifuged and resuspended to a final concentration of 200
mg/mi while C. albicans isolates were diluted with sterile water to OD60o=3. Small petri dishes
(3.5 cm) containing NGM agar were spotted with a mixture of 10 ml streptomycin (stock
solution 50 mg/ml), 2.5 ml of E. coli, 0.5 ml of C. albicans and 7 ml of sterile water. The plates
were incubated overnight at 25*C and 20 young synchronized N2 C. elegans adults were
transferred on the spotted plates. Synchronous populations of adult worms were obtained by
plating eggs on NGM plates seeded with E. coli OP50 at 20*C for 2-3 days. In this time frame,
the eggs hatch and the larvae reach young adulthood. The survival assay was carried at 20*C and
worms were scored daily by gentle prodding with a platinum wire; dead worms were discarded
while live ones were transferred to seeded plates grown overnight at 25*C. Worms accidentally
killed while transferring or found dead on the edges of the plates were censored. Statistical
analysis was performed using SPSS software; survival curves were obtained using the Kaplan-
Meier method and p-values by using the log-rank test.
Filamentation assay
Overnight cultures grown in YPD at 30*C were normalized to OD60o=l with sterile water and
spotted on Spider agar media (1% mannitol, 1% Difco nutrient broth, 0.2% K2HPO4). Plates
were incubated at 37 *C and colonies photographed 3, 7 and 10 days post spotting. As a negative
control for filamentation cphl/cphl efgl/efgl [32] double mutant strain was used in this study.
Filamentation was scored by observing the edge of each colony and assigning a score out of 7
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with 1 corresponding to non-filamentous, 7 corresponding to hyper filamentous, and 2-6
corresponding to intermediate filamentation phenotypes.
In vitro adhesion assay
The In vitro adhesion assay was performed as previously described for S. cerevisiae[33]. Briefly,
cultures were grown in Synthetic Complete (SC) media + 0.15% glucose at 30*C overnight.
Cells were then centrifuged at maximal speed and resuspended to OD6oo=0.5 in fresh media. 200
ml of each culture were dispensed into 8 wells of a flat bottom 96-well plate and incubated at
37*C for 4 hours. The content of the plate was then decanted and 50 ml of crystal violet added to
each well. After 45 minutes of incubation at room temperature, the content of the plate was
decanted and the plate was rinsed ten times in DI water by alternate submerging and decanting.
200 ml of 75% methanol was added to each well and absorbance was measured after 30 minutes
at OD59o. An edt1/edt] knockout mutant[34] was used as a negative control for adhesion.
Supplemental data
Supplemental tables can be found in Appendix 2.
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Chapter 3: Methods for Massively Parallel DNA Sequence Analysis
97
98
Introduction
The recent development of massively parallel sequencing technology has enabled new
areas of inquiry never before possible. However, the innovation and progression of massively
parallel sequencing comes with new challenges in areas including sequence quality scoring,
alignment assembly, as well as variant discovery and annotation[ 1].
Quality scoring is determined in a chemistry/platform-specific manner (usually in real-
time by the sequencer); integration of raw sequence quality affects both alignment and variant
detection. Mapping quality scores, a related concept to raw base quality scores, assess how well a
read is aligned to a reference genome. This score integrates raw base quality and is also used for
variant detection. While these metrics are invaluable for both alignment assembly and variant
discovery re-alignment has been shown to be a necessary step for improved variant detection[2].
As many of these tools have been designed to integrate existing human datasets, I demonstrate
here how we integrate these approaches for non-human applications.
Aligning short reads to a genome is a non-trivial problem and initially was a bottleneck
for analysis[3]. Challenges pertaining to alignment include the large number of reads and the
short read size. Not unique to short-read alignment are difficulties with aligning repetitive
sequence elements. The most successful approaches are hashing methods, as I describe below.
These methods integrate raw base quality scores and provide similar quality scoring describing
the read's alignment.
Ultimately, the goal for re-sequencing is to relate newly discovered genomic variants and
to characterize them or relate them to phenotype. There are many different types of variants that
are of interest; in this chapter I describe how we identify and annotate single nucleotide
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polymorphisms (SNPs) and integrate SNP data to identify regions with loss of heterozygosity
(LOH). I also describe how we identify large regions with copy-number variations (CNVs).
SNP discovery is at the core of both Chapters 1 and 2, and is an essential goal for re-
sequencing. Many methods exist for SNP calling from NGS data, though some are platform
specific[4] or are parameterized for a specific organism[5]. An additional challenge is the need
for filtration of likely false positives, which can be achieved by PCR validation, a cross-
validation method[6], use of contextual statistical annotation, or both. Once a SNP is identified,
it can be annotated based on the genomic feature it impacts. SNP identification can also be used
to determine the presence of LOH events, which are of particular significance in Chapter 2.
As a function of coverage, CNVs are discernable from DNA NGS data even before
reliable SNP calls. Many methods exist to determine boundaries for CNVs, often coupling
analysis to structure variants, such as inversions and translocations[7-9]. Other methods focus
largely on coverage[ 10], but because of the repetitive nature of larger genomes, the experimental
design sought out by particular studies (e.g. tumor-normal comparisons), or the cost of
sufficiently high coverage of large genomes, this approach tends to be less favorable. Given that
the genome size of our target genomes spanned from 12-14 megabases, we routinely achieve
-20x coverage. As such, I implement a coverage-based method.
In this chapter, I detail the NGS analytical pipeline (Figure 1) that I developed and used
in Chapters 1 and 2. I use existing tools when they are appropriate for a particular task, such as
aligners, re-aligners and variant detectors. When tools already exist but are designed for a
particular organism, I re-parameterize them, such as for SNP calling in non-human organisms.
In cases where few tools exist (or none existed at the initiation of this research), such as rapid
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Figure 1. Overview of analytical pipeline
An NGS method gives rise to DNA sequence data. The short reads are aligned to a reference
genome (via MAQ or BWA). Small indels bias read alignment via local mismatching, so they
are removed via local re-alignment. Upon re-alignment, large and small variant detection
commences. Then, SNPs are called (MAQ/Samtools as in Chapter 1, or GATK as in Chapter 2)
while CNVs and larger structural variations are assessed via multiple methods. SNP calling
requires additional filtration for non-haploid organisms. SNPs can be annotated by their changes
to resultant proteins, changes in codon frequency, or effects to promoter binding sites. Regions
for LOH determination can be rapidly classified.
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Cluster computing parallelizes much of this pipeline;
most samples are analyzed concurrently
localization and classification of SNPs, I devise an algorithm that is generalizable to any
sequenced and annotated genome.
Alignment and Re-alignment
There are many ways with which NGS short-reads can be aligned to a reference genome.
The method in Chapter 1 is MAQ[ 11], an early approach for short read alignment, and the
method in Chapter 2 is BWA[12], a faster but comparably accurate method. Alignment
methodology is typically not organism-specific, and as such, these algorithms were run with
default parameters.
phred scores
phred is a standard method to score each base in a read[13, 14], on which early variant
detection was predicated. Often referred to as the "quality" score for a base, it is defined as
Q = -10 log10 P, where Q is the quality score, and P is the probability of error for that base call.
The way this error probability is defined depends on the technological platform from which the
sequence data is generated, but in brief, it relates to a signal-to-noise ratio. Even as NGS
technology has matured, phred scaled quality scores for bases are required for both
alignment[ 11, 12, 15] and variant detection methodologies[2, 5, 16, 17]. For early variant
detection, putative hits were assigned a probabilistic score (e.g. via a Bayesian approach) and/or
followed up with PCR validation.
MAQ
MAQ[ 1] maps short DNA sequence reads to a reference genome and identifies short
insertions and deletions (indels) and SNPs. MAQ assesses each read's ungapped alignment to
the reference genome via a hashing method. Each read will have a mismatch score, defined as
102
the sum of qualities at mismatching bases. MAQ selects the minimal mismatch score. Because
of the errors in base calling from the sequencer itself, mismatched bases with a high quality score
penalize an alignment more than those with low base quality. To evaluate the reliability of
alignments, MAQ assigns each individual alignment a phred-scaled quality (mapping quality)
score to determine the probability that the true alignment is not the one found by MAQ. Reads
that can be mapped to multiple loci with equally high mapping quality will be assigned at
random to any of those loci, but will be assigned a mapping quality of zero. This will allow for
subsequent analysis to filter out any contribution from those reads towards genotyping, as their
actual location is unknown. We do not discard them outright since those reads may contribute to
an estimate of overall copy number of a repetitive sequence.
BWA
The Burrows-Wheeler Aligner, or BWA[12] is based on a Burrows-Wheeler
transform[18], which is a "backward search". This method relies on hashing the genome instead
of the reads, as was the process in MAQ. The benefits to this approach are (1) the complexity of
read mapping to the genome is a function of the read's size, not the genome's size, (2) the
algorithm has a relatively small memory footprint and thus (3) the time to complete alignment is
greatly improved over other methods. This method performs a gapped alignment for single-end
reads. For paired-end reads, gapped alignments are conducted on each mate independently. A
read will potentially map to a position if the total number of differences (both mismatches and
gaps) is less than a threshold k. This threshold defaults to having fewer than 4% difference of a
read of length I assuming a 2% uniform base error. For paired-end reads, there is an additional
step in alignment: for a given read, good hits are sorted by their chromosomal coordinates and
then a linear scan is conducted for the best mapped pairing of both reads. Once mapped, reads
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are assigned a mapping quality that integrates mismatching data as described in MAQ, with an
added caveat that it is assumed that a true hit can always be found (MAQ does not assume this,
and as a result it underestimates mapping quality). BWA does not come with an associated
variant caller. For Chapter 2 we use BWA with default parameters for paired-end alignment.
Re-alignment
Because of the degree of divergence between a reference genome and a re-sequenced
genome, alignment artifacts are likely to exist. First, small indels may erroneously appear as
many mismatching bases, which are then mistaken as SNPs. Additionally, each read is mapped
independently, and thus it is not possible to minimize mismatches across an alignment, as that
requires insight gleaned from all reads. Furthermore, even when indels are properly identified in
the interior of a read during the initial alignment, gap insertion penalties prevent gapped
alignment toward the beginning or end of a read. To address these issues, we used the local
realignment tool in the GATK package[5], which serves to transform regions with misalignments
due to indels into clean reads containing a consensus indel suitable for standard variant discovery
approaches. This tool is run in two phases, Realigner Target Creator and Indel Realigner. The
Realigner Target Creater can integrate regions with known indels, or it can be run naively. In the
realignment step, Indel Realigner is used with the intervals specified from the Target Creator.
Following local realignment, the GATK Unified Genotyper identifies variations including indels
and SNPs[2], and CNV determination can occur independently. In chapter 1 the progenitor and
evolved strains are highly related to the reference Saccharomyces cerevisiae strain, S288C.
Given this relatedness and the strain's haploid chromosome complement, we did not pursue a re-
alignment step. However, in Chapter 2, a large degree of heterogeneity is observed between the
clinically isolated samples of C. albicans and the reference genome SC5314. Thus, in Chapter 2,
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we run the Target Creator without specifying known variation and let the algorithm determine
suspect intervals before using the Indel Realigner.
SNP Calling
The uncertainty associated with individual bases affects not only alignment, as described
above, but also genotyping, and SNP calling in particular[19]. This uncertainty influences all
downstream analysis, as alignment and errors in base calling affect the ability to infer genotypes.
MAQ's internal SNP caller produces a consensus genotype inferred from a Bayesian
statistical model. Each consensus genotype is associated with a phred score of the probability of
error. Potential SNPs are detected by comparing the consensus sequence to the reference
genome. In Chapter 1, there is no ambiguity regarding the clonality of the progenitor or evolved
samples. Thus, SNP filtration consists of identifying strain-specific, coding, non-synonymous
SNPs, confirming them via PCR, and upon validation, characterizing them for their contributions
phenotypically.
GATK's Unified Genotyper[2] integrates data from one or multiple samples. It uses a
Bayesian genotype likelihood model to simultaneously estimate the most likely genotypes and
allele frequency in a population of samples. For each locus for which a variant occurs in at least
one sample, there is an emitted posterior probability of there being a segregating variant allele.
The resulting variant detection is accompanied by a phred-scaled confidence value.
Clonality Detection
Clonality determination is made in a time-course dependent manner, in which clinical
isolates from a given patient are genotyped together versus a sequenced version of the reference
strain, SC5314. A distance matrix is calculated using all varying loci, where a difference in
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genotype between a homozygous genotype and a heterozygous genotype is scored with a
distance of %2, and two different homozygous genotypes is scored with a distance of 1. The
neighbor-joining method, as implemented in Phylip[20], is applied to each distance matrix for
tree construction to determine distance of all time series isolates, with rooting using SC5314 as
an outgroup. A distance of 22,000 is defined as being non-clonal.
Filtering SNPs
Upon removal of non-clonal isolates and the reference strain, we re-genotype the time
series data using the Unified Genotyper. To reduce the number of false-positives, we rely on
contextual annotations provided by GATK:
" QD: quality-by-depth, which is the variant confidence divided by the unfiltered depth,
e MQ: root mean square of the mapping quality of reads across all samples at that locus,
* DP: depth of coverage,
e FS: the phred-scaled value of the p-value of a Fisher's Exact Test for strand bias (i.e. a
variant is observed only on reads oriented in one direction, and not the reverse
complement), and
* HS: the consistency of the site with two, and only two, segregating haplotypes.
In human sequencing, these measures are used for filteration in combination with dbSNP /
HapMap data using GATK's Variant Quality Score Recalibator (VQSR). Because a HapMap
dataset is not available in C. albicans, we adhere as closely as we can to "best principles"
established by the GATK team. For QD, we filter all SNPs with a score less than five. For MQ,
we remove all variations with a score less than two standard deviations below the mean. For DP,
FS, and HS, we remove all reads with a score two standard deviations above the mean (Figure 2).
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Figure 2: SNPs that are likely to be false positives are filtered from subsequent analysis
SNP filtration criteria are determined dynamically from the multiple-sample SNP variant callfile
(VCF) files. These data include a quality score as well as many statistical contextual
annotations. Because of a lack of HapMap, SNPs are filtered by single parameters: (A) DP >
PDP +2 (YDP, (B) FS > pFS +20 FS, (C)MQ < pMQ- 2 cMQ, (D) HS > pHs +2aas and (E) QD < 5.
Regions highlighted in yellow ovals (A-D) or highlighted in red (E) indicate filtration removed
those SNP calls.
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Classification of Mutations
Many variations are typically observed between an isolate's DNA and the reference
genome. It is therefore important to have a method with which to classify these variations. Few
tools have been generalized to classify mutations in any organism[21-23] and none existed at the
beginning of this work. I therefore developed a method that is broadly applicable, and takes as
input a genome annotation file (e.g. GFF, BED) and its corresponding sequence. I then use
these data to construct a serialized data structure that supports rapid searching. My
implementation requires two phases: indexing and then searching.
Indexing is a common procedure; in brief, it consists of parsing a file and hashing keys to
descriptive information. In this case, an annotation file is parsed for exon data. Each exon is
keyed first by its chromosome and then by its start coordinate on the Watson strand (Figure 3a).
The second table then maps to the exon's gene information. The nested approach reduces search
complexity. Once parsed, the file is serialized, thus serving as a single time investment.
Searching/annotating a variant is made much easier with the described indexing structure.
Searching consists of using a variant's chromosome name to retrieve the chromosome-specific
hash-table. The start coordinates for all exons are sorted, and a binary search is conducted
(figure 3b)[24]. If the variant's coordinate precedes the query exon's start coordinate, the search
fails. If the variant's coordinate exceeds the query exon's start coordinate, then the variant's
coordinate is compared to the stop coordinate for the exon. If the stop coordinate is greater than
the variant's coordinate, then the variant is mapped. If not, the search fails. Each failed search
reduces the search space by half until the search converges. If the variant remains unmapped, the
nearest two exons and their distances to the variant are reported.
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Figure 3. Design and use of an efficient genome annotation data structure
(A) A nested-hash table is constructed from parsing a genome-specific annotation file. The first
key is the chromosome's name/number and the second is the exon's start coordinate relative to
the Watson strand. The second hash entry maps to the exon's end coordinate as well as other
descriptive data. Once the structure is populated, it is serialized for subsequent use.
(B) Mapping is determined via a binary search. A variation's chromosome and coordinate (pink)
are tested against the nested hash (yellow, with comparison in orange). Failed mapping reduces
the search space by half until either mapping the variation within an exon is successful (top), or
convergence of search space occurs (bottom), implying that the variation is flanked by exons.
Boundary conditions are tested prior to searching.
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Downstream analysis is modular and supports many different avenues of investigation.
For example, in both Chapters 1 and 2, mutations occurring within an exon allowed for
comparison of reference amino acid sequence and variant-adjusted amino acid sequence.
Copy-Number Variation
CNV detection as implemented here occurs in two phases. The first involves depth
determination for all loci in the genome. We accomplish this by using a depth-of-coverage
walker that is part of the standard implementation of GATK[5]. In brief, this method takes a
SAM or BAM file as input, as well as other optional parameters, and produces a per-locus depth
readout. I use this method with standard parameters, except minimum mapping quality - a
phred-scaled metric that assesses the quality of a read alignment - for which I used a parameter
of 10, which corresponds to at most a 10% error. This threshold is used because it eliminates
any contributions from non-uniquely aligned reads but is not overly conservative (the default
setting includes all aligned reads).
The second step is a binning method. The user can pre-select a window size; for this
work, a window size of 5kb. The per-locus depth computed in the previous step is then counted
for all intervals of the window size across the nuclear genome (Figure 4a). Each window is then
normalized to the median count across all windows, and multiplied by the ploidy of the.organism
(Figure 4b). This number can either be determined in advance through methods such as FACS,
or can be left as 1 and corrected as necessary. I then use a sliding window method to go through
each normalized bin, defining a potential CNV if 70% of 10 consecutive bins had a normalized
count > 2.5x. Regional/chromosome copy-number variants (e.g. trisomy) are identified if >
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Figure 4. Determination and visualization of copy-number variations
Coverage data is broken in to windows of pre-determined size. (A) Base coverage for each
window is determined across the nuclear genome. The median base count across all windows is
used to normalize each window(B). If ploidy is known for the strain, each window can be
multiplied by the ploidy for stoichiometric representation. Different approaches can be used to
determine CNVs. (C) A CNV is shown here in the left arm of chromosome 5, demonstrating the
phenomenon of i5L, or an isochromosome in the left arm of chromosome 5.
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15% of the chromosome is identified as having a CNV. Boundaries are confirmed by visual
inspection in the Integrative Genome Viewer[25] (Figure 4c).
Loss-of-Heterozygosity Determination
For each time course, we assembled the high quality SNPs (post-filtering, above) from multi-
sample calling into the columns of a matrix, ordered by genome position, with the isolates in
rows, ordered temporally. The genetic state of each locus in each sample was coded to
distinguish loci homozygous for the haploid reference (-1), heterozygous SNPs (0), and
homozygous SNPs for the non-reference state (1) (Figure 5a). We then applied a sliding window
method across each chromosome, only looking at sites in which a SNP call was made in at least
one isolate. An LOH event was defined as occurring if (1) at least one isolate had a
heterozygosity content > 40%, and (2) at least one other isolate had a heterozygosity content <
5%. Window sizes were of length 500. Boundaries were trimmed such that if a window
terminated in a heterozygous site in the isolate for which the LOH occurred, it was trimmed back
until it was homozygous. If two 500+ windows were within 7 KB of each, the region was
assessed to determine if the event was actually one event and merged if the heteryzgous sites in
the inter-window space had homozygosed. If two isolates had LOHs that overlapped but did not
have precisely identical boundaries, the LOH regions were combined such that the LOH interval
for both isolates was the same. All LOH regions were confirmed by visual inspection (Figure
5b).
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Figure 5. Visualization and identifying LOH
Genotypes from all positions are mapped relative to a haploid reference genome. Any variation
that is observed in any isolate will cause all isolates to be included for genotyping at that locus.
All variations are mapped to color space (A). A sliding window approach scans intervals of size
500; if one sample shows greater than 40% heterozygosity, while another shows less than 5%,
that window indicates an LOH event. Depicted here is a visual representation of the of a whole
genome time series as described (B). White represents a heterozygous genotype, and blue and
red represent homozygous genotypes, regions that large changes from white to blue or red
demonstrate LOH. Because the sliding window approach is whole genome and agnostic to
previously identified variation, the resolution and boundary detection represent significant
improvements over other methods, such as SNP arrays. The left panel shows the whole genome,
while the right is used highlights LOH discovery in yellow.
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Overview
In the work presented here, we have used massively parallel sequencing to study in vivo
and in vitro evolutionary trajectories in yeast. In the experimentally evolved strain S. cerevisiae,
we identified newly arising adaptive alleles from divergent selection and characterized each for
its contribution toward evolved fitness. In so doing, we identify patterns of convergent evolution
as well as the genetic basis of the first instance of synthetically evolved incipient speciation in
yeast. We then applied a similar approach to in vivo clinical isolates of C. albicans. This
approach yielded insights into: (1) the extent of clonality in serial clinical isolates; (2) mitotic
recombination as a means of increasing the copy-number of adaptive alleles; (3) the
presence/role of genes known to affect drug resistance; and (4) the presence of many previously
uncharacterized genes, implicating them in drug resistance acquisition and host adaptation in a
clinically significant pathogen. Here, I describe work that has followed the general trend of our
research and propose future paths for investigation.
Mechanism of Speciation
Our work in S. cerevisiae identified not only which alleles were newly arising under
conditions of strong selection, but also allowed us to characterize the fitness contributions of
those alleles. With the evolved alleles identified, we were able to show that ecologically
adaptive alleles arising from divergent evolutionary stresses resulted in a DM interaction.
However, at the conclusion of our work, there remained several open questions, the most
important of which is how the evolved alleles of PMA1 and MKT1 result in reduced fitness.
While our work demonstrated the likely transcriptional effects caused by the mutated
MKTl allele, the exact role of PMA1 remained unclear. The emergence of evolved PMA1
118
alleles in both sequenced high-salt evolved strains (S2 and S6) initially suggested that those
alleles could be constitutively active. Hyperosmotic environments affect membrane potential,
and one way to mitigate this stress is via modulating proton pumps. However, given that
mutations in PMAl occurred independently, twice, the likelihood that both would be gain-of-
function mutations was less likely. Perreiras et al. went on to characterize the mutant PMA1
allele both with and without the evolved MKT1 allele[1] and showed: (1) PMA1 is a loss-of-
function mutation and (2) while PMA1 does not alter transcription, the lowered intracellular pH
caused by the evolved PMA1 alleles exacerbates the already low expression of hexose
transporter genes regulated by MKT 1. It is this interaction that delays cell division, thus causing
decreased fitness in hybrids that we demonstrated in Chapter 1.
Our work, and the work that has immediately followed, represents a single pathway by
which incipient speciation occurs. There are many avenues for further work. In the original
work by Dettman et al., there are six strains evolved in high salt conditions (S1-S6) and six
strains evolved under low glucose, minimal conditions (M7-M12)[2]. In that original work, each
pairing (S1XM7, S2XM8, etc.) displayed hybrid inferiority. As a follow up, the rest of the
strains in this set should be sequenced. Further, to determine the extent to which hybrid
incompatibility is a widespread and recurring phenomenon, it would be of great interest to
phenotypically characterize the remaining 30 pairings not tested in the original work (S1XM8,
S1XM9, etc.). With the genomes sequenced and all pairings made and assessed, the degree to
which this theme is commonplace would be addressed. Other avenues for consideration may
include expanding the different selective conditions and determining how large the mutational
landscape can be that can result in DM level interactions. Further, the initial experiment was
conducted in diploids[2] but all subsequent characterization has been in haploids. To further test
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DM interactions in a system more similar to the yeast's biology, genotyping and phenotyping as
done in our work and in follow-up work should be in diploids.
Drug Resistance Evolution
Understanding drug resistance evolution in clinical settings serves two purposes, the first
of which is studying a fundamental question in evolutionary biology. The second purpose is
relating knowledge of evolution of drug resistance and exploiting it in the clinical setting so as to
improve patient outcome. In our work, we note that C. albicans acquires resistance to
fluconazole through many varied mechanisms. We demonstrate that both commonly known and
under-reported mechanisms result in increased levels of resistance. Further, we show a utility in
sequencing, both for its ability to uncover all genetic variation for clinical isolates as well as its
use in clonality determination. Both are essential to meaningful interpretation of results and,
unfortunately, we see that previous work cannot guarantee lineage-relationships, thereby
muddling conclusions. The level of detail of this type of work, and its importance to human
health, is well recognized, as others are applying similar approaches to different diseases[3-6].
Future work can be divided into four categories: (1) further characterization of known mutations,
(2) additional C. albicans sequencing, (3) additional clinical time series sequencing in other
diseases, and (4) identification of negative selection.
Further characterization of known mutations
The work presented in Chapter 2 focuses predominantly on persistent, recurrent, non-
synonymous substitutions to relate to drug resistance as a primary phenotype. While work has
been initiated to characterize these time series isolates with respect to changes in fitness (both
with and without drug), virulence, adhesion, and filamentation, with respect to the same set of
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genes, our approach does not examine effects caused by to noncoding mutations. Also, we
observe changes in genes regulating drug response (e.g. MRRl and TACl), suggesting
transcriptional re-programming in these time series. Thus, the next avenue for investigation
would be to score all persistent, noncoding mutation in promoter regions. By using a PSSM
approach and scanning for changes to transcription factor binding site affinity relative to the
progenitor genotype, predictions for changes in gene regulation are possible. Already, we have
initiated work to profile transcriptional activity in each strain (data not shown). Further
profiling, coupled with recurrent changes to promoters or their binding sites, represents a whole
new avenue by which to understand the dynamics of in vivo drug resistance evolution.
C. albicans sequencing
The greatest obstacle we have in generalizing our conclusions from Chapter 2 is power;
there are two approaches by which we can improve this. The first approach is additional
sequencing of pair-wise sensitive/resistant isolates derived from many individual patients that are
clonally related. While this may strengthen our ability to conclude the importance of LOH on
the right arm of chromosome 3, it comes at the expense of fine-grain resolution of incremental
gains in MIC and which mutations co-occur. Work by Toprak and Veres et al. show that
incremental gains can often occur by similar mutations occurring in the same order[7] in parallel
evolving strains. Thus, it seems that a second approach would be of greater benefit - that is,
sequencing deep time courses from patients. Given the diversity we observe in clonally derived
strains, this approach is of greater priority than many matched pairs for two reasons: (1) The
gain in resolution occurring at both a genotype and phenotype level would be valuable to further
enhance our understanding of drug resistance progression in this pathogen; and (2) the
progression of a phenotype coupled to a dense time series allows for removal of transient
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mutations that can arise under a high mutation rate, thus allowing for greater genotype-
phenotype association. While the field will benefit from either, it seems that the first priority
should be on the acquisition and sequencing of deep, clonally derived time series.
Drug resistance acquisition elucidation via clinical series
While not classically considered within the purview of population genetics, concepts
from this field apply to diseases ranging from bacterial infections to cancer. Fundamentally, for
example, recurrence in cancer is a disease of drug resistance; sub-clones of an initial tumor are
able to escape initial therapy, thus making subsequent treatment with the same chemotherapeutic
protocol as the initial treatment undesirable[8]. Already, some are attempting approaches similar
to what we have described here[5, 6, 9] to identify recurrent changes in patients and make
therapeutic decisions based on sequencing results. This area of research is very fertile and has
applications for diseases requiring on-going treatment.
Identification of negative selection
Our work, as well as that of others, focuses on mutated genes that are mutating as being
causative of the drug resistant evolved phenotype. Targeting and exploiting the newly mutating
genes is a successful strategy[10] but comes with a risk of resistance mutations that will render
therapy inert[ 11]. Unlike diseases such as cancer, however, microbes offer a completely
different avenue for treatment; one where evolution of new resistance is less of a problem. In
our work, nearly one-third of the genome shows persistent mutations. But this is only generated
from seven time courses. If we had more data, the next step would be to identify genes under
negative selection. Genes that are evolutionarily constrained during drug resistant evolution,
especially those lacking human paralogs, are ideal targets for clinical targeting. High-throughput
chemical screening of existing agents, or targeted disruption of these genes via novel synthetic
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compounds represents an ideal, synergistic treatment scheme for high-risk patients with chronic
infections (e.g. HIV patients with recurrent oropharyngeal candidiasis or tuberculosis, etc).
While furthering the study of evolutionary mechanisms is important for clinical development, the
existence of inexpensive massively parallel sequencing will allow for completely new inroads to
treat exogenous causes for disease.
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Appendix 1: Chapter 1 Supplemental Tables
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Tale S1. SNPs and Gene-Cluster Stze Changes im Hapidd Representatves of S2, S, and
Vn
1 45191I-( s-U 4W iaan aAmMve aeu an 
7 646331 C-AM-! GCD2 No efect on fitnm eseted
10 456758 C-A P-H MET3 Cooks auno-gromwt phenotype
(auiotrop) in low glucose
12 560742 C-G Issergenic region 3' No effect an inss detected
to YLR208W and
YLR29C
14 530695-538465 Expanim, ENA], Adaqtive dam1nimant in high salt.
EWA2, EN5 Synrgisic with evolved alele of PA
14 543274 A-G D-G LAP2 No efect on fitnes det*cd
2 464706, G -T, Y- CYC8 Adaptive defainant in high salt
synergstc wilk the 86 evolved alele of
PMAJ
7 481584 A-C, L-W PMAI Adaptive a:anin t in high salt. Cooms
slow growth in YPD and low glucose
7 390007, G-A Noncoding, No efect on Ianss detected
prouner
of TBP2
11 274875, T-A Nonceding, No effect on fitnes detected
of CAB3
12 470406-486202 Conurinn ASP3- No effect on fitness detected
1. ASP3-2, ASP3-3.
ASP3-4
4 1112209 C-A C-F TIM)) No efect ca ftu- *et-t
5 525696 C-G T-I APH) Fitness benefit afbe the dimaxic shift in low
fil -MS phenotype
7 126872 T-G F-V MDS3 Fitness benefit before the MiS ir shif in
low glucose. Evolved allele confers a
spontion deicincy: 10.4% + 0.8 SE
(n=12 m su imen-) vs. 30.1+1.0 SE
(=-50)
12 64832 C-T Q-Q U3I4 No effect on fieness deteced
14 467221 A-G D-G IrT) Fitness benefit after the dauutic shif in low
15 432852 G-A K-K SGTI No effect on fitnes detected
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Table S2. Comprehensive list of SNPs. In blue, SNP verified by Sanger sequencing. In red, SNP
proven false. 0, no SNP detected relative to the reference sequence.
Progenitor S2 S6 M8
Total Reads 23405332 18921232 11650340 9917256
Mapped Reads 17287248 10774490 8202201 7304120
Fracton Reads 73.86% 56.94% 70.40% 73.65%
Coverage 51.861744 45.7915825 34.85935425 31.04251
Chromosome Position Reference Prog base S2 base S6 base M8 base
1 3981 A T T T T
1 3982 T A A A A
1 5244 G A A A A
1 27127 T 0 0 C 0
1 27130 C 0 0 G 0
1 36120 C A A A A
1 36814 A C C C C
1 40231 C G G G G
1 41240 A G G G G
1 41664 T G G G G
1 41700 C A 0 A A
1 41703 C A 0 A A
1 46231 C G G G G
1 46833 G A A A A
1 47821 T A A A A
1 47826 C T T T T
1 48772 T A A A A
1 49904 C A A A A
1 50327 C A A A A
1 55746 A G G G G
1 55954 A T T T T
1 62767 A G G G G
1 70794 C G G G G
1 70874 A G G G G
1 96740 G C C C C
1 97025 A T T T T
1 97026 T A A A A
1 97678 C G G G G
1 97679 C G G G G
1 98350 C G G G G
1 98351 G C C C C
1 99564 T 0 0 0 C
1 99841 A T T T T
1 100399 G C C C C
1 110470 C G G G G
1 110471 G C C C C
1 113702 C G 0 G G
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1 113703 G C 0 C C
1 120442 C G G G G
1 134852 T A A A A
1 134854 G T T T T
1 152189 C A A A A
1 152190 A C C C C
1 167048 G C C C C
1 167551 G C C C C
1 167802 C T T T T
1 172018 A G 0 0 0
1 172041 A 0 G 0 G
1 172042 G 0 0 0 T
1 172432 C 0 T 0 0
1 172434 G 0 C 0 0
1 174173 G C 0 C C
1 174187 C G 0 G G
1 174188 G C 0 C C
1 175378 T C 0 C C
1 178256 G C C C C
1 178647 T 0 0 C 0
1 179683 T A A A A
1 179761 C A A A A
1 193625 A T T T T
1 199804 T G G G G
2 11053 T C C C C
2 11308 A T T T T
2 11309 A T T T T
2 11345 A G G G G
2 11379 A C 0 C C
2 13102 C A A A A
2 13477 G A A A A
2 13492 A T T T T
2 13553 G A A A A
2 13966 C A A A A
2 13982 Gi A A A A
2 15101 T G G G G
2 15332 G C C C C
2 15510 G T T T T
2 15518 A G G .. G
2 15835 T C C C C
2 16380 C T 0 T T
2 16392 A G G G G
2 17455 A C C C C
2 23855 C 0 0 A 0
2 23856 C 0 0 A 0
2 23913 C A 0 A A
2 30009 C 0 0 T T
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2 36312 T A A A A
2 36673 A T T T T
2 38067 C T T T T
2 38210 A T T T T
2 38728 C A A A A
2 38800 C A A A 0
2 38908 G A A A A
2 38917 C T T T T
2 38920 C A A A A
2 42377 C G G G G
2 45495 T A A A A
2 48369 A T T T T
2 55145 A C C C C
2 59751 T C C C C
2 68154 T G G G G
2 68155 G A A A A
2 73450 C G G G G
2 75208 A G G G G
2 89277 G T T T T
2 92679 C A A A A
2 95345 G T T T T
2 113436 G 0 0 0 A
2 114868 G A A A A
2 114870 A G G G G
2 201635 G C C C C
2 210433 A G G G G
2 220413 A G G G G
2 220414 G A A A A
2 237839 G A A A A
2 237892 G A A A A
2 238116 G A A A A
2 238133 G A A A A
2 241359 G A A A A
2 241396 G A A A A
2 245111 T A A A A
2 250039 T G G G G
2 250403 C G G G G
2 254495 G T T T T
2 254532 C A 0 0 A
2 254616 T A A A A
2 315270 C G G G G
2 315271 G C C C C
2 323835 C G G G G
2 323836 G C C C C
2 370774 C T T T T
2 374011 T A A A A
2 375081 C A A A A
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I
2 375272 T A A A A
2 376497 A T T T T
2 385360 C G G G G
2 385361 G C C C C
2 388774 T A A A A
2 388775 T A A A A
2 392557 C G 0 G G
2 392558 G C 0 C C
2 392568 C G 0 G G
2 392569 0 C 0 C C
2 426394 C G 0 G G
2 426396 G C 0 C C
2 432380 T C C C C
2 433377 C G G G G
2 433378 G C C C C
2 437344 A G G G G
2 439496 T G G G G
2 447535 C G G G G
2 447536 G C C C C
2 456359 C T T T T
2 464706 G 0 0 T 0
2 488600 T A A A A
2 488601 C T T T T
2 513365 A G G G G
2 514965 A C C C C
2 514966 C A A A A
2 527099 A G G G G
2 547442 A T T T T
2 625500 T C C C C
2 627421 T G G G 0
2 627486 A T 0 T T
2 627487 T A 0 A A
2 631907 G A A A A
2 631912 G A A A A
2 631936 G A 0 0 0
2 631940 C A 0 A 0
2 631981 A G G G G
2 633139 T A A A A
2 634934 C T T T T
2 635192 A G G G G
2 635247 A G G G G
2 635822 C G G G G
2 636141 A G G G G
2 636306 A T T T 0
2 636309 A G G G 0
2 636336 G A 0 A A
2 636342 G A 0 A A
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2 738454 C A 0 A A
2 739341 A T T T T
2 740291 C G G G G
2 740292 G C C C C
2 743936 G C 0 C C
2 743938 C G 0 G G
2 754908 T C C C C
2 774080 C G G G G
2 774430 C G G G G
2 780541 C A A A A
2 781354 G C C C C
2 786736 C T T T T
2 786737 T C C C C
2 793986 A C C C C
2 793987 C A A A A
2 796707 A G G G G
3 101652 A T T T T
3 101655 T A A A A
3 143129 T C C C C
3 148613 C T 0 0 0
3 152641 G A A A A
3 162275 A G G G G
3 162357 T C C C C
3 162636 T G G G G
3 162690 G A A A A
3 163055 T C C C C
3 250563 A T T T T
3 275421 A G G G G
4 24415 C A A A A
4 27070 C T T T T
4 30786 G A A A A
4 108307 T A A A A
4 119470 G A A A A
4 119564 T A A A A
4 121289 G A A A A
4 130626 T A 0 A A
4 132292 T A A A A
4 277105 C G 0 G G
4 277106 G C 0 C C
4 369164 T G 0 0 0
4 392616 A G G G G
4 396436 G 0 0 0 T
4 396451 T G 0 G G
4 396504 C G G G G
4 864217 A G G G G
4 1063029 C A A A A
4 1112209 C 0 0 0 A
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4 1176396 T 0 0 C C
4 1253390 T C C C C
4 1296177 C G G G G
4 1400867 C T T T T
4 1402298 C T 0 T T
4 1433703 A T 0 T T
4 1457020 C T T T T
4 1491661 G A A A A
4 1491667 G C C C C
4 1516839 T A A 0 0
4 1519599 C G G G G
4 1519663 C G G G G
4 1524960 A 0 0 G 0
5 9168 G T T T T
5 18079 A T T T T
5 48384 T C C C C
5 108806 C A 0 0 0
5 154530 T A A A A
5 232634 C G G G G
5 278525 C G G G G
5 278526 G C C C C
5 305258 G A A A A
5 305828 A G G G G
5 305886 A 0 0 0 C
5 305968 T A A A A
5 308627 C G G G G
5 308984 G T T T T
5 309047 G C C C C
5 352390 A G G G G
5 434284 C T T T T
5 502222 T A A A A
5 517524 T C C C C
5 525696 C 0 0 0 T
6 4827 T A 0 A A
6 48020 A G G G G
6 58032 G A A A A
6 58035 G A A A A
6 66443 C A A A A
6 83382 G A A A A
6 95000 A G G G G
6 95385 C G 0 G G
6 95410 T C 0 C C
6 118584 G A A A A
6 173057 C T T T T
6 191312 T A A A A
6 191388 G T T T T
6 219387 A G G G G
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6 236216 C A A A A
6 241576 A T T T T
6 248160 A T T T T
7 89735 G C C C C
7 89751 T 0 C 0 0
7 95444 A C 0 0 0
7 98172 G A A A A
7 125488 T 0 A 0 0
7 125489 C 0 T 0 0
7 125909 C G G G G
7 125910 G C C C C
7 126872 T 0 0 0 G
7 203957 C A A A A
7 230256 C T T T T
7 275965 C G G G G
7 276384 A T T T T
7 303591 A C C C C
7 384063 C G G G G
7 384064 G C C C C
7 384846 C G 0 G G
7 384847 G C 0 C C
7 386981 C 0 0 0 G
7 386982 G 0 0 0 C
7 390007 G 0 0 A 0
7 397085 C G G G G
7 397086 G C C C C
7 397241 A C 0 C C
7 413366 G C C C C
7 413367 C G G G 0
7 481584 A 0 0 C 0
7 481971 G 0 C 0 0
7 598535 C T T T T
7 607109 T G G G G
7 610095 A G G G G
7 622408 A T T T T
7 630688 C T T T T
7 646331 C 0 A 0 0
7 783805 A C C C C
7 796569 A C C C C
7 796570 C A A A A
7 948219 A T T T T
7 999271 C T T T T
7 999367 A C 0 C C
7 1031948 C A A A A
7 1032373 G A A A A
7 1033108 C T T T T
7 1041870 C T T T T
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7 1042083 A G G G G
7 1042185 A G G G G
7 1042308 A G G G G
7 1042313 A G G G G
7 1042563 G A A A A
8 62687 G A A A A
8 212260 C 0 T 0 0
8 217753 G T T T T
8 240687 G A A A A
8 417057 G A A A A
8 445616 C 0 0 0 G
8 445617 A 0 0 0 C
8 496180 G A A A A
9 203638 A C C C C
9 318692 T A A A A
10 76241 T C C C C
10 81335 T G 0 G G
10 81927 A T T T T
10 84958 G A A A A
10 89005 C A A A A
10 90365 A C 0 C C
10 96057 G C C C C
10 97489 C G G G G
10 99469 C G G G G
10 99767 G C 0 C C
10 99778 G 0 0 C 0
10 99792 A T T T T
10 99793 A T 0 T T
10 102276 C G G G G
10 102610 A C C C C
10 102642 A G G G G
10 102643 A C C C C
10 113842 A A A A
10 123309 T C 0 C C
10 123314 T C 0 C C
10 129111 T C C C C
10 171997 C G G G G
10 171998 G C C C C
10 179434 C G G G G
10 179436 G C C C C
10 204551 G T T 0 T
10 204552 T G G G G
10 205348 C A A A A
10 414288 C G 0 G G
10 414289 G C 0 C C
10 421511 G A 0 A A
10 456758 C 0 A 0 0
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10 625481 G A A A A
10 627368 C T T T T
10 627370 T C C C C
10 627525 C G G G G
10 627526 C G G G G
10 629481 T A A A A
10 664658 G T 0 T T
10 670284 T G G G G
10 676911 G A A A A
10 687983 A G G G G
10 708355 T A A A A
10 708439 A T T T T
10 709355 C T 0 T T
10 713833 C G G G G
10 715086 G 0 0 0 A
10 716150 A T T T T
10 716503 C A A A A
10 717672 C A A A A
10 717776 G A A A A
10 722286 G T 0 T T
10 724285 T G G G G
10 724993 G T T T T
10 727113 C G G G G
11 7131 C G G G G
11 7132 G C C C C
11 69325 T C 0 C C
11 69326 G T 0 T T
11 189366 C G 0 0 0
11 192315 A T T T T
11 192316 T A A A A
11 197105 C G G G G
11 197106 G C C C C
11 199377 A T 0 0 0
11 199378 T A 0 A 0
11 242811 T A A A A
11 253006 A T T T T
11 253007 T A A A A
11 274875 T 0 0 A 0
11 316656 C T T T T
11 335190 C T T T T
11 357929 T C C C C
11 393438 C G G G G
11 393439 G C C C C
11 453012 T A A A A
11 457775 C T T T T
11 463435 G T T T T
11 463468 G T T T T
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I
11 479596 C T T T T
11 509993 C G 0 G G
11 509994 G C 0 C C
11 610650 C G G G G
11 618236 G A A A A
11 618237 A G G G G
11 666408 T 0 0 G G
12 12 A C 0 0 0
12 13 C A 0 0 0
12 5741 T C 0 0 C
12 5757 A T 0 0 T
12 5808 T 0 0 0 C
12 32901 T 0 0 0 G
12 32902 G A 0 0 A
12 64832 C 0 0 0 T
12 185062 G A A A A
12 192416 C T T T T
12 193483 A C C C C
12 210771 A T T T T
12 528751 T A A A A
12 560742 C 0 G 0 0
12 699963 G A A A A
12 725938 G A A A A
12 750224 C T T T T
12 762846 A T T T T
12 767026 T C C C C
12 767027 C T T T T
12 828902 C T T T T
12 1039433 T A A A A
13 34473 T G G G G
13 325904 T A A A A
13 448332 G A 0 A A
13 448333 A G 0 G G
13 672128 T C C C C
13 680935 T C 0 C C
13 680939 C T 0 T T
13 794225 G C 0 C C
13 808976 A T T T T
13 809197 A G G G G
13 851734 G 0 A 0 A
13 851740 G A A A A
13 864682 G T T T T
13 924339 G 0 0 T 0
14 25775 G A A A A
14 132573 T C 0 C C
14 189081 C G 0 G G
14 189082 G C 0 C C
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14 274732 G C C C C
14 276356 A G 0 G G
14 278945 T G G G G
14 290429 T G G G G
14 299120 C G G G G
14 300950 T 0 0 0 A
14 304165 G T T T T
14 306231 C A A A A
14 307728 T G G G G
14 308753 G C C C C
14 315278 T G G G G
14 359024 C T T T T
14 359342 C 0 0 0 T
14 359347 C 0 0 0 T
14 374744 T C C C C
14 374768 A C C C C
14 374810 A C C C C
14 377889 G T T T T
14 383566 A G G G G
14 415073 C 0 T T T
14 415090 C 0 T T T
14 415098 C 0 T T T
14 467221 A 0 0 0 G
14 471769 A G G G G
14 543274 A 0 G 0 0
14 766523 C T T T T
15 35765 G C C C C
15 36013 T A A A A
15 36056 G A A A A
15 36119 G C C C C
15 36149 G A A A A
15 49829 G T T T T
15 49912 A T 0 T T
15 49919 A T 0 T 0
15 49922 T 0 A 0 A
15 49941 G T T T T
15 50001 C T T T T
15 50009 A T T T T
15 50011 C T T T T
15 50069 G T T T T
15 50081 T C C C C
15 50430 G C C C C
15 50431 G C C C C
15 50767 C T T T T
15 52199 C T T T T
15 56036 C G G G G
15 57699 A T T T T
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Table S3 (primary data for Figures 1A and 1C): Fitness of segregants from the S2XP cross
in high salt and low glucose. Shown are the genotypes for all relevant alleles (columns
"Intergenic" to "MET3"), mating type and fitness in low glucose (20h) and high salt for 48
progeny from an S2XP cross as well as for the haploid progenitor (P) and S2 evolved strain,
measured in the same assay. + denotes evolved allele; - denotes ancestral allele.
Strain PMA1- Low High
No. MAT Intergenic ENA 1 LAP2 GCD2 MET3 glucose salt
sce3243 alpha - + - - - + 0.03 1.01
sce3244 a - + + - - - 0.13 1.67
sce3245 a + - + + + - 0.15 1.1
sce3246 alpha + - - + + + 0.04 0.47
sce3247 alpha - - + - - + 0.03 0.89
sce3248 a + - + - + - 0.14 0.95
sce3249 a - + - + + + 0.03 0.53
sce3250 alpha + - - + - - 0.31 0.54
sce3251 alpha - - + - + - 0.23 0.98
sce3252 a + + - + - + 0.04 0.75
sce3253 a - - + - + - 0.2 1
sce3254 alpha + + - + - + 0.04 0.49
sce3255 alpha + - - - + - 0.27 0.42
sce3256 alpha - - + + - + 0.04 0.92
sce3257 a + + - + - + 0.04 0.38
sce3258 a - + + - + - 0.18 1.47
sce3259 alpha + + - - - + 0.04 0.56
sce3260 alpha + - - + - + 0.04 0.39
sce3261 alpha + - - + + + 0.04 0.49
sce3262 alpha - + + + + 0.04 1.55
sce3263 alpha + - + + + - 0.32 0.35
sce3264 alpha + + + + - 0.23 0.87
sce3265 alpha - - + + - - 0.28 0.49
sce3266 alha + + + - + - 0.22 1.44
sce3267 alpha -- + + -- 0.23 0.88
sce3268 alpha + + - + + - 0.27 0.42
sce3269 a + - - - + - 0.35 0.36
sce3270 a + + - + - + 0.04 0.51
sce3271 a - - + + - + 0.04 1
sce3272 alpha - + + - - - 0.22 1.43
sce3273 a + + - + - - 0.28 0.57
sce3274 alpha - - - + - - 0.32 0.37
sce3275 alpha - + - - - + 0.04 0.52
sce3276 a - + + - + + 0.04 1.56
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sce3277 a - - - - - + 0.03 0.35
sce3278 a + - - + + - 0.35 0.36
sce3279 a - - - + + - 0.35 0.35
sce3280 alpha - - + + - + 0.04 0.96
sce3281 alpha - - - - + - 0.25 0.39
sce3282 alpha + + - + - - 0.29 0.52
sce3283 a - + + - + + 0.04 1.74
sce3284 alpha - + - + + - 0.33 0.49
sce3285 alpha + + - + - + 0.04 0.5
sce3286 a + + + - - - 0.27 1.47
sce3287 alpha - - - + - + 0.04 0.45
sce3288 a + + + + + + 0.04 1.52
sce3289 alpha + - - - - + 0.04 0.32
sce3290 alpha - + + + - - 0.3 1.52
P alpha - - - - - - 0.26 0.41
S2 a + + + + + + 0.04 1.8
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Table S4 (primary data for Figures 2B and 2D): Fitness of segregants from the S6XP cross
in high salt. Shown are the genotypes for all relevant alleles, mating type and fitness in high salt
for 48 progeny from an S6XP cross as well as for the haploid progenitor (P) and S6 evolved
strain, measured in the same assay. + denotes evolved allele; - denotes ancestral allele.
Strain No. MAT PMA1-2 CYC8 ASP High Salt
sce4198 alpha - - + 0.35
sce4202 a - - + 0.35
sce4187 a - - + 0.36
sce4l9O alpha - - - 0.36
sce4209 a - - + 0.4
sce4177 a - - - 0.42
sce4216 a - - + 0.44
sce4212 a - - - 0.45
sce4215 a - - - 0.5
sce4183 alpha - - 0.52
sce4220 alpha + - + 0.65
sce4200 alpha + - + 0.69
sce4221 a + - - 0.7
sce4203 a + - + 0.71
sce4211 alpha + - + 0.71
sce4194 a + - + 0.73
sce4179 a + - + 0.75
sce4176 a + - + 0.8
sce4196 a + - - 0.8
sce4174 alpha - + - 0.83
sce4180 a + - - 0.83
sce4189 alpha + - + 0.87
sce4199 a - + - 0.88
sce4182 a + - - 0.88
sce4206 a + - - 0.88
sce4188 alpha - + - 0.89
sce4178 alpha - + + 0.9
sce4191 a - + + 0.9
sce4192 a + - - 0.92
sce4204 alpha - + - 0.92
sce4218 alpha - + + 0.92
sce4197 alpha - + - 0.95
sce4195 alpha - + + 1
sce4207 alpha - + + 1
sce4181 alpha - + - 1.05
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sce4213 a - + - 1.08
sce4219 a - + - 1.1
sce4184 a - + + 1.13
sce4208 alpha + + - 1.3
sce4185 alpha + + + 1.35
sce4210 a + + + 1.38
sce4186 a + + - 1.4
sce4214 alpha + + - 1.45
sce4201 a + + - 1.48
sce4217 alpha + + 1.5
sce4193 alpha + + + 1.75
sce4175 alpha + + + 1.9
sce4205 alpha + + - 1.92
S6 1.48
P 0.45
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Table SS (primary data for Figures 2A and 2B: Fitness of segregants from the M8XP cross
in low glucose 20, 24, and 30 h and in high salt. Shown are the genotypes for all relevant
alleles, mating type, and fitness in each condition for the 48 progeny from an M8XP cross, as
well as for the haploid progenitor (P) and M8 evolved strain, measured in the same assay. +
denotes evolved allele; - denotes ancestral allele.
Strain No. MAT RPH1 MDS3 SGT1 MKT1 TIM11 LG 20h LG 24h LG 30h High Salt
Sce3440 a + - + - - 0.11 0.57 0.85 0.09
Sce3441 alpha - + - - + 0.14 0.53 0.7 0.1
Sce3442 a - - - + - 0.04 0.19 0.59 0.04
Sce3443 alpha + + + + + 0.05 0.6 0.99 0.07
Sce3444 alpha - - - + + 0.04 0.57 1.03 0.04
Sce3445 a + + + - - 0.13 0.52 0.75 0.11
Sce3446 alpha + - - - + 0.1 0.61 0.87 0.12
Sce3447 a - + + + - 0.07 0.4 0.52 0.06
Sce3448 a - + + + + 0.13 0.58 0.98 0.06
Sce3449 a + - - - - 0.1 0.7 1.03 0.09
Sce3450 alpha + + + + - 0.1 0.57 0.84 0.07
Sce3451 alpha - - - - + 0.1 0.62 0.85 0.08
Sce3452 alpha - + - - - 0.14 0.44 0.54 0.1
Sce3453 a + + + - + 0.14 0.64 0.85 0.11
Sce3454 alpha + - - + - 0.05 0.61 0.99 0.04
Sce3455 a - - + + + 0.06 0.33 0.67 0.05
Sce3456 alpha + - - + + 0.05 0.31 0.78 0.04
Sce3457 a + + + - - 0.13 0.54 0.84 0.13
Sce3458 alpha - + + - + 0.12 0.5 0.63 0.11
Sce3459 a - - - + - 0.04 0.39 0.84 0.04
Sce3460 alpha - - - - - 0.13 0.65 0.82 0.1
Sce3461 a + - - + + 0.07 0.65 0.93 0.06
Sce3463 alpha - + - - + 0.16 0.54 0.73 0.11
Sce3464 alpha + - - + + 0.13 0.61 0.98 0.06
Sce3465 a + + - - - 0.13 0.46 0.53 0.1
Sce3466 alpha + + - + - 0.09 0.26 0.42 0.07
Sce3467 a - + + + - 0.11 0.56 0.91 0.08
Sce3468 a - - + + + 0.09 0.76 1.23 0.06
Sce3469 alpha + + + - - 0.16 0.36 0.42 0.1
Sce3470 a + - + - - 0.13 0.75 1.01 0.09
Sce3471 a + - + - - 0.09 0.73 1 0.09
Sce3472 alpha + - + - + 0.1 0.62 0.84 0.09
Sce3473 a - + + + + 0.08 0.45 0.56 0.08
Sce3474 a + + - - - 0.14 0.52 0.72 0.08
Sce3475 a + - + - - 0.1 0.74 0.99 0.09
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Sce3476 alpha
Sce3477
Sce3478
Sce3479
Sce3480
Sce3481
Sce3482
alpha
a
a
alpha
a
a
_+_
_+_
-_
+
+
+
+
+
+
+
+
+
+
+ 0.11 0.69 0.9
+
0.12
0.14
0.14
0.11
0.07
0.07
0.77
0.48
0.44
0.61
0.44
0.36
1.01
0.61
0.5
0.85
0.59
0.44
Sce3483 a + - - - - 0.09 0.69 1.04 0.09
Sce3484 a - + - - + 0.14 0.56 0.76 0.12
Sce3485 alpha + - - - + 0.11 0.64 0.88 0.1
Sce3486 alpha + - + + - 0.09 0.69 1.12 0.07
Sce3487 alpha + - - + + 0.08 0.76 1.02 0.05
P a - - - - - 0.09 0.62 0.82 ND
M8 alpha + + + + + 0.13 0.78 1.35 ND
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0.08
0.08
0.1
0.12
0.09
0.09
0.08
Table S6 (primary data for Supplemental Figures 1A and 1B): Fitness of segregants from
the S2XM8 cross in high salt and low glucose (20h). Shown are the genotypes for all relevant
alleles (columns "Intergenic" to "SGT1"), mating type, and fitness in high salt and low glucose
(20h) for 96 progeny from an S2XM8 cross, as well as for the haploid progenitor (P) , the S2
evolved strain and the M8 evolved strain measured in the same assay. + denotes evolved allele; -
denotes ancestral allele.
Strain LG High
No. Mat Intergenic PMA1 ENA MET3 GCD2 LAP2 MDS3 RPH1 TIM11 MKT1 SGT1 (20h) Salt
sce3343 a + + - - + + - - + - + 0.20 0.52
sce3343 a + + - - + + - - + - + 0.20 0.52
sce3344 a + + - - + - + + - + + 0.10 0.56
sce3345 alpha - - + + - + + - - - - 0.01 0.43
sce3346 alpha - - + + - - - + + + - 0.01 0.13
sce3347 alpha - + - - + + - + + - + 0.17 0.46
sce3348 a - - + + - + + + - - - 0.02 0.42
sce3349 alpha + + - - + - + - + + + 0.15 0.63
sce3350 a + - + + - - - - - + - 0.02 0.19
sce3351 a - + + + + + - + - 0.02 0.22
sce3352 alpha + + - - + + - - + - + 0.18 0.23
sce3353 alpha - - - + - + + - + + 0.02 0.09
sce3354 a + + + - - + - - + - - 0.21 0.82
sce3355 alpha - - + + - + - - - + - 0.02 0.16
sce3356 a + - - + + - + - + + + 0.02 0.28
sce3357 a - + - - + - + - - + 0.16 0.56
sce3358 alpha + + + - - + + + + - - 0.25 0.68
sce3359 a - - - + + - + - + - 0.02 0.06
sce3360 alpha - + + - + - - + + + + 0.07 0.74
sce3361 a + + + - - + + - - - - 0.25 0.87
sce3362 alpha + - - + - + + - + - + 0.02 0.14
sce3363 alpha - + + - + - + - + + - 0.18 1.19
sce3364 a + + - - - + + - - - - 0.16 0.45
sce3365 a - - + - - - + - + + 0.02 0.07
sce3366 alpha - - + + + + - + + - + 0.02 0.42
sce3367 alpha + - + + - + + + + + 0.02 0.30
sce3368 alpha - + + - + - - - + + - 0.10 0.91
sce3369 a + - - + + + + - - - - 0.02 0.20
sce3370 a - + - - - + - + - - + 0.15 0.52
sce3371 alpha - + - - + + + - - - - 0.20 0.64
sce3372 a + + + - - + - + - + + 0.09 0.90
sce3373 alpha + - + + - - - - + + + 0.02 0.16
sce3374 a + - - + + - + + + - - 0.02 0.17
sce3375 a
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- + - + + + - + - - - 0.02 0.45sce3375 a
sce3376 alpha 
- - - + - - - + - + 0.24 0.14
sce3377 alpha + - + - - + + + + + + 0.11 0.18
sce3378 a - + + + - . + - - + - 0.02 1.49
sce3379 alpha + - + - - - - + + + - 0.09 0.14
sce3380 a + - - - + + + - + - + 0.25 0.19
sce3381 a - + + + + - + + - + - 0.02 1.32
sce3382 alpha - + - + - + - - - - + 0.02 6.62
sce3383 alpha + + - - - - + - - + - 6.11 *.6
sce3384 a - - + + - + - - + - + 0.03 0.26
sce3385 alpha - + + - + - - + - + - 0.06 9.85
sce3386 a + - - + + + + + + - + 0.02 0.20
sce3387 a - + - + + + - + + - - 0.02 0.56
sce3388 alpha - - - - - - + - - + + 0.14 0.13
sce3339 alpha + + - + - + + - - - - 0.02 0.79
sce3390 a + - - - + - - + + + + 0.11 0.0
sce3391 alpha - - - + + - + - + - + 0.02 0.20
sce3392 alpha - + - - + + + - + - - 0.18 0.51
sce3393 a + + + - - + - + - + - 0.07 0.76
sce3394 a + - + + - - - + - + + 0.01 0.25
sce3395 a + - + - + + + + - + + 0.05 0.24
sce33% alpha - - - - - + - - + - - 0.12 0.16
sce3397 alpha - + - + - - + - + - - 0.01 0.58
sce3398 a + + + + + - - + - + + 0.01 0.79
ace3399 alpha + + + + + + - + + - + 0.02 _0.%
sce3400 a - - + - - - + + - - - 0.21 041
sce3401 a - + - + - + - - + + - 0.02 0.26
sce3402 alpha + - - - + - + - - + + 0.07 0.13
sce3403 alpha + + + - + - + - + + + 0.02 1.14
sce3404 a - - - + + + - - - + - 6.01 0.05
sce3405 alpha + + - - - - - + + - + 0.13 045
sce3406 a - - + + - + + + - - - 0.01 0.37
sce3407 alpha - + + + - - + - - + - 4.01 1.20
sce3408 alpha + - - - - + + + + + + 0.11 0.10
sce3409 a - - + - + + - + + - + 0.13 0.29
sce341 a - + - + + - - - - - - 6.02 6.46
sce3411 alpha + + + - - + + - + + + 0.01 1.02
sce3412 a - - - + - + + - - - - 0.01 0.21
sce3414 alpha - + + - + - - + - + + 0.02 0.68
sce3415 a + . + + + - + - - + + 0.01 0.26
sce3416 a + - - + - - - - + - - 0.02 0.12
sce3417 alpha - + - - - + + + - - - 0.12 0.58
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sce3418 alpha 
- + + - + + - + + + 
- 0.07 0.75
sce3419 alpha + + - + - - - - + + - 0.01 0.51
sce3420 a + + - + + - + - + - - 0.02 0.55
sce3421 a - - - - + + + + - + + 0.10 0.15
sce3422 alpha 
- + - - + - + - - + 0.16 0.34
sce3423 a + 
- - - + + + + + - - 0.30 0.17
sce3424 alpha 
- + - + + + + - + - + 0.02 0.61
sce3425 a + 
- + - - - - + - + - 0.08 0.19
sce3426 alpha 
- + + + - - - - - + + 0.02 0.88
sce3427 alpha + 
- - + + + + - - - - 0.02 0.19
sce3428 a -
- + + - + - + + - 0.02 0.44
sce3429 a + + + - - + - + - - + 0.16 0.97
sce3430 alpha 
- + - - + - - + + + + 0.05 0.30
sce3431 a - + - + - - - + - + + 0.02 0.37
sce3432 alpha + 
- + - - + + - - - - 0.21 0.41
sce3433 a + + - + + - + + + - + 0.02 0.73
sce3434 alpha 
- - - - + + - - + + - 0.12 0.42
sce3435 a + 
- + + - - + + + + - 0.02 0.21
sce3436 alpha + + - - - + + - - - + 0.19 0.55
sce3437 a - + + - + + - + + - + 0.08 1.02
sce3438 alpha 
-
- - + + - - - - + - 0.02 0.08
P- 
- - 0.22 0.18
S2 a + + + + + + 
- - - 0.02 0.80
M8 alpha 
-
- . - - - + + + + + 0.42 0.16
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Table S6A (primary data for Figure 4A and Figure S2). Fitness of segregants from the
S2XM8 cross that harbor the MET3 ancestral allele in low glucose at 20, 24 and 30 hours.
Shown are the genotypes for all relevant alleles (columns "MET3" to "TIM 11"), mating type,
and fitness in low glucose (20, 24, and 30 h) for 48 progeny from an S2XM8 cross that harbor
the MET3 ancestral allele, as well as for the haploid progenitor (P), the S2 evolved strain (no
growth due to the evolved MET3 allele), and the M8 evolved strain measured in the same assay.
+ denotes evolved allele; - denotes ancestral allele.
Strain LG LG LG
no. Mat MET3 PMA1 ENA GCD2 genic LAP2 RPH1 MDS3 MKTI SGTI TIM11 (20h) (24h) (3)
ace3343 a - + - + + + - - - + + 0.20 0.56 6.65
sce3344 a - + - + + - + + + + - 0.10 0.03 0.23
sce3347 alpha - + - + - + + - - + + 0.17 0.66 0.82
sce3349 alpha - + - + + - - + + + + 0.15 0.35 0.43
sce3352 alpha - + - + + + - - - + + 0.18 0.65 0.96
sce3354 a - + + - + + - - - - + 0.21 0.75 1.14
sce3357 a - + - + - - + - - + - 0.16 0.73 1.19
sce3358 alpha - + + - + + + + - - + 0.25 0.63 1.00
sce3360 alpha - + + + - - + - + + + 0.07 0.67 1.19
sce3361 a - + + - + + - + - - - 0.25 0.65 1.03
sce3363 alpha - + + + - - - + + - + 0.18 0.66 1.21
sce3364 a - + - - + + - + - - - 0.16 0.59 0.89
sce3368 alpha - + + + - - - - + - + 0.10 0.28 0.64
sce3370 a - + - - - + + - - + - 0.15 0.77 1.22
sce3371 alpha - + - + - + - + - - - 0.20 0.57 0.81
ace3372 a - + + - + + + - + + - 0.09 0.64 1.17
sce3376 alpha - - - + - - - - + + 0.24 0.64 0.94
sce3377 alpha - - + - + + + + + + + 0.11 0.31 0.51
ace3379 alpha - - + - + - + - + - + 0.09 0.57 0.89
sce3380 a - - - + + + - + - + + 0.25 0.57 0.87
sce3383 alpha - + - - + - - + + - - 0.11 0.23 0.47
ace3385 alpha - + + + - - + - + - - 0.06 0.24 0.83
sce3388 alpha - - - - - - + + + - 0.14 0.56 0.91
sce3390 a - - - + + - + - + + + 0.11 0.84 1.49
sce3392 alpha - + - + - + - + - - + 0.18 0.60 0.87
sce3393 a - + + - + + + - + - - 0.07 0.70 1.14
sce3395 a - - + + + + + + + + - 0.05 0.63 1.18
sce3396 alpha - - - - - + - - - - + 0.12 0.69 1.06
sce3400 a - - + - - - + + - - - 0.21 0.64 1.01
sce3402 alpha - - - + + - - + + + - 0.07 0.59 1.08
sce3403 alpha - + + + + - - + + + + 0.02 0.55 0.85
sce3405 alpha - + - - + - + - - + + 0.13 0.69 1.06
sce3408 alpha - - - - + + + + + + + 0.11 0.65 1.21
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sce3409 a -
- + + - + + - - + + 0.13 0.70 1.13
sce3411 alpha - + + - + + - + + + + 0.01 0.09 0.50
sce3414 alpha - + + + - - + - + + 
- 0.02 0.38 0.95
sce3417 alpha - + - - - + + + 
- - - 0.12 0.55 0.68
sce3418 alpha - + + + - + + - + 
- + 0.07 0.27 0.75
sce3421 a - - - + - + + + + + - 0.10 0.73 0.84
sce3422 alpha - - + - - + + - - + 
- 0.16 0.94 1.22
sce3423 a - - - + + + + + - - + 0.30 0.62 1.03
sce3425 a - - + - + - + - + - - .08 0.80 1.45
sce3429 a - + + - + + + - - + - 0.16 0.76 1.15
sce3430 alpha - + - + - - + 
- + + + 0.05 0.39 0.85
sce3432 alpha - - + - + + + - - - 0.21 0.61 1.03
sce3434 alpha -
- - + - + - - + - + 0.12 0.73 1.31
e3436 alpha - + -+ +- + - 0.19 0.62 1.02
sce3437 a - + + + - + + - - + + 0.08 0.75 1.10
P a -
- - - 0.22 0.62 0.92
M8 alpha 
-
- . - - - + + + + + 0.42 0.78 1.44
S2 a + + + + + + 
- - - 0.02 0.02 0.02
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Table S7 (primary data for Supplemental Figure 1C and 1D): Fitness of segregants from
the S6XM8 cross in high salt and low glucose (20h). Shown are the genotypes for all relevant
alleles (columns "CYC8" to "TIM 1 1"), mating type,
salt for 96 progeny from an S6XM8 cross as well
evolved strain and the M8 evolved strain measured in
denotes ancestral allele.
and fitness in low glucose (20h) and high
as for the haploid progenitor (P), the S6
the same assay. + denotes evolved allele; -
Strain no. MAT CYC8 PMAI ASP3 MDS3 MKT1 RPHI SGT2 TIMIlI LG (20h) Hi h salt
sce4305 alpha - - - + + - - + 0.55 0.46
sce4306 a + + - - - + + - 0.02 2.08
sce4307 alpha - + + - - - + + 0.05 1.10
sce4308 a + - + + + + - - 0.32 1.78
sce4309 a + + - - - - + + 0.02 2.37
sce4310 a - + - - - + + - 0.05 1.27
sce4311 alpha - - + + + - - - 0.52 0.34
sce4312 alpha + - + + + + - + 0.35 1.87
sce4313 a + + - + + + + - 0.02 2.16
sce4314 alpha + - + - - - + - 0.25 1.70
sce4315 a - + + + + - - + 0.04 1.03
sce4316 alpha - - - - + - 0.35 0.56
sce4317 alpha + + + + - + + - 0.03 1.96
sce4318 alpha - - - - + + + + 0.26 0.38
sce4319 a - + + + + - - + 0.04 1.08
sce4320 a + - - - - - - - 0.28 1.79
sce4321 alpha + + + - - - - + 0.03 2.18
sce4322 alpha + - + + - + + 0.49 1.72
sce4323 a - - - - + + + - 0.27 0.44
sce4324 a - + + + . + - - 0.08 1.10
sce4325 alpha + - + + - + + - 0.45 1.53
sce4326 alpha + + - - + - + - 0.01 1.94
sce4327 a - - - - - - - + 0.44 0.43
sce4328 a - + + + + + - + 0.05 1.00
sce4329 a - + - + - + + + 0.09 1.32
sce4330 a + + + - - - - + 0.03 2.09
sce4331 alpha - - - + + - + - 0.53 0.30
sce4332 alpha + - + - + + - - 0.23 1.40
sce4333 a + - - + + + - + 0.43 1.31
sce4334 a + + + + - + + - 0.04 1.96
sce4335 alpha - - + - + - - + 0.27 0.20
sce4336 alpha - + - - - - + - 0.06 1.02
sce4337 a - + - + + + - - 0.04 0.98
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sce4338 a + 0 -.1 1.74
sce4339 al ha + - + - - - - + 0.21 1.28
sce4340 al ha - - - + - + + + 0.45 0.42
sce4341 a - + + + - + + + 0.08 1.40
sce4342 alpha + + + + - + - 0.03 2.12
sce4343 a 
-
- + + - + 0.30 0.25
sce4344 alpha + ND - - - - - 0.24 1.11
sce4345 alpha - + + + - - - - 0.06 1.12
sce4346 a + - + - + + + + 0.18 1.01
sce4347 alpha - + ND - + - - + 0.02 0.91
sce4348 a + - - + - + + - 0.37 1.27
sce4349 a - - + + - + - + 0.45 0.37
sce4350 a + + + + 0.06 2.07
sce4351 alpha - + + - + + + - 0.03 0.63
sce4352 alpha + - - - + 
- + - 0.24 1.38
sce4353 alpha - - + - + 
-
- 0.22 0.23
sce4354 a + + + + 
- + - 0.01 2.16
sce4355 alpha + - + + - + - + 0.40 1.32
sce4356 a - + + + - + + + 0.07 1.30
sce4357 a + + 
- + - - + 0.01 2.04
sce4358 alpha + + ND - - + - - 0.03 1.91
sce4359 a - - + + -
- + - 0.51 0.48
sce4360 alvha + + + + 0.56 2.25
sce4361 alpha - + 
- - + + - - 0.03 0.89
sce4362 al 
-
- + 
- 0.17 1.20
sce4363 a 
-
- + + - + 
- 0.48 0.39
sce4364 a + + - + - - + - 0.06 2.12
sce4365 alpha + + + + + 0.58 0.25
sce4366 a - + + 0.30 0.50
sce4367 a + + + + + 0.02 1.64
sce4368 alpha + + 
- + -
- -
- 0.05 2.06
sce4369 a + 
- .
- + 
- + + 0.25 1.34
sce4370 alpha + + 0.07 1.10
sce4371 a -
- + + + + - 0.53 0.25
sce4372 alpha + + + + - + 
- + 0.05 2.03
sce4373 al ha + - -
- - - 0.26 1.47
sce4374 a - + 
- + + + + 
-_ 0.07 1.31
sce4375 alpha + + + +T + + + 0.04 2.03
sce4376 a -
- + 
- + 
- -- 0.30 0.23
+
+
+ + I
. .'Y
+ 0.01
069
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sce4377
sce4378
+
+ 049 022
a -
+ +
001+
sce4379 a + - - + - - + - 0.39 1.41
sce4380 alpha + + - - - - - + 0.03 2.09
sce4381 alpha - + + + + + + + 0.05 1.05
sce4382 alpha - - - - - - + - 0.45 0.48
sce4383 a + - - - - + - + 0.29 1.33
sce4384 a + + + + + - - - 0.02 2.01
sce4385 a + - - + - + + - 0.04 0.11
sce4386 a + + + - - + - - 0.01 0.30
sce4387 alpha - - - - + - + - 0.37 0.27
sce4388 alpha - + + + + - - + 0.05 0.96
sce4389 alpha + + + - + + + + 0.01 1.97
sce4390 a + + - + - - + + 0.07 2.13
sce4391 a - - + + - + - - 0.48 0.65
sce4392 alpha - - - - + - - - 0.42 0.40
sce4393 a - + - + - - - - 0.09 1.64
sce4394 a - - - + + + + + 0.54 0.34
sce4395 alpha + - + - + + + - 0.18 1.68
sce4396 alpha + + + - - - - + 0.04 2.08
sce4397 a - - + + + - - + 0.53 0.32
sce4398 alpha + + - - + - + + 0.01 2.20
sce4399 a + - + + - + - - 0.43 1.63
sce4400 alpha - + - - - + + + 0.06 1.20
P a - - - - - - - - 0.37 0.75
M8 alpha - - - + + + + + 0.57 ND
S6 a + + + - - - - - ND 1.48
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Table SS. Single-locus P values appear on top line. Pairwise interaction P values appear in
the matrix.
A. S2XP Offspring in High Salt. P values for single-locus effects and pairwise interactions
PMA1 ENA LAP2 MET3 GCD2
<10 exp -4 0.008 0.005 0.763 0.418
PMA1 <10 exp -4 0.264 0.742 0.166
ENA 0.005 0.579 0.111
LAP2 0.546 0.423
MET3 0.008
GCD2 I I
Significant values in red. Near-significant values in blue. 15 comparisons in total. Significance
threshold = 0.05 / 15 = 0.0033. The putative ENA - LAP2 interaction is negative, with the
evolved allele of LAP2 showing a growth deficit when combined with the ancestral allele of
ENA. This interaction does not appear in the S2XM8 cross and was not experimentally tested
further here. The evolved alleles of MET3 and GCD2 may be synergistic with one another; note
that PMA1, MET3 and GCD2 were the only three-way interaction identified in any of the
crosses and environments.
B. S6XP Offspring in High Salt. P values for single-locus effects and pairwise interactions
PMA1 CYC8 ASP
<0.002 < 10 exp -4 0.729
PMAI 0.007 0.79
CYC8 0.406
ASP
Significant values in red. Six comparisons. P-value threshold 0.05 / 6 = 0.0083
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C. M8XP Offspring in Low Glucose 20h. P
interactions
values for single-locus effects and pairwise
MKT1 SGTI MDS3 RPH1 TIMlI
<10 exp -4 0.748 0.003 0.752 0.491
MKT1 0.109 0.258 0.175 0.69
SGTI 0.013 0.157 0.364
MDS3 0.294 0.921
RPHI 0.269
TIMI 1
Significant values in red. 15 comparisons in total.
D. M8XP Offspring in Low
interactions
Significance threshold = 0.05 / 15 = 0.0033.
Glucose 24h. P values for single-locus effects and pairwise
MKTI SGT1 MDS3 RPHI TIMII
0.037 0.552 0.002 0.015 0.42
MKTI 0.863 0.146 0.665 0.242
SGTI 0.544 0.32 0.108
MDS3 0.138 0.153
RPH1 _0.197
TIMI 1 I
Significant values in red. 15 comparisons in total. Significance threshold = 0.05 / 15 = 0.0033.
E. M8XP Offspring in Low Glucose 30h.
interactions.
P values for single-locus effects and pairwise
MKT1 SGT1 MDS3 RPHI TIMlI
0.684 0.862 <10 exp -4 0.021 0.238
MKT1 0.512 0.727 0.924 0.253
SGT1 0.649 0.54 0.263
MDS3 0.747 0.094
RPH1 0.356
TIM 1l 1
Significant values in red. 15 comparisons in total. Significance threshold = 0.05 / 15 = 0.0033.
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F. S6XM8 Offspring in Low Glucose. P values for single locus effects and pairwise interactions
PMA1 CYC8 ASP3 MKT1 SGT1 MDS3 RPH1 TIMlI
<10 exp -4 0.005 0.425 0.206 0.689 0.01 0.51 0.812
PMA1 0.001 0.655 0.401 0.447 <10 exp -4 0.687 0.433
CYC8 0.302 0.651 0.202 0.934 0.317 0.946
ASP3 0.522 0.687 0.477 0.504 0.208
MKT1 0.732 0.409 0.91 0.155
SGT1 0.361 0.734 0.86
MDS3 0.294 0.576
RPH1 0.23
TIMI1
Significant values in red. 36 comparisons in total. P-value threshold = 0.05 /36 = 0.0014.
green, comparisons not valid because the S6 allele of PMA1 grows
glucose environment.
In
very poorly in the low-
G. S6XM8 Offspring in High Salt. P values for single locus effects and pairwise interactions
PMAI CYC8 ASP3 MKT1 SGT1 MDS3 RPH1 TIMlI
<10 exp -4 <10 exp -4 0.955 0.008 0.798 0.795 0.163 0.622
PMA1 0.214 0.038 0.87 0.091 0.664 0.129 0.3
CYC8 0.487 0.026 0.572 0.716 0.056 0.413
ASP3 0.956 0.357 0.708 0.072 0.775
MKT1 0.292 0.92 0.514 0.177
SGTI 0.365 0.304 0.202
MDS3 0.916 0.479
RPH1 0.048
TIM 1I
Significant values in red. 36 comparisons in total. P-value threshold = 0.05 /36 =0.0014
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H. S2XM8 Offspring in
interactions
Low Glucose 20h. P values for single-locus effects and pairwise
PMA1 ENA LAP2 MET3 GCD2 MKT1 SGT1 MDS3 RPHI
0.15 0.371 0.003 <10 ex -4 0.789 0.001 0.683 0.547 0.77
PMAI 0.768 0.358 0.453 0.388 0.44 0.533 0.722 0.588
ENA 0.837 0.079 0.199 0.149 0.039 0.983 0.931
LAP2 0.028 0.711 0.584 0.621 0.623 0.985
MET3 0.481 <10 ex -4 0.084 0.133 0.047
GCD2 0.29 0.496 0.601 0.117
MKT1 0.802 0.517 0.796
SGT1 0.07 0.927
MDS3 0.796
RPHI
TIMI1
Significant values in red. Near-significant values in blue. 55 comparisons in total. P-value
threshold = 0.05 /55 = 0.0009. MET3 comparisons in green not valid as MET3e does not grow
in in the low-glucose environment.
I. S2XM8 Offspring in High Salt. P values for single-locus effects and pairwise interactions.
PMA1 ENA LAP2 MET3 GCD2 MKT1 SGT1 MDS3 RPHI
<10 ex -4 <10 exp -4 0.977 0.106 0.877 0.79 0.578 0.524 0.586
PMA I <10 ex -4 0.052 0.708 0.892 0.0017 0.651 0.245 0.761
ENA 0.538 0.363 0.047 0.183 0.949 0.841 0.136
LAP2 0.801 0.175 0.263 0.391 0.028 0.11
MET3 0.922 0.775 0.511 0.276 0.751
GCD2 0.267 0.656 0.341 0.145
MKT1 0.283 0.198 0.09
SGT1 0.016 0.404
MDS3 0.025
RPH1
TIMI1
Significant values in red. Near-significant values in blue. 55 comparisons in total. P-value
threshold = 0.05 / 55 = 0.0009. 55 comparisons. The putative interaction between PMA1 and
MKTl is slightly positive. P-value threshold =0.05 / 55 = 0.0009.
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J. S2XM8 MET3a
pairwise interactions
Offspring in Low Glucose at 20h. P values for single locus effects and
PMA1 ENA LAP2 GCD2 MKT1 SGT1 MDS3 RPH1 TIMlI
0.466 0.066 0.029 0.525 <10 exp -4 0.094 0.14 0.048 0.595
PMA1 0.752 0.064 0.77 0.78 0.853 0.838 0.784 0.405
ENA 0.93 0.015 0.214 0.195 0.3 0.818 0.264
LAP2 0.437 0.875 0.472 0.837 0.66 0.983
GCD2 0.529 0.975 0.961 0.44 0.081
MKT1 0.615 0.215 0.738 0.615
SGT1 0.001 0.847 0.938
MDS3 0.108 0.7
RPH1 0.415
TIMI 1
Significant values in red. 45 comparisons in total. P-value threshold = 0.05 /45 = 0.0011.
K. S2XM8 MET3a
pairwise interactions
Offspring in Low Glucose at 24h. P values for single locus effects and
45 comparisons in total. P-value threshold = 0.05 /45 = 0.0011. Note that the PMAI - MKT1
interaction in blue falls just short of the significance threshold corrected for multiple
comparisons. This interaction was nonetheless selected for further study because it has the
lowest P value of any of the 125 valid comparisons between S2 or S6 and M8 SNPS in all
crosses and environments.
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PMA1 ENA LAP2 GCD2 MKT1 SGT1 MDS3 RPHI TIMlI
0.029 0.873 0.072 0.307 0.002 0.754 0.046 0.335 0.772
PMAI 0.879 0.102 0.243 0.0149 0.691 0.724 0.973 0.605
ENA 0.565 0.425 0.311 0.997 0.491 0.662 0.093
LAP2 0.445 0.589 0.791 0.939 0.957 0.086
GCD2 1 0.793 0.409 0.079 0.179 0.101
MKT1 0.474 0.871 0.937 0.939
SGTI 0.047 0.277 0.547
MDS3 0.938 0.909
RPH1 0.938
TIMI 1 I
L. S2XM8 MET3a
pairwise interactions
Offspring in Low Glucose at 30h. P values for single locus effects and
PMAI ENA LAP2 GCD2 MKT1 SGT1 MDS3 RPH1 TIMI 1
0.027 0.252 0.562 0.448 0.326 0.921 0.008 0.111 0.636
PMA1 0.21 0.226 0.236 0.135 0.532 0.994 0.599 0.951
ENA 0.599 0.934 0.576 0.745 0.448 0.81 0.038
LAP2 0.997 0.502 0.95 0.46 0.44 0.346
GCD2 0.517 0.926 0.257 0.625 0.31
MKT1 0.377 0.29 0.77 0.85
SGT1 0.295 0.244 0.316
MDS3 0.39 0.353
RPHI 0.952
TIM 1 l
45 comparisons in total. P-value threshold = 0.05 /45 = 0.0011.
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Supplementary Table 1. SNP categorization and LOH boundaries.
A. Shown here are a SNP classifications per time course.
All Backeround
Coding Synonymous 24547 19085 1979 3483
Non-synonymous 15481 11955 1095 2431
Intronic 448 317 50 81
Nonoding Promoter Potential 20410 14242 1669 4499
Notpromoter 16318 11174 1545 3599
PT7 All Background Persistent Transient
Coding Synonymous 21028 20148 880 0
Non-synonymous 13042 12442 600 0
Intronic 371 363 8 0
Nonoding Promoter Potential 15632 14584 1048 0
Not promoter 12527 11707 820 0
PT9 All Background Persistent Transient
Coding Synonymous 23070 13483 9587 0
Non-synonymous 14395 8899 5496 0
Intronic 422 209 213 0
Nonoding Promoter Potential 19243 11002 8241 0
Not promoter 14990 8422 6568 0I
PT14 All Background Persistent Transient
Coding Synonymous 33966 31220 1597 1149
Non-synonymous 21753 19840 1113 800
Intronic 634 593 22 19
Nonoding Promoter Potential 29396 26467 1707 1222
Not promoter 23054 20213 1750 1091
PT15 All Background Persistent Transient
Coding Synonymous 29961 26151 3810 0
Non-synonymous 18383 16101 2282 0
Intronic 596 501 95 0
Nonoding Promoter Potential 23164 19740 3424 0
Not promoter 18190 15444 2746 0
PT16 All Background Persistent Transient
Coding Synonymous 33252 28817 4236 199
Non-synonymous 21522 18423 2896 203
Intronic 687 575 105 7
Nonoding Promoter Potential 29336 24427 4356 553
Not promoter 23215 18912 3910 393
160
PT1
Coding Synonymous 31614 23422 8192 0
Non-synonymous 20214 15054 5160 0
Intronic 622 432 190 0
Nonoding Promoter Potential 27312 20166 7146 0
Not promoter 21301 16488 4813 0
PT42 All Background Persistent Transient
Coding Synonymous 21533 21013 520 0
Non-synonymous 13453 13067 386 0
Intronic 373 352 21 0
Nonoding Promoter Potential 16415 15814 601 0
Not promoter 12625 12160 465 0
PT43 All Background Persistent Transient
Coding Synonymous 33185 31019 2166 0
Non-synonymous 20781 19432 1349 0
Intronic 604 534 70 0
Nonoding Promoter Potential 27015 24783 2232 0
Not promoter 21072 19207 1865 0
PT59 All Background Persistent Transient
Coding Synonymous 19278 16285 2806 187
Non-synonymous 12368 10549 1664 155
Intronic 374 276 93 5
Nonoding Promoter Potential 15587 12628 2542 417
Not promoter 12234 9704 2213 317
B. Shown here are the boundaries coordinates for LOH determination
Time Course
Patient Strain Ca21chrl Ca21chr2 Ca21chr3 Ca2Ichr4 Ca2Ichr5 Ca2Ichr6 Ca2Ichr7 Ca2IchrR
3832-
2 1068234
897974-
3_ 1795835
897974-4 _ 1795835
897974-
6 1795835
897974-
1795835
897974-
8 1795835
897974-
9 1795835
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Persistent TransientPT30
I1I
I I - 1897974-
1795835
12 897974-1795835
13 897974- 8232-1795835 170933
14 897974- 8232-1795835 170933
15 897974- 8232-
1795835 170933
8232-
16 897974- 1709331795835 171204-
245012
17 897974-1795835
8232-
170933
171204-
2450f12
412
7 -7 1547-2307 351895
1002
15142-
4543- 780735
3795 1686646 1029764- 796170-1710375- 1797437 849685
3185786 872252-
1027763
580
168911-
14 2440 24601- 553875419452 590181-
941547
2501 1090417- 24601-
1686401 419452
945 1714728-
3744- 1881053
3744-
15 456576
1619 481476- 4991-1238655 266741
1314147-
1416222
3107
3119 913796-1798558
16 250757-545661 466016-
3120 913796- 557563- 704830
1798558 833109 705492-
833566- 1181271
1602135
11797-
266628
5106 1839295- 5317- 270449-2913061 1869518 908781
30 1017877-
1817646
1851-
5108 459269856580-
1124728
3731
42 -
3733
162
157253-1649 1302666 110956-
3034 409423
3917
2201226-
5 4617 3180846
4639 2201226- 807800-3180846 1796049
Supplementary Table 2.
homozygous genotypes
following its occurrence.
Drivers of LOH. Shown are genes with mutations that transition from
pre-LOH event, to homozygous genotypes of another genotype
A 1 indicates that this type of mutation has occurred in this gene and
time course, a 0 indicates that it has not.
ORF Gene PT1 PT7 PT9 PT14 PT15 PT43 PT59
orfl9.6061 orfl9.6061 0 0 1 0 0 0 0
orfl9.6020 orfl9.6020 0 0 1 0 0 0 0
orfl9.6356 orfl9.6356 0 0 0 0 0 0 1
orfl9.1834 orfl9.1834 0 0 0 0 0 0 1
orfl9.1135 CASI 0 0 0 0 0 0 1
orfl9.4965 orfl9.4965 0 0 0 0 0 0 1
orfl9.4905 orfl9.4905 0 0 0 0 0 0 1
orfl9.1166 CTA3 0 0 1 0 0 0 0
orfl9.2296 orfl9.2296 0 0 1 0 0 0 0
orfl9.2049 orfl9.2049 0 0 0 0 1 0 0
orfl9.1513 FABI 0 0 0 0 1 0 0
orfl9.193 orfl9.193 0 0 0 0 1 0 0
orfl9.4498 orfl9.4498 0 0 0 0 1 0 0
orfl 9.1453 SPT5 0 0 0 0 1. 0 0
orfl9.1684 orfl9.1684 0 1 0 0 0 0 0
orfl9.6979 orfl9.6979 0 0 0 1 0 0 0
orfl9.7372 MRR1 0 0 1 0 0 0 0
orfl9.7349 CHS4 1 0 0 0 0 0 0
orfl9.6790 orfl9.6790 0 0 1 0 0 0 0
orfl9.974 ROT2 0 0 0 0 1 0 0
orfl9.570 IFF8 0 0 0 0 0 1 0
orfl9.1934 HST3 0 0 0 0 0 1 0
orfl9.1932 CFL4 0 0 0 0 0 1 0
orfl9.922 ERGI1 1 0 0 0 0 0 0
orfl9.5580 TELl 0 0 1 0_0 0 0
orfl9.5742 ALS9 0 0 1 01 0 0 0
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Supplementary Table 3. Recurrent persistent mutations occurring in temporally distinct
clinical series. Shown are mutations that acquire non-synonymous mutations that persist through
the series. A 1 indicates a mutation in a given gene and its corresponding time course. A 0
indicates its absence. A 0 indicates no mutations.
A. Mutations in time courses that are persistent and non-synonymous
ORF Gene PT1 PT7 PT9 PT14 PTI5 PT43 PT59 SUM
orfl9.736 SRB8 1 1 1 1 1 1 1 7
orfl9.2404 orfl9.2404 1 0 1 1 0 1 1 5
orfl9.4697 MDN1 1 1 1 0 1 0 1 5
orfl9.1596 FGR28 0 0 1 1 1 1 1 5
orfl9.1616 FGR23 0 1 1 1 1 0 1 5
orfl9.5045 orfl9.5045 0 1 1 0 1 1 1 5
orfl9.3188 TACI 1 1 1 0 1 1 0 5
orfl9.2850 orfl9.2850 0 1 1 1 1 0 1 5
orfl9.7029 orfl9.7029 1 0 1 1 1 1 0 5
orfl9.2650 orfl9.2650 0 0 1 1 1 1 1 5
orfl9.7032 orfl9.7032 1 0 1 0 1 1 1 5
orfl9.1606 orfl9.1606 0 1 1 1 1 1 0 5
orfl9.5592 orfl9.5592 1 1 0 1 1 1 0 5
orfl9.5596 orfl9.5596 0 1 0 1 1 1 1 5
orfl9.169 CHO2 0 1 1 0 1 1 1 5
orfl9.4346 orfl9.4346 0 1 1 0 1 1 1 5
orfl9.5297 orfl9.5297 1 0 1 1 0 1 1 5
orfl9.5597 POLS 0 1 0 1 1 1 1 5
orfl9.230 orfl9.230 1 0 1 1 1 1 0 5
orfl9.4658 orfl9.4658 1 1 1 1 0 0 1 5
orfl9.6277 orfl9.6277 1 1 0 1 1 1 0 5
orfl9.4958 ECM25 1 1 0 1 1 0 1 5
orfl9.1769 orfl9.1769 0 1 0 1 0 1 1 4
orfl9.2629 orfl9.2629 0 0 1 0 1 1 1 4
orfl9.1298 NUP84 1 0 1 0 1 1 0 4
orfl9.4498 orfl9.4498 1 1 0 1 0 1 0 4
orfl9.4068 orfl9.4068 1 1 1 1 0 0 0 4
orfl9.7204 orfl9.7204 0 1 0 1 0 1 1 4
orfl9.3473 orfl9.3473 0 1 0 1 0 1 1 4
orfl9.2761 orfl9.2761 1 0 1 0 1 0 1 4
orfl9.5710 orfl9.5710 1 1 0 0 1 0 1 4
orfl9.3706 orfl9.3706 1 0 1 0 1 1 0 4
orfl9.4673 BMT9 0 1 1 1 0 1 0 4
orfl9.2647 ZCF14 1 0 0 0 1 1 1 4
orfl9.2646 ZCF13 0 0 0 1 1 1 1 4
orfl9.4557 orfl9.4557 1 1 0 0 1 0 1 4
orfl9.4288 CTA7 0 0 0 1 1 1 1 4
orfl9.4655 OPT6 0 1 1 0 1 0 1 4
orfl9.2747 RGT1 0 0 1 1 1 0 1 4
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orfl9.7472 IFF4 0 0 1 1 1 1 0 4
orfl9.255 ZCF1 0 1 1 1 1 0 0 4
orfl9.2168 orfl9.2168 0 1 1 0 1 1 0 4
orfl9.5038 orfl9.5038 0 1 1 0 1 1 0 4
orfl9.1808 orfl9.1808 0 1 1 0 1 0 1 4
orfl9.4337 orfl9.4337 1 0 1 0 1 0 1 4
orfl9.2652 TEF4 1 0 1 0 1 1 0 4
orfl9.4239 orfl9.4239 0 0 1 1 1 0 1 4
orfl9.649 orfl9.649 0 1 1 0 0 1 1 4
orfl9.4649 ZCF27 1 1 1 0 1 0 0 4
orfl9.4643 orfl9.4643 0 1 1 0 1 1 0 4
orfl9.5065 orfl9.5065 1 1 0 0 1 1 0 4
orfl9.366 orfl9.366 0 1 1 1 0 0 1 4
orfl9.6862 orfl9.6862 0 0 1 1 1 1 0 4
orfl9.5510 orfl9.5510 0 1 0 0 1 1 1 4
orfl9.3629 DSE1 1 0 1 0 1 0 0 3
orfl9.76 SPB1 1 0 0 0 1 1 0 3
orfl9.1768 orfl9.1768 0 0 1 1 1 0 0 3
orfl9.1766 orfl9.1766 0 1 1 0 1 0 0 3
orfl9.4510 IFA4 0 1 1 0 0 0 1 3
orfl9.4961 STP2 1 1 0 1 0 0 0 3
orfl9.115 orfl9.115 0 1 0 0 1 0 1 3
orfl9.371 orfl9.371 0 0 1 1 0 0 1 3
orfl9.5504 orfl9.5504 1 0 0 0 1 1 0 3
orfl9.2400 orfl9.2400 0 0 1 0 0 1 1 3
orfl9.4245 orfl9.4245 0 0 0 1 0 1 1 3
orfl9.4243 orfl9.4243 0 1 1 0 1 0 0 3
orfl9.3239 CTF18 1 1 1 0 0 0 0 3
orfl9.3463 orfl9.3463 0 0 0 1 1 0 1 3
orfl9.3906 orfl9.3906 0 1 1 0 1 0 0 3
orfl9.2901 NUP60 0 0 1 0 1 1 0 3
orfl9.1690 TOSI 0 0 0 1 1 1 0 3
orfl9.3910 orfl9.3910 0 0 1 1 1 0 0 3
orfl9.3916 orfl9.3916 0 0 1 0 1 0 1 3
orfl9.2433 orf19.2433 1 1 0 0 1 0 0 3
orfl9.3190 HAL9 0 1 1 0 0 0 1 3
orfl9.4901 orfl9.4901 0 0 0 0 1 1 1 3
orfl9.1531 orfl9.1531 1 1 1 0 0 0 0 3
orfl9.1532 SAM37 1 0 1 0 0 1 0 3
orf9.5705 NAM2 1 0 0 0 1 0 1 3
orfl9.7561 DEFI 0 0 0 1 1 1 0 3
orfl9.175 orfl9.175 0 0 1 0 0 1 1 3
orfl9.1748 orfl9.1748 0 1 1 0 1 0 0 3
orfl9.1356 orfl9.1356 0 0 0 1 1 1 0 3
orfl9.1359 orfl9.1359 0 0 1 1 1 0 0 3
orfl9.1492 PRP39 1 1 1 0 0 0 0 3
orfl9.2510 orfl9.2510 0 0 1 0 1 1 0 3
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orfl9.1111 orfl9.11l1 0 0 1 1 0 1 0 3
orfl9.4280 orfl9.4280 0 1 0 0 1 0 1 3
orfl9.3997 ADHI 1 0 0 0 0 1 1 3
orfl9.1555 SAC3 0 0 1 1 1 0 0 3
orfl9.1624.1 orfl9.1624.1 0 1 1 0 0 1 0 3
orfl9.1795 PUF3 0 0 1 1 0 1 0 3
orfl9.4191.1 orfl9.4191.1 0 1 1 0 1 0 0 3
orfl9.6280 orfl9.6280 0 1 0 1 0 0 1 3
orfl9.894 orfl9.894 1 1 1 0 0 0 0 3
orf19.3380 HWP2 0 0 1 0 1 1 0 3
orfl9.3100 orfl9.3100 0 1 0 0 1 0 1 3
orfl9.92 orfl9.92 0 0 0 0 1 1 1 3
orfl9.3429 FGR47 0 0 0 1 1 0 1 3
orfl9.6979 orfl9.6979 1 1 0 0 0 1 0 3
orfl9.1500 orfl9.1500 1 1 0 0 0 0 1 3
orfl9.5918 orfl9.5918 0 1 1 0 1 0 0 3
orfl9.4459 orfl9.4459 1 0 0 0 1 0 1 3
orfl9.3986 PPR1 0 1 0 0 1 0 1 3
orfl9.1607 ALR1 0 1 0 1 0 1 0 3
orfl9.6480 orfl9.6480 1 1 0 0 1 0 0 3
orfl9.1083 orfl9.1083 0 1 0 0 1 1 0 3
orfl9.4918 orfl9.4918 0 0 0 1 1 0 1 3
orfl9.427 orfl9.427 1 1 0 0 1 0 0 3
orfl9.4257 INTl 1 0 0 0 0 1 1 3
orfl9.1400 orfl9.1400 1 0 1 0 1 0 0 3
orfl9.4715 orfl9.4715 0 0 1 0 1 0 1 3
orfl9.1662 orfl9.1662 0 0 1 1 1 0 0 3
orfl9.1096 orfl9.1096 1 0 0 0 1 1 0 3
orfl9.5976 orfl9.5976 1 0 0 1 0 1 0 3
orfl9.2182 BLM3 0 0 1 1 1 0 0 3
orfl9.7027 orfl9.7027 0 0 1 1 0 1 0 3
orfl9.7023 orfl9.7023 1 0 0 1 0 1 0 3
orfl9.2724 orfl9.2724 0 0 1 1 0 1 0 3
orfl9.6544 LPI9 0 0 0 1 1 1 0 3
orfl9.3203 RCY1 1 1 0 0 1 0 0 3
orfl9.4369 orfl9.4369 0 0 1 0 1 0 1 3
orfl9.5141 orfl9.5141 0 0 1 0 1 0 1 3
orfl9.290 KRE5 1 0 1 0 1 0 0 3
orfl9.194 orfl9.194 0 0 1 0 0 1 1 3
orfl9.6499 orfl9.6499 0 0 1 0 1 1 0 3
orfl9.1841 orfl9.1841 1 1 0 0 0 0 1 3
orfl9.2266 orfl9.2266 1 0 0 0 1 1 0 3
orfl9.6921 orfl9.6921 0 0 0 1 1 0 1 3
orfl9.7036 orfl9.7036 0 1 0 0 1 1 0 3
orfl9.4394 orfl9.4394 1 1 0 0 1 0 0 3
orfl9.4553 orfl9.4553 0 1 0 1 1 0 0 3
orfl9.3603 orfl9.3603 0 0 1 1 1 0 0 3
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orfl9.4348 orfl9.4348 0 0 1 0 1 0 1 3
orfl9.4080 orfl9.4080 0 0 0 1 1 1 0 3
orfl9.1608 orfl9.1608 0 1 1 0 1 0 0 3
orfl9.1798 TSC2 1 0 1 0 1 0 0 3
orfl9.1113 orfl9.1113 0 0 1 1 0 1 0 3
orfl9.262 SMC3 0 0 1 1 0 1 0 3
orfl9.5915 DUR35 0 0 1 0 1 1 0 3
orfl9.6694 orfl9.6694 1 1 1 0 0 0 0 3
orfl9.1296 orfl9.1296 0 1 1 1 0 0 0 3
orfl9.7194 orfl9.7194 0 0 0 1 0 1 1 3
orfl9.7193 orfl9.7193 1 1 0 1 0 0 0 3
orfl9.4965 orfl9.4965 1 0 0 0 0 1 1 3
orfl9.4064 GPI7 1 0 0 1 1 0 0 3
orfl9.4412 orfl9.4412 0 1 1 0 1 0 0 3
orfl9.1622 YCGI 0 1 0 0 1 1 0 3
orf19.3615 orfl9.3615 1 1 1 0 0 0 0 3
orfl9.3613 orfl9.3613 0 1 0 0 1 1 0 3
orfl9.1106 orfl9.1106 0 0 1 1 0 1 0 3
orfl9.267 orfl9.267 0 1 1 0 0 1 0 3
orfl9.5505 HIS7 0 1 0 0 1 0 1 3
orfl9.4570 orfl9.4570 0 1 1 0 1 0 0 3
orfl9.4145 ZCF20 1 0 1 0 1 0 0 3
orfl9.2879 IFF5 0 0 1 0 1 0 1 3
orfl9.5854.1 orfl9.5854.1 0 0 1 0 1 1 0 3
orf19.5752 orfl9.5752 1 1 0 0 0 0 1 3
orfl9.6999 orfl9.6999 0 0 0 0 1 1 1 3
orfl9.5621 orfl9.5621 1 0 0 1 1 0 0 3
orfl9.6592 orfl9.6592 0 0 0 1 1 1 0 3
orfl9.6919 orfl9.6919 1 1 0 0 0 0 1 3
orfl9.4315 orfl9.4315 1 0 1 0 1 0 0 3
orfl9.4325 orfl9.4325 1 0 1 0 0 1 0 3
orfl9.4404 PGA49 0 0 1 0 1 1 0 3
orfl9.2907 PGA42 1 0 1 0 1 0 0 3
orfl9.4225 LEU3 0 0 1 0 1 1 0 3
orfl9.1772 orfl9.1772 0 1 1 0 1 0 0 3
orfl9.5924 ZCF31 0 0 1 0 1 1 0 3
orfl9.7277 orfl9.7277 0 1 0 0 1 1 0 3
orfl9.3773 CDL1 0 1 1 1 0 0 0 3
orfl9.3170 orfl9.3170 0 0 1 1 0 1 0 3
orfl9.3178 orfl9.3178 1 0 1 1 0 0 0 3
orfl9.2826 orfl9.2826 0 0 1 0 1 1 0 3
orfl9.4683 MLP1 1 0 1 0 1 0 0 3
orfl9.6294 MYOl 1 0 1 0 1 0 0 3
orfl9.5134 orfl9.5134 1 0 1 0 0 1 0 3
orfl9.5058 SMIl 0 0 0 1 1 1 0 3
orfl9.5003 orfl9.5003 0 1 0 1 0 1 0 3
orfl9.2547 orfl9.2547 0 1 1 0 0 1 0 3
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orfl9.3098 orfl9.3098 0 0 1 0 1 0 1 3
orfl9.3166 orfl9.3166 1 0 1 0 1 0 0 3
orfl9.3437 orfl9.3437 0 1 0 1 1 0 0 3
orfl9.3439 orf19.3439 1 0 0 0 1 0 1 3
orfl9.1706 MET18 0 0 0 1 1 1 0 3
orfl9.1144 orfl9.1144 1 0 0 1 1 0 0 3
orfl9.2847.1 orfl9.2847.1 0 0 1 1 0 1 0 3
orfl9.8 orfl9.8 0 0 1 1 0 1 0 3
orfl9.229 orfl9.229 0 0 1 1 0 1 0 3
orfl9.1327 RBT1 0 0 1 1 1 0 0 3
orfl9.7342 AXL1 0 0 0 1 1 1 0 3
orfl9.2797 orfl9.2797 0 0 0 1 1 0 1 3
orfl9.1551 orfl9.1551 0 1 1 1 0 0 0 3
orfl9.1779 MP65 0 0 1 0 1 1 0 3
orfl9.4316 orfl9.4316 1 0 0 1 1 0 0 3
orfl9.102 orfl9.102 0 0 0 0 1 1 1 3
orfl9.1305 orfl9.1305 1 0 1 0 1 0 0 3
orfl9.3937 orf19.3937 0 0 1 0 1 1 0 3
orfl9.5949 FAS2 1 1 0 0 0 1 0 3
orfl9.746 orfl9.746 1 0 1 0 0 1 0 3
orfl9.745 VAC8 0 0 0 1 0 1 1 3
orfl9.6260 orfl9.6260 0 1 0 0 1 1 0 3
orfl9.6344 RBK1 1 1 0 0 0 1 0 3
orfl9.3148 orfl9.3148 0 0 1 1 0 1 0 3
orf19.2929 GSCI 1 1 0 0 0 0 0 2
orfI9.1541 orfl9.1541 1 0 1 0 0 0 0 2
orfl9.2383 YKU80 0 0 1 0 0 0 1 2
orfl9.4251 ZCF22 0 0 1 0 1 0 0 2
orfl9.3213 orfl9.3213 0 0 0 1 0 0 1 2
orfl9.3216 orfl9.3216 0 0 0 0 1 1 0 2
orfl9.3214 orfl9.3214 0 0 1 1 0 0 0 2
orfl9.4339 VPS4 0 1 1 0 0 0 0 2
orfl9.2893 orfl9.2893 0 0 0 0 1 0 1 2
orfl9.400 GCF1 1 0 0 0 0 1 0 2
orfl9.757 orfl9.757 1 0 0 0 1 0 0 2
orfl9.114 orfl9.114 0 0 0 0 1 0 1 2
orfl9.1299 RPN6 1 0 1 0 0 0 0 2
orfl9.2624 orfl9.2624 0 1 1 0 0 0 0 2
orfl9.5138 IFA21 0 0 1 0 1 0 0 2
orfI9.1108 HAMI 0 0 0 0 1 1 0 2
orfl9.7343 orf19.7343 0 0 0 1 1 0 0 2
orfl9.113 CIPI 0 0 0 0 1 0 1 2
orfl9.4248 orfl9.4248 1 0 0 1 0 0 0 2
orfl9.3267 orf19.3267 0 1 1 0 0 0 0 2
orfl9.4066 orfl9.4066 0 0 1 0 1 0 0 2
orfl9.1684 orfl9.1684 0 0 1 0 0 1 0 2
orfl9.1681 orfl9.1681 0 1 0 0 1 0 0 2
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orfl9.3601 orfl9.3601 0 0 0 0 1 1 0 2
orfl9.6420 PGA13 0 0 1 0 0 1 0 2
orfl9.301 PGA18 0 0 1 0 1 0 0 2
orfl9.5043 orfl9.5043 0 0 0 0 1 0 1 2
orfl9.1828 BUD16 1 0 0 0 1 0 0 2
orfl9.5999 DYNI 0 0 0 0 1 1 0 2
orfl9.6494 WHI3 0 0 0 0 1 1 0 2
orfl9.1366 orfl9.1366 0 0 1 0 1 0 0 2
orfl9.1210 orfl9.1210 1 1 0 0 0 0 0 2
orfl9.922 ERGI1 0 0 1 0 0 0 1 2
orfl9.2465 POL32 0 1 0 0 1 0 0 2
orfl9.2768 AMS1 0 0 1 0 1 0 0 2
orfl9.923 THRI 0 0 1 0 0 0 1 2
orfl9.787 orfl9.787 0 1 0 0 0 0 1 2
orfl9.4878 orfl9.4878 1 0 0 1 0 0 0 2
orfl9.5714 SAPI 1 0 0 0 0 0 1 2
orfl9.3694 orfl9.3694 1 0 0 1 0 0 0 2
orfl9.2505 orfl9.2505 0 0 1 0 1 0 0 2
orfl9.4232 PTH1 0 0 1 0 1 0 0 2
orfl09.4270 orfl9.4270 0 1 0 0 1 0 0 2
orfl9.6798 SSN6 0 0 0 1 0 1 0 2
orfl9.1698 orfl9.1698 1 0 0 0 1 0 0 2
orfl9.6336 PGA25 0 1 0 0 1 0 0 2
orfl9.3470 orfl9.3470 0 0 0 0 1 0 1 2
orfl9.5729 FGR17 0 0 0 0 1 0 1 2
orfl9.124 CICi 0 1 0 0 1 0 0 2
orfl9.1834 orfl9.1834 0 0 0 0 1 0 1 2
orfl9.5057 orfl9.5057 0 1 1 0 0 0 0 2
orfl9.5053 orfl9.5053 0 0 1 0 1 0 0 2
orfl9.5051 orf19.5051 0 0 1 1 0 0 0 2
orfl9.5496 AVT1 0 0 0 0 1 1 0 2
orfl9.3907 orfl9.3907 0 0 0 0 1 0 1 2
orfl9.2884 CDC68 0 0 1 0 1 0 0 2
orfl9.1509 RODI 0 0 1 0 0 0 1 2
orfl9.3877 orfl9.3877 1 0 1 0 0 0 0 2
orfl9.3878 orfl9.3878 0 0 1 0 0 1 0 2
orfl9.7215 orfl9.7215 1 0 0 0 0 0 1 2
orfl9.792 orfl9.792 1 0 0 0 0 0 1 2
orfl9.2604 orfl9.2604 0 1 0 0 0 0 1 2
orfl9.4265 UAP1 0 0 0 0 1 1 0 2
orfl9.7369 orfl9.7369 1 0 0 0 1 0 0 2
orfl9.7366 orfl9.7366 0 0 0 0 1 0 1 2
orfl9.7365 orfl9.7365 0 1 0 0 1 0 0 2
orfl9.1033 STR2 1 0 0 1 0 0 0 2
orfl9.2516 orfl9.2516 0 0 0 1 1 0 0 2
orfl9.2515 orfl9.2515 0 0 1 1 0 0 0 2
orfl9.3648 orfl9.3648 0 0 0 0 1 1 0 2
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orfl9.4752 MSN4 1 1 0 0 0 0 0 2
orfl9.4913 orfl9.4913 1 1 0 0 0 0 0 2
orfl9.7201 SLA2 1 0 1 0 0 0 0 2
orfl9.4465 orfl9.4465 0 1 0 0 1 0 0 2
orfl9.6536 I11 1 0 0 0 1 0 0 2
orfl9.5302 PGA31 1 0 1 0 0 0 0 2
orfl9.4133 orfl9.4133 0 1 1 0 0 0 0 2
orfl9.4131 orfl9.4131 0 0 1 0 1 0 0 2
orfl9.4234 orfl9.4234 0 0 0 0 1 1 0 2
orfl9.5736 ALSS 0 1 1 0 0 0 0 2
orfl9.1816 ALS3 0 0 0 0 1 1 0 2
orfl9.6424 orfl9.6424 0 0 1 1 0 0 0 2
orfl9.5046 RAMI 1 0 0 0 1 0 0 2
orfl9.1762 OCAI 0 1 0 0 0 1 0 2
orfl9.3077 VID21 0 0 1 0 1 0 0 2
orfl9.5730 orfl9.5730 0 0 0 0 1 0 1 2
orfl9.6282 orfl9.6282 1 0 1 0 0 0 0 2
orfl9.5552 orfl9.5552 0 1 0 0 1 0 0 2
orfl9.5380 LYS144 0 0 1 0 1 0 0 2
orfl9.2457 orfl9.2457 1 0 0 0 1 0 0 2
orfl9.2452 orfl9.2452 1 1 0 0 0 0 0 2
orfl9.90 orfl9.90 0 0 0 0 0 1 1 2
orfl9.22% orfl9.2296 0 0 0 1 1 0 0 2
orf19.2675 orfl9.2675 0 0 1 0 1 0 0 2
orfl9.6970 orfl9.6970 0 0 0 1 0 1 0 2
orfl9.6973 orfl9.6973 0 0 0 0 1 1 0 2
orfl9.1499 CTF1 0 0 0 1 0 0 1 2
orfl9.1504 orfl9.1504 0 0 1 1 0 0 0 2
orfl9.1755 SET2 0 0 0 0 1 1 0 2
orfl9.1078 HBR2 1 0 0 0 1 0 0 2
orfl9.4921 orfl9.4921 0 0 0 1 0 1 0 2
orfl9.3254 orfl9.3254 0 0 0 1 1 0 0 2
orfl9.6317 ADE6 0 0 0 0 1 0 1 2
orfl9.4148 orfl9.4148 0 0 1 0 1 0 0 2
orfl9.4266 SPR28 0 0 0 0 1 1 0 2
orfl9.4705 orfl9.4705 0 0 1 0 1 0 0 2
orfl9.3180 orfl9.3180 0 0 1 0 1 0 0 2
orfl9.4703 orfl9.4703 0 0 1 0 0 1 0 2
orfl9.1119 MTR1O 0 0 1 0 0 1 0 2
orfl9.2775 IDIl 0 0 1 0 1 0 0 2
orfl9.1656 orfl9.1656 1 0 1 0 0 0 0 2
orfl9.5167 IFMI 1 0 0 0 1 0 0 2
orfl9.2883 CS099 0 0 0 1 0 1 0 2
orfl9.1240 orfl9.1240 0 0 1 0 1 0 0 2
orfl9.5725 orfl9.5725 1 0 0 0 1 0 0 2
orfn9.5728 orfl9.5728 0 1 0 0 0 0 1 2
orfl9.6573 BEM2 1 0 0 1 0 0 0 2
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orfl9.1826 MDM34 1 1 0 0 0 0 0 2
orfl9.1864 orfl9.1864 1 0 0 1 0 0 0 2
orfl9.7499 orfl9.7499 1 0 0 0 0 0 1 2
orfl9.2445 orfl9.2445 0 1 0 0 1 0 0 2
orfl9.2763 orfl9.2763 0 0 1 0 1 0 0 2
orfl9.245 DDC1 0 0 0 1 1 0 0 2
orfl9.4279 MNN1 0 0 1 0 1 0 0 2
orfl9.2881 MNN4 0 0 1 0 1 0 0 2
orfl9.7547 orfl9.7547 0 0 0 1 0 1 0 2
orfl9.3627 orfl9.3627 0 0 1 1 0 0 0 2
orfl9.3624 orfl9.3624 0 0 1 0 1 0 0 2
orfl9.3621 orfl9.3621 1 0 0 0 0 1 0 2
orfl9.2713 orfl9.2713 1 0 0 0 1 0 0 2
orfl9.5568 VPS51 0 0 0 0 1 0 1 2
orfl9.2688 NANI 0 0 1 0 1 0 0 2
orfl9.4627 orfl9.4627 1 0 0 0 1 0 0 2
orfl9.4405 PPS1 0 0 1 0 0 1 0 2
orfl9.2847 orfl9.2847 0 1 0 0 0 0 1 2
orfl9.4713 orfl9.4713 0 0 1 0 1 0 0 2
orfl9.130 orfl9.130 0 0 0 0 1 1 0 2
orfl9.522 orfl9.522 0 0 1 0 1 0 0 2
orfl9.4640 PWP1 1 0 0 0 0 1 0 2
orfl9.1253 PHO4 0 0 1 0 0 0 1 2
orfl9.1091 orfl9.1091 1 0 0 0 0 1 0 2
orfl9.5970 orfl9.5970 0 0 0 0 1 1 0 2
orfl9.188 orfl9.188 0 0 0 1 0 1 0 2
orfl9.1893 orfl9.1893 1 0 0 0 1 0 0 2
orfl9.4829 DOAl 0 0 0 1 1 0 0 2
orfl9.1878 orfl9.1878 1 0 0 0 1 0 0 2
orfl9.2476 orfl9.2476 0 1 0 0 1 0 0 2
orfl9.2274 orfl9.2274 0 0 0 1 0 1 0 2
orfl9.243 OXR1 0 0 1 0 1 0 0 2
orfl9.6349 RVS162 0 0 0 0 0 1 1 2
orfl9.1527 orfl9.1527 1 0 1 0 0 0 0 2
orfl9.3637 orf19.3637 0 0 1 0 1 0 0 2
orfl9.3633 orfl9.3633 0 0 1 1 0 0 0 2
orfl9.1901 MCM3 1 0 1 0 0 0 0 2
orfl9.4366 orfl9.4366 0 1 1 0 0 0 0 2
orfl9.4764 orfl9.4764 0 0 0 0 1 1 0 2
orfl9.248 APL5 0 0 0 0 1 1 0 2
orfl9.3231 CDC27 0 0 1 1 0 0 0 2
orfl9.4284 BUR2 0 0 1 0 1 0 0 2
orfl9.5575 orfl9.5575 0 0 0 1 0 0 1 2
orfl9.1265 orfl9.1265 0 0 1 0 1 0 0 2
orfl9.1266 orfl9.1266 0 0 1 0 1 0 0 2
orfl9.5701 orfl9.5701 0 0 0 0 1 1 0 2
orfl9.5704 orfl9.5704 0 0 0 1 1 0 0 2
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orfl9.6588 NBP2 0 1 0 0 0 0 1 2
orfl9.193 orfl9.193 0 0 1 0 0 0 1 2
orfl9.5569 orfl9.5569 1 0 0 0 0 1 0 2
orfl9.6492 orfl9.6492 0 1 0 0 1 0 0 2
orfl9.1849 orfl9.1849 1 0 0 0 0 0 1 2
orfl9.2399 orfl9.2399 0 0 1 1 0 0 0 2
orfl9.2265 orfl9.2265 1 0 0 0 1 0 0 2
orfl9.250 SLC1 1 0 0 0 1 0 0 2
orfl9.731 EMP46 0 1 0 0 1 0 0 2
orfl9.3829 PHR1 1 0 0 0 1 0 0 2
orfl9.1325 ECM38 0 0 1 0 1 0 0 2
orfl9.7038 orfl9.7038 0 1 0 0 0 1 0 2
orfl9.7034 orfl9.7034 0 0 0 0 0 1 1 2
orfl9.2733 orfl9.2733 0 0 1 0 0 0 1 2
orfl9.2739 orfl9.2739 1 0 1 0 0 0 0 2
orfl9.6478 YCF1 1 0 0 0 1 0 0 2
orfl9.3735 orfl9.3735 0 0 1 0 0 0 1 2
orfl9.2137 orfl9.2137 0 0 0 0 1 0 1 2
orfl9.5653 ATP2 0 0 1 1 0 0 0 2
orfl9.3604 orfl9.3604 0 0 0 0 1 0 1 2
orfl9.3605 PEX17 1 1 0 0 0 0 0 2
orfl9.3607 orfl9.3607 0 0 0 0 1 1 0 2
orfl9.2370 DSL1 0 1 0 0 0 1 0 2
orfl9.101 RIM9 0 0 0 1 0 1 0 2
orfl9.4771 orfl9.4771 0 0 0 0 1 1 0 2
orfl9.3443 OYE2 0 1 0 0 1 0 0 2
orfl9.4704 AROl 0 0 1 0 1 0 0 2
orfl9.6387 HSP104 0 1 0 0 0 1 0 2
orfl9.5177 orfl9.5177 1 0 1 0 0 0 0 2
orfl9.6126 KGD2 0 0 1 1 0 0 0 2
orfl9.1075 orfl9.1075 1 0 0 0 1 0 0 2
orfl9.718 RRNI 0 1 0 0 1 0 0 2
orfl9.6152 orfl9.6152 1 0 1 0 0 0 0 2
orfl9.276 orfl9.276 0 0 1 0 1 0 0 2
orfl9.2258 orfl9.2258 0 0 0 1 1 0 0 2
orfl9.2259 orfl9.2259 0 0 1 0 1 0 0 2
orfl9.7519 orfl9.7519 1 1 0 0 0 0 0 2
orfl9.7044 RIM15 0 0 1 1 0 0 0 2
orfl9.1345 LIP8 1 0 0 0 1 0 0 2
orfl9.2740 orfl9.2740 0 0 1 0 1 0 0 2
orfl9.3422 FMP27 0 0 0 0 1 0 1 2
orfl9.4963 orfl9.4963 1 0 0 0 0 1 0 2
orfl9.3433 OYE23 0 0 0 0 1 1 0 2
orfl9.4414 orfl9.4414 1 0 1 0 0 0 0 2
orfl9.6977 GPI1 0 1 0 0 1 0 0 2
orfl9.3417 ACF2 0 0 0 0 1 0 1 2
orfl9.3617 orfl9.3617 1 0 0 0 0 0 1 2
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orfl9.3610 orfl9.3610 0 0 0 0 1 1 0 2
orfl9.2678 BUBI 0 0 1 0 1 0 0 2
orfl9.4349 orfl9.4349 0 0 1 0 0 0 1 2
orfl9.2819 orfl9.2819 0 0 1 0 1 0 0 2
orfl9.1275 GATI 0 0 0 1 1 0 0 2
orfl9.4744 orfl9.4744 0 1 0 0 1 0 0 2
orfl9.4646 UEC1 0 1 0 0 0 0 1 2
orfl9.2238 LTE1 0 0 1 0 0 1 0 2
orfl9.1611 orfl9.1611 1 1 0 0 0 0 0 2
orfl9.1610 orfl9.1610 0 0 1 0 1 0 0 2
orfl9.4184 orfl9.4184 0 0 1 0 1 0 0 2
orfl9.5328 GCN1 0 0 1 0 1 0 0 2
orfl9.4318 MIG1 0 0 1 0 0 0 1 2
orfl9.4568 ZCF25 0 0 1 0 1 0 0 2
orfl9.5295 orf19.5295 0 0 1 0 1 0 0 2
orfl9.2216 PDS5 0 0 1 0 1 0 0 2
orfl9.1041 orfl9.1041 0 1 0 1 0 0 0 2
orfl9.1719 SGA1 0 0 0 1 1 0 0 2
orfl9.4416 VPS13 0 0 0 1 1 0 0 2
orfl9.6913 GCN2 0 0 1 0 1 0 0 2
orfl9.4403 VPSIl 0 0 1 0 1 0 0 2
orfl9.7071 FGR2 0 0 0 0 1 1 0 2
orfl9.6832 orfl9.6832 0 0 0 0 0 1 1 2
orfl9.1821 orfl9.1821 0 0 0 0 1 0 1 2
orfl9.265 orfl9.265 0 0 1 0 1 0 0 2
orfl9.48 orfl9.48 0 1 0 0 0 0 1 2
orfl9.6586 orfl9.6586 0 0 0 1 0 1 0 2
orfl9.6580 orfl9.6580 0 0 0 0 1 1 0 2
orfl9.2787 PRYl 0 1 0 1 0 0 0 2
orfl9.6901 orf19.6901 1 0 1 0 0 0 0 2
orfl9.864 orfl9.864 1 0 1 0 0 0 0 2
orfl9.7051 orfl9.7051 1 0 0 0 1 0 0 2
orfl9.7052 orfl9.7052 0 0 1 0 1 0 0 2
orfl9.4791 orfl9.4791 1 0 0 1 0 0 0 2
orfl9.7473 orfl9.7473 0 1 1 0 0 0 0 2
orfl9.2115 orfl9.2115 1 0 1 0 0 0 0 2
orfl9.4757 NARI 0 0 0 1 0 1 0 2
orfl9.1166 CTA3 0 0 0 0 1 0 1 2
orfl9.4175 TOKI 0 0 1 0 1 0 0 2
orfl9.4357 orfl9.4357 0 0 0 1 1 0 0 2
orfl9.2808 ZCF16 0 0 0 1 1 0 0 2
orfl9.139 TRAl 0 1 0 1 0 0 0 2
orfl9.1595 orfl9.1595 0 1 1 0 0 0 0 2
orfl9.4750 orfl9.4750 0 0 0 0 1 1 0 2
orfl9.1624 orfl9.1624 0 0 1 0 1 0 0 2
orfl9.5713 YMX6 1 0 0 0 1 0 0 2
orfl9.4392 DEM1 0 0 1 1 0 0 0 2
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orfl9.2534 PIN4 0 1 0 1 0 0 0 2
orfl9.2752 ADRI 0 0 0 1 1 0 0 2
orfl9.1192 DNA2 0 0 0 0 1 0 1 2
orfl9.3969 SFL2 0 0 0 0 1 1 0 2
orfl9.4072 IFF6 0 0 0 1 1 0 0 2
orfl9.570 IFF8 0 0 1 0 0 0 1 2
orfl9.5755 orfl9.5755 0 0 0 1 1 0 0 2
orf19.6136 orfl9.6136 0 1 1 0 0 0 0 2
orfl9.3976 orfl9.3976 0 0 0 0 1 0 1 2
orfl9.5620 orfl9.5620 1 0 0 0 0 1 0 2
orfl9.258 orfl9.258 0 0 0 0 1 1 0 2
orfl9.257 orf19.257 0 0 1 0 1 0 0 2
orfl9.251 orfl9.251 0 0 0 0 1 1 0 2
orfl9.36 orfl9.36 0 1 0 1 0 0 0 2
orfl9.2231 orfl9.2231 0 0 0 1 0 1 0 2
orfl9.5934 orfl9.5934 0 0 0 0 1 1 0 2
orfl9.5935 orfl9.5935 0 0 1 1 0 0 0 2
orfl9.6918 orfl9.6918 0 0 1 1 0 0 0 2
orfl9.810 orfl9.810 0 0 1 0 0 1 0 2
orfl9.929 orfl9.929 0 1 1 0 0 0 0 2
orfl9.1251 BRN1 0 0 1 0 1 0 0 2
orfl9.2165 orfl9.2165 0 0 1 0 1 0 0 2
orfl9.2169 orfl9.2169 1 0 1 0 0 0 0 2
orfl9.1456 orfl9.1456 0 0 0 1 0 1 0 2
orfl9.7001 YCK2 0 0 0 0 1 0 1 2
orfl9.3367 orfl9.3367 0 0 1 0 1 0 0 2
orfl9.2760 orfl9.2760 0 0 1 0 1 0 0 2
orfl9.3368 orfl9.3368 0 0 0 1 1 0 0 2
orfl9.2835 orfl9.2835 0 0 1 0 0 0 1 2
orf19.5148 CYRI 0 0 1 0 0 0 1 2
orfl9.1580 orfl9.1580 0 0 1 1 0 0 0 2
orfl9.4136 YBL053 0 0 1 0 1 0 0 2
orfl9.3803 MNN22 1 0 1 0 0 0 0 2
orfl9.1714 PGA44 0 0 1 0 0 0 1 2
orfl9.3984 orfl9.3984 0 0 0 0 1 0 1 2
orfl9.1121 orfl9.1121 0 1 1 0 0 0 0 2
orfl9.1774 orfl9.1774 0 0 1 0 1 0 0 2
orfl9.868 ADAEC 0 0 1 1 0 0 0 2
orfl9.5748 orfl9.5748 1 0 0 0 1 0 0 2
orfl9.6690 orfl9.6690 0 0 1 1 0 0 0 2
orfl9.6698 orfl9.6698 0 1 0 0 0 0 1 2
orfl9.6453 orfl9.6453 0 1 0 0 1 0 0 2
orfl9.1338 orfl9.1338 1 1 0 0 0 0 0 2
orfl9.3965 orfl9.3965 0 1 0 0 1 0 0 2
orfl9.4167 orfl9.4167 0 1 0 0 1 0 0 2
orfl9.246 orfl9.246 0 0 1 1 0 0 0 2
orfl9.719 orfl9.719 0 0 1 0 0 0 1 2
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orfl9.7274 orfl9.7274 0 1 0 1 0 0 0 2
orfl9.1802 orfl9.1802 1 0 1 0 0 0 0 2
orfl9.2682 orfl9.2682 0 0 1 0 1 0 0 2
orfl9.2680 orfl9.2680 1 0 1 0 0 0 0 2
orfl9.1670 BROl 0 0 0 0 1 1 0 2
orfl9.2175 orfl9.2175 0 0 1 0 1 0 0 2
orfl9.3793 orf19.3793 0 0 1 0 0 1 0 2
orfl9.1680 TFP1 0 1 1 0 0 0 0 2
orfl9.4686 orfl9.4686 0 0 0 1 0 1 0 2
orfl9.4680 orfl9.4680 0 0 1 0 1 0 0 2
orfl9.4515 orfl9.4515 1 0 1 0 0 0 0 2
orfl9.2778 orfl9.2778 0 0 0 0 1 1 0 2
orfl9.2770 orfl9.2770 0 1 1 0 0 0 0 2
orfl9.3428 orfl9.3428 0 0 0 0 1 1 0 2
orfl9.4135 PRC2 0 0 1 0 1 0 0 2
orfl9.4305.1 orfl9.4305.1 0 1 0 0 0 1 0 2
orfl9.4209 orfl9.4209 0 0 0 0 0 1 1 2
orfl9.2915 orfl9.2915 0 0 1 0 1 0 0 2
orfl9.4870 DBP3 1 0 0 0 1 0 0 2
orfl9.1824 PGA50 0 0 0 0 1 0 1 2
orfl9.3886 orfl9.3886 0 0 0 1 0 1 0 2
orfl9.1030 orfl9.1030 0 0 0 1 1 0 0 2
orfl9.1843 ALG6 0 1 1 0 0 0 0 2
orfl9.6687 orfl9.6687 1 0 1 0 0 0 0 2
orfl9.5648 orfl9.5648 0 0 1 0 1 0 0 2
orfl9.1326 orfl9.1326 0 1 0 0 0 1 0 2
orfl9.807 CHS5 1 0 1 0 0 0 0 2
orfl9.721 orfl9.721 1 0 1 0 0 0 0 2
orfl9.1763 IFRI 0 1 1 0 0 0 0 2
orfl9.6891 RFC1 1 0 1 0 0 0 0 2
orfl9.839 orfl9.839 0 0 1 0 0 0 1 2
orfl9.831 orfl9.831 1 0 1 0 0 0 0 2
orfl9.836 orfl9.836 1 0 1 0 0 0 0 2
orfl9.3592 JEMI 0 0 1 0 0 1 0 2
orfl9.2368 orfl9.2368 0 0 1 0 0 0 1 2
orf19.3825 RCE1 0 0 1 0 1 0 0 2
orf9.3781 orfl9.3781 0 0 1 0 1 0 0 2
orfl9.3784 orfl9.3784 0 0 1 0 1 0 0 2
orfl9.7475 PHO81 0 0 0 0 1 1 0 2
orfl9.2791 BBC1 0 1 0 1 0 0 0 2
orfl9.2397.3 orfl9.2397.3 0 0 1 0 1 0 0 2
orfl9.2781 orfl9.2781 0 0 0 1 1 0 0 2
orfl9.2786 orfl9.2786 0 0 0 0 1 1 0 2
orfl9.2784 orfl9.2784 0 1 0 0 0 1 0 2
orfl9.658 GIN1 0 0 0 1 0 1 0 2
orfl9.3434 TRY5 0 0 0 0 1 0 1 2
orfl9.4707 orfl9.4707 1 0 0 0 1 0 0 2
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orfl9.4761 HST1 0 0 0 1 1 0 0 2
orfl9.7030 SSR1 0 0 1 0 1 0 0 2
orfl9.3547 orfl9.3547 0 0 1 1 0 0 0 2
orfl9.1495 orfl9.1495 1 0 1 0 0 0 0 2
orfl9.4213 FET31 0 0 0 0 1 0 1 2
orfl9.4653 orfl9.4653 0 0 1 0 1 0 0 2
orfl9.4305 orfl9.4305 1 0 0 0 1 0 0 2
orfl9.1915 MPP1O 0 0 1 0 0 0 1 2
orfl9.3897 orfl9.3897 0 0 1 0 1 0 0 2
orfl9.134 orfl9.134 0 1 0 0 0 0 1 2
orfl9.6143 orfl9.6143 0 0 1 0 0 0 1 2
orfl9.1314 orfl9.1314 0 0 1 0 1 0 0 2
orfl9.6476 orfl9.6476 0 1 0 0 0 1 0 2
orfl9.3945 orfl9.3945 0 1 1 0 0 0 0 2
orfl9.5300 orfl9.5300 0 0 1 0 1 0 0 2
orfl9.1839 RPA190 0 1 0 0 1 0 0 2
orfl9.3187 ZNC1 0 1 1 0 0 0 0 2
orfl9.5491 orfl9.5491 0 0 0 0 0 1 1 2
orfl9.9 orfl9.9 0 0 0 1 0 1 0 2
orfl9.5068 IREl 0 0 0 0 1 0 1 2
orfl9.4273 orfl9.4273 0 0 0 0 1 1 0 2
orfl9.6202 RBT4 0 1 0 0 0 1 0 2
orfl9.2372 orfl9.2372 0 0 1 0 1 0 0 2
orfl9.2681 RBT7 1 0 0 0 1 0 0 2
orfl9.4519 SUV3 0 1 1 0 0 0 0 2
orfl9.6803 HUTI 0 0 0 1 0 1 0 2
orfl9.4766 ARG81 0 1 0 0 1 0 0 2
orfl9.2748 ARG83 0 0 0 0 1 1 0 2
orfl9.1538 TLG2 0 1 0 1 0 0 0 2
orfl9.2307 orfl9.2307 0 0 0 1 0 0 1 2
orfl9.6313 MNT4 0 0 0 1 0 1 0 2
orfl9.1791 orfl9.1791 0 0 0 1 1 0 0 2
orfl9.1792 orfl9.1792 0 0 0 0 1 0 1 2
orfl9.1794 orfl9.1794 0 1 0 0 1 0 0 2
orfl9.1797 orfl9.1797 0 1 0 0 0 0 1 2
orfl9.3447 orfl9.3447 0 0 0 1 1 0 0 2
orfl9.1557 orfl9.1557 0 0 1 0 0 1 0 2
orfl9.5723 POXI 0 1 0 0 0 1 0 2
orfl9.6511 LIG1 0 0 1 0 1 0 0 2
orfl9.3204 orfl9.3204 0 0 1 0 1 0 0 2
orfl9.3202 orf19.3202 0 0 1 0 1 0 0 2
orfl9.4000 GRFIO 1 0 0 0 0 0 1 2
orfl9.1177 orfl9.1177 0 0 0 1 0 0 1 2
orfl9.1771 orfl9.1771 0 1 0 1 0 0 0 2
orfl9.107 orfl9.107 0 0 0 0 1 0 1 2
orfl9.1747 KIP2 0 0 0 0 1 1 0 2
orfl9.748 orfl9.748 0 0 1 0 1 0 0 2
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orfl9.216 orfl9.216 1 0 0 0 1 0 0 2
orfl9.215 orfl9.215 1 0 1 0 0 0 0 2
orfl9.849 orfl9.849 1 0 0 0 0 1 0 2
orfl9.3840 orfl9.3840 0 0 0 1 0 1 0 2
orfl9.1943 orfl9.1943 0 1 0 0 1 0 0 2
orfl9.6566 orfl9.6566 0 0 1 0 1 0 0 2
orfl9.697 orfl9.697 0 0 1 0 0 0 1 2
orfl9.6310 orfl9.6310 0 0 0 1 1 0 0 2
orfl9.6861 orfl9.6861 0 0 1 0 1 0 0 2
orfl9.6319 orfl9.6319 1 1 0 0 0 0 0 2
orfl9.5516 orfl9.5516 0 0 0 1 1 0 0 2
orfl9.1264 CFL2 1 0 1 0 0 0 0 2
orfl9.5962 HGT4 0 1 0 0 1 0 0 2
orfl9.7131 orfl9.7131 1 0 0 1 0 0 0 2
orfl9.2415 orfl9.2415 0 0 1 0 0 0 1 2
orfl9.2418 orf19.2418 0 0 1 0 0 0 1 2
orfl9.1620 orfl9.1620 0 0 0 0 0 1 0 1
orfl9.6831 PRP5 0 1 0 0 0 0 0 1
orfl9.4816 orfl9.4816 0 1 0 0 0 0 0 1
orfl9.3329 orfl9.3329 0 0 0 1 0 0 0 1
orfl9.7356 orfl9.7356 0 0 0 0 1 0 0 1
orfl9.7357 orfl9.7357 0 0 0 0 1 0 0 1
orfl9.7353 orf19.7353 0 0 0 0 1 0 0 1
orfl9.4120 LASI 0 0 1 0 0 0 0 1
orfl9.1782 orfl9.1782 0 0 0 1 0 0 0 1
orfl9.1780 orfl9.1780 0 0 0 0 1 0 0 1
orfl9.4183 MUCl 0 0 0 0 1 0 0 1
orfl9.3458 orfl9.3458 1 0 0 0 0 0 0 1
orfl9.1789 orfl9.1789 0 0 0 0 1 0 0 1
orfl9.1547 orfl9.1547 1 0 0 0 0 0 0 1
orfl9.1546 orfl9.1546 0 0 1 0 0 0 0 1
orfl9.1548 orfl9.1548 0 0 0 0 1 0 0 1
orfl9.5491.1 ATP14 0 0 1 0 0 0 0 1
orfl9.2170 PHM7 0 0 1 0 0 0 0 1
orfl9.4719 CWH41 0 0 1 0 0 0 0 1
orfl9.260 SLD1 0 0 1 0 0 0 0 1
orfl9.4258 orfl9.4258 0 0 0 0 1 0 0 1
orfl9.4253 orf19.4253 0 0 0 1 0 0 0 1
orfl9.2839 CIRT4B 0 0 0 1 0 0 0 1
orfl9.3219 orfl9.3219 0 0 0 0 1 0 0 1
orfl9.1631 ERG6 0 0 1 0 0 0 0 1
orfl9.6026 ERG2 0 1 0 0 0 0 0 1
orfl9.4606 ERG8 0 0 1 0 0 0 0 1
orfl9.3616 ERG9 1 0 0 0 0 0 0 1
orfl9.4078 orfl9.4078 0 0 1 0 0 0 0 1
orfl9.4678 orfl9.4678 1 0 0 0 0 0 0 1
orfl9.335 orfl9.335 0 0 0 0 1 0 0 1
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orfl9.4676 orfl9.4676 0 0 1 0 0 0 0 1
orfl9.4672 orfl9.4672 0 0 1 0 0 0 0 1
orfl9.1212 orfl9.1212 0 0 0 0 0 1 0 1
orfl9.4101 orfl9.4101 0 0 0 0 1 0 0 1
orfl9.4106 orfl9.4106 0 0 0 0 1 0 0 1
orfl9.1160 orfl9.1160 0 1 0 0 0 0 0 1
orfl9.367 CNH1 0 0 1 0 0 0 0 1
orfl9.2892 orfl9.2892 0 0 0 0 1 0 0 1
orfl9.2890 orfl9.2890 0 0 1 0 0 0 0 1
orf19.2891 orfl9.2891 0 0 0 0 1 0 0 1
orfl9.593 FGR32 0 0 0 0 0 0 1 1
orfl9.2873 TOP2 0 0 1 0 0 0 0 1
orfl9.1767 orfl9.1767 0 0 0 1 0 0 0 1
orfl9.3159 UTP20 0 0 0 0 1 0 0 1
orfl9.5031 SSK1 0 1 0 0 0 0 0 1
orfl9.4657 orfl9.4657 0 0 1 0 0 0 0 1
orfl9.1217 orfl9.1217 0 0 0 0 1 0 0 1
orfl9.5430 BUD21 0 0 0 0 0 0 1 1
orfl9.2131 orfl9.2131 0 0 0 0 1 0 0 1
orfl9.6416 orfl9.6416 1 0 0 0 0 0 0 1
orfl9.1371 orfl9.1371 0 0 1 0 0 0 0 1
orfl9.5676 orfl9.5676 0 0 0 0 1 0 0 1
orfl9.3926 RNYl1 0 0 1 0 0 0 0 1
orfl9.3929 orfl9.3929 0 0 0 0 1 0 0 1
orfl9.5561 RAV2 0 0 0 0 1 0 0 1
orfl9.5486.1 SMD2 0 0 0 0 1 0 0 1
orfl9.390 CDC42 1 0 0 0 0 0 0 1
orf19.2715 RPC53 0 0 1 0 0 0 0 1
orfl9.5692 orf19.5692 0 1 0 0 0 0 0 1
orfl9.6422 SSYS 0 0 1 0 0 0 0 1
orfl9.3480 orfl9.3480 0 0 0 0 1 0 0 1
orfl9.3859 orf19.3859 1 0 0 0 0 0 0 1
orfl9.4853 HCM1 0 0 0 1 0 0 0 1
orfl9.1207 orfI9.1207 0 0 1 0 0 0 0 1
orfl9.3631 STN1 0 0 0 0 0 1 0 1
orfl9.5210 orfl9.5210 0 0 1 0 0 0 0 1
orfl9.5212 orfl9.5212 0 0 1 0 0 0 0 1
orfl9.1998 orfl9.1998 0 0 1 0 0 0 0 1
orfl9.816 DCK2 0 0 1 0 0 0 0 1
orfl9.6164 orfl9.6164 0 0 1 0 0 0 0 1
orfl9.1993 orfl9.1993 0 0 1 0 0 0 0 1
orfl9.1822 UME6 0 0 0 0 0 0 1 1
orfI9.1994 orfl9.1994 0 0 0 1 0 0 0 1
orfl9.1995 orfl9.1995 0 0 1 0 0 0 0 1
orfl9.690 PLB2 0 0 0 0 1 0 0 1
orfl9.376 orfl9.376 0 0 0 0 0 0 1 1
orfl9.2988 orfl9.2988 0 0 0 0 1 0 0 1
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orfl9.4451 RIAl 0 0 0 0 1 0 0 1
orfl9.2081 POM152 0 0 1 0 0 0 0 1
orfl9.1618 GFA1 0 0 1 0 0 0 0 1
orfl9.4063 GPT1 0 0 0 0 1 0 0 1
orfl9.686 orfl9.686 0 0 0 0 0 1 0 1
orfl9.1311 SP075 0 0 0 0 1 0 0 1
orfl9.6635 orfl9.6635 0 0 0 0 1 0 0 1
orfl9.7105 FARI 0 0 1 0 0 0 0 1
orfl9.4119 SP072 0 0 1 0 0 0 0 1
orfl9.651 LYPI 0 0 0 0 0 0 1 1
orfl9.2537 orfl9.2537 0 0 0 0 0 1 0 1
orfl9.3054 RPN3 0 0 0 0 1 0 0 1
orfl9.2539 orfl9.2539 0 0 0 0 0 1 0 1
orfl9.3457 SWD3 0 0 0 0 1 0 0 1
orfl9.7177 KAP120 0 0 0 0 0 1 0 1
orfl9.3139 orfl9.3139 0 0 1 0 0 0 0 1
orfl9.3135 orfl9.3135 0 1 0 0 0 0 0 1
orfl9.2401 orfl9.2401 0 0 1 0 0 0 0 1
orfl9.2532 PRS 0 0 1 0 0 0 0 1
orfl9.6742 orfl9.6742 1 0 0 0 0 0 0 1
orfl9.5507 ENPI 0 0 0 0 0 1 0 1
orfl9.4803 orfl9.4803 1 0 0 0 0 0 0 1
orfl9.3688 orfl9.3688 1 0 0 0 0 0 0 1
orfl9.3689 orfl9.3689 1 0 0 0 0 0 0 1
orfl9.1490 MSB2 1 0 0 0 0 0 0 1
orfl9.3865 RFX1 0 0 0 1 0 0 0 1
orfl9.7345 orfl9.7345 0 0 0 1 0 0 0 1
orfl9.7344 orfl9.7344 0 0 0 0 1 0 0 1
orfl9.3048 orfl9.3048 0 1 0 0 0 0 0 1
orfl9.3715 ASFI 0 0 0 0 0 1 0 1
orfl9.1576 orfl9.1576 0 0 1 0 0 0 0 1
orfl9.1578 orfl9.1578 0 0 1 0 0 0 0 1
orfl9.5164 ECM39 0 0 1 0 0 0 0 1
orfl9.4244 orfl9.4244 0 1 0 0 0 0 0 1
orfl9.4247 orfl9.4247 1 0 0 0 0 0 0 1
orfl9.4246 orfl9.4246 0 0 1 0 0 0 0 1
orfl9.4241 orfl9.4241 1 0 0 0 0 0 0 1
orfl9.4240 orfl9.4240 0 0 0 0 1 0 0 1
orfl9.3594 orfl9.3594 0 0 0 0 1 0 0 1
orfl9.3260 orfl9.3260 0 0 0 0 1 0 0 1
orfl9.834 orfl9.834 0 0 1 0 0 0 0 1
orfl9.4062 TRY2 0 0 0 0 1 0 0 1
orfl9.1686 orfl9.1686 0 0 1 0 0 0 0 1
orfl9.707 APG7 0 0 0 1 0 0 0 1
orfl9.1685 ZCF7 0 0 0 1 0 0 0 1
orfl9.1682 orfl9.1682 0 1 0 0 0 0 0 1
orfl9.1649 RNA1 0 1 0 0 0 0 0 1
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orfl9.5674 PGAIO 1 0 0 0 0 0 0 1
orfl9.2878 PGA15 0 0 1 0 0 0 0 1
orfl9.2033 PGA19 1 0 0 0 0 0 0 1
orfl9.2018.2 orfl9.2018.2 0 0 1 0 0 0 0 1
orfl9.7251 WSC4 0 0 0 0 0 1 0 1
orfl9.4665 orfl9.4665 1 0 0 0 0 0 0 1
orfl9.1416 COXi1 0 0 1 0 0 0 0 1
orfl9.4110 orfl9.4110 0 0 0 0 1 0 0 1
orfl9.4112 orfl9.4112 0 0 1 0 0 0 0 1
orfl9.4115 orfl9.4115 0 0 0 0 0 1 0 1
orfl9.4117 orfl9.4117 0 0 0 0 0 0 1 1
orfl9.7275 FGR24 0 0 0 1 0 0 0 1
orfl9.4268 UTP13 0 1 0 0 0 0 0 1
orfl9.4765 PGA6 0 0 0 0 1 0 0 1
orfl9.3122.2 orfl9.3122.2 0 0 0 0 1 0 0 1
orfl9.5041 orfl9.5041 0 0 1 0 0 0 0 1
orfl9.3555 BUD14 0 1 0 0 0 0 0 1
orf19.1369 orfl9.1369 0 0 1 0 0 0 0 1
orfl9.4739 MSSI16 0 0 0 0 1 0 0 1
orfl9.4328 CCC2 0 0 0 0 1 0 0 1
orfl9.4848 SKI3 0 0 0 0 1 0 0 1
orfl9.353 ULPI 0 0 0 0 1 0 0 1
orfl9.1295 VASI 0 0 0 0 0 1 0 1
orfl9.6041 RPO41 0 0 0 0 1 0 0 1
orfl9.6247 orfl9.6247 0 0 0 0 1 0 0 1
orfl9.6244 orfl9.6244 0 0 0 0 0 0 1 1
orfl9.1215 orfl9.1215 0 0 0 0 0 1 0 1
orfl9.1214 orfl9.1214 0 0 0 0 0 1 0 1
orfl9.1961 orfl9.1961 0 0 1 0 0 0 0 1
orfl9.6240 orfl9.6240 0 0 0 0 1 0 0 1
orfl9.1219 orfl9.1219 0 0 0 0 1 0 0 1
orfl9.5221 orfl9.5221 1 0 0 0 0 0 0 1
orfl9.5223 orfl9.5223 1 0 0 0 0 0 0 1
orfl9.5224 orfl9.5224 1 0 0 0 0 0 0 1
orfl9.6248 orfl9.6248 0 0 0 0 1 0 0 1
orfl9.4033 PRP22 1 0 0 0 0 0 0 1
orfl9.1981 orfl9.1981 0 0 1 0 0 0 0 1
orfl9.1671 UTR2 0 0 0 1 0 0 0 1
orfl9.305 orfl9.305 0 0 0 0 1 0 0 1
orfl9.304 orfl9.304 0 0 0 0 1 0 0 1
orfl9.7594 orfl9.7594 0 0 1 0 0 0 0 1
orfl9.2735 SEN2 0 0 1 0 0 0 0 1
orfl9.5938 SENI 0 0 1 0 0 0 0 1
orfl9.2320 orfl9.2320 0 0 0 0 0 1 0 1
orfl9.7203 orfl9.7203 0 1 0 0 0 0 0 1
orfl9.2325 orfl9.2325 0 0 0 1 0 0 0 1
orfl9.5145 SSP96 0 0 1 0 0 0 0 1
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orfl9.6625 orfl9.6625 0 0 1 0 0 0 0 1
orfl9.2198 FLC3 0 0 0 0 1 0 0 1
orfl9.1813 FLC2 0 0 1 0 0 0 0 1
orfl9.2517 orfl9.2517 0 0 1 0 0 0 0 1
orfl9.4867 SWEl 0 0 0 0 0 0 1 1
orfl9.2184 orfl9.2184 0 0 0 0 1 0 0 1
orfl9.3125 orfl9.3125 0 0 1 0 0 0 0 1
orfl9.3124 orfl9.3124 0 0 1 0 0 0 0 1
orfl9.3120 orfl9.3120 0 0 1 0 0 0 0 1
orfl9.2823 RFG1 0 0 0 0 0 1 0 1
orfl9.2431 orfl9.2431 0 0 0 0 1 0 0 1
orfl9.2723 HITI 0 1 0 0 0 0 0 1
orfl9.6928 SAP9 0 0 0 0 0 0 1 1
orfl9.5585 SAPS 0 0 0 0 1 0 0 1
orfl9.4875 orfl9.4875 0 0 0 1 0 0 0 1
orfl9.4872 orfl9.4872 0 0 0 0 1 0 0 1
orfl9.3697 orfl9.3697 0 0 0 1 0 0 0 1
orfl9.7376 orfl9.7376 1 0 0 0 0 0 0 1
orfl9.2509 orfl9.2509 1 0 0 0 0 0 0 1
orfl9.2500 orfl9.2500 0 0 0 0 1 0 0 1
orfl9.2051 orfl9.2051 0 0 1 0 0 0 0 1
orfl9.2506 orfl9.2506 0 0 0 0 1 0 0 1
orfl9.3950 MSM1 0 0 0 0 1 0 0 1
orfl9.984 PHO8 1 0 0 0 0 0 0 1
orfl9.1648 RAD50 0 0 0 0 1 0 0 1
orfl9.4903 orfl9.4903 0 0 0 0 1 0 0 1
orfl9.4907 orfl9.4907 0 0 0 0 1 0 0 1
orfl9.4904 orfl9.4904 0 0 0 0 1 0 0 1
orfl9.4905 orfl9.4905 0 0 0 0 0 0 1 1
orfl9.4908 orfl9.4908 1 0 0 0 0 0 0 1
orfl9.3208 DAL52 0 1 0 0 0 0 0 1
orfl9.2623 ECM22 0 0 1 0 0 0 0 1
orfl9.3586 orfl9.3586 0 1 0 0 0 0 0 1
orfl9.4473 SPC19 1 0 0 0 0 0 0 1
orfl9.4471 orfl9.4471 0 0 0 0 0 0 1 1
orfl9.3271 orfl9.3271 0 0 1 0 0 0 0 1
orfl9.3971 orfl9.3971 0 0 0 0 1 0 0 1
orfl9.4295 orfl9.4295 0 0 0 0 0 1 0 1
orfl9.939 NAM7 0 0 1 0 0 0 0 1
orfl9.35.1 orfl9.35.1 0 0 1 0 0 0 0 1
orfl9.3675 GAL7 1 0 0 0 0 0 0 1
orfl9.4866 CPP1 0 0 0 0 0 0 1 1
orfl9.2044 PGA27 0 0 1 0 0 0 0 1
orfl9.4615 orfl9.4615 0 0 1 0 0 0 0 1
orfl9.3477 orfl9.3477 0 1 0 0 0 0 0 1
orfl9.3476 orfl9.3476 0 0 0 0 1 0 0 1
orfl9.3093 MSH2 0 0 0 0 1 0 0 1
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orfl9.4128 orfl9.4128 0 0 0 1 0 0 0 1
orfl9.559 FGR14 0 0 0 0 1 0 0 1
orfl9.3700 TOM70 0 0 0 0 1 0 0 1
orfl9.5479 FGR12 0 0 0 0 1 0 0 1
orfl9.4067 FGR18 0 0 0 0 1 0 0 1
orfl9.5094 BULl 0 0 0 0 1 0 0 1
orfl9.4059 orfl9.4059 0 0 0 0 1 0 0 1
orfl9.3112 ZRTI 0 0 1 0 0 0 0 1
orfl9.1585 ZRT2 0 0 1 0 0 0 0 1
orfl9.105 HAL22 0 0 0 0 0 1 0 1
orfl9.1439 IPK1 0 0 0 0 1 0 0 1
orfl9.1563 ECM3 0 0 1 0 0 0 0 1
orfl9.5299 ECM1 0 1 0 0 0 0 0 1
orfl9.5052 orfl9.5052 0 0 1 0 0 0 0 1
orfl9.1089 PEXI1 0 0 0 0 1 0 0 1
orfl9.1831 orf19.1831 0 0 0 0 1 0 0 1
orfl9.7282 PEX13 0 0 0 0 1 0 0 1
orfl9.1805 PEX14 0 0 0 0 0 1 0 1
orfl9.4635 NIPI 0 0 0 0 1 0 0 1
orfl9.610 EFGI 0 0 0 0 0 1 0 1
orfl9.1741 DITI 0 0 1 0 0 0 0 1
orfl9.2984 MST1 0 0 0 0 1 0 0 1
orfl9.695 RGS2 0 0 0 0 0 0 1 1
orfl9.1353 orfl9.1353 0 1 0 0 0 0 0 1
orfl9.3908 orfl9.3908 0 0 1 0 0 0 0 1
orfl9.3904 orfl9.3904 0 0 0 1 0 0 0 1
orfl9.3901 orfl9.3901 0 0 0 0 1 0 0 1
orfl9.407 GCD6 1 0 0 0 0 0 0 1
orfl9.5459 orfl9.5459 0 0 1 0 0 0 0 1
orfl9.481 GCD1 0 0 0 0 1 0 0 1
orfl9.5530 NAB3 0 0 0 0 1 0 0 1
orfl9.2560 CDC60 0 0 1 0 0 0 0 1
orfl9.775 orfl9.775 0 0 0 0 1 0 0 1
orfl9.3207 CCN1 0 0 0 0 0 0 1 1
orfl9.6507 orfl9.6507 0 0 1 0 0 0 0 1
orfl9.3876 ZCF19 0 0 0 0 1 0 0 1
orfl9.5239 orfl9.5239 0 0 0 0 1 0 0 1
orfl9.6508 orf19.6508 0 0 1 0 0 0 0 1
orfl9.1229 orfl9.1229 0 1 0 0 0 0 0 1
orfl9.3711 orfl9.3711 0 0 1 0 0 0 0 1
orfl9.3240 ERG27 0 0 1 0 0 0 0 1
orfl9.178 orfl9.178 0 0 0 0 0 1 0 1
orfl9.177 orfl9.177 0 0 0 1 0 0 0 1
orfl9.5558 RBF1 0 0 0 1 0 0 0 1
orfl9.173 orfl9.173 0 0 0 0 0 0 1 1
orfl9.1944 GPRI 0 0 0 0 1 0 0 1
orfl9.315 orfl9.315 0 0 0 0 0 1 0 1
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orfl9.318 orfl9.318 0 0 0 0 1 0 0 1
orfl9.7213 orfl9.7213 0 0 0 1 0 0 0 1
orfl9.2332 orfl9.2332 0 0 0 0 1 0 0 1
orfl9.6347 orfl9.6347 0 0 0 0 1 0 0 1
orfl9.6612 orfl9.6612 1 0 0 0 0 0 0 1
orfl9.6342 orfl9.6342 0 0 0 0 1 0 0 1
orfl9.3589 SPOil 0 0 0 0 1 0 0
orfl9.111 CAN2 0 0 0 0 1 0 0 1
orfl9.84 CAN3 0 0 0 0 1 0 0 1
orfl9.1597 ABG1 1 0 0 0 0 0 0 1
orfl9.646 GLN1 0 1 0 0 0 0 0 1
orfl9.5759 SNQ2 0 0 0 0 1 0 0 1
orfl9.5760 IHD1 0 0 0 0 0 0 1 1
orfl9.5074 orfl9.5074 0 0 0 0 0 1 0 1
orfl9.956 orfl9.956 0 0 1 0 0 0 0 1
orfl9.3110 orfl9.3110 0 0 1 0 0 0 0 1
orfl9.2429 orfl9.2429 0 0 0 0 1 0 0 1
orfl9.7108 orfl9.7108 0 0 0 1 0 0 0 1
orfl9.7101 orfl9.7101 0 0 1 0 0 0 0 1
orfl9.6981 orfl9.6981 0 0 0 0 0 0 1 1
orfl9.6982 orfl9.6982 0 0 0 0 0 1 0 1
orfl9.6986 orfl9.6986 0 0 0 0 0 0 1 1
orfl9.5527 orfl9.5527 0 0 0 0 1 0 0 1
orfl9.918 CDRII 0 0 0 0 1 0 0 1
orfl9.2605 orfl9.2605 0 0 1 0 0 0 0 1
orfl9.458.1 orfl9.458.1 0 0 0 0 0 1 0 1
orfl9.4688 DAG7 0 0 1 0 0 0 0 1
orfl9.4865 orfl9.4865 1 0 0 0 0 0 0 1
orfl9.4862 orf19.4862 0 0 0 1 0 0 0 1
orfl9.7368 orf19.7368 0 0 0 0 0 1 0 1
orfl9.2514 orfl9.2514 0 0 0 0 0 1 0 1
orfl9.3649 orfl9.3649 0 0 0 0 1 0 0 1
orfl9.1519 orfl9.1519 0 0 1 0 0 0 0 1
orfl9.3644 orfl9.3644 0 0 0 0 1 0 0 1
orfl9.3647 SEC8 0 0 0 0 1 0 0 1
orfl9.4912 orfl9.4912 1 0 0 0 0 0 0 1
orfl9.4262 orfl9.4262 0 0 0 0 0 1 0 1
orfl9.3241 orfl9.3241 0 0 1 0 0 0 0 1
orfl9.3245 orfl9.3245 0 0 1 0 0 0 0 1
orfl9.4269 orfl9.4269 0 0 0 0 1 0 0 1
orfl9.3247 orfl9.3247 0 1 0 0 0 0 0 1
orfl9.6792 RRD1 0 0 0 0 1 0 0 1
orfl9.4286 orfl9.4286 0 0 0 0 1 0 0 1
orfl9.6967 USO6 0 0 0 0 1 0 0 1
orfl9.1427 orfl9.1427 0 0 0 0 1 0 0 1
orfl9.1428 DUOl 0 0 0 0 0 1 0 1
orfl9.2758 PGA38 0 0 0 1 0 0 0 1
183
orfl9.2608 ADHS 0 1 0 0 0 0 0 1
orfl9.271 ADH4 0 0 0 0 1 0 0 1
orfl9.7521 REPI 0 0 1 0 0 0 0 1
orfl9.3923 PGA37 0 0 1 0 0 0 0 1
orfl9.4607 orfl9.4607 0 0 1 0 0 0 0 1
orfl9.3481 orfl9.3481 0 1 0 0 0 0 0 1
orfl9.669 PRM1 0 0 0 0 1 0 0 1
orfl9.1405 PHO13 0 0 1 0 0 0 0 1
orfl9.4132 orf19.4132 0 1 0 0 0 0 0 1
orfl9.4737 TPO3 0 0 0 1 0 0 0 1
orfl9.7148 TPO2 0 0 0 1 0 0 0 1
orfl9.1736 orfl9.1736 0 0 1 0 0 0 0 1
orfI9.1734 orfl9.1734 0 0 1 0 0 0 0 1
orfl9.1730 orfl9.1730 0 0 0 0 1 0 0 1
orfl9.4162 MLH1 0 0 1 0 0 0 0 1
orfl9.6396 orfl9.6396 0 0 0 0 0 1 0 1
orfl9.5742 ALS9 0 0 0 0 1 0 0 1
orfl9.2209 YVC1 0 0 1 0 0 0 0 1
orfl9.3113 orfl9.3113 0 0 0 0 0 1 0 1
orfl9.1378 SUP35 0 0 1 0 0 0 0 1
orfl9.2585 orfl9.2585 0 0 1 0 0 0 0 1
orfl9.1646 orfl9.1646 0 0 0 1 0 0 0 1
orfl9.2241 PST1 0 0 0 0 0 0 1 1
orfl9.1270 FRE3 0 0 1 0 0 0 0 1
orfl9.3529 ABP2 1 0 0 0 0 0 0 1
orfl9.5902 RAS2 0 0 1 0 0 0 0 1
orfl9.1349 orfl9.1349 0 0 0 1 0 0 0 1
orfl9.1348 orfl9.1348 0 0 1 0 0 0 0 1
orfl9.5426 orfl9.5426 1 0 0 0 0 0 0 1
orfl9.3924 orfl9.3924 0 0 0 0 1 0 0 1
orfl9.540 orfl9.540 0 0 0 0 1 0 0 1
orfl9.1236 orfl9.1236 0 0 1 0 0 0 0 1
orfl9.3809 BASI 0 0 1 0 0 0 0 1
orfl9.149 orfl9.149 0 0 0 1 0 0 0 1
orfl9.6283 orfl9.6283 1 0 0 0 0 0 0 1
orfl9.899 orfl9.899 0 0 1 0 0 0 0 1
orfl9.6284 orfl9.6284 0 0 0 1 0 0 0 1
orfl9.323 orfl9.323 0 0 0 0 1 0 0 1
orfl9.6863 VPH1 0 0 1 0 0 0 0 1
orfl9.3255 TENI 0 1 0 0 0 0 0 1
orfl9.2504 BMS1 0 0 1 0 0 0 0 1
orfl9.4975 HYRI 0 0 0 1 0 0 0 1
orfl9.3608 orfl9.3608 0 0 0 0 0 1 0 1
orf19.6357 orfl9.6357 0 0 0 0 1 0 0 1
orfl9.6356 orfl9.6356 0 0 0 0 0 1 0 1
orfl9.6602 orfl9.6602 0 0 0 0 1 0 0 1
orfl9.5884 orfl9.5884 0 0 0 0 1 0 0 1
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orfl9.5555 orfl9.5555 0 0 0 1 0 0 0 1
orfl9.6199 orfl9.6199 0 1 0 0 0 0 0 1
orfl9.57 PSF2 0 0 0 0 1 0 0 1
orfl9.1321 HWP1 0 0 0 0 1 0 0 1
orfl9.2649 PCL1 1 0 0 0 0 0 0 1
orfl9.4012 PCL5 0 0 0 0 1 0 0 1
orfl9.7489 orfl9.7489 0 0 1 0 0 0 0 1
orfl9.1367 MTW1 0 0 0 0 0 1 0 1
orfl9.3107 orfl9.3107 0 0 0 0 1 0 0 1
orfl9.3105 orfl9.3105 0 0 1 0 0 0 0 1
orfl9.2458 orfl9.2458 0 0 0 0 1 0 0 1
orfl9.2455 orfl9.2455 1 0 0 0 0 0 0 1
orfl9.896 CHK1 0 0 1 0 0 0 0 1
orfl9.3109 orfl9.3109 0 0 0 1 0 0 0 1
orfl9.4255 ECM331 0 0 1 0 0 0 0 1
orfl9.95 orfl9.95 1 0 0 0 0 0 0 1
orfl9.2671 orfl9.2671 0 0 1 0 0 0 0 1
orfl9.7392 orf19.7392 0 0 0 0 1 0 0 1
orfl9.7002 orfl9.7002 1 0 0 0 0 0 0 1
orfl9.7007 orfl9.7007 0 0 0 0 1 0 0 1
orfl9.2070 orfl9.2070 0 0 1 0 0 0 0 1
orfl9.7553 orfl9.7553 1 0 0 0 0 0 0 1
orfl9.3494 CTF5 0 1 0 0 0 0 0 1
orfl9.1505 orfl9.1505 0 1 0 0 0 0 0 1
orfl9.3764 GSG1 0 0 0 0 1 0 0 1
orfl9.6053 CIS2 0 0 0 0 1 0 0 1
orfl9.7037 YAE1 0 0 0 0 0 1 0 1
orfl9.5911 CMK1 0 0 1 0 0 0 0 1
orfl9.4928 SEC2 0 0 0 0 1 0 0 1
orfl9.3250 orfl9.3250 0 0 1 0 0 0 0 1
orfl9.4654 orfl9.4654 0 0 0 0 1 0 0 1
orfl9.4307 orf19.4307 0 0 0 0 1 0 0 1
orfl9.1430 orfl9.1430 0 0 0 0 1 0 0 1
orfl9.1433 orfl9.1433 0 0 0 0 1 0 0 1
orfl9.1434 orfl9.1434 0 0 1 0 0 0 0 1
orfl9.1438 orfl9.1438 0 0 1 0 0 0 0 1
orfl9.3742 orfl9.3742 0 0 0 0 0 0 1 1
orfl9.4639 orfl9.4639 1 0 0 0 0 0 0 1
orfl9.4637 orfl9.4637 0 0 0 0 1 0 0 1
orfl9.2842 GZF3 0 0 0 0 0 1 0 1
orfl9.1202 orfl9.1202 0 0 0 0 1 0 0 1
orfl9.4142 orfl9.4142 0 0 1 0 0 0 0 1
orfl9.4149 orfl9.4149 0 1 0 0 0 0 0 1
orfl9.2852 orfl9.2852 0 1 0 0 0 0 0 1
orfl9.2853 orfl9.2853 0 0 1 0 0 0 0 1
orfl9.2857 orfl9.2857 0 0 0 0 1 0 0 1
orfl9.728 TSC11 0 1 0 0 0 0 0 1
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orfl9.6255 orfl9.6255 0 0 0 0 1 0 0 1
orfl9.1720 orfl9.1720 0 0 0 0 0 1 0 1
orfl9.4308 HSL1 0 0 0 0 1 0 0 1
orfl9.4701 orfl9.4701 0 1 0 0 0 0 0 1
orfl9.4702 orfl9.4702 0 0 1 0 0 0 0 1
orfl9.3199 PIKA 0 0 0 0 1 0 0 1
orfl9.2919 MPH1 0 0 1 0 0 0 0 1
orfl9.5605 orfl9.5605 0 0 0 0 0 1 0 1
orfl9.3774.1 orfl9.3774.1 0 0 0 0 1 0 0 1
orfl9.1115 GUKI 0 0 0 0 1 0 0 1
orfl9.1453 SPTS 0 0 0 1 0 0 0 1
orfl9.557 orfl9.557 0 0 0 0 0 0 1 1
orfl9.1260 LEA 0 0 0 0 1 0 0 1
orfl9.6569 orfl9.6569 0 0 0 0 1 0 0 1
orfl9.3815 orfl9.3815 0 0 0 0 0 0 1 1
orfl9.854 UGAll 0 0 0 1 0 0 0 1
orfl9.1086 orfl9.1086 0 0 0 1 0 0 0 1
orf19.1087 orfl9.1087 0 0 0 0 1 0 0 1
orfl9.154 orfl9.154 0 0 0 1 0 0 0 1
orfl9.5720 orfl9.5720 0 1 0 0 0 0 0 1
orfl9.5724 orfl9.5724 0 0 0 0 0 1 0 1
orfl9.5095 orfl9.5095 0 0 0 1 0 0 0 1
orfl9.2771 BEM3 0 0 0 0 0 1 0 1
orfl9.5821 orfl9.5821 0 0 0 0 0 1 0 1
orfl9.5940 ZCF32 0 1 0 0 0 0 0 1
orfl9.5124 RBR3 1 0 0 0 0 0 0 1
orfl9.6360 orfl9.6360 0 0 0 1 0 0 0 1
orfl9.6366 orfl9.6366 0 0 1 0 0 0 0 1
orfl9.5894 orfl9.5894 0 0 0 0 1 0 0 1
orf19.3895 CHT2 0 0 1 0 0 0 0 1
orfl9.1515 CHT4 0 0 1 0 0 0 0 1
orfl9.5543 orfl9.5543 0 1 0 0 0 0 0 1
orfl9.6168 orfl9.6168 0 0 1 0 0 0 0 1
orfl9.4548 MAK32 0 1 0 0 0 0 0 1
orfl9.6382 orfl9.6382 1 0 0 0 0 0 0 1
orfl9.1863 orfl9.1863 1 0 0 0 0 0 0 1
orfl9.7494 orfl9.7494 0 0 1 0 0 0 0 1
orfl9.7497 orfl9.7497 1 0 0 0 0 0 0 1
orfl9.7490 orfl9.7490 0 0 0 0 1 0 0 1
orfl9.2449 orfl9.2449 0 0 0 0 1 0 0 1
orfl9.2440 orfl9.2440 0 0 0 0 1 0 0 1
orfl9.2442 orfl9.2442 0 0 0 0 0 0 1 1
orfl9.6705 orfl9.6705 0 1 0 0 0 0 0 1
orfl9.6703 orfl9.6703 0 0 1 0 0 0 0 1
orfl9.1860.1 orfl9.1860.1 0 0 1 0 0 0 0 1
orfl9.2285 orfl9.2285 0 0 1 0 0 0 0 1
orfl9.81 orfl9.81 0 0 0 0 0 1 0 1
186
orfl9.3962 HAS1 0 0 0 0 0 0 1 1
orfl9.2664 orfl9.2664 0 0 0 0 1 0 0 1
orfl9.2540 SAS3 0 0 0 1 0 0 0 1
orfl9.6953 IRS4 0 0 0 0 1 0 0 1
orfl9.1002 orfl9.1002 0 0 0 0 1 0 0 1
orfl9.7011 orfl9.7011 0 0 1 0 0 0 0 1
orfl9.7012 orfl9.7012 0 0 1 0 0 0 0 1
orfl9.7545 orfl9.7545 0 0 1 0 0 0 0 1
orfl9.6017 orfl9.6017 0 0 0 0 1 0 0 1
orfl9.1005 orfl9.1005 0 0 0 0 1 0 0 1
orfl9.4932 orfl9.4932 1 0 0 0 0 0 0 1
orfl9.4936 orfl9.4936 1 0 0 0 0 0 0 1
orfl9.6637 orfl9.6637 0 0 0 0 1 0 0 1
orfl9.3713 orfl9.3713 0 0 1 0 0 0 0 1
orfl9.55 orf19.55 1 0 0 0 0 0 0 1
orfl9.3618 YWP1 1 0 0 0 0 0 0 1
orfl9.3719 orfl9.3719 0 0 1 0 0 0 0 1
orfl9.2717 SASlO 0 0 0 0 1 0 0 1
orfl9.3539 orfl9.3539 0 0 0 1 0 0 0 1
orfl9.1047 ERBI 0 0 0 1 0 0 0 1
orfl9.1404 orfl9.1404 0 0 0 0 1 0 0 1
orfl9.4626 orfl9.4626 0 0 0 0 1 0 0 1
orfl9.4622 orfl9.4622 0 0 1 0 0 0 0 1
orfl9.4621 orfl9.4621 0 0 1 0 0 0 0 1
orfl9.4153 orfl9.4153 0 1 0 0 0 0 0 1
orfl9.568 SPE2 0 0 0 0 0 0 1 1
orfl9.5977 CEMI 0 0 0 0 1 0 0 1
orfl9.6032 SPEl 0 0 0 0 1 0 0 1
orfl9.1718 ZCF8 0 0 0 0 1 0 0 1
orfl9.1717 orfl9.1717 0 0 0 1 0 0 0 1
orfl9.4815 YTM1 0 0 0 1 0 0 0 1
orfl9.7175 HLJ1 0 0 0 0 0 0 1 1
orfl9.1664 orfl9.1664 0 0 0 0 0 1 0 1
orfl9.1667 orfl9.1667 0 0 0 0 1 0 0 1
orfl9.132 orfl9.132 0 0 0 0 0 0 1 1
orfl9.5782 orfl9.5782 0 0 1 0 0 0 0 1
orfl9.5391 orfl9.5391 0 0 0 0 1 0 0 1
orfl9.131 orfl9.131 0 0 0 0 1 0 0 1
orfl9.641 orfl9.641 0 0 0 0 0 1 0 1
orfl9.1317 OSH3 0 0 0 0 1 0 0 1
orfl9.5156 orfl9.5156 0 0 1 0 0 0 0 1
orfl9.7115 SAC7 0 0 0 0 0 0 1 1
orfl9.3474 IPL1 0 0 0 0 0 0 1 1
orfl9.5544 SAC6 0 0 0 0 1 0 0 1
orfl9.768 SYGI 0 0 0 0 1 0 0 1
orfl9.1926 SEF2 1 0 0 0 0 0 0 1
orfl9.520 orfl9.520 0 0 0 0 0 0 1 1
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orfl9.3828 orfl9.3828 0 0 0 1 0 0 0 1
orfl9.2324 UBA4 0 0 0 0 1 0 0 1
orfl9.1258 orfl9.1258 0 0 1 0 0 0 0 1
orfl9.3276 PWP2 0 0 1 0 0 0 0 1
orfl9.3827 orfl9.3827 0 0 1 0 0 0 0 1
orfl9.5861.1 orfl9.5861.1 0 0 0 0 1 0 0 1
orfl9.7512 orfl9.7512 0 0 1 0 0 0 0 1
orfl9.5580 TELl 0 0 0 0 0 1 0 1
orfl9.635 orfl9.635 0 0 0 0 1 0 0 1
orfl9.634 orfl9.634 0 0 0 1 0 0 0 1
orfl9.3966 CRH12 0 0 0 0 0 1 0 1
orf19.2706 CRH1 0 0 1 0 0 0 0 1
orfl9.184 orfl9.184 0 0 0 0 0 0 1 1
orf19.182 orfl9.182 0 1 0 0 0 0 0 1
orfl9.1897 orfl9.1897 0 0 0 0 0 1 0 1
orfl9.5579 orfl9.5579 0 1 0 0 0 0 0 1
orfl9.1890 orf19.1890 0 0 1 0 0 0 0 1
orfl9.5573 orfl9.5573 1 0 0 0 0 0 0 1
orfl9.5574 orfl9.5574 0 0 0 0 0 1 0 1
orfI9.1383 orfl9.1383 0 0 0 0 1 0 0 1
orfl9.1381 orfl9.1381 0 0 0 0 1 0 0 1
orfl9.3826 orf19.3826 0 0 1 0 0 0 0 1
orfl9.4002 DUNI 0 0 0 0 1 0 0 1
orfl9.1876 orfl9.1876 0 0 0 0 1 0 0 1
orfl9.1693 CAS4 0 0 1 0 0 0 0 1
orfl9.985 orfl9.985 0 1 0 0 0 0 0 1
orfl9.3940 orfl9.3940 0 0 0 0 0 1 0 1
orfl9.450 orfl9.450 1 0 0 0 0 0 0 1
orfl9.980 orfl9.980 0 1 0 0 0 0 0 1
orfl9.4772 SSU81 0 0 0 1 0 0 0 1
orfl9.2478 orfl9.2478 0 1 0 0 0 0 0 1
orfl9.7159 orfl9.7159 0 0 0 1 0 0 0 1
orfl9.5076.1 orfl9.5076.1 0 0 0 0 1 0 0 1
orfl9.2278 orfl9.2278 0 0 0 0 1 0 0
orfl9.866 RAD32 0 0 1 0 0 0 0 1
orfl9.1638 orfl9.1638 0 0 0 0 1 0 0 1
orfl9.6952 orfl9.6952 0 0 0 0 1 0 0 1
orfl9.3010 orfl9.3010 1 0 0 0 0 0 0 1
orfl9.7232 IRRI 0 0 0 0 1 0 0 1
orfl9.7024 orfl9.7024 0 0 0 0 1 0 0 1
orfl9.6008 orfl9.6008 0 1 0 0 0 0 0 1
orfl9.2010 orfl9.2010 0 1 0 0 0 0 0 1
orfl9.6003 orfl9.6003 0 0 0 0 1 0 0 1
orfl9.2728 orfl9.2728 0 0 0 0 1 0 0 1
orfl9.2725 orfl9.2725 0 0 0 0 0 1 0
orfl9.979 FASI 0 0 1 0 0 0 0 1
orfl9.3639 orfl9.3639 1 0 0 0 0 0 0 1
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orfl9.2721 orfl9.2721 0 0 0 0 1 0 0 1
orfl9.1529 orfl9.1529 0 0 0 0 0 1 0 1
orfl9.1528 orfl9.1528 1 0 0 0 0 0 0 1
orfl9.4354 MCM2 0 0 0 0 0 1 0 1
orfl9.4946 orfl9.4946 0 0 0 0 1 0 0 1
orfl9.4942 orfl9.4942 0 0 0 0 1 0 0 1
orfl9.3704 orfl9.3704 0 0 0 0 1 0 0 1
orfl9.2653 orfl9.2653 0 0 0 0 1 0 0 1
orfl9.1412 orf19.1412 0 0 0 0 1 0 0 1
orfl9.1411 orfl9.1411 0 0 0 0 1 0 0 1
orfl9.3522 orfl9.3522 0 0 1 0 0 0 0 1
orfl9.1414 orfl9.1414 0 0 0 0 1 0 0 1
orfl9.4894 orfl9.4894 0 0 0 0 1 0 0 1
orfl9.4896 orfl9.4896 0 0 0 0 1 0 0 1
orfl9.4893 orfl9.4893 0 0 0 0 1 0 0 1
orfl9.4365 orfl9.4365 0 0 0 0 0 0 1 1
orfl9.7359 CRZ1 1 0 0 0 0 0 0 1
orfl9.2356 CRZ2 0 0 0 0 0 0 1 1
orfl9.1605 PMS1 0 0 1 0 0 0 0 1
orfl9.2509.1 orfl9.2509.1 0 0 0 0 1 0 0 1
orfl9.4094 orfl9.4094 0 0 1 0 0 0 0 1
orfl9.4767 ZCF28 0 0 0 0 0 1 0 1
orfl9.4097 orfl9.4097 0 0 0 0 1 0 0 1
orfl9.4760 orfl9.4760 0 0 0 0 1 0 0 1
orfl9.4768 orfl9.4768 0 0 0 0 1 0 0 1
orfl9.6345 RPG1A 0 0 0 0 0 1 0 1
orfl9.2364 MISil 1 0 0 0 0 0 0 1
orfl9.1676 orf19.1676 0 0 0 1 0 0 0 1
orfl9.6214 ATC 0 0 0 0 1 0 0 1
orfl9.1914 FAV3 0 0 0 1 0 0 0 1
orfl9.1679 orfl9.1679 0 1 0 0 0 0 0 1
orfl9.1678 orfl9.1678 1 0 0 0 0 0 0 1
orfl9.4169 orfl9.4169 0 0 1 0 0 0 0 1
orfl9.4160 orfl9.4160 0 0 1 0 0 0 0 1
orfl9.4164 orfl9.4164 0 0 1 0 0 0 0 1
orfl9.4166 ZCF21 0 0 1 0 0 0 0 1
orfl9.2783 PIR32 0 1 0 0 0 0 0 1
orfl9.5381 orfl9.5381 0 0 0 0 1 0 0 1
orfl9.5367 RDH54 0 0 1 0 0 0 0 1
orfl9.4645 BEMI 0 0 0 0 1 0 0 1
orfl9.533 orfl9.533 0 0 1 0 0 0 0 1
orfl9.2825 orfl9.2825 0 0 0 0 0 0 1 1
orfl9.1268 orfl9.1268 0 0 1 0 0 0 0 1
orfl9.3833 orfl9.3833 0 1 0 0 0 0 0 1
orfl9.3831 orfl9.3831 0 0 0 0 1 0 0 1
orfl9.1066 GIG1 0 0 0 0 1 0 0 1
orfl9.5702 orfl9.5702 0 0 0 0 1 0 0 1
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orf19.1386 orfl9.1386 0 0 0 0 1 0 0 1
orfl9.5963 orfl9.5963 0 0 0 0 1 0 0 1
orfl9.144 SNU114 0 1 0 0 0 0 0 1
orfl9.2711.1 orfl9.2711.1 1 0 0 0 0 0 0 1
orfl9.5965 orfl9.5965 0 0 0 0 1 0 0 1
orfl9.3666 orfl9.3666 0 1 0 0 0 0 0 1
orfl9.199 orfl9.199 0 0 0 0 1 0 0 1
orfl9.5255 PXA2 0 0 0 1 0 0 0 1
orfl9.860 BMT8 0 1 0 0 0 0 0 1
orfl9.1203 SR077 0 0 0 0 1 0 0 1
orfl9.1367.1 orfl9.1367.1 0 0 1 0 0 0 0 1
orfl9.3282 BMT3 0 0 1 0 0 0 0 1
orfl9.5566 orfl9.5566 1 0 0 0 0 0 0 1
orfl9.5602 BMT6 0 0 0 0 1 0 0 1
orfl9.5612 BMT4 0 0 0 0 1 0 0 1
orfl9.6147 orfl9.6147 0 0 0 0 1 0 0 1
orfl9.6493 orfl9.6493 0 0 0 0 1 0 0 1
orfl9.6491 orfl9.6491 0 0 1 0 0 0 0 1
orfl9.4585 TFGI 0 0 1 0 0 0 0 1
orfl9.5365 orfl9.5365 0 0 0 0 1 0 0 1
orfl9.5500 MAK16 0 0 0 0 1 0 0 1
orfl9.2619 PHO113 0 1 0 0 0 0 0 1
orfl9.3727 PHOl12 0 0 1 0 0 0 0 1
orfl9.1844 orfl9.1844 0 0 0 0 1 0 0 1
orfl9.996 orfl9.996 0 0 0 0 1 0 0 1
orfl9.445 orfl9.445 1 0 0 0 0 0 0 1
orfl9.5097 CAT8 0 0 0 0 1 0 0 1
orfl9.5343 ASHI 0 0 0 0 1 0 0 1
orfl9.448 orfl9.448 0 0 0 1 0 0 0 1
orfl9.2261 orfl9.2261 0 0 1 0 0 0 0 1
orfl9.2260 orf19.2260 0 0 0 0 1 0 0 1
orfl9.2263 orfl9.2263 0 0 0 0 0 0 1 1
orfl9.69 orfl9.69 0 0 0 0 1 0 0 1
orfl9.1286 orfl9.1286 0 1 0 0 0 0 0 1
orfl9.1287 orfl9.1287 0 0 0 0 1 0 0 1
orfl9.1285 orfl9.1285 0 0 0 0 1 0 0 1
orfl9.801 TBF1 0 0 1 0 0 0 0 1
orfl9.1945 AURI 0 0 0 0 1 0 0 1
orfl9.1743 ACSI 0 0 1 0 0 0 0 1
orfl9.5672 MEP2 0 0 1 0 0 0 0 1
orfl9.377 PHR3 0 0 0 0 1 0 0 1
orfl9.2000 orfl9.2000 0 0 0 1 0 0 0 1
orfl9.2002 orfl9.2002 0 1 0 0 0 0 0 1
orfl9.2736 HFL2 0 0 1 0 0 0 0 1
orfl9.4746 JIPS 0 0 0 0 1 0 0 1
orfl9.3010.1 ECM33 0 0 0 0 1 0 0 1
orf19.4955 orfl9.4955 0 0 0 0 0 1 0 1
190
orfl9.4951 orfl9.4951 0 0 0 0 1 0 0 1
orfl9.3252 DAL81 0 0 1 0 0 0 0 1
orfl9.6309 MSSI1 0 0 0 0 0 0 1 1
orfl9.3285 orfl9.3285 0 0 1 0 0 0 0 1
orfl9.2651 CAM1-1 0 0 0 0 1 0 0 1
orfl9.3281 orfl9.3281 0 0 0 0 1 0 0 1
orfl9.3775 SSK2 0 0 1 0 0 0 0 1
orfl9.3553 RPF2 0 0 1 0 0 0 0 1
orfl9.4420 orfl9.4420 0 0 1 0 0 0 0 1
orfl9.7452 orfl9.7452 0 0 0 0 0 1 0 1
orfl9.3593 RPT6 0 0 1 0 0 0 0 1
orfl9.5440 RPT2 0 0 0 0 0 0 1 1
orfl9.7529 EPLI 1 0 0 0 0 0 0 1
orfl9.3512 orfl9.3512 0 0 1 0 0 0 0 1
orfl9.4261 TIF5 0 0 0 0 0 1 0 1
orfl9.4395 orfl9.4395 0 0 0 0 1 0 0 1
orfl9.7624 orfl9.7624 0 0 0 0 1 0 0 1
orfl9.4391 orfl9.4391 0 0 0 1 0 0 0 1
orfl9.3423 TIF3 0 0 0 0 1 0 0 1
orfl9.4399 orfl9.4399 0 0 0 0 1 0 0 1
orfl9.4398 orfl9.4398 0 0 1 0 0 0 0 1
orfl9.4883 orfl9.4883 0 0 0 0 1 0 0 1
orfl9.7158 orfl9.7158 1 0 0 0 0 0 0 1
orfl9.4880 orfl9.4880 0 0 0 0 0 1 0 1
orfl9.1279 CDS1 0 0 0 0 1 0 0 1
orfl9.3600 orf19.3600 1 0 0 0 0 0 0 1
orfl9.3356 ESPI 0 1 0 0 0 0 0 1
orfl9.2868 orfl9.2868 0 0 1 0 0 0 0 1
orfl9.2863 orfl9.2863 0 0 0 1 0 0 0 1
orfl9.4372 orfl9.4372 0 0 0 0 1 0 0 1
orfl9.2867 orfl9.2867 0 0 0 0 1 0 0 1
orfl9.723 BCR1 0 0 1 0 0 0 0 1
orfl9.4088 orf19.4088 0 1 0 0 0 0 0 1
orfl9.4081 orfl9.4081 0 0 1 0 0 0 0 1
orfl9.2335 orfl9.2335 0 0 0 0 1 0 0 1
orfl9.2616 UGT51CI 0 0 0 0 1 0 0 1
orfl9.4341 orfl9.4341 0 1 0 0 0 0 0 1
orfl9.1604 orfl9.1604 0 0 1 0 0 0 0 1
orfl9.1600 orfl9.1600 0 0 0 0 1 0 0 1
orfl9.1609 orfl9.1609 0 0 0 0 1 0 0 1
orfl9.4174 orfl9.4174 0 0 1 0 0 0 0 1
orfl9.4172 orfl9.4172 0 0 1 0 0 0 0 1
orfl9.4171 orfl9.4171 0 0 1 0 0 0 0 1
orfl9.4274 PUTI 0 0 0 0 1 0 0 1
orfl9.2552 orfl9.2552 0 0 0 0 0 0 1 1
orfl9.5498 EFHl 0 0 0 0 1 0 0 1
orfl9.1084 CDC39 0 0 0 0 0 1 0 1
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orfl9.3623 SMC2 0 0 1 0 0 0 0 1
orfl9.1116 orfl9.1116 0 0 1 0 0 0 0 1
orfl9.5531 CDC37 0 0 0 0 0 1 0 1
orfl9.6556 orfl9.6556 0 0 0 0 1 0 0 1
orfl9.1272 orfl9.1272 0 0 0 0 1 0 0 1
orfl9.1059 HHFI 0 0 0 1 0 0 0 1
orfl9.3468 ALGIlI 0 0 0 0 1 0 0 1
orfl9.4890 CLA4 0 0 0 1 0 0 0 1
orfl9.6559 orfl9.6559 1 0 0 0 0 0 0 1
orfl9.6558 orfl9.6558 1 0 0 0 0 0 0 1
orfl9.10 ALK8 0 0 1 0 0 0 0 1
orfl9.612 orfl9.612 0 0 0 0 1 0 0 1
orfl9.6673 HEX 0 0 0 0 1 0 0 1
orfl9.1343 orfl9.1343 0 0 0 0 1 0 0 1
orfl9.6031 VPS27 1 0 0 0 0 0 0 1
orfl9.6670 CAC2 0 0 0 0 1 0 0 1
orfl9.6005 HGT5 0 0 0 0 1 0 0 1
orfl9.3668 HGT2 0 0 0 0 1 0 0 1
orfl9.291 orfl9.291 1 0 0 0 0 0 0 1
orfl9.5601 orfl9.5601 0 0 0 0 1 0 0 1
orfl9.5358 orfl9.5358 0 0 0 0 1 0 0 1
orfl9.2135 TSM1 0 0 0 1 0 0 0 1
orfl9.6482 orfl9.6482 0 0 0 0 0 1 0 1
orfl9.6488 orfl9.6488 0 0 1 0 0 0 0 1
orfl9.5353 orfl9.5353 1 0 0 0 0 0 0 1
orfl9.470 orfl9.470 0 0 1 0 0 0 0 1
orfl9.477 orfl9.477 0 0 1 0 0 0 0 1
orfl9.1613 ILV2 0 0 1 0 0 0 0 1
orfl9.3461 orfl9.3461 0 0 0 0 0 1 0 1
orfl9.5771 PBP2 0 0 1 0 0 0 0 1
orfl9.6739 orfl9.6739 0 0 0 0 1 0 0 1
orfl9.696 STE2 0 0 0 1 0 0 0 1
orfl9.2257 orfl9.2257 0 0 1 0 0 0 0 1
orfl9.6481 YPS7 0 0 1 0 0 0 0 1
orfl9.2252 orfl9.2252 0 0 0 0 1 0 0 1
orfl9.51 orfl9.51 0 0 0 1 0 0 0 1
orfl9.5506 PLC1 0 0 0 1 0 0 0 1
orfl9.6934 orfl9.6934 0 0 1 0 0 0 0 1
orfl9.2038 orfl9.2038 0 0 1 0 0 0 0 1
orfl9.879 orfl9.879 0 0 1 0 0 0 0 1
orfl9.7511 orfl9.7511 0 0 1 0 0 0 0 1
orfl9.7043 orfl9.7043 0 0 0 0 1 0 0 1
orfl9.871 orfl9.871 0 0 0 1 0 0 0 1
orfl9.6022 orfl9.6022 0 1 0 0 0 0 0 1
orfl9.6018 LRO1 0 0 0 0 1 0 0 1
orfl9.5926 ARGil 0 0 0 0 1 0 0 1
orfl9.6027 orfl9.6027 0 1 0 0 0 0 0 1
192
orfl9.2133 LIP4 0 0 0 1 0 0 0 1
orfl9.6025 orfl9.6025 0 0 0 1 0 0 0 1
orfl9.6024 orfl9.6024 0 1 0 0 0 0 0 1
orfl9.5172 LIP9 0 0 0 0 0 0 1 1
orfl9.2746 orfl9.2746 0 0 1 0 0 0 0 1
orfl9.4966 orfl9.4966 0 0 0 0 1 0 0 1
orfl9.3680 SEP7 0 1 0 0 0 0 0 1
orfl9.3728 orfl9.3728 0 0 1 0 0 0 0 1
orfl9.4415 orfl9.4415 0 0 1 0 0 0 0 1
orfl9.3722 orfl9.3722 0 0 1 0 0 0 0 1
orfl9.3726 orfl9.3726 0 0 1 0 0 0 0 1
orfl9.6496 TRS33 0 0 0 0 1 0 0 1
orfl9.484 MRPL40 0 0 0 0 1 0 0 1
orfl9.7468 orfl9.7468 0 0 0 0 1 0 0 1
orfl9.2106 orfl9.2106 1 0 0 0 0 0 0 1
orfl9.7460 orfl9.7460 0 0 1 0 0 0 0 1
orfl9.2488 FALl 0 0 0 0 1 0 0 1
orfl9.7463 orfl9.7463 0 0 1 0 0 0 0 1
orfl9.5919 MEAl 0 0 0 0 0 0 1 1
orfl9.3501 orfl9.3501 0 0 0 0 1 0 0 1
orfl9.1479 orfl9.1479 0 1 0 0 0 0 0 1
orfl9.1476 orfl9.1476 0 0 1 0 0 0 0 1
orfl9.1525 orfl9.1525 0 0 0 0 0 1 0 1
orfl9.6533 MSK1 0 0 0 0 0 1 0 1
orfl9.2818 orfl9.2818 0 0 1 0 0 0 0 1
orfl9.4747 HEM14 0 1 0 0 0 0 0 1
orfl9.4347 orfl9.4347 1 0 0 0 0 0 0 1
orfl9.4340 orfl9.4340 1 0 0 0 0 0 0 1
orfl9.434 PRD1 0 0 0 0 1 0 0 1
orfl9.4748 orfl9.4748 1 0 0 0 0 0 0 1
orfl9.647.3 orfl9.647.3 0 0 0 0 1 0 0 1
orfl9.4741 orfl9.4741 0 0 0 0 1 0 0 1
orfl9.4981 orfl9.4981 0 0 0 0 1 0 0 1
orfl9.1757 orfl9.1757 0 0 1 0 0 0 0 1
orfl9.2922 orfl9.2922 0 0 1 0 0 0 0 1
orfl9.2921 orf19.2921 0 0 1 0 0 0 0 1
orfl9.2928 orfl9.2928 1 0 0 0 0 0 0 1
orfl9.1617 orfl9.1617 0 0 0 0 1 0 0 1
orfl9.1619 orfl9.1619 0 0 0 0 1 0 0 1
orfl9.4182 orf19.4182 0 0 1 0 0 0 0 1
orfl9.4187 orfl9.4187 0 0 1 0 0 0 0 1
orfl9.4185 orfl9.4185 0 0 1 0 0 0 0 1
orfl9.4189 orfl9.4189 0 0 0 0 1 0 0 1
orfl9.1753 PUS7 0 0 0 0 1 0 0 1
orfl9.4682 HGT17 0 0 0 0 1 0 0 1
orfl9.6141 HGT16 0 0 0 1 0 0 0 1
orfl9.1358 GCN4 0 0 0 0 1 0 0 1
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orfl9.4533 orfl9.4533 0 0 0 0 1 0 0 1
orfl9.579 FOLI 0 0 1 0 0 0 0 I
orfl9.4482 IFI3 1 0 0 0 0 0 0 1
orfl9.4573 ZCF26 0 0 0 0 1 0 0 1
orfl9.511 orfl9.511 0 0 1 0 0 0 0 1
orfl9.512 orfl9.512 0 0 0 0 0 0 1 1
orfl9.3954 orfl9.3954 0 0 0 0 0 1 0 1
orfl9.3628 RSP5 0 0 1 0 0 0 0 1
orfl9.3374 ECEl 0 0 1 0 0 0 0 1
orfl9.3337 orfl9.3337 0 0 0 0 1 0 0 1
orfl9.1045 orfl9.1045 0 0 0 1 0 0 0 1
orfl9.5083 DRG1 0 0 0 0 1 0 0 1
orfl9.5765 orf19.5765 0 0 0 1 0 0 0 1
orfl9.5767 orfl9.5767 0 0 0 0 1 0 0 1
orfl9.761 TC089 1 0 0 0 0 0 0 1
orfl9.609 orfl9.609 0 1 0 0 0 0 0 1
orfl9.6985 TEAl 0 1 0 0 0 0 0 1
orfl9.604 orfl9.604 0 0 0 1 0 0 0 1
orfI9.852 SAP98 0 0 1 0 0 0 0 1
orfl9.7442 orfl9.7442 0 0 0 0 0 1 0 1
orfl9.3122 ARR3 0 0 0 0 1 0 0 1
orfl9.391 UPC2 1 0 0 0 0 0 0 1
orfl9.7499.1 orfl9.7499.1 0 0 0 0 1 0 0 1
orfl9.5587 orfl9.5587 0 0 0 0 1 0 0 1
orfl9.5586 orfl9.5586 0 0 0 0 0 1 0 1
orfl9.5589 orfl9.5589 0 0 0 0 1 0 0 1
orfl9.505 SRV2 0 0 0 0 1 0 0 1
orfl9.5617 orfl9.5617 0 0 0 0 1 0 0 1
orfl9.3298 CCHI 0 0 0 0 1 0 0 1
orfl9.3894 orfl9.3894 1 0 0 0 0 0 0 1
orfl9.1827 orfl9.1827 0 0 0 0 1 0 0 1
orfl9.5362 PSO2 0 0 0 1 0 0 0 1
orfl9.1823 orfl9.1823 0 0 0 0 0 0 1 1
orf19.5830 orfl9.5830 0 0 1 0 0 0 0 1
orfl9.467 orfl9.467 0 0 0 1 0 0 0 1
orfl9.261 orfl9.261 0 0 0 0 1 0 0 1
orfl9.2247 orfl9.2247 0 0 0 1 0 0 0 1
orfl9.2246 orfl9.2246 0 0 0 0 1 0 0 1
orfl9.6230 orfl9.6230 0 0 0 0 1 0 0 1
orfl9.6585 orfl9.6585 1 0 0 0 0 0 0 1
orfl9.6587 orf19.6587 0 1 0 0 0 0 0 1
orfl9.6583 orfI9.6583 0 0 0 1 0 0 0 1
orfl9.6909 orfl9.6909 0 1 0 0 0 0 0 1
orfl9.4969 KEMI 0 0 0 0 1 0 0 1
orfl9.5548 LYS14 0 0 0 0 1 0 0 1
orfl9.7057 orfl9.7057 0 0 0 0 1 0 0 1
orfl9.2024 orfl9.2024 0 0 0 0 0 1 0 1
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orfl9.3050 AGEI 0 0 0 0 1 0 0 1
orfl9.3630 RRP8 0 1 0 0 0 0 0 1
orfl9.4976 orfl9.4976 0 0 0 1 0 0 0 1
orfl9.2834 RPD3 0 0 0 0 0 1 0 1
orfl9.4407 orfl9.4407 0 0 0 0 1 0 0 1
orfl9.3758 orfl9.3758 0 1 0 0 0 0 0 1
orfl9.2110 orfl9.2110 0 0 1 0 0 0 0 1
orfl9.3196 orfl9.3196 0 1 0 0 0 0 0 1
orfl9.6550 orfl9.6550 0 0 0 0 1 0 0 1
orfl9.3573 PEX6 0 0 0 0 0 1 0 1
orfl9.3409 SEC12 0 0 0 0 1 0 0 1
orfl9.4571 orfl9.4571 0 0 1 0 0 0 0 1
orfl9.3102 CTA6 1 0 0 0 0 0 0 1
orfl9.3376 orfl9.3376 0 0 0 0 1 0 0 1
orfl9.3371 JABI 0 0 1 0 0 0 0 1
orfl9.3373 orfl9.3373 0 0 1 0 0 0 0 1
orfl9.2805 PEX8 0 1 0 0 0 0 0 1
orfl9.2804 orfl9.2804 0 0 1 0 0 0 0 1
orfl9.451 SOKI 1 0 0 0 0 0 0 1
orfl9.3405 ZCF18 0 0 0 0 1 0 0 1
orfl9.3818 GOAl 0 0 0 0 1 0 0 1
orfl9.1592 orfl9.1592 0 0 0 0 0 1 0 1
orfl9.4756 orfl9.4756 0 0 0 0 0 1 0 1
orfl9.4751 orfl9.4751 0 0 0 1 0 0 0 1
orfl9.4998 ROBI 1 0 0 0 0 0 0 1
orfl9.2236 FHL1 0 0 0 0 0 0 1 1
orfl9.3227 FTH2 0 0 0 0 0 1 0 1
orfl9.4995 orfl9.4995 0 0 0 0 0 1 0 1
orfl9.2930 orfl9.2930 0 1 0 0 0 0 0 1
orfl9.7074 orfl9.7074 0 1 0 0 0 0 0 1
orfl9.5121 OPT5 0 0 0 0 1 0 0 1
orfl9.2938 orfl9.2938 0 0 0 0 1 0 0 1
orfl9.3506 DBR1 0 0 0 0 1 0 0 1
orfl9.1626 orfl9.1626 0 0 1 0 0 0 0 1
orfl9.4195 orfl9.4195 0 0 0 0 0 0 1 1
orfl9.3990 orfl9.3990 0 0 0 0 0 1 0 1
orfl9.7173 orf19.7173 0 0 0 1 0 0 0 1
orfl9.808 orfl9.808 0 0 1 0 0 0 0 1
orfl9.7271 orfl9.7271 0 0 0 1 0 0 0 1
orfl9.5291 orfl9.5291 0 0 0 0 0 1 0 1
orfl9.4048 DESI 0 1 0 0 0 0 0 1
orfl9.4808 NUP188 0 0 0 1 0 0 0 1
orfl9.1363 orfl9.1363 0 0 0 0 1 0 0 1
orfl9.4361 IFF3 0 0 0 1 0 0 0 1
orfl9.5634 FRP1 0 0 1 0 0 0 0 1
orfl9.6522 orf9.6522 0 0 0 0 1 0 0 1
orfl9.2654 RMS1 0 0 0 0 0 1 0 1
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orfl9.3557 GPI19 0 0 0 1 0 0 0 1
orfl9.1050 orfl9.1050 1 0 0 0 0 0 0 1
orfl9.832 GPI13 0 0 1 0 0 0 0 1
orfl9.5026 orfl9.5026 0 1 0 0 0 0 0 1
orfl9.5757 orfl9.5757 0 0 0 0 0 0 1 1
orfl9.1804 orfl9.1804 0 0 0 0 0 1 0 1
orfl9.1902 NOC4 0 0 0 0 0 1 0 1
orfl9.2579 orfl9.2579 0 0 1 0 0 0 0 1
orfl9.992 LKH 1 0 0 0 0 1 0 0 1
orfl9.676 orfl9.676 0 0 0 0 0 1 0 1
orfl9.6138 orfl9.6138 0 0 1 0 0 0 0 1
orfl9.3973 orfl9.3973 0 1 0 0 0 0 0 1
orfl9.5626 orfl9.5626 0 0 0 1 0 0 0 1
orf19.5628 orfl9.5628 0 0 0 1 0 0 0 1
orfl9.1032 SKOl 0 0 0 1 0 0 0 1
orfl9.2361 SPT10 0 0 1 0 0 0 0 1
orfl9.5808 orfl9.5808 0 0 1 0 0 0 0 1
orfl9.494 orfl9.494 0 0 0 0 0 1 0 1
orfl9.3150 GRE2 0 0 1 0 0 0 0 1
orfl9.499 orfl9.499 0 0 1 0 0 0 0 1
orfl9.702 orf19.702 0 0 0 0 1 0 0 1
orfl9.254 orfl9.254 0 0 1 0 0 0 0 1
orfl9.35 orfl9.35 0 0 1 0 0 0 0 1
orfl9.7564 DPB2 0 0 0 0 1 0 0 1
orfl9.5930 orfl9.5930 0 0 0 0 1 0 0 1
orfl9.5931 ARVI 0 0 0 0 0 1 0 1
orfl9.5932 orfl9.5932 0 0 0 0 1 0 0 1
orfl9.3599 TIF4631 0 0 0 1 0 0 0 1
orfl9.4610 orfl9.4610 0 0 0 0 1 0 0 1
orfl9.6912 orfl9.6912 0 0 1 0 0 0 0 1
orfl9.2582 orfl9.2582 0 0 0 0 0 0 1 1
orfl9.7063 orfl9.7063 0 0 1 0 0 0 0 1
orfl9.7067 orfl9.7067 0 0 0 0 1 0 0 1
orfl9.7088 orfl9.7088 1 0 0 0 0 0 0 1
orfl9.5484 SERI 0 0 0 0 1 0 0 1
orfl9.2563 orfl9.2563 0 0 1 0 0 0 0 1
orfl9.210 orfl9.210 0 0 0 0 1 0 0 1
orfl9.7086 orfl9.7086 0 0 0 0 1 0 0 1
orfl9.3823 ZDS1 0 0 0 0 1 0 0 1
orf19.5640 PEX5 0 0 1 0 0 0 0 1
orfl9.925 orfl9.925 0 0 1 0 0 0 0 1
orfl9.2005 REGI 0 0 1 0 0 0 0 1
orfl9.5001 CUP2 0 0 0 1 0 0 0 1
orfl9.59 REIl 1 0 0 0 0 0 0 1
orfl9.1450 orfI9.1450 1 0 0 0 0 0 0 1
orfl9.4222 SST2 0 0 0 0 1 0 0 1
orfl9.3152 AMO2 0 0 1 0 0 0 0 1
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orfl9.4690 orfl9.4690 0 0 1 0 0 0 0 1
orfl9.4691 orfl9.4691 0 0 0 0 1 0 0 1
orfl9.4508 orfl9.4508 0 0 1 0 0 0 0 1
orfl9.4509 orfl9.4509 0 0 1 0 0 0 0 1
orfl9.4502 orfl9.4502 0 0 1 0 0 0 0 1
orfl9.3364 orfl9.3364 0 0 1 0 0 0 0 1
orfl9.5243 TRP3 1 0 0 0 0 0 0 1
orfl9.4326 orfl9.4326 0 1 0 0 0 0 0 1
orfl9.940 BUD2 0 0 1 0 0 0 0 1
orfl9.2838 orfl9.2838 0 0 0 0 0 0 1 1
orfl9.4299 MSW1 0 0 0 0 1 0 0 1
orfl9.4592 HSX11 1 0 0 0 0 0 0 1
orfl9.5758 SAL6 0 0 0 0 0 0 1 1
orfl9.20 RTS1 0 0 0 0 1 0 0 1
orfl9.5170 ENA21 0 0 0 0 1 0 0 1
orfl9.4214 orfl9.4214 0 0 0 0 0 0 1 1
orfl9.24 RTA2 0 0 1 0 0 0 0 1
orfl9.2012 NOT3 0 0 1 0 0 0 0 1
orfl9.6011 SIN3 0 0 0 0 1 0 0 1
orfl9.5897 orfl9.5897 0 0 0 0 1 0 0 1
orfl9.3734 GEF2 0 0 1 0 0 0 0 1
orfl9.2903 AGOl 0 0 1 0 0 0 0 1
orfl9.1634 orfl9.1634 0 0 1 0 0 0 0 1
orfl9.2908 orfl9.2908 0 0 0 0 1 0 0 1
orfl9.1632 orfl9.1632 0 0 1 0 0 0 0 1
orfl9.2998 TSR2 1 0 0 0 0 0 0 1
orfl9.6321 PGA48 0 0 0 0 0 0 1 1
orfl9.4851 TFA1 0 0 0 1 0 0 0 1
orfl9.3638 PGA46 0 0 0 0 1 0 0 1
orfl9.2906 PGA41 0 0 0 0 1 0 0 1
orfl9.2910 PGA43 0 0 0 0 1 0 0 1
orfl9.3765 RAX2 0 0 0 0 0 1 0 1
orfl9.3980 orfl9.3980 0 0 0 0 1 0 0 1
orfl9.2917.1 orfl9.2917.1 0 0 1 0 0 0 0 1
orfl9.234 PHA2 1 0 0 0 0 0 0 1
orfl9.5005 OSM2 0 0 0 0 1 0 0 1
orfl9.1123 orfl9.1123 0 0 0 0 0 1 0 1
orfl9.4784 CRP1 0 0 0 0 1 0 0 1
orfl9.231 APL2 0 0 1 0 0 0 0 1
orfl9.272 FAA21 0 0 0 0 1 0 0 1
orfl9.5288 IFE2 0 0 0 0 0 0 1 1
orfl9.769 IFEl 1 0 0 0 0 0 0 1
orfl9.1026 orfl9.1026 1 0 0 0 0 0 0 1
orfl9.5747 orfl9.5747 0 0 0 0 1 0 0 1
orfl9.5035 orfl9.5035 1 0 0 0 0 0 0 1
orfl9.5034 orfl9.5034 0 1 0 0 0 0 0 1
orfl9.5037 HRQ2 0 0 0 0 1 0 0 1
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orfl9.1891 APRI 1 0 0 0 0 0 0 1
orfl9.5162 BCK1 0 0 0 0 1 0 0 1
orfl9.4924 orfl9.4924 0 0 0 0 0 1 0 1
orfl9.666 orfl9.666 0 0 0 0 1 0 0 1
orfl9.1413 YFH1 0 0 0 0 1 0 0 1
orfl9.6691 orfl9.6691 0 0 0 0 0 1 0 1
orfl9.6693 orfl9.6693 0 0 1 0 0 0 0 1
orfl9.2507 ARP9 0 0 1 0 0 0 0 1
orfl9.5623 ARP4 0 0 0 0 1 0 0 1
orfl9.2641 ARP 0 0 0 0 1 0 0 1
orfl9.6450 orf19.6450 1 0 0 0 0 0 0 1
orfl9.6456 orfI9.6456 0 0 0 0 0 1 0 1
orfl9.6457 orfl9.6457 0 0 0 0 1 0 0 1
orfl9.5322 orfl9.5322 1 0 0 0 0 0 0 1
orfl9.2154 HXK1 1 0 0 0 0 0 0 1
orfl9.4242 CST20 1 0 0 0 0 0 0 1
orfl9.5817 orfl9.5817 0 0 1 0 0 0 0 1
orfl9.302 orfl9.302 0 0 0 0 1 0 0 1
orfl9.1324 RAD2 0 0 1 0 0 0 0 1
orfl9.5061 ADE5,7 0 0 0 0 1 0 0 1
orfl9.4275 RAD9 0 0 0 0 1 0 0 1
orfl9.2228 orf19.2228 0 0 0 0 0 0 1 1
orfl9.29 orfl9.29 0 0 1 0 0 0 0 1
orfl9.2227 orfl9.2227 0 0 1 0 0 0 0 1
orfl9.22 orfl9.22 0 0 0 0 1 0 0 1
orfl9.21 orfl9.21 0 0 0 0 1 0 0 1
orfl9.1935 orfl9.1935 0 0 1 0 0 0 0 1
orf19.1933 orfl9.1933 0 0 0 0 1 0 0 1
orfl9.5253 orfl9.5253 0 0 0 0 0 1 0 1
orfl9.5921 orfl9.5921 0 0 0 0 1 0 0 1
orfl9.645.1 VMA13 0 0 0 0 1 0 0 1
orfl9.740 HAP41 0 0 0 1 0 0 0 1
orfl9.6033 CMP1 0 0 0 0 0 0 1 1
orfl9.804 orfl9.804 0 0 0 0 0 0 1 1
orfl9.805 orfl9.805 0 0 0 1 0 0 0 1
orfl9.7073 orfl9.7073 0 0 0 0 1 0 0 1
orfl9.7079 orfl9.7079 0 0 1 0 0 0 0 1
orfl9.6679 orfl9.6679 0 0 0 1 0 0 0 1
orfl9.2138 ILSI 0 0 0 1 0 0 0 1
orfl9.6852 orfl9.6852 0 0 0 0 1 0 0 1
orfl9.3086 orfl9.3086 0 0 1 0 0 0 0 1
orfl9.3083 orfl9.3083 0 0 0 0 0 0 1 1
orfl9.3080 orf19.3080 0 0 1 0 0 0 0 1
orfl9.7095 orfl9.7095 0 0 0 0 1 0 0 1
orfl9.2574 orfl9.2574 0 0 1 0 0 0 0 1
orfl9.7096 orfI9.7096 0 1 0 0 0 0 0 1
orfl9.2832 INNI 0 0 0 0 0 1 0 1
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orfl9.3777 orfl9.3777 0 0 0 0 0 1 0 1
orfl9.937 orfl9.937 0 0 0 0 0 0 1 1
orfl9.2684 orfl9.2684 0 0 0 1 0 0 0 1
orfl9.3177 orfl9.3177 0 0 0 0 1 0 0 1
orfl9.3175 orfl9.3175 1 0 0 0 0 0 0 1
orfl9.3211 RCF3 0 0 0 0 1 0 0 1
orfl9.3798 orfl9.3798 0 0 1 0 0 0 0 1
orfl9.3796 DCR1 0 0 0 0 1 0 0 1
orfl9.3797 orfl9.3797 0 0 0 0 1 0 0 1
orfl9.2365 POL2 0 0 1 0 0 0 0 1
orfl9.4511 orfl9.4511 0 0 1 0 0 0 0 1
orfl9.6628 orfl9.6628 0 0 0 0 1 0 0 1
orfl9.2779 orfl9.2779 0 0 0 0 0 1 0 1
orfl9.22.1 orfl9.22.1 0 0 0 0 1 0 0 1
orfl9.7300 orfl9.7300 0 0 0 0 1 0 0 1
orfl9.2471 GIM5 1 0 0 0 0 0 0 1
orfl9.7083 DCC1 0 0 0 0 1 0 0 1
orfl9.56 ARG2 0 0 0 0 1 0 0 1
orfl9.2827 orfl9.2827 0 1 0 0 0 0 0 1
orfl9.2822 orfl9.2822 0 0 0 0 0 0 1 1
orfl9.4332 orfl9.4332 0 0 0 0 0 1 0 1
orfl9.5776 TOMI 0 0 0 0 0 1 0 1
orfl9.2828 orfl9.2828 0 0 0 0 1 0 0 1
orfl9.2474 PRC3 0 0 0 0 1 0 0 1
orfl9.1401 EAPI 0 0 0 1 0 0 0 1
orfl9.87 GPX1 0 0 0 0 1 0 0 1
orfl9.4203 orfl9.4203 0 0 0 0 0 0 1 1
orfl9.5630 APA2 0 0 0 0 1 0 0 1
orfl9.3552 orfl9.3552 0 0 1 0 0 0 0 1
orfl9.4028 orfl9.4028 0 0 0 0 1 0 0 1
orfl9.913.2 orfl9.913.2 0 0 0 0 0 1 0 1
orfl9.2917 orfl9.2917 0 0 0 0 0 1 0 1
orfl9.2914 orfl9.2914 0 0 1 0 0 0 0 1
orfl9.1661 DBP5 0 0 0 0 1 0 0 1
orfl9.5015 MYO2 0 0 0 1 0 0 0 1
orfl9.738 MYO5 0 0 1 0 0 0 0 1
orfl9.4077 MITI 0 0 0 1 0 0 0 1
orfl9.2767 PGA59 0 0 0 0 0 0 1 1
orfl9.2685 PGA54 0 0 1 0 0 0 0 1
orfl9.5191 FGR6-1 0 0 0 0 0 0 1 1
orfl9.5137 orfl9.5137 0 0 0 1 0 0 0 1
orfl9.5139 orfl9.5139 1 0 0 0 0 0 0 1
orfl9.100 orfl9.100 0 0 0 0 1 0 0 1
orfl9.3228 orfl9.3228 0 0 1 0 0 0 0 1
orfl9.5595 SHE3 0 0 0 0 0 0 1 1
orfl9.3699 TEPI 0 0 0 0 1 0 0 1
orfl9.7059 orfl9.7059 0 0 0 0 1 0 0 1
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orfl9.5009 orfl9.5009 0 0 0 0 1 0 0 1
orfl9.1223 DBF2 0 0 1 0 0 0 0 1
orfl9.653 orfn9.653 0 1 0 0 0 0 0 1
orfl9.120 orfl9.120 0 1 0 0 0 0 0 1
orfl9.1659 ALG8 0 0 0 0 0 1 0 1
orfl9.1990 SNX4 1 0 0 0 0 0 0 1
orfl9.1221 ALG2 0 0 0 0 0 1 0 1
orfl9.4410 ALGI 0 0 0 0 1 0 0 1
orfl9.2187 ALG7 0 0 1 0 0 0 0 1
orfl9.1238 TUB4 0 0 1 0 0 0 0 1
orfl9.2215 GLEI 0 0 0 0 0 0 1 1
orfl9.1323 orfl9.1323 0 0 0 0 1 0 0 1
orfl9.6114 orfl9.6114 0 0 1 0 0 0 0 1
orfl9.4015 CAGI 0 0 0 0 1 0 0 1
orfl9.5644 orfl9.5644 1 0 0 0 0 0 0 1
orfl9.6119 orfl9.6119 0 0 1 0 0 0 0 1
orfl9.5488 orfl9.5488 0 0 0 0 1 0 0 1
orfl9.5489 orfl9.5489 0 0 0 0 1 0 0 1
orf19.3071 MIHI 1 0 0 0 0 0 0 1
orfl9.5155 CHS6 0 0 1 0 0 0 0 1
orf19.5865 orfl9.5865 0 0 1 0 0 0 0 1
orf19.5869 orfl9.5869 0 0 1 0 0 0 0 1
orfl9.4322 DAP2 0 0 0 0 1 0 0 1
orfl9.1836 APN2 0 0 0 0 1 0 0 1
orfl9.239 orfl9.239 1 0 0 0 0 0 0 1
orfl9.2210 orfl9.2210 0 0 1 0 0 0 0 1
orfl9.4054 CTA24 0 0 0 0 0 1 0 1
orf19.2213 orfl9.2213 1 0 0 0 0 0 0 1
orfl9.4608 PDC12 0 0 0 1 0 0 0 1
orfl9.5269 orfl9.5269 0 0 0 0 1 0 0 1
orfl9.5262 orfl9.5262 0 0 0 0 1 0 0 1
orfl9.4630 CPA1 0 0 0 0 1 0 0 1
orfI9.6686 ENP2 0 0 0 0 0 0 1 1
orfl9.349 orfl9.349 0 0 0 0 1 0 0 1
orfl9.341 orfl9.341 0 0 0 0 1 0 0 1
orfl9.346 orfl9.346 0 1 0 0 0 0 0 1
orfl9.797 BAT21 0 0 0 1 0 0 0 1
orfl9.6065 orfl9.6065 0 0 0 0 1 0 0 1
orfl9.2367 orfl9.2367 0 1 0 0 0 0 0 1
orfl9.2362 orfl9.2362 0 0 0 0 1 0 0 1
orfl9.5050 MTO1 0 0 1 0 0 0 0 1
orfl9.1814 orfl9.1814 0 0 1 0 0 0 0 1
orfl9.3091 orfl9.3091 0 0 1 0 0 0 0 1
orfl9.2549 orfl9.2549 0 0 0 0 0 1 0 1
orfl9.6014 RRSI 0 0 0 0 1 0 0 1
orfl9.4884 WORI 1 0 0 0 0 0 0 1
orfl9.1789.1 LYS1 0 0 0 1 0 0 0 1
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orfl9.3762 orfl9.3762 1 0 0 0 0 0 0 1
orfl9.2143 orfl9.2143 0 0 0 1 0 0 0 1
orfl9.3163 orfl9.3163 1 0 0 0 0 0 0 1
orfl9.1445 ESC4 1 0 0 0 0 0 0 1
orfl9.3780 orfl9.3780 0 0 0 0 1 0 0 1
orfl9.3783 orfl9.3783 0 0 1 0 0 0 0 1
orfl9.3787 orfl9.3787 0 0 0 0 0 1 0 1
orfl9.2454 PH087 1 0 0 0 0 0 0 1
orfl9.4520 orfl9.4520 0 1 0 0 0 0 0 1
orfl9.4521 orfl9.4521 0 0 1 0 0 0 0 1
orfl9.4834 orfl9.4834 0 0 0 0 1 0 0 1
orfl9.4529 orfl9.4529 0 0 0 0 1 0 0 1
orfl9.2991 HOL1 0 0 0 0 1 0 0 1
orfl9.3304 orfl9.3304 0 1 0 0 0 0 0 1
orfl9.3431 orfl9.3431 0 0 0 0 1 0 0 1
orfl9.3430 orfl9.3430 0 1 0 0 0 0 0 1
orfl9.3635 orfl9.3635 1 0 0 0 0 0 0 1
orfl9.2580 HST2 1 0 0 0 0 0 0 1
orfl9.4789 orfl9.4789 1 0 0 0 0 0 0 1
orfl9.5526 SEC20 0 0 0 0 0 0 1 1
orfl9.4732 SEC24 0 0 0 0 1 0 0 1
orfl9.3545 orfl9.3545 0 0 1 0 0 0 0 1
orfl9.3543 orfl9.3543 0 0 0 1 0 0 0 1
orfl9.2968 orfl9.2968 0 0 0 0 1 0 0 1
orfl9.4014 orfl9.4014 1 0 0 0 0 0 0 1
orfl9.2963 orfl9.2963 0 1 0 0 0 0 0 1
orfl9.6512 EXO70 0 0 1 0 0 0 0 1
orfl9.4013 orfl9.4013 0 0 0 0 1 0 0 1
orfl9.581 orfl9.581 0 0 1 0 0 0 0 1
orfl9.1491 orfl9.1491 0 0 1 0 0 0 0 1
orfl9.6796 orfl9.6796 1 0 0 0 0 0 0 1
orfl9.1497 ZCF6 0 0 1 0 0 0 0 1
orfl9.943 FET33 0 0 1 0 0 0 0 1
orfl9.4656 orfl9.4656 1 0 0 0 0 0 0 1
orfl9.4306 orfl9.4306 0 0 0 0 1 0 0 1
orfl9.4076 MET1O 0 0 0 0 0 1 0 1
orfl9.2863.1 orfl9.2863.1 0 0 0 1 0 0 0 1
orfl9.4679 AGP2 0 0 1 0 0 0 0 1
orfl9.6243 VPS34 0 0 0 0 1 0 0 1
orfl9.156 FGRS1 0 0 1 0 0 0 0 1
orfl9.1143 orfl9.1143 0 0 0 0 1 0 0 1
orfl9.5163 SFI1 0 0 1 0 0 0 0 1
orfl9.795 VPS36 0 0 1 0 0 0 0 1
orfl9.7574 orfl9.7574 0 0 0 0 1 0 0 1
orfl9.4755 KEX2 0 0 0 0 1 0 0 1
orfl9.4934 OP4 0 0 0 0 0 0 1 1
orfl9.6266 orfl9.6266 0 0 0 1 0 0 0 1
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orfl9.3746 IFCI 0 0 1 0 0 0 0
orfl9.3749 IFC3 0 0 0 0 0 0 1 1
orfl9.1524 SPR3 0 0 1 0 0 0 0 1
orfl9.5019 orfl9.5019 1 0 0 0 0 0 0 1
orfl9.5959 NOP14 0 0 0 0 1 0 0 1
orfl9.1008 orfl9.1008 0 0 1 0 0 0 0 1
orfl9.1009 orfl9.1009 0 0 0 1 0 0 0 1
orf19.3370 DOT4 0 0 1 0 0 0 0 1
orfl9.5557 MNN4-4 0 0 0 0 0 1 0 1
orfl9.5783 orfl9.5783 0 0 1 0 0 0 0 1
orf19.133 orfl9.133 0 0 0 0 0 0 1 1
orfl9.77.1 orfl9.77.1 0 1 0 0 0 0 0 1
orfl9.5780 orfl9.5780 1 0 0 0 0 0 0 1
orfl9.137 orfl9.137 0 0 0 0 1 0 0 1
orfl9.643 orfl9.643 0 0 1 0 0 0 0 1
orfl9.1942 SGE1 0 0 0 0 0 0 1 1
orfl9.6477 orfl9.6477 0 0 0 0 1 0 0 1
orfl9.1310 orfl9.1310 0 0 0 0 1 0 0 1
orfl9.5306 orfl9.5306 0 0 1 0 0 0 0 1
orfl9.5499 orfl9.5499 0 0 0 0 1 0 0 1
orfl9.5495 orfl9.5495 0 0 0 0 1 0 0 1
orfl9.4082 DDR48 0 0 1 0 0 0 0 1
orfl9.3756 CHRI 0 1 0 0 0 0 0 
orfl9.5879 orfl9.5879 0 0 1 0 0 0 0 1
orfl9.1633 UTP4 0 0 0 0 1 0 0 1
orfl9.6789 orfl9.6789 0 0 0 0 1 0 0 1
orfl9.6786 orfl9.6786 0 0 0 0 1 0 0 1
orfl9.1958 orfl9.1958 0 1 0 0 0 0 0 1
orfl9.6275 orfl9.6275 0 0 0 0 1 0 0 1
orfl9.5270 orfl9.5270 0 0 0 0 1 0 0 1
orfl9.5274 orfl9.5274 0 0 0 1 0 0 0 1
orfl9.1290 XKSI 0 0 1 0 0 0 0 1
orfl9.2911 SEC3 0 0 0 0 0 1 0 1
orfl9.1842 orfl9.1842 0 0 0 0 0 1 0 1
orfl9.352 orfl9.352 0 0 0 0 1 0 0 1
orfl9.2598 VMA4 0 0 0 0 1 0 0 1
orfl9.6307 orfl9.6307 0 0 1 0 0 0 0 1
orfl9.6305 orf19.6305 0 0 1 0 0 0 0 1
orfl9.6654 orfl9.6654 0 0 0 0 0 1 0 1
orfl9.6308 orfl9.6308 0 0 0 0 0 0 1 1
orfl9.4773 AOX2 1 0 0 0 0 0 0 1
orfl9.5244 MCD4 1 0 0 0 0 0 0 1
orfl9.2558 orfl9.2558 0 1 0 0 0 0 0 1
orfl9.1333 SNG3 0 0 0 0 1 0 0 1
orfl9.6899 orfl9.6899 0 0 0 0 1 0 0 1
orf19.1756 GPD1 0 0 0 0 1 0 0 1
orfl9.6893 orfl9.6893 0 0 1 0 0 0 0 1
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orfl9.6897 orfl9.6897 0 0 1 0 0 0 0 1
orfl9.5292 AXL2 0 0 0 0 1 0 0 1
orfl9.915 orfl9.915 0 0 0 1 0 0 0 1
orfl9.3156 orfl9.3156 0 0 1 0 0 0 0 1
orfl9.6249 HAKI 0 0 0 0 1 0 0 1
orfl9.4820 orfl9.4820 0 0 0 0 1 0 0 1
orfl9.4825 orfl9.4825 0 0 0 0 1 0 0 1
orfl9.4532 orfl9.4532 1 0 0 0 0 0 0 1
orfl9.3269 GSL2 0 0 0 1 0 0 0 1
orfl9.2495 GSL1 0 0 0 1 0 0 0 1
orfl9.2795 orfl9.2795 1 0 0 0 0 0 0 1
orfl9.4785 PTC1 0 0 0 0 0 1 0 1
orfl9.2538 PTC2 0 0 0 0 0 1 0 1
orfl9.3705 PTC6 0 0 0 1 0 0 0 1
orfl9.3446 orfl9.3446 0 0 0 0 1 0 0 1
orfl9.1796 orfl9.1796 0 0 0 0 1 0 0 1
orfl9.1799 GAP5 0 0 1 0 0 0 0 1
orfl9.3449 orfl9.3449 0 0 0 1 0 0 0 1
orfl9.94 orfl9.94 0 0 0 0 1 0 0 1
orfl9.4799 orfl9.4799 1 0 0 0 0 0 0 1
orfl9.4220 orfl9.4220 0 0 1 0 0 0 0 1
orfl9.6972 SMI1B 0 0 0 0 0 1 0 1
orfl9.4001 orfl9.4001 0 0 0 0 1 0 0 1
orfl9.2977 orfl9.2977 0 0 0 1 0 0 0 1
orfl9.2971 orfl9.2971 0 0 0 0 1 0 0 1
orfl9.3404 orfl9.3404 0 0 0 0 1 0 0 1
orfl9.4099 ECM17 0 0 0 0 1 0 0 1
orfl9.5844 orfl9.5844 0 0 0 1 0 0 0 1
orfl9.1782.1 orfl9.1782.1 0 0 0 0 1 0 0 1
orfl9.4788 ARG5,6 1 0 0 0 0 0 0 1
orfl9.4642 orfl9.4642 0 0 1 0 0 0 0 1
orfl9.4310 orfl9.4310 1 0 0 0 0 0 0 1
orfl9.6140 FRE30 1 0 0 0 0 0 0 1
orfl9.5059 GCS1 0 0 0 0 1 0 0 1
orfl9.2615 MDL1 0 0 0 0 1 0 0 1
orfl9.1778 orfl9.1778 0 0 1 0 0 0 0 1
orfl9.5967 FGR44 0 1 0 0 0 0 0 1
orfl9.4769 IPTI 0 0 0 0 1 0 0 1
orfl9.1777 orfl9.1777 0 0 1 0 0 0 0 1
orfl9.3209 FGR42 1 0 0 0 0 0 0 1
orfl9.6534.2 orfl9.6534.2 0 0 0 0 1 0 0 1
orfl9.1968.1 orfl9.1968.1 0 0 0 0 0 0 1 1
orfl9.5066 orfl9.5066 0 0 0 0 1 0 0 1
orfl9.3770 ARG8 0 0 1 0 0 0 0 1
orfl9.1683 PPH21 0 1 0 0 0 0 0 1
orfl9.5610 ARG3 1 0 0 0 0 0 0 1
orfl9.6877 PNG2 0 1 0 0 0 0 0 1
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orfl9.652 orfl9.652 0 0 1 0 0 0 0 1
orfl9.6469 orfl9.6469 0 0 0 0 1 0 0 1
orfl9.1303 orf19.1303 0 0 1 0 0 0 0 1
orfl9.1302 orfl9.1302 0 0 0 0 1 0 0 1
orfl9.1300 orfl9.1300 0 0 0 0 1 0 0 1
orfl9.1306 orfl9.1306 0 0 0 0 1 0 0 1
orfl9.3264 CCE1 0 0 1 0 0 0 0 1
orfl9.4952 orfl9.4952 0 0 0 0 0 1 0 1
orfl9.5465 orfl9.5465 0 0 0 0 0 1 0 1
orfl9.4899 GCAl 0 0 0 1 0 0 0 1
orfl9.999 GCA2 0 0 0 0 1 0 0 1
orfl9.5688 orfl9.5688 0 0 0 0 0 1 0 1
orfl9.217 orfl9.217 0 0 1 0 0 0 0 1
orfl9.6797 orfl9.6797 0 0 0 1 0 0 0 1
orfl9.580 orfl9.580 0 0 1 0 0 0 0 1
orfl9.587 orfl9.587 0 0 1 0 0 0 0 1
orfl9.6790 orfl9.6790 0 0 0 0 1 0 0 1
orfl9.6269 orfl9.6269 0 0 0 0 1 0 0 1
orfl9.3841 orfl9.3841 0 0 0 1 0 0 0 1
orfl9.5203 orfl9.5203 0 0 0 0 1 0 0 1
orfl9.3140 orfl9.3140 0 0 1 0 0 0 0 1
orfl9.17 SCP1 0 0 1 0 0 0 0 1
orfl9.2099 orfl9.2099 1 0 0 0 0 0 0 1
orfl9.2090 orfl9.2090 0 0 1 0 0 0 0 1
orfl9.2091 orfl9.2091 0 0 1 0 0 0 0 1
orfl9.5958 CDR2 0 0 0 1 0 0 0 1
orfl9.7223 orfl9.7223 0 1 0 0 0 0 0 1
orfl9.7539.1 orfl9.7539.1 0 0 1 0 0 0 0 1
orfl9.5518 orfl9.5518 1 0 0 0 0 0 0 1
orfl9.6864 orfl9.6864 0 0 1 0 0 0 0 1
orfl9.6316 orfl9.6316 0 0 0 0 0 0 1 1
orfl9.6869 orfl9.6869 0 0 1 0 0 0 0 1
orfl9.5515 orfl9.5515 1 0 0 0 0 0 0 1
orfl9.5607 orfl9.5607 1 0 0 0 0 0 0 1
orfl9.2528 orfl9.2528 0 0 0 1 0 0 0 1
orfl9.3000 ORC1 0 0 0 0 1 0 0 1
orfl9.6888 orfl9.6888 0 0 1 0 0 0 0 1
orfl9.1932 CFL4 0 0 1 0 0 0 0 1
orfl9.1263 CFLI 0 0 1 0 0 0 0 1
orfl9.5011 KAR9 1 0 0 0 0 0 0 1
orfl9.6449 orfl9.6449 0 0 0 0 0 1 0 1
orfl9.7130 orfl9.7130 1 0 0 0 0 0 0 1
orfl9.1246 orfl9.1246 0 0 1 0 0 0 0
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B. Shown are mutations that are persistent, non-synonymous, and coupled to an increase in MIC.
ORF Gene PT1 PT7 PT9 PT14 PT15 PT43 PT59 SUM
orfl9.736 SRB8 0 1 1 1 1 1 1 6
orfl9.5045 orfl9.5045 0 1 1 0 1 1 1 5
orfl9.3188 TACI 1 1 1 0 1 1 0 5
orfl9.7029 orfl9.7029 1 0 1 1 1 1 0 5
orfl9.1606 orfl9.1606 0 1 1 1 1 1 0 5
orfl9.5592 orfl9.5592 1 1 0 1 1 1 0 5
orfl9.5596 orfl9.5596 0 1 0 1 1 1 1 5
orfl9.169 CHO2 0 1 1 0 1 1 1 5
orfl9.4346 orfl9.4346 0 1 1 0 1 1 1 5
orfl9.6277 orfl9.6277 1 1 0 1 1 1 0 5
orfl9.1769 orfl9.1769 0 1 0 1 0 1 1 4
orfl9.2404 orfl9.2404 1 0 1 0 0 1 1 4
orfl9.2629 orfl9.2629 0 0 1 0 1 1 1 4
orfl9.1298 NUP84 1 0 1 0 1 1 0 4
orfl9.4697 MDN1 0 1 1 0 1 0 1 4
orfl9.1596 FGR28 0 0 1 0 1 1 1 4
orfl9.1616 FGR23 0 1 1 0 1 0 1 4
orfl9.3473 orfl9.3473 0 1 0 1 0 1 1 4
orfl9.2850 orfl9.2850 0 1 1 0 1 0 1 4
orfl9.5710 orfl9.5710 1 1 0 0 1 0 1 4
orfl9.2650 orfl9.2650 0 0 1 0 1 1 1 4
orfl9.4673 BMT9 0 1 1 1 0 1 0 4
orfl9.7032 orfl9.7032 0 0 1 0 1 1 1 4
orfl9.2646 ZCF13 0 0 0 1 1 1 1 4
orfl9.4557 orfl9.4557 1 1 0 0 1 0 1 4
orfl9.5297 orfl9.5297 0 0 1 1 0 1 1 4
orfl9.4655 OPT6 0 1 1 0 1 0 1 4
orfl9.2747 RGT1 0 0 1 1 1 0 1 4
orfl9.7472 IFF4 0 0 1 1 1 1 0 4
orfl9.2168 orfl9.2168 0 1 1 0 1 1 0 4
orfl9.5038 orfl9.5038 0 1 1 0 1 1 0 4
orfl9.1808 orfl9.1808 0 1 1 0 1 0 1 4
orfl9.5597 POLS 0 1 0 0 1 1 1 4
orfl9.4337 orfl9.4337 1 0 1 0 1 0 1 4
orfl9.230 orfl9.230 1 0 1 0 1 1 0 4
orfl9.2652 TEF4 1 0 1 0 1 1 0 4
orfl9.649 orfl9.649 0 1 1 0 0 1 1 4
orfl9.4649 ZCF27 1 1 1 0 1 0 0 4
orfl9.4643 orfl9.4643 0 1 1 0 1 1 0 4
orfl9.366 orfl9.366 0 1 1 1 0 0 1 4
orfl9.5510 orfl9.5510 0 1 0 0 1 1 1 4
orfl9.3629 DSE1 1 0 1 0 1 0 0 3
orfl9.1766 orfl9.1766 0 1 1 0 1 0 0 3
orfl9.4510 IFA4 0 1 1 0 0 0 1 3
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orfl9.4961 STP2 1 1 0 1 0 0 0 3
orfl9.115 orfl9.115 0 1 0 0 1 0 1 3
orfl9.371 orfl9.371 0 0 1 1 0 0 1 3
orfl9.5504 orfl9.5504 1 0 0 0 1 1 0 3
orfl9.2400 orfl9.2400 0 0 1 0 0 1 1 3
orf19.4243 orfl9.4243 0 1 1 0 1 0 0 3
orfl9.4068 orfl9.4068 1 1 1 0 0 0 0 3
orfI9.3239 CTF18 1 1 1 0 0 0 0 3
orfl9.3906 orfl9.3906 0 1 1 0 1 0 0 3
orfl9.2901 NUP60 0 0 1 0 1 1 0 3
orfl9.3916 orfl9.3916 0 0 1 0 1 0 1 3
orfl9.7204 orfl9.7204 0 1 0 0 0 1 1 3
orfl9.2433 orfl9.2433 1 1 0 0 1 0 0 3
orfl9.3190 HAL9 0 1 1 0 0 0 1 3
orfl9.4901 orfl9.4901 0 0 0 0 1 1 1 3
orfl9.7561 DEFI 0 0 0 1 1 1 0 3
orfl9.175 orfl9.175 0 0 1 0 0 1 1 3
orfl9.1748 orfl9.1748 0 1 1 0 1 0 0 3
orfl9.1356 orfl9.1356 0 0 0 1 1 1 0 3
orfl9.2510 orfl9.2510 0 0 1 0 1 1 0 3
orfl9.1111 orfl9.1111 0 0 1 1 0 1 0 3
orfl9.4280 orfl9.4280 0 1 0 0 1 0 1 3
orfl9.3997 ADHI 1 0 0 0 0 1 1 3
orfl9.1555 SAC3 0 0 1 1 1 0 0 3
orfl9.1624.1 orfl9.1624.1 0 1 1 0 0 1 0 3
orfl9.1795 PUF3 0 0 1 1 0 1 0 3
orfl9.4191.1 orfl9.4191.1 0 1 1 0 1 0 0 3
orfl9.6280 orfl9.6280 0 1 0 1 0 0 1 3
orfl9.894 orfl9.894 1 1 1 0 0 0 0 3
orfl9.3380 HWP2 0 0 1 0 1 1 0 3
orfl9.3100 orfl9.3100 0 1 0 0 1 0 1 3
orfl9.92 orfl9.92 0 0 0 0 1 1 1 3
orfl9.6979 orfl9.6979 1 1 0 0 0 1 0 3
orfl9.1500 orfl9.1500 1 1 0 0 0 0 1 3
orfl9.5918 orfl9.5918 0 1 1 0 1 0 0 3
orfl9.3986 PPR1 0 1 0 0 1 0 1 3
orfl9.1607 ALR1 0 1 0 1 0 1 0 3
orfl9.1083 orfl9.1083 0 1 0 0 1 1 0 3
orfl9.4918 orfl9.4918 0 0 0 1 1 0 1 3
orfl9.4257 INTl 1 0 0 0 0 1 1 3
orfl9.1400 orfl9.1400 1 0 1 0 1 0 0 3
orfl9.4715 orfl9.4715 0 0 1 0 1 0 1 3
orfl9.7023 orfl9.7023 1 0 0 1 0 1 0 3
orfl9.2724 orfl9.2724 0 0 1 1 0 1 0 3
orfl9.3706 orfl9.3706 0 0 1 0 1 1 0 3
orfl9.6544 LPI9 0 0 0 1 1 1 0 3
orf19.4369 orfl9.4369 0 0 1 0 1 0 1 3
206
orfl9.5141 orfl9.5141 0 0 1 0 1 0 1 3
orfl9.290 KRE5 1 0 1 0 1 0 0 3
orfl9.194 orfl9.194 0 0 1 0 0 1 1 3
orfl9.6499 orfl9.6499 0 0 1 0 1 1 0 3
orfl9.2266 orfl9.2266 1 0 0 0 1 1 0 3
orfl9.7036 orfl9.7036 0 1 0 0 1 1 0 3
orfl9.2647 ZCF14 0 0 0 0 1 1 1 3
orfl9.4394 orfl9.4394 1 1 0 0 1 0 0 3
orfl9.3613 orfl9.3613 0 1 0 0 1 1 0 3
orfl9.3603 orfl9.3603 0 0 1 1 1 0 0 3
orfl9.4348 orfl9.4348 0 0 1 0 1 0 1 3
orfl9.4080 orfl9.4080 0 0 0 1 1 1 0 3
orfl9.1608 orfl9.1608 0 1 1 0 1 0 0 3
orfl9.1798 TSC2 1 0 1 0 1 0 0 3
orfl9.1113 orfl9.1113 0 0 1 1 0 1 0 3
orfl9.262 SMC3 0 0 1 1 0 1 0 3
orfl9.5915 DUR35 0 0 1 0 1 1 0 3
orfl9.6694 orfl9.6694 1 1 1 0 0 0 0 3
orfl9.4965 orfl9.4965 1 0 0 0 0 1 1 3
orfl9.4412 orfl9.4412 0 1 1 0 1 0 0 3
orfl9.1622 YCG1 0 1 0 0 1 1 0 3
orfl9.1106 orfl9.1106 0 0 1 1 0 1 0 3
orfl9.267 orfl9.267 0 1 1 0 0 1 0 3
orfl9.5505 HIS7 0 1 0 0 1 0 1 3
orfl9.4570 orfl9.4570 0 1 1 0 1 0 0 3
orfl9.4288 CTA7 0 0 0 0 1 1 1 3
orfl9.4145 ZCF20 1 0 1 0 1 0 0 3
orfl9.2879 IFF5 0 0 1 0 1 0 1 3
orfl9.5854.1 orfl9.5854.1 0 0 1 0 1 1 0 3
orfl9.6999 orfl9.6999 0 0 0 0 1 1 1 3
orfl9.5621 orfl9.5621 1 0 0 1 1 0 0 3
orfl9.255 ZCF1 0 1 1 0 1 0 0 3
orfl9.6592 orfl9.6592 0 0 0 1 1 1 0 3
orfl9.6919 orfl9.6919 1 1 0 0 0 0 1 3
orfl9.2761 orfl9.2761 0 0 1 0 1 0 1 3
orfl9.4404 PGA49 0 0 1 0 1 1 0 3
orfl9.4225 LEU3 0 0 1 0 1 1 0 3
orfl9.1772 orfl9.1772 0 1 1 0 1 0 0 3
orfl9.5924 ZCF31 0 0 1 0 1 1 0 3
orfl9.7277 orfl9.7277 0 1 0 0 1 1 0 3
orfl9.2826 orfl9.2826 0 0 1 0 1 1 0 3
orfl9.5058 SMIl 0 0 0 1 1 1 0 3
orfl9.5003 orfl9.5003 0 1 0 1 0 1 0 3
orfl9.2547 orfl9.2547 0 1 1 0 0 1 0 3
orfl9.3098 orfl9.3098 0 0 1 0 1 0 1 3
orfl9.3166 orfl9.3166 1 0 1 0 1 0 0 3
orfl9.4239 orfl9.4239 0 0 1 0 1 0 1 3
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orfl9.4658 orfl9.4658 0 1 1 0 0 0 1 3
orfl9.229 orfl9.229 0 0 1 1 0 1 0 3
orfl9.1327 RBTI 0 0 1 1 1 0 0 3
orfl9.4958 ECM25 0 1 0 0 1 0 1 3
orfl9.7342 AXLI 0 0 0 1 1 1 0 3
orfl9.2797 orfl9.2797 0 0 0 1 1 0 1 3
orfl9.1551 orfl9.1551 0 1 1 1 0 0 0 3
orfl9.1779 MP65 0 0 1 0 1 1 0 3
orfl9.5065 orfl9.5065 0 1 0 0 1 1 0 3
orfl9.102 orfl9.102 0 0 0 0 1 1 1 3
orfl9.3937 orfl9.3937 0 0 1 0 1 1 0 3
orf19.5949 FAS2 1 1 0 0 0 1 0 3
orfl9.746 orfl9.746 1 0 1 0 0 1 0 3
orfl9.745 VAC8 0 0 0 1 0 1 1 3
orfl9.6260 orfl9.6260 0 1 0 0 1 1 0 3
orfl9.6862 orfl9.6862 0 0 1 0 1 1 0 3
orfl9.4683 MLP1 1 0 1 0 1 0 0 3
orfl9.2929 GSC1 I 1 0 0 0 0 0 2
orfl9.2383 YKU80 0 0 1 0 0 0 1 2
orfl9.4251 ZCF22 0 0 1 0 1 0 0 2
orfl9.3216 orft9.3216 0 0 0 0 1 1 0 2
orfl9.3214 orfl9.3214 0 0 1 1 0 0 0 2
orfl9.4339 VPS4 0 1 1 0 0 0 0 2
orfl9.76 SPB1 0 0 0 0 1 1 0 2
orfl9.1768 orfl9.1768 0 0 1 0 1 0 0 2
orf19.2893 orfl9.2893 0 0 0 0 1 0 1 2
orfl9.114 orfl9.114 0 0 0 0 1 0 1 2
orfl9.2624 orfl9.2624 0 1 1 0 0 0 0 2
orfl9.5138 IFA21 0 0 1 0 1 0 0 2
orf19.1108 HAMI 0 0 0 0 1 1 0 2
orfl9.113 CIPI 0 0 0 0 1 0 1 2
orfl9.4498 orfl9.4498 0 1 0 0 0 1 0 2
orf19.4248 orfl9.4248 1 0 0 1 0 0 0 2
orfl9.4245 orfl9.4245 0 0 0 0 0 1 1 2
orfl9.3267 orfl9.3267 0 1 1 0 0 0 0 2
orfl9.4066 orfl9.4066 0 0 1 0 1 0 0 2
orfl9.1684 orfl9.1684 0 0 1 0 0 1 0 2
orfl9.1681 orfl9.1681 0 1 0 0 1 0 0 2
orfl9.3601 orfl9.3601 0 0 0 0 1 1 0 2
orfl9.6420 PGA13 0 0 1 0 0 1 0 2
orfl9.301 PGA18 0 0 1 0 1 0 0 2
orfl9.3463 orfl9.3463 0 0 0 0 1 0 1 2
orfl9.5043 orfl9.5043 0 0 0 0 1 0 1 2
orfl9.1828 BUD16 1 0 0 0 1 0 0 2
orfl9.5999 DYNI 0 0 0 0 1 1 0 2
orfl9.3910 orfl9.3910 0 0 1 0 1 0 0 2
orfl9.1366 orfl9.1366 0 0 1 0 1 0 0 2
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orfl9.1210 orfl9.1210 1 1 0 0 0 0 0 2
orfl9.922 ERGIl 0 0 1 0 0 0 1 2
orfl9.2768 AMS1 0 0 1 0 1 0 0 2
orfl9.923 THRI 0 0 1 0 0 0 1 2
orfl9.787 orfl9.787 0 1 0 0 0 0 1 2
orfl9.5714 SAPI 1 0 0 0 0 0 1 2
orfl9.2505 orfl9.2505 0 0 1 0 1 0 0 2
orfl9.4232 PTH1 0 0 1 0 1 0 0 2
orfl9.4270 orfl9.4270 0 1 0 0 1 0 0 2
orfl9.1698 orfl9.1698 1 0 0 0 1 0 0 2
orfl9.1531 orfl9.1531 0 1 1 0 0 0 0 2
orfl9.1532 SAM37 0 0 1 0 0 1 0 2
orfl9.5705 NAM2 0 0 0 0 1 0 1 2
orfl9.6336 PGA25 0 1 0 0 1 0 0 2
orfl9.3470 orfl9.3470 0 0 0 0 1 0 1 2
orfl9.5729 FGR17 0 0 0 0 1 0 1 2
orfl9.124 CIC 0 1 0 0 1 0 0 2
orfl9.1834 orfl9.1834 0 0 0 0 1 0 1 2
orfl9.5057 orfl9.5057 0 1 1 0 0 0 0 2
orfl9.5053 orfl9.5053 0 0 1 0 1 0 0 2
orfl9.5051 orfl9.5051 0 0 1 1 0 0 0 2
orfl9.5496 AVT1 0 0 0 0 1 1 0 2
orfl9.3907 orfl9.3907 0 0 0 0 1 0 1 2
orfl9.1359 orfl9.1359 0 0 1 0 1 0 0 2
orfl9.2884 CDC68 0 0 1 0 1 0 0 2
orfl9.1509 RODI 0 0 1 0 0 0 1 2
orfl9.3878 orfl9.3878 0 0 1 0 0 1 0 2
orfl9.1492 PRP39 0 1 1 0 0 0 0 2
orfl9.7215 orfl9.7215 1 0 0 0 0 0 1 2
orfl9.2604 orfl9.2604 0 1 0 0 0 0 1 2
orfl9.4265 UAP1 0 0 0 0 1 1 0 2
orfl9.7369 orfl9.7369 1 0 0 0 1 0 0 2
orfl9.7366 orfl9.7366 0 0 0 0 1 0 1 2
orfl9.7365 orfl9.7365 0 1 0 0 1 0 0 2
orfl9.2516 orfl9.2516 0 0 0 1 1 0 0 2
orfl9.3648 orfl9.3648 0 0 0 0 1 1 0 2
orfl9.4465 orfl9.4465 0 1 0 0 1 0 0 2
orfl9.6536 I 1 1 0 0 0 1 0 0 2
orfl9.4133 orfl9.4133 0 1 1 0 0 0 0 2
orfl9.4131 orf19.4131 0 0 1 0 1 0 0 2
orfl9.4234 orfl9.4234 0 0 0 0 1 1 0 2
orfl9.5736 ALS5 0 1 1 0 0 0 0 2
orfl9.1816 ALS3 0 0 0 0 1 1 0 2
orfl9.6424 orfl9.6424 0 0 1 1 0 0 0 2
orfl9.1762 OCAl 0 1 0 0 0 1 0 2
orfl9.3077 VID21 0 0 1 0 1 0 0 2
orfl9.5730 orfl9.5730 0 0 0 0 1 0 1 2
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orfl9.5552 orfl9.5552 0 1 0 0 1 0 0 2
orfl9.5380 LYS144 0 0 1 0 1 0 0 2
orfl9.2457 orfl9.2457 1 0 0 0 1 0 0 2
orfl9.2452 orfl9.2452 1 1 0 0 0 0 0 2
orfl9.90 orfl9.90 0 0 0 0 0 1 1 2
orfl9.2296 orfl9.2296 0 0 0 1 1 0 0 2
orfl9.2675 orf19.2675 0 0 1 0 1 0 0 2
orfl9.6973 orfl9.6973 0 0 0 0 1 1 0 2
orfl9.1755 SET2 0 0 0 0 1 1 0 2
orfl9.4459 orfl9.4459 0 0 0 0 1 0 1 2
orfl9.6317 ADE6 0 0 0 0 1 0 1 2
orfl9.4148 orfl9.4148 0 0 1 0 1 0 0 2
orfl9.4266 SPR28 0 0 0 0 1 1 0 2
orfl9.4705 orfl9.4705 0 0 1 0 1 0 0 2
orfl9.3180 orfl9.3180 0 0 1 0 1 0 0 2
orfl9.4703 orfl9.4703 0 0 1 0 0 1 0 2
orfl9.1119 MTR1O 0 0 1 0 0 1 0 2
orfl9.2775 IDIl 0 0 1 0 1 0 0 2
orfl9.1656 orfl9.1656 1 0 1 0 0 0 0 2
orfl9.6480 orfl9.6480 0 1 0 0 1 0 0 2
orfl9.5167 IFM1 1 0 0 0 1 0 0 2
orf19.1240 orfl9.1240 0 0 1 0 1 0 0 2
orfl9.5728 orf19.5728 0 1 0 0 0 0 1 2
orfI9.6573 BEM2 1 0 0 1 0 0 0 2
orfl9.7499 orfl9.7499 1 0 0 0 0 0 1 2
orfl9.427 orfl9.427 0 1 0 0 1 0 0 2
orfl9.2445 orfl9.2445 0 1 0 0 1 0 0 2
orfl9.6494 WHI3 0 0 0 0 1 1 0 2
orfl9.2763 orfl9.2763 0 0 1 0 1 0 0 2
orfl9.245 DDC1 0 0 0 1 1 0 0 2
orfl9.4279 MNN1 0 0 1 0 1 0 0 2
orfl9.2881 MNN4 0 0 1 0 1 0 0 2
orfl9.7547 orfl9.7547 0 0 0 1 0 1 0 2
orfl9.3627 orfl9.3627 0 0 1 1 0 0 0 2
orfl9.3624 orfl9.3624 0 0 1 0 1 0 0 2
orfl9.3621 orfl9.3621 1 0 0 0 0 1 0 2
orfl9.5568 VPS51 0 0 0 0 1 0 1 2
orfl9.2688 NANI 0 0 1 0 1 0 0 2
orfl9.4627 orfl9.4627 1 0 0 0 1 0 0 2
orfl9.4405 PPS1 0 0 1 0 0 1 0 2
orf19.2847 orfl9.2847 0 1 0 0 0 0 1 2
orfl9.4713 orfl9.4713 0 0 1 0 1 0 0 2
orfl9.1662 orfl9.1662 0 0 1 0 1 0 0 2
orfl9.130 orfl9.130 0 0 0 0 1 1 0 2
orfl9.522 orfl9.522 0 0 1 0 1 0 0 2
orfl9.4640 PWP1 1 0 0 0 0 1 0 2
orfl9.1253 PHO4 0 0 1 0 0 0 1 2
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orfl9.1096 orfl9.1096 0 0 0 0 1 1 0 2
orfl9.1091 orfl9.1091 1 0 0 0 0 1 0 2
orfl9.5976 orfl9.5976 0 0 0 1 0 1 0 2
orfl9.5970 orfl9.5970 0 0 0 0 1 1 0 2
orfl9.2182 BLM3 0 0 1 0 1 0 0 2
orfl9.188 orfl9.188 0 0 0 1 0 1 0 2
orfl9.1893 orfl9.1893 1 0 0 0 1 0 0 2
orfl9.1878 orfl9.1878 1 0 0 0 1 0 0 2
orfl9.2274 orfl9.2274 0 0 0 1 0 1 0 2
orfl9.243 OXR1 0 0 1 0 1 0 0 2
orfl9.6349 RVS162 0 0 0 0 0 1 1 2
orfl9.7027 orfl9.7027 0 0 1 0 0 1 0 2
orfl9.1527 orfl9.1527 1 0 1 0 0 0 0 2
orfl9.3637 orfl9.3637 0 0 1 0 1 0 0 2
orfl9.3633 orfl9.3633 0 0 1 1 0 0 0 2
orfl9.3203 RCY1 0 1 0 0 1 0 0 2
orfl9.4366 orfl9.4366 0 1 1 0 0 0 0 2
orfl9.4764 orfl9.4764 0 0 0 0 1 1 0 2
orfl 9.248 APLS 0 0 0 0 1 1 0 2
orfl9.4284 BUR2 0 0 1 0 1 0 0 2
orfl9.1265 orfl9.1265 0 0 1 0 1 0 0 2
orfl9.1266 orfl9.1266 0 0 1 0 1 0 0 2
orfl9.5701 orfl9.5701 0 0 0 0 1 1 0 2
orfl9.5704 orfl9.5704 0 0 0 1 1 0 0 2
orfl9.6588 NBP2 0 1 0 .0 0 0 1 2
orfl9.193 orf19.193 0 0 1 0 0 0 1 2
orfl9.6492 orfl9.6492 0 1 0 0 1 0 0 2
orfl9.1849 orfl9.1849 1 0 0 0 0 0 1 2
orfl9.2399 orfl9.2399 0 0 1 1 0 0 0 2
orfl9.1841 orfl9.1841 0 1 0 0 0 0 1 2
orfl9.2265 orf19.2265 1 0 0 0 1 0 0 2
orfl9.73 1 EMP46 0 1 0 0 1 0 0 2
orfl9.6921 orfl9.6921 0 0 0 0 1 0 1 2
orfl9.3829 PHR1 1 0 0 0 1 0 0 2
orfl9.1325 ECM38 0 0 1 0 1 0 0 2
orfl9.7038 orfl9.7038 0 1 0 0 0 1 0 2
orfl9.7034 orfl9.7034 0 0 0 0 0 1 1 2
orfl9.2733 orfl9.2733 0 0 1 0 0 0 1 2
orfl9.6478 YCF1 1 0 0 0 1 0 0 2
orfl9.3735 orfl9.3735 0 0 1 0 0 0 1 2
orfl9.2137 orfl9.2137 0 0 0 0 1 0 1 2
orfl9.2476 orfl9.2476 0 1 0 0 1 0 0 2
orfl9.4553 orfl9.4553 0 1 0 0 1 0 0 2
orfl9.3604 orfl9.3604 0 0 0 0 1 0 1 2
orfl9.3607 orfl9.3607 0 0 0 0 1 1 0 2
orfl9.2370 DSL1 0 1 0 0 0 1 0 2
orfl9.101 RIM9 0 0 0 1 0 1 0 2
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orfl9.4771 orfl9.4771 0 0 0 0 1 1 0 2
orfl9.3443 OYE2 0 1 0 0 1 0 0 2
orfl9.4704 AROl 0 0 1 0 1 0 0 2
orfl9.6387 HSP104 0 1 0 0 0 1 0 2
orfl9.5177 orfl9.5177 1 0 1 0 0 0 0 2
orfl9.1075 orfl9.1075 1 0 0 0 1 0 0 2
orfl9.718 RRNI1 0 1 0 0 1 0 0 2
orfl9.6152 orfl9.6152 1 0 1 0 0 0 0 2
orfl9.276 orfl9.276 0 0 1 0 1 0 0 2
orfl9.2258 orfl9.2258 0 0 0 1 1 0 0 2
orfl9.2259 orfl9.2259 0 0 1 0 1 0 0 2
orfl9.1296 orfl9.1296 0 1 1 0 0 0 0 2
orfl9.7194 orf19.7194 0 0 0 0 0 1 1 2
orfl9.7519 orf19.7519 1 1 0 0 0 0 0 2
orfl9.7044 RIM15 0 0 1 1 0 0 0 2
orfl9.1345 LIP8 1 0 0 0 1 0 0 2
orfl9.2740 orfl9.2740 0 0 1 0 1 0 0 2
orfl9.3422 FMP27 0 0 0 0 1 0 1 2
orfl9.4963 orfl9.4963 1 0 0 0 0 1 0 2
orfl9.3433 OYE23 0 0 0 0 1 1 0 2
orfl9.4414 orfl9.4414 1 0 1 0 0 0 0 2
orfl9.6977 GPI1 0 1 0 0 1 0 0 2
orfl9.3417 ACF2 0 0 0 0 1 0 1 2
orfl9.3617 orfl9.3617 1 0 0 0 0 0 1 2
orfl9.3615 orfl9.3615 0 1 1 0 0 0 0 2
orfl9.3610 orfl9.3610 0 0 0 0 1 1 0 2
orfl9.2678 BUB1 0 0 1 0 1 0 0 2
orfl9.4349 orfl9.4349 0 0 1 0 0 0 1 2
orfl9.2819 orf19.2819 0 0 1 0 1 0 0 2
orfl9.4744 orfl9.4744 0 1 0 0 1 0 0 2
orfl9.4646 UEC1 0 1 0 0 0 0 1 2
orfl9.1690 TOSI 0 0 0 0 1 1 0 2
orfl9.2238 LTE1 0 0 1 0 0 1 0 2
orfl9.1610 orfl9.1610 0 0 1 0 1 0 0 2
orfl9.4184 orfl9.4184 0 0 1 0 1 0 0 2
orfl9.5328 GCN1 0 0 1 0 1 0 0 2
orfl9.4318 MIGI 0 0 1 0 0 0 1 2
orfl9.4568 ZCF25 0 0 1 0 1 0 0 2
orfl9.5295 orfl9.5295 0 0 1 0 1 0 0 2
orfl9.2216 PDSS 0 0 1 0 1 0 0 2
orfl9.1041 orfl9.1041 0 1 0 1 0 0 0 2
orfl9.1719 SGA1 0 0 0 1 1 0 0 2
orfl9.6913 GCN2 0 0 1 0 1 0 0 2
orfl9.4403 VPSII 0 0 1 0 1 0 0 2
orfl9.7071 FGR2 0 0 0 0 1 1 0 2
orfl9.6832 orfl9.6832 0 0 0 0 0 1 1 2
orfl9.1821 orfl9.1821 0 0 0 0 1 0 1 2
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orfl9.265 orfl9.265 0 0 1 0 1 0 0 2
orfl9.48 orfl9.48 0 1 0 0 0 0 1 2
orfl9.6580 orfl9.6580 0 0 0 0 1 1 0 2
orfl9.6901 orfl9.6901 1 0 1 0 0 0 0 2
orfl9.7051 orfl9.7051 1 0 0 0 1 0 0 2
orfl9.7052 orfl9.7052 0 0 1 0 1 0 0 2
orfl9.5723 POXI 0 1 0 0 0 1 0 2
orfl9.7473 orfl9.7473 0 1 1 0 0 0 0 2
orfl9.1166 CTA3 0 0 0 0 1 0 1 2
orfl9.4175 TOKI 0 0 1 0 1 0 0 2
orfl9.1595 orfl9.1595 0 1 1 0 0 0 0 2
orfl9.4750 orfl9.4750 0 0 0 0 1 1 0 2
orfl9.1624 orfl9.1624 0 0 1 0 1 0 0 2
orfl9.5713 YMX6 1 0 0 0 1 0 0 2
orfl9.4392 DEMI 0 0 1 1 0 0 0 2
orfl9.2752 ADRI 0 0 0 1 1 0 0 2
orfl9.1192 DNA2 0 0 0 0 1 0 1 2
orfl9.3969 SFL2 0 0 0 0 1 1 0 2
orfl9.570 IFF8 0 0 1 0 0 0 1 2
orfl9.5752 orfl9.5752 0 1 0 0 0 0 1 2
orfl9.6136 orfl9.6136 0 1 1 0 0 0 0 2
orfl9.3976 orfl9.3976 0 0 0 0 1 0 1 2
orfl9.5620 orfl9.5620 1 0 0 0 0 1 0 2
orfl9.258 orfl9.258 0 0 0 0 1 1 0 2
orfl9.257 orfl9.257 0 0 1 0 1 0 0 2
orfl9.251 orfl9.251 0 0 0 0 1 1 0 2
orfl9.36 orfl9.36 0 1 0 1 0 0 0 2
orfl9.5934 orfl9.5934 0 0 0 0 1 1 0 2
orfl9.5935 orfl9.5935 0 0 1 1 0 0 0 2
orfl9.6918 orfl9.6918 0 0 1 1 0 0 0 2
orfl9.810 orfl9.810 0 0 1 0 0 1 0 2
orfl9.4315 orfl9.4315 0 0 1 0 1 0 0 2
orfl9.929 orfl9.929 0 1 1 0 0 0 0 2
orfl9.1251 BRN1 0 0 1 0 1 0 0 2
orfl9.2165 orfl9.2165 0 0 1 0 1 0 0 2
orfl9.1456 orfl9.1456 0 0 0 1 0 1 0 2
orfl9.7001 YCK2 0 0 0 0 1 0 1 2
orfl9.3367 orfl9.3367 0 0 1 0 1 0 0 2
orfl9.2760 orfl9.2760 0 0 1 0 1 0 0 2
orfl9.3368 orfl9.3368 0 0 0 1 1 0 0 2
orfl9.4325 orfl9.4325 0 0 1 0 0 1 0 2
orfl9.2835 orfl9.2835 0 0 1 0 0 0 1 2
orfl9.5148 CYRI 0 0 1 0 0 0 1 2
orfl9.4136 YBL053 0 0 1 0 1 0 0 2
orfl9.3803 MNN22 1 0 1 0 0 0 0 2
orfl9.1714 PGA44 0 0 1 0 0 0 1 2
orfl9.2907 PGA42 0 0 1 0 1 0 0 2
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orfl9.3984 orfl9.3984 0 0 0 0 1 0 1 2
orfl9.1121 orfl9.1121 0 1 1 0 0 0 0 2
orfl9.3429 FGR47 0 0 0 0 1 0 1 2
orfl9.1774 orfl9.1774 0 0 1 0 1 0 0 2
orfl9.868 ADAEC 0 0 1 1 0 0 0 2
orfl9.6690 orf19.6690 0 0 1 1 0 0 0 2
orfl9.6698 orfl9.6698 0 1 0 0 0 0 1 2
orfl9.6453 orfl9.6453 0 1 0 0 1 0 0 2
orf19.1338 orfl9.1338 1 1 0 0 0 0 0 2
orfl9.3965 orfl9.3965 0 1 0 0 1 0 0 2
orfl9.4167 orfl9.4167 0 1 0 0 1 0 0 2
orfl9.2465 POL32 0 1 0 0 1 0 0 2
orfl9.246 orfl9.246 0 0 1 1 0 0 0 2
orfl9.719 orfl9.719 0 0 1 0 0 0 1 2
orfl9.7274 orfl9.7274 0 1 0 1 0 0 0 2
orfl9.3773 CDL1 0 1 1 0 0 0 0 2
orfl9.2682 orfl9.2682 0 0 1 0 1 0 0 2
orfl9.2680 orfl9.2680 1 0 1 0 0 0 0 2
orfl9.1670 BROl 0 0 0 0 1 1 0 2
orfl9.2175 orfl9.2175 0 0 1 0 1 0 0 2
orfl9.3170 orfl9.3170 0 0 1 0 0 1 0 2
orfl9.3793 orfl9.3793 0 0 1 0 0 1 0 2
orfl9.1680 TFPI 0 1 1 0 0 0 0 2
orfl9.4680 orfl9.4680 0 0 1 0 1 0 0 2
orfl9.4515 orfl9.4515 1 0 1 0 0 0 0 2
orfl9.2778 orfl9.2778 0 0 0 0 1 1 0 2
orfl9.2770 orfl9.2770 0 1 1 0 0 0 0 2
orfl9.3428 orfl9.3428 0 0 0 0 1 1 0 2
orfl9.4135 PRC2 0 0 1 0 1 0 0 2
orfl9.4305.1 orfl9.4305.1 0 1 0 0 0 1 0 2
orfl9.4209 orfl9.4209 0 0 0 0 0 1 1 2
orfl9.2915 orfl9.2915 0 0 1 0 1 0 0 2
orfl9.6294 MYOl 0 0 1 0 1 0 0 2
orfl9.1824 PGA50 0 0 0 0 1 0 1 2
orfl9.5134 orfl9.5134 0 0 1 0 0 1 0 2
orfl9.1843 ALG6 0 1 1 0 0 0 0 2
orfl9.5648 orfl9.5648 0 0 1 0 1 0 0 2
orfl9.1326 orfl9.1326 0 1 0 0 0 1 0 2
orfl9.721 orfl9.721 1 0 1 0 0 0 0 2
orfl9.1763 IFRI 0 1 1 0 0 0 0 2
orfl9.6891 RFC1 1 0 1 0 0 0 0 2
orfl9.839 orfl9.839 0 0 1 0 0 0 1 2
orfl9.836 orfl9.836 1 0 1 0 0 0 0 2
orfl9.3592 JEMI 0 0 1 0 0 1 0 2
orfl9.2368 orfl9.2368 0 0 1 0 0 0 1 2
orfl9.3825 RCE1 0 0 1 0 1 0 0 2
orfl9.3781 orfl9.3781 0 0 1 0 1 0 0 2
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orfl9.3784 orfl9.3784 0 0 1 0 1 0 0 2
orfl9.7475 PHO81 0 0 0 0 1 1 0 2
orfl9.2397.3 orfl9.2397.3 0 0 1 0 1 0 0 2
orfl9.2781 orfl9.2781 0 0 0 1 1 0 0 2
orfl9.2786 orfl9.2786 0 0 0 0 1 1 0 2
orfl9.2784 orfl9.2784 0 1 0 0 0 1 0 2
orfl9.3437 orfl9.3437 0 1 0 0 1 0 0 2
orfl9.3434 TRY5 0 0 0 0 1 0 1 2
orfl9.3439 orfl9.3439 0 0 0 0 1 0 1 2
orfl9.4707 orfl9.4707 1 0 0 0 1 0 0 2
orfl9.7030 SSR1 0 0 1 0 1 0 0 2
orfl9.1495 orfl9.1495 1 0 1 0 0 0 0 2
orfl9.4213 FET31 0 0 0 0 1 0 1 2
orfl9.4653 orfl9.4653 0 0 1 0 1 0 0 2
orfl9.1915 MPP1O 0 0 1 0 0 0 1 2
orfl9.1706 MET18 0 0 0 0 1 1 0 2
orfl9.1144 orfl9.1144 0 0 0 1 1 0 0 2
orfl9.3897 orfl9.3897 0 0 1 0 1 0 0 2
orfl9.134 orfl9.134 0 1 0 0 0 0 1 2
orfl9.6143 orfl9.6143 0 0 1 0 0 0 1 2
orfl9.2847.1 orfl9.2847.1 0 0 1 0 0 1 0 2
orfl9.1314 orfl9.1314 0 0 1 0 1 0 0 2
orfl9.6476 orf19.6476 0 1 0 0 0 1 0 2
orfl9.3945 orfl9.3945 0 1 1 0 0 0 0 2
orfl9.5300 orfl9.5300 0 0 1 0 1 0 0 2
orfl9.1839 RPA190 0 1 0 0 1 0 0 2
orfl9.3187 ZNC1 0 1 1 0 0 0 0 2
orfl9.5491 orfl9.5491 0 0 0 0 0 1 1 2
orfl9.8 orfl9.8 0 0 1 0 0 1 0 2
orfl9.9 orfl9.9 0 0 0 1 0 1 0 2
orfl9.5068 IREl 0 0 0 0 1 0 1 2
orfl9.4273 orfl9.4273 0 0 0 0 1 1 0 2
orfl9.6202 RBT4 0 1 0 0 0 1 0 2
orfl9.2372 orfl9.2372 0 0 1 0 1 0 0 2
orfl9.4519 SUV3 0 1 1 0 0 0 0 2
orfl9.4766 ARG81 0 1 0 0 1 0 0 2
orfl9.2748 ARG83 0 0 0 0 1 1 0 2
orfl9.1538 TLG2 0 1 0 1 0 0 0 2
orfl9.3447 orfl9.3447 0 0 0 1 1 0 0 2
orfl9.1792 orfl9.1792 0 0 0 0 1 0 1 2
orfl9.1794 orfl9.1794 0 1 0 0 1 0 0 2
orfl9.1797 orfl9.1797 0 1 0 0 0 0 1 2
orfl9.1557 orfl9.1557 0 0 1 0 0 1 0 2
orfl9.6511 LIG1 0 0 1 0 1 0 0 2
orfl9.3204 orfl9.3204 0 0 1 0 1 0 0 2
orfl9.3202 orfl9.3202 0 0 1 0 1 0 0 2
orfl9.1177 orfl9.1177 0 0 0 1 0 0 1 2
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orfl9.107 orfl9.107 0 0 0 0 1 0 1 2
orfl9.1747 KIP2 0 0 0 0 1 1 0 2
orfl9.1305 orfl9.1305 0 0 1 0 1 0 0 2
orfl9.748 orfl9.748 0 0 1 0 1 0 0 2
orfl9.216 orfl9.216 1 0 0 0 1 0 0 2
orfl9.215 orfl9.215 1 0 1 0 0 0 0 2
orfl9.849 orfl9.849 1 0 0 0 0 1 0 2
orfl9.3840 orfl9.3840 0 0 0 1 0 1 0 2
orfl9.1943 orfl9.1943 0 1 0 0 1 0 0 2
orfl9.6344 RBK1 0 1 0 0 0 1 0 2
orfl9.6566 orfl9.6566 0 0 1 0 1 0 0 2
orfl9.697 orfl9.697 0 0 1 0 0 0 1 2
orfl9.6310 orfl9.6310 0 0 0 1 1 0 0 2
orfl9.6861 orfl9.6861 0 0 1 0 1 0 0 2
orfl9.6319 orfl9.6319 1 1 0 0 0 0 0 2
orfl9.1264 CFL2 1 0 1 0 0 0 0 2
orfl9.5962 HGT4 0 1 0 0 1 0 0 2
orfl9.3148 orfl9.3148 0 0 1 0 0 1 0 2
orfl9.2415 orfl9.2415 0 0 1 0 0 0 1 2
orfl9.2418 orf19.2418 0 0 1 0 0 0 1 2
orfl9.1620 orfl9.1620 0 0 0 0 0 1 0 1
orfl9.6831 PRPS 0 1 0 0 0 0 0 1
orfl9.4816 orfl9.4816 0 1 0 0 0 0 0 1
orfl9.3329 orfl9.3329 0 0 0 1 0 0 0 1
orfl9.7356 orfl9.7356 0 0 0 0 1 0 0 1
orfl9.7357 orfl9.7357 0 0 0 0 1 0 0 1
orfl9.7353 orfl9.7353 0 0 0 0 1 0 0 1
orfl9.4120 LASI 0 0 1 0 0 0 0 1
orf19.1780 orfl9.1780 0 0 0 0 1 0 0 1
orfl9.4183 MUCI 0 0 0 0 1 0 0 1
orfl9.3458 orfl9.3458 1 0 0 0 0 0 0 1
orfl9.1789 orfl9.1789 0 0 0 0 1 0 0 1
orfl9.1541 orfl9.1541 0 0 1 0 0 0 0 1
orf19.1546 orfl9.1546 0 0 1 0 0 0 0 1
orfl9.1548 orfl9.1548 0 0 0 0 1 0 0 1
orfl9.5491.1 ATP14 0 0 1 0 0 0 0 1
orfl9.2170 PHM7 0 0 1 0 0 0 0 1
orfl9.4719 CWH41 0 0 1 0 0 0 0 1
orfl9.260 SLDI 0 0 1 0 0 0 0 1
orfl9.4258 orfl9.4258 0 0 0 0 1 0 0 1
orfl9.3213 orfl9.3213 0 0 0 0 0 0 1 1
orfl9.2839 CIRT4B 0 0 0 1 0 0 0 1
orfl9.3219 orfl9.3219 0 0 0 0 1 0 0 1
orfl9.1631 ERG6 0 0 1 0 0 0 0 1
orfl9.6026 ERG2 0 1 0 0 0 0 0 1
orfl9.4606 ERG8 0 0 1 0 0 0 0 1
orfl9.3616 ERG9 1 0 0 0 0 0 0 1
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orfl9.4078 orfl9.4078 0 0 1 0 0 0 0 1
orfl9.335 orfl9.335 0 0 0 0 1 0 0 1
orfl9.4676 orfl9.4676 0 0 1 0 0 0 0 1
orfl9.4672 orfl9.4672 0 0 1 0 0 0 0 1
orfl9.1212 orfl9.1212 0 0 0 0 0 1 0 1
orfl9.4101 orfl9.4101 0 0 0 0 1 0 0 1
orfl9.4106 orfl9.4106 0 0 0 0 1 0 0 1
orfl9.1160 orfl9.1160 0 1 0 0 0 0 0 1
orfl9.367 CNH1 0 0 1 0 0 0 0 1
orfl9.2892 orfl9.2892 0 0 0 0 1 0 0 1
orfl9.2890 orfl9.2890 0 0 1 0 0 0 0 1
orfl9.2891 orfl9.2891 0 0 0 0 1 0 0 1
orfl9.593 FGR32 0 0 0 0 0 0 1 1
orfl9.2873 TOP2 0 0 1 0 0 0 0 1
orfl9.1767 orfl9.1767 0 0 0 1 0 0 0 1
orfl9.3159 UTP20 0 0 0 0 1 0 0 1
orfl9.5031 SSK1 0 1 0 0 0 0 0 1
orfl9.5074 orfl9.5074 0 0 0 0 0 1 0 1
orfl9.5430 BUD21 0 0 0 0 0 0 1 1
orfl9.2131 orfl9.2131 0 0 0 0 1 0 0 1
orfl9.1371 orfl9.1371 0 0 1 0 0 0 0 1
orfl9.5676 orfl9.5676 0 0 0 0 1 0 0 1
orfl9.3926 RNYl1 0 0 1 0 0 0 0 1
orfl9.3929 orfl9.3929 0 0 0 0 1 0 0 1
orfl9.5561 RAV2 0 0 0 0 1 0 0 1
orfl9.400 GCF1 0 0 0 0 0 1 0 1
orfl9.5486.1 SMD2 0 0 0 0 1 0 0 1
orfl9.390 CDC42 1 0 0 0 0 0 0 1
orfl9.2715 RPC53 0 0 1 0 0 0 0 1
orfl9.757 orfl9.757 0 0 0 0 1 0 0 1
orfl9.5692 orfl9.5692 0 1 0 0 0 0 0 1
orfl9.6422 SSY5 0 0 1 0 0 0 0 1
orfl9.3480 orfl9.3480 0 0 0 0 1 0 0 1
orfl9.3859 orfl9.3859 1 0 0 0 0 0 0 1
orfl9.1207 orfl9.1207 0 0 1 0 0 0 0 1
orfl9.3631 STN1 0 0 0 0 0 1 0 1
orfl9.5210 orfl9.5210 0 0 1 0 0 0 0 1
orfl9.5212 orfl9.5212 0 0 1 0 0 0 0 1
orfl9.1998 orfl9.1998 0 0 1 0 0 0 0 1
orfl9.816 DCK2 0 0 1 0 0 0 0 1
orfl9.6164 orf19.6164 0 0 1 0 0 0 0 1
orfl9.1993 orfl9.1993 0 0 1 0 0 0 0 1
orfl9.1822 UME6 0 0 0 0 0 0 1 1
orfl9.1995 orfl9.1995 0 0 1 0 0 0 0 1
orfl9.690 PLB2 0 0 0 0 1 0 0 1
orfl9.376 orfl9.376 0 0 0 0 0 0 1 1
orfl9.2988 orfl9.2988 0 0 0 0 1 0 0 1
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orfl9.4451 RIAl 0 0 0 0 1 0 0 1
orfl9.2081 POM152 0 0 1 0 0 0 0 1
orfl9.1618 GFA1 0 0 1 0 0 0 0 1
orfl9.4063 GPTI 0 0 0 0 1 0 0 1
orfl9.686 orfl9.686 0 0 0 0 0 1 0 1
orfl9.1311 SP075 0 0 0 0 1 0 0 1
orfl9.6635 orfl9.6635 0 0 0 0 1 0 0 1
orfl9.7105 FARI 0 0 1 0 0 0 0 1
orfl9.4119 SP072 0 0 1 0 0 0 0 1
orfl9.651 LYPI 0 0 0 0 0 0 1 1
orfl9.2537 orfl9.2537 0 0 0 0 0 1 0 1
orfl9.3054 RPN3 0 0 0 0 1 0 0 1
orfl9.1299 RPN6 0 0 1 0 0 0 0 1
orfl9.2539 orfl9.2539 0 0 0 0 0 1 0 1
orfl9.3457 SWD3 0 0 0 0 1 0 0 1
orfl9.7177 KAP120 0 0 0 0 0 1 0 1
orf19.3139 orfl9.3139 0 0 1 0 0 0 0 1
orfl9.3135 orfl9.3135 0 1 0 0 0 0 0 1
orfl9.2401 orfl9.2401 0 0 1 0 0 0 0 1
orfl9.2532 PRS 0 0 1 0 0 0 0 1
orfl9.6742 orfl9.6742 1 0 0 0 0 0 0 1
orfl9.5507 ENPI 0 0 0 0 0 1 0 1
orfl9.3688 orfl9.3688 1 0 0 0 0 0 0 1
orfl9.3689 orfl9.3689 1 0 0 0 0 0 0 1
orfl9.7344 orfl9.7344 0 0 0 0 1 0 0 1
orfl9.7343 orfl9.7343 0 0 0 0 1 0 0 1
orfl9.3048 orfl9.3048 0 1 0 0 0 0 0 1
orfl9.3715 ASFI 0 0 0 0 0 1 0 1
orfl9.1576 orfl9.1576 0 0 1 0 0 0 0 1
orf19.1578 orfl9.1578 0 0 1 0 0 0 0 1
orfl9.5164 ECM39 0 0 1 0 0 0 0 1
orfl9.4244 orfl9.4244 0 1 0 0 0 0 0 1
orfl9.4247 orfl9.4247 1 0 0 0 0 0 0 1
orfl9.4246 orfl9.4246 0 0 1 0 0 0 0 1
orfl9.4241 orfl9.4241 1 0 0 0 0 0 0 1
orfl9.4240 orfl9.4240 0 0 0 0 1 0 0 1
orf19.3594 orfl9.3594 0 0 0 0 1 0 0 1
orfl9.3260 orfl9.3260 0 0 0 0 1 0 0 1
orfl9.834 orfl9.834 0 0 1 0 0 0 0 1
orfl9.4062 TRY2 0 0 0 0 1 0 0
orfl9.1686 orfl9.1686 0 0 1 0 0 0 0 1
orfl9.2616 UGT51CI 0 0 0 0 1 0 0 1
orfl9.1685 ZCF7 0 0 0 1 0 0 0 1
orfl9.1682 orfl9.1682 0 1 0 0 0 0 0 1
orfl9.1649 RNA1 0 1 0 0 0 0 0
orfl9.5674 PGA1O 1 0 0 0 0 0 0 1
orfl9.2878 PGA15 0 0 1 0 0 0 0 1
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orfl9.2018.2 orfl9.2018.2 0 0 1 0 0 0 0 1
orfl9.7251 WSC4 0 0 0 0 0 1 0 1
orfl9.4665 orfl9.4665 1 0 0 0 0 0 0 1
orfl9.1416 COXi1 0 0 1 0 0 0 0 1
orfl9.4110 orfl9.4110 0 0 0 0 1 0 0 1
orfl9.4112 orfl9.4112 0 0 1 0 0 0 0 1
orfl9.4115 orfl9.4115 0 0 0 0 0 1 0 1
orfl9.4117 orfl9.4117 0 0 0 0 0 0 1 1
orfl9.1757 orfl9.1757 0 0 1 0 0 0 0 1
orfl9.4268 UTP13 0 1 0 0 0 0 0 1
orfl9.4765 PGA6 0 0 0 0 1 0 0 1
orfl9.3122.2 orfl9.3122.2 0 0 0 0 1 0 0 1
orfl9.5041 orfl9.5041 0 0 1 0 0 0 0 1
orfl9.3555 BUD14 0 1 0 0 0 0 0 1
orfl9.3962 HASI 0 0 0 0 0 0 1 1
orfl9.1369 orfl9.1369 0 0 1 0 0 0 0 1
orfl9.4739 MSS116 0 0 0 0 1 0 0 1
orf19.4328 CCC2 0 0 0 0 1 0 0 1
orfl9.4848 SKI3 0 0 0 0 1 0 0 1
orfl9.353 ULPI 0 0 0 0 1 0 0 1
orfl9.1295 VASI 0 0 0 0 0 1 0 1
orfl9.6041 RPO41 0 0 0 0 1 0 0 1
orfl9.6247 orfl9.6247 0 0 0 0 1 0 0 1
orfl9.6244 orfl9.6244 0 0 0 0 0 0 1 1
orfl9.1215 orfl9.1215 0 0 0 0 0 1 0 1
orfl9.1214 orfl9.1214 0 0 0 0 0 1 0 1
orfl9.1217 orfl9.1217 0 0 0 0 1 0 0 1
orfl9.6240 orfl9.6240 0 0 0 0 1 0 0 1
orfl9.1219 orfl9.1219 0 0 0 0 1 0 0 1
orfl9.5221 orfl9.5221 1 0 0 0 0 0 0 1
orfl9.5223 orfl9.5223 1 0 0 0 0 0 0 1
orfl9.6248 orfl9.6248 0 0 0 0 1 0 0 1
orfl9.4033 PRP22 1 0 0 0 0 0 0 1
orfl9.1981 orfl9.1981 0 0 1 0 0 0 0 1
orfl9.305 orfl9.305 0 0 0 0 1 0 0 1
orfl9.304 orfl9.304 0 0 0 0 1 0 0 1
orfl9.7594 orfl9.7594 0 0 1 0 0 0 0 1
orfl9.302 orfl9.302 0 0 0 0 1 0 0 1
orfl9.2735 SEN2 0 0 1 0 0 0 0 1
orfl9.5938 SENI 0 0 1 0 0 0 0 1
orfl9.2320 orfl9.2320 0 0 0 0 0 1 0 1
orfl9.7203 orfl9.7203 0 1 0 0 0 0 0 1
orfl9.5145 SSP96 0 0 1 0 0 0 0 1
orfl9.6625 orfl9.6625 0 0 1 0 0 0 0 1
orfl9.2198 FLC3 0 0 0 0 1 0 0 1
orfl9.1813 FLC2 0 0 1 0 0 0 0 1
orfl9.4867 SWEl 0 0 0 0 0 0 1 1
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orfl9.2184 orfl9.2184 0 0 0 0 1 0 0 1
orfl9.3125 orfl9.3125 0 0 1 0 0 0 0 1
orfl9.3124 orfl9.3124 0 0 1 0 0 0 0 1
orfl9.3120 orfl9.3120 0 0 1 0 0 0 0 1
orfl9.2823 RFG1 0 0 0 0 0 1 0 1
orfl9.2431 orfl9.2431 0 0 0 0 1 0 0 1
orf19.2723 HITI 0 1 0 0 0 0 0 1
orfl9.6928 SAP9 0 0 0 0 0 0 1 1
orfl9.5585 SAPS 0 0 0 0 1 0 0 1
orfl9.4875 orfl9.4875 0 0 0 1 0 0 0 1
orfl9.4872 orfl9.4872 0 0 0 0 1 0 0 1
orfl9.3697 orfl9.3697 0 0 0 1 0 0 0 1
orfl9.3694 orfl9.3694 0 0 0 1 0 0 0 1
orfl9.7376 orfl9.7376 1 0 0 0 0 0 0 1
orfl9.2509 orfl9.2509 1 0 0 0 0 0 0 1
orfl9.2500 orfl9.2500 0 0 0 0 1 0 0 1
orfl9.2051 orfl9.2051 0 0 1 0 0 0 0 1
orfl9.2506 orfl9.2506 0 0 0 0 1 0 0 1
orfl9.3950 MSM1 0 0 0 0 1 0 0 1
orfl9.984 PHO8 1 0 0 0 0 0 0 1
orfl9.1648 RAD50 0 0 0 0 1 0 0 1
orfl9.4903 orfl9.4903 0 0 0 0 1 0 0 1
orfl9.6798 SSN6 0 0 0 0 0 1 0 1
orfl9.4907 orfl9.4907 0 0 0 0 1 0 0 1
orfl9.4904 orfl9.4904 0 0 0 0 1 0 0 1
orfl9.4905 orfl9.4905 0 0 0 0 0 0 1 1
orf19.3208 DALS2 0 1 0 0 0 0 0 1
orfl9.2623 ECM22 0 0 1 0 0 0 0 1
orfl9.3586 orf19.3586 0 1 0 0 0 0 0 1
orfl9.4471 orfl9.4471 0 0 0 0 0 0 1 1
orfl9.3271 orf19.3271 0 0 1 0 0 0 0 1
orfl9.3971 orfl9.3971 0 0 0 0 1 0 0 1
orfl9.4295 orfl9.4295 0 0 0 0 0 1 0 1
orfl9.939 NAM7 0 0 1 0 0 0 0 1
orfl9.35.1 orfl9.35.1 0 0 1 0 0 0 0 1
orfl9.3675 GAL7 1 0 0 0 0 0 0 1
orfl9.4866 CPP1 0 0 0 0 0 0 1 1
orfl9.2044 PGA27 0 0 1 0 0 0 0 1
orfl9.4615 orfl9.4615 0 0 1 0 0 0 0 1
orfl9.3477 orfl9.3477 0 1 0 0 0 0 0 1
orfl9.3476 orfl9.3476 0 0 0 0 1 0 0 1
orfl9.3093 MSH2 0 0 0 0 1 0 0 1
orfl9.559 FGR14 0 0 0 0 1 0 0 1
orfl9.3700 TOM70 0 0 0 0 1 0 0 1
orfl9.5479 FGR12 0 0 0 0 1 0 0 1
orfl9.4067 FGR18 0 0 0 0 1 0 0 1
orfl9.5094 BULl 0 0 0 0 1 0 0 1
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orfl9.4059 orfl9.4059 0 0 0 0 1 0 0 1
orfl9.3112 ZRT1 0 0 1 0 0 0 0 1
orfl9.1585 ZRT2 0 0 1 0 0 0 0 1
orfl9.105 HAL22 0 0 0 0 0 1 0 1
orfl9.1439 IPK1 0 0 0 0 1 0 0 1
orfl9.1563 ECM3 0 0 1 0 0 0 0 1
orfl9.5299 ECM1 0 1 0 0 0 0 0 1
orfl9.5052 orfl9.5052 0 0 1 0 0 0 0 1
orfl9.1089 PEXI1 0 0 0 0 1 0 0 1
orfl9.1831 orfl9.1831 0 0 0 0 1 0 0 1
orfl9.7282 PEX13 0 0 0 0 1 0 0 1
orfl9.1805 PEX14 0 0 0 0 0 1 0 1
orfl9.4635 NIPI 0 0 0 0 1 0 0 1
orfl9.610 EFG1 0 0 0 0 0 1 0 1
orfl9.1741 DITI 0 0 1 0 0 0 0 1
orfl9.2984 MST1 0 0 0 0 1 0 0 1
orfl9.695 RGS2 0 0 0 0 0 0 1 1
orfl9.1353 orfl9.1353 0 1 0 0 0 0 0 1
orfl9.3908 orfl9.3908 0 0 1 0 0 0 0 1
orfl9.3901 orfl9.3901 0 0 0 0 1 0 0 1
orfl9.407 GCD6 1 0 0 0 0 0 0 1
orfl9.5459 orfl9.5459 0 0 1 0 0 0 0 1
orfl9.481 GCD1 0 0 0 0 1 0 0 1
orfl9.5530 NAB3 0 0 0 0 1 0 0 1
orfl9.2560 CDC60 0 0 1 0 0 0 0 1
orfl9.775 orfl9.775 0 0 0 0 1 0 0 1
orfl9.3207 CCN1 0 0 0 0 0 0 1 1
orfl9.6507 orfl9.6507 0 0 1 0 0 0 0 1
orfl9.3877 orfl9.3877 0 0 1 0 0 0 0 1
orfl9.3876 ZCF19 0 0 0 0 1 0 0 1
orfl9.5239 orfl9.5239 0 0 0 0 1 0 0 1
orfl9.6508 orfl9.6508 0 0 1 0 0 0 0 1
orfl9.1229 orfl9.1229 0 1 0 0 0 0 0 1
orfl9.3240 ERG27 0 0 1 0 0 0 0 1
orfl9.178 orfl9.178 0 0 0 0 0 1 0 1
orfl9.5558 RBF1 0 0 0 1 0 0 0 1
orfl9.173 orfl9.173 0 0 0 0 0 0 1 1
orfl9.1944 GPR1 0 0 0 0 1 0 0 1
orfl9.315 orfl9.315 0 0 0 0 0 1 0 1
orfl9.318 orfl9.318 0 0 0 0 1 0 0 1
orfl9.2332 orfl9.2332 0 0 0 0 1 0 0 1
orfl9.6347 orfl9.6347 0 0 0 0 1 0 0 1
orfl9.6612 orfl9.6612 1 0 0 0 0 0 0 1
orfl9.6342 orfl9.6342 0 0 0 0 1 0 0 1
orfl9.3589 SPOIl 0 0 0 0 1 0 0 1
orfl9.111 CAN2 0 0 0 0 1 0 0 1
orfl9.84 CAN3 0 0 0 0 1 0 0 1
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orfl9.646 GLN1 0 1 0 0 0 0 0 _
orfl9.5759 SN 2 0 0 0 0 1 0 0 _
orfl9.5760 IHD1 0 0 0 0 0 0 1 1
orfl9.956 orfl9.956 0 0 1 0 0 0 0 1
orfl9.3110 orfl9.3110 0 0 1 0 0 0 0 _
orfl9.2429 orfl9.2429 0 0 0 0 1 0 0 1
orfl9.3113 orfl9.3113 0 0 0 0 0 1 0 1
orfl9.792 orfl9.792 0 0 0 0 0 0 1 1
orfl9.7101 orfl9.7101 0 0 1 0 0 0 0 1
orfl9.6981 orfl9.6981 0 0 0 0 0 0 1 1
orfl9.6982 orfl9.6982 0 0 0 0 0 1 0 1
orfl9.6986 orfl9.6986 0 0 0 0 0 0 1 1
orfl9.5527 orfl9.5527 0 0 0 0 1 0 0 1
orfl9.918 CDRl1 0 0 0 0 1 0 0 1
orfl9.2605 orfl9.2605 0 0 1 0 0 0 0 1
orfl9.458.1 orfl9.458.1 0 0 0 0 0 1 0 1
orfl9.4688 DAG7 0 0 1 0 0 0 0 1
orfl9.4865 orfl9.4865 1 0 0 0 0 0 0 1
orfl9.4862 orfl9.4862 0 0 0 1 0 0 0 1
orfl9.7368 orfl9.7368 0 0 0 0 0 1 0 1
orfl9.2517 orfl9.2517 0 0 1 0 0 0 0 1
orfl9.2515 orfl9.2515 0 0 1 0 0 0 0 1
orfl9.2514 orfl9.2514 0 0 0 0 0 1 0 1
orfl9.3649 orfl9.3649 0 0 0 0 1 0 0 1
orfl9.4752 MSN4 0 1 0 0 0 0 0 1
orfl9.1519 orfl9.1519 0 0 1 0 0 0 0 1
orfl9.3644 orfl9.3644 0 0 0 0 1 0 0 1
orfl9.3647 SEC8 0 0 0 0 1 0 0 1
orfl9.4913 orfl9.4913 0 1 0 0 0 0 0 1
orfl9.4912 orfl9.4912 1 0 0 0 0 0 0 1
orfl9.4262 orfl9.4262 0 0 0 0 0 1 0 1
orfl9.3241 orfl9.3241 0 0 1 0 0 0 0 1
orfl9.7201 SLA2 0 0 1 0 0 0 0 1
orfl9.3245 orfl9.3245 0 0 1 0 0 0 0 1
orfl9.4269 orfl9.4269 0 0 0 0 1 0 0 1
orfl9.3247 orfl9.3247 0 1 0 0 0 0 0 1
orfl9.6792 RRD1 0 0 0 0 1 0 0 1
orfl9.4286 orfl9.4286 0 0 0 0 1 0 0 1
orfl9.6967 USO6 0 0 0 0 1 0 0 1
orfl9.1427 orfl9.1427 0 0 0 0 1 0 0 1
orfl9.1428 DUOl 0 0 0 0 0 1 0 1
orfl9.2608 ADH5 0 1 0 0 0 0 0 1
orfl9.271 ADH4 0 0 0 0 1 0 0 1
orfl9.5302 PGA31 0 0 1 0 0 0 0 1
orfl9.7521 REPI 0 0 1 0 0 0 0 1
orfl9.3923 PGA37 0 0 1 0 0 0 0 1
orfl9.4607 orfl9.4607 0 0 1 0 0 0 0 1
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orfl9.3481 orfl9.3481 0 1 0 0 0 0 0 1
orfl9.669 PRM1 0 0 0 0 1 0 0 1
orfl9.1405 PHO13 0 0 1 0 0 0 0 1
orfl9.4132 orfl9.4132 0 1 0 0 0 0 0 1
orfl9.4737 TPO3 0 0 0 1 0 0 0 1
orfl9.1736 orfl9.1736 0 0 1 0 0 0 0 1
orfl9.1734 orfl9.1734 0 0 1 0 0 0 0 1
orfl9.1730 orfl9.1730 0 0 0 0 1 0 0 1
orfl9.4162 MLH1 0 0 1 0 0 0 0 1
orfl9.6396 orfl9.6396 0 0 0 0 0 1 0 1
orfl9.5742 ALS9 0 0 0 0 1 0 0 1
orfl9.2209 YVC1 0 0 1 0 0 0 0 1
orfl9.1378 SUP35 0 0 1 0 0 0 0 1
orfl9.2585 orfl9.2585 0 0 1 0 0 0 0 1
orfl9.2241 PST1 0 0 0 0 0 0 1 1
orfl9.1270 FRE3 0 0 1 0 0 0 0 1
orfl9.3529 ABP2 1 0 0 0 0 0 0 1
orfl9.5902 RAS2 0 0 1 0 0 0 0 1
orfl9.1348 orfl9.1348 0 0 1 0 0 0 0 1
orfl9.3924 orfl9.3924 0 0 0 0 1 0 0 1
orfl9.5046 RAMI 0 0 0 0 1 0 0 1
orfl9.540 orfl9.540 0 0 0 0 1 0 0 1
orfl9.1236 orfl9.1236 0 0 1 0 0 0 0 1
orfl9.3809 BASI 0 0 1 0 0 0 0 1
orfl9.149 orfl9.149 0 0 0 1 0 0 0 1
orfl9.6283 orfl9.6283 1 0 0 0 0 0 0 1
orfl9.6282 orfl9.6282 0 0 1 0 0 0 0 1
orfl9.899 orfl9.899 0 0 1 0 0 0 0 1
orfl9.6284 orfl9.6284 0 0 0 1 0 0 0 1
orfl9.323 orfl9.323 0 0 0 0 1 0 0 1
orfl9.6863 VPH1 0 0 1 0 0 0 0 1
orfl9.3255 TENI 0 1 0 0 0 0 0 1
orfl9.2504 BMS1 0 0 1 0 0 0 0 1
orfl9.3608 orfl9.3608 0 0 0 0 0 1 0 1
orfl9.6357 orfl9.6357 0 0 0 0 1 0 0 1
orfl9.6356 orfl9.6356 0 0 0 0 0 1 0 1
orfl9.6602 orfl9.6602 0 0 0 0 1 0 0 1
orfl9.5884 orfl9.5884 0 0 0 0 1 0 0 1
orfl9.5555 orfl9.5555 0 0 0 1 0 0 0 1
orfl9.6199 orfl9.6199 0 1 0 0 0 0 0 1
orfl9.57 PSF2 0 0 0 0 1 0 0 1
orfl9.1321 HWP1 0 0 0 0 1 0 0 1
orfl9.4012 PCL5 0 0 0 0 1 0 0 1
orfl9.7489 orfl9.7489 0 0 1 0 0 0 0 1
orfl9.1367 MTW1 0 0 0 0 0 1 0 1
orfl9.3107 orfl9.3107 0 0 0 0 1 0 0 1
orfl9.3105 orfl9.3105 0 0 1 0 0 0 0 1
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orf19.2458 orfl9.2458 0 0 0 0 1 0 0 1
orfl9.2455 orfl9.2455 1 0 0 0 0 0 0 1
orfl9.896 CHK1 0 0 1 0 0 0 0 1
orfl9.3109 orfl9.3109 0 0 0 1 0 0 0 1
orfl9.4255 ECM331 0 0 1 0 0 0 0 1
orfl9.2671 orfl9.2671 0 0 1 0 0 0 0 1
orfl9.6970 orfl9.6970 0 0 0 0 0 1 0 1
orfl9.7392 orf19.7392 0 0 0 0 1 0 0 1
orf19.7002 orfl9.7002 1 0 0 0 0 0 0 1
orfl9.7007 orfl9.7007 0 0 0 0 1 0 0 1
orfl9.2070 orfl9.2070 0 0 1 0 0 0 0 1
orfl9.7553 orfl9.7553 1 0 0 0 0 0 0 1
orfl9.3494 CTFS 0 1 0 0 0 0 0 1
orfl9.1499 CTF1 0 0 0 0 0 0 1 1
orfl9.1505 orfl9.1505 0 1 0 0 0 0 0 1
orfl9.1504 orfl9.1504 0 0 1 0 0 0 0 1
orfl9.3764 GSGI 0 0 0 0 1 0 0 1
orfl9.6053 CIS2 0 0 0 0 1 0 0 1
orfl9.7037 YAE1 0 0 0 0 0 1 0 1
orfl9.5911 CMK1 0 0 1 0 0 0 0 1
orfl9.1078 HBR2 0 0 0 0 1 0 0 1
orfl9.4921 orfl9.4921 0 0 0 0 0 1 0 1
orfl9.3254 orfl9.3254 0 0 0 0 1 0 0 1
orfl9.4928 SEC2 0 0 0 0 1 0 0 _
orfl9.3250 orfl9.3250 0 0 1 0 0 0 0 1
orfl9.4654 orfl9.4654 0 0 0 0 1 0 0 1
orfl9.1430 orf19.1430 0 0 0 0 1 0 0 1
orfl9.1433 orfl9.1433 0 0 0 0 1 0 0 1
orfl9.1434 orfl9.1434 0 0 1 0 0 0 0 1
orfl9.1438 orfl9.1438 0 0 1 0 0 0 0 1
orfl9.3742 orfl9.3742 0 0 0 0 0 0 1 1
orfl9.4639 orfl9.4639 1 0 0 0 0 0 0 1
orfl9.4637 orfl9.4637 0 0 0 0 1 0 0 1
orfl9.2842 GZF3 0 0 0 0 0 1 0 1
orfl9.1202 orfl9.1202 0 0 0 0 1 0 0 1
orfl9.4142 orfl9.4142 0 0 1 0 0 0 0 1
orfl9.4149 orfl9.4149 0 1 0 0 0 0 0 1
orfl9.2852 orfl9.2852 0 1 0 0 0 0 0 1
orfl9.2853 orfl9.2853 0 0 1 0 0 0 0 1
orfl9.2857 orfl9.2857 0 0 0 0 1 0 0 1
orfl9.728 TSCI1 0 1 0 0 0 0 0 1
orfl9.6255 orfl9.6255 0 0 0 0 1 0 0 1
orfl9.1720 orfl9.1720 0 0 0 0 0 1 0 1
orfl9.4308 HSLI 0 0 0 0 1 0 0 1
orfl9.4701 orfl9.4701 0 1 0 0 0 0 0 1
orfl9.4702 orf19.4702 0 0 1 0 0 0 0 1
orfl9.3199 PIKA 0 0 0 0 1 0 0 1
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orfl9.2919 MPH1 0 0 1 0 0 0 0 1
orfl9.5605 orfl9.5605 0 0 0 0 0 1 0 1
orfl9.3774.1 orfl9.3774.1 0 0 0 0 1 0 0 1
orfl9.1115 GUKI 0 0 0 0 1 0 0 1
orfl9.1453 SPT5 0 0 0 1 0 0 0 1
orfl9.557 orfl9.557 0 0 0 0 0 0 1 1
orfl9.2883 CS099 0 0 0 0 0 1 0 1
orfl9.1260 LEAl 0 0 0 0 1 0 0 1
orfl9.6569 orfl9.6569 0 0 0 0 1 0 0 1
orfl9.1246 orfl9.1246 0 0 1 0 0 0 0 1
orfl9.3815 orf19.3815 0 0 0 0 0 0 1 1
orfl9.854 UGAll 0 0 0 1 0 0 0 1
orfl9.1087 orfl9.1087 0 0 0 0 1 0 0 1
orfl9.5720 orfl9.5720 0 1 0 0 0 0 0 1
orfl9.5725 orfl9.5725 0 0 0 0 1 0 0 1
orfl9.5724 orfl9.5724 0 0 0 0 0 1 0 1
orfl9.2771 BEM3 0 0 0 0 0 1 0 1
orfl9.5821 orfl9.5821 0 0 0 0 0 1 0 1
orfl9.5940 ZCF32 0 1 0 0 0 0 0 1
orfl9.6366 orfl9.6366 0 0 1 0 0 0 0 1
orfl9.1826 MDM34 0 1 0 0 0 0 0 1
orfl9.5894 orfl9.5894 0 0 0 0 1 0 0 1
orfl9.3895 CHT2 0 0 1 0 0 0 0 1
orfl9.1515 CHT4 0 0 1 0 0 0 0 1
orfl9.5543 orfl9.5543 0 1 0 0 0 0 0 1
orfl9.6168 orfl9.6168 0 0 1 0 0 0 0 1
orfl9.4548 MAK32 0 1 0 0 0 0 0 1
orfl9.6382 orfl9.6382 1 0 0 0 0 0 0 1
orfl9.1863 orfl9.1863 1 0 0 0 0 0 0 1
orfl9.1864 orfl9.1864 1 0 0 0 0 0 0 1
orfl9.7494 orfl9.7494 0 0 1 0 0 0 0 1
orfl9.7497 orfl9.7497 1 0 0 0 0 0 0 1
orfl9.7490 orfl9.7490 0 0 0 0 1 0 0 1
orfl9.2449 orfl9.2449 0 0 0 0 1 0 0 1
orfl9.2440 orfl9.2440 0 0 0 0 1 0 0 1
orfl9.2442 orf19.2442 0 0 0 0 0 0 1 1
orfl9.6705 orfl9.6705 0 1 0 0 0 0 0 1
orfl9.6703 orfl9.6703 0 0 1 0 0 0 0 1
orfl9.1860.1 orfl9.1860.1 0 0 1 0 0 0 0 1
orfl9.2285 orfl9.2285 0 0 1 0 0 0 0 1
orfl9.81 orfl9.81 0 0 0 0 0 1 0 1
orfl9.2664 orfl9.2664 0 0 0 0 1 0 0 1
orfl9.2540 SAS3 0 0 0 1 0 0 0 1
orfl9.6953 IRS4 0 0 0 0 1 0 0 1
orfl9.1002 orfl9.1002 0 0 0 0 1 0 0 1
orfl9.7011 orfl9.7011 0 0 1 0 0 0 0 1
orfl9.7012 orfl9.7012 0 0 1 0 0 0 0 1
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orfl9.7545 orfl9.7545 0 0 1 0 0 0 0 _
orfl9.6017 orfl9.6017 0 0 0 0 1 0 0 _
orfl9.1005 orfl9.1005 0 0 0 0 1 0 0 1
orfl9.2713 orfl9.2713 0 0 0 0 1 0 0 1
orfl9.4936 orfl9.4936 1 0 0 0 0 0 0 1
orfl9.6637 orfl9.6637 0 0 0 0 1 0 0 1
orfl9.3713 orfl9.3713 0 0 1 0 0 0 0 1
orfl9.3711 orfl9.3711 0 0 1 0 0 0 0 1
orfl9.3618 YWP1 1 0 0 0 0 0 0 1
orfl9.3719 orfl9.3719 0 0 1 0 0 0 0 1
orfl9.2717 SASlO 0 0 0 0 1 0 0 1
orfl9.3539 orfl9.3539 0 0 0 1 0 0 0 1
orfl9.1047 ERBI 0 0 0 1 0 0 0 1
orfl9.1404 orfl9.1404 0 0 0 0 1 0 0 1
orfl9.4626 orfl9.4626 0 0 0 0 1 0 0 1
orfl9.4622 orfl9.4622 0 0 1 0 0 0 0 1
orfl9.4621 orfl9.4621 0 0 1 0 0 0 0 1
orfl9.4153 orfl9.4153 0 1 0 0 0 0 0 1
orfl9.568 SPE2 0 0 0 0 0 0 1 1
orfl9.5977 CEMI 0 0 0 0 1 0 0 1
orfl9.6032 SPEl 0 0 0 0 1 0 0 1
orfl9.1718 ZCF8 0 0 0 0 1 0 0 1
orfl9.1791 orfl9.1791 0 0 0 0 1 0 0 1
orfl9.7175 HLJI 0 0 0 0 0 0 1 1
orfl9.1580 orfl9.1580 0 0 1 0 0 0 0 1
orfl9.1664 orfl9.1664 0 0 0 0 0 1 0 1
orfl9.1667 orfl9.1667 0 0 0 0 1 0 0 1
orfl9.132 orfl9.132 0 0 0 0 0 0 1 1
orfl9.5782 orfl9.5782 0 0 1 0 0 0 0 1
orfl9.5391 orfl9.5391 0 0 0 0 1 0 0 1
orfl9.131 orfl9.131 0 0 0 0 1 0 0 1
orfl9.641 orfl9.641 0 0 0 0 0 1 0 1
orfl9.1317 OSH3 0 0 0 0 1 0 0 1
orfl9.5156 orfl9.5156 0 0 1 0 0 0 0 1
orfl9.7115 SAC7 0 0 0 0 0 0 1 1
orfl9.3474 IPLI 0 0 0 0 0 0 1 1
orfl9.5544 SAC6 0 0 0 0 1 0 0 1
orfl9.768 SYGI 0 0 0 0 1 0 0 1
orfl9.1926 SEF2 1 0 0 0 0 0 0 1
orfl9.520 orfl9.520 0 0 0 0 0 0 1 1
orfl9.3828 orfl9.3828 0 0 0 1 0 0 0 1
orfl9.2324 UBA4 0 0 0 0 1 0 0 1
orfl9.1258 orfl9.1258 0 0 1 0 0 0 0 1
orfl9.3276 PWP2 0 0 1 0 0 0 0 1
orfl9.3827 orfl9.3827 0 0 1 0 0 0 0 1
orfl9.5861.1 orfl9.5861.1 0 0 0 0 1 0 0 1
orfl9.7512 orfl9.7512 0 0 1 0 0 0 0 1
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orfl9.5580 TELl 0 0 0 0 0 1 0 1
orfl9.4305 orfl9.4305 0 0 0 0 1 0 0 1
orfl9.635 orfl9.635 0 0 0 0 1 0 0 1
orfl9.3966 CRH12 0 0 0 0 0 1 0 1
orfl9.2706 CRH1 0 0 1 0 0 0 0 1
orfl9.184 orfl9.184 0 0 0 0 0 0 1 1
orfl9.182 orfl9.182 0 1 0 0 0 0 0 1
orfl9.1897 orfl9.1897 0 0 0 0 0 1 0 1
orfl9.5579 orfl9.5579 0 1 0 0 0 0 0 1
orfl9.1890 orfl9.1890 0 0 1 0 0 0 0 1
orfl9.5573 orfl9.5573 1 0 0 0 0 0 0 1
orfl9.5574 orfl9.5574 0 0 0 0 0 1 0 1
orfl9.5575 orfl9.5575 0 0 0 0 0 0 1 1
orfl9.1383 orfl9.1383 0 0 0 0 1 0 0 1
orfl9.1381 orfl9.1381 0 0 0 0 1 0 0 1
orfl9.3826 orfl9.3826 0 0 1 0 0 0 0 1
orfl9.4002 DUN1 0 0 0 0 1 0 0 1
orfl9.1876 orfl9.1876 0 0 0 0 1 0 0 1
orfl9.1693 CAS4 0 0 1 0 0 0 0 1
orfl9.985 orfl9.985 0 1 0 0 0 0 0 1
orfl9.3940 orfl9.3940 0 0 0 0 0 1 0 1
orfl9.980 orfl9.980 0 1 0 0 0 0 0 1
orfl9.7624 orfl9.7624 0 0 0 0 1 0 0 1
orfl9.2478 orfl9.2478 0 1 0 0 0 0 0 1
orfl9.5076.1 orfl9.5076.1 0 0 0 0 1 0 0 1
orfl9.2278 orfl9.2278 0 0 0 0 1 0 0 1
orf19.866 RAD32 0 0 1 0 0 0 0 1
orfl9.1638 orfl9.1638 0 0 0 0 1 0 0 1
orfl9.6952 orfl9.6952 0 0 0 0 1 0 0 1
orfl9.3010 orfl9.3010 1 0 0 0 0 0 0 1
orfl9.7232 IRRI 0 0 0 0 1 0 0 1
orfl9.7024 orfl9.7024 0 0 0 0 1 0 0 1
orfl9.6008 orfl9.6008 0 1 0 0 0 0 0 1
orfl9.2010 orfl9.2010 0 1 0 0 0 0 0 1
orfl9.6003 orfl9.6003 0 0 0 0 1 0 0 1
orfl9.2728 orfl9.2728 0 0 0 0 1 0 0 1
orfl9.2725 orfl9.2725 0 0 0 0 0 1 0 1
orfl9.979 FASI 0 0 1 0 0 0 0 1
orfl9.4747 HEM14 0 1 0 0 0 0 0 1
orfl9.2721 orfl9.2721 0 0 0 0 1 0 0 1
orfl9.1529 orfl9.1529 0 0 0 0 0 1 0 1
orfl9.1901 MCM3 0 0 1 0 0 0 0 1
orfl9.4354 MCM2 0 0 0 0 0 1 0 1
orfl9.4946 orfl9.4946 0 0 0 0 1 0 0 1
orfl9.4942 orfl9.4942 0 0 0 0 1 0 0 1
orfl9.3704 orfl9.3704 0 0 0 0 1 0 0 1
orfl9.2653 orfl9.2653 0 0 0 0 1 0 0 1
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orfl9.1412 orfl9.1412 0 0 0 0 1 0 0 1
orfl9.1411 orfl9.1411 0 0 0 0 1 0 0 1
orfl9.3522 orf19.3522 0 0 1 0 0 0 0 1
orfl9.1414 orfl9.1414 0 0 0 0 1 0 0 1
orfl9.4894 orfl9.4894 0 0 0 0 1 0 0 1
orfl9.4896 orfl9.4896 0 0 0 0 1 0 0 1
orfl9.4893 orfl9.4893 0 0 0 0 1 0 0 1
orfl9.4365 orfl9.4365 0 0 0 0 0 0 1 1
orfl9.7359 CRZI 1 0 0 0 0 0 0 1
orfl9.2356 CRZ2 0 0 0 0 0 0 1 1
orfl9.1605 PMS1 0 0 1 0 0 0 0 1
orfl9.2509.1 orfl9.2509.1 0 0 0 0 1 0 0 1
orfl9.4094 orfl9.4094 0 0 1 0 0 0 0 1
orfl9.4767 ZCF28 0 0 0 0 0 1 0 1
orfl9.4097 orfl9.4097 0 0 0 0 1 0 0 1
orfl9.4760 orfl9.4760 0 0 0 0 1 0 0 1
orfl9.4768 orfl9.4768 0 0 0 0 1 0 0 1
orfl9.6345 RPG1A 0 0 0 0 0 1 0 1
orfl9.2364 MiSil 1 0 0 0 0 0 0 1
orfl9.6214 ATC 0 0 0 0 1 0 0 1
orfl9.231 APL2 0 0 1 0 0 0 0 1
orfl9.1679 orfl9.1679 0 1 0 0 0 0 0 1
orfl9.4169 orfl9.4169 0 0 1 0 0 0 0 1
orfl9.484 MRPL40 0 0 0 0 1 0 0 1
orfl9.4160 orfl9.4160 0 0 1 0 0 0 0 1
orfl9.4164 orfl9.4164 0 0 1 0 0 0 0 1
orfl9.4166 ZCF21 0 0 1 0 0 0 0 1
orfl9.2783 PIR32 0 1 0 0 0 0 0 1
orfl9.5381 orfl9.5381 0 0 0 0 1 0 0 1
orfl9.3231 CDC27 0 0 1 0 0 0 0 1
orfl9.5367 RDH54 0 0 1 0 0 0 0 1
orfl9.4645 BEMI 0 0 0 0 1 0 0 1
orf19.533 orfl9.533 0 0 1 0 0 0 0 1
orfl9.2825 orfl9.2825 0 0 0 0 0 0 1 1
orfl9.4829 DOAl 0 0 0 0 1 0 0 1
orfl9.1268 orfl9.1268 0 0 1 0 0 0 0 1
orfl9.3833 orfl9.3833 0 1 0 0 0 0 0 1
orfl9.3831 orfl9.3831 0 0 0 0 1 0 0 1
orfl9.1066 GIG1 0 0 0 0 1 0 0 1
orfl9.5702 orfl9.5702 0 0 0 0 1 0 0 1
orfl9.1386 orfl9.1386 0 0 0 0 1 0 0 1
orfl9.5963 orfl9.5963 0 0 0 0 1 0 0 1
orfl9.144 SNU114 0 1 0 0 0 0 0 1
orfl9.2711.1 orfl9.2711.1 1 0 0 0 0 0 0 1
orfl9.5965 orfl9.5965 0 0 0 0 1 0 0 1
orfl9.3666 orfl9.3666 0 1 0 0 0 0 0 1
orfl9.199 orfl9.199 0 0 0 0 1 0 0 1
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orfl9.5255 PXA2 0 0 0 1 0 0 0 _
orfl9.860 BMT8 0 1 0 0 0 0 0 1
orfl9.1203 SR077 0 0 0 0 1 0 0 1
orfl9.5569 orfl9.5569 0 0 0 0 0 1 0 1
orfl9.1367.1 orfl9.1367.1 0 0 1 0 0 0 0 1
orfl9.3282 BMT3 0 0 1 0 0 0 0 1
orfl9.5566 orfl9.5566 1 0 0 0 0 0 0 1
orfl9.5602 BMT6 0 0 0 0 1 0 0 1
orfl9.5612 BMT4 0 0 0 0 1 0 0 1
orfl9.6147 orfl9.6147 0 0 0 0 1 0 0 1
orfl9.6493 orfl9.6493 0 0 0 0 1 0 0 1
orfl9.6491 orfl9.6491 0 0 1 0 0 0 0 1
orfl9.4585 TFG1 0 0 1 0 0 0 0 1
orfl9.5365 orfl9.5365 0 0 0 0 1 0 0 1
orfl9.5500 MAK16 0 0 0 0 1 0 0 1
orfl9.2619 PHO113 0 1 0 0 0 0 0 1
orfl9.3727 PHO112 0 0 1 0 0 0 0 1
orfl9.1844 orfl9.1844 0 0 0 0 1 0 0 1
orfl9.996 orfl9.996 0 0 0 0 1 0 0 1
orfl9.445 orfl9.445 1 0 0 0 0 0 0 1
orfl9.5097 CAT8 0 0 0 0 1 0 0 1
orfl9.5343 ASHI 0 0 0 0 1 0 0 1
orfl9.448 orfl9.448 0 0 0 1 0 0 0 1
orfl9.2261 orfl9.2261 0 0 1 0 0 0 0 1
orfl9.2260 orfl9.2260 0 0 0 0 1 0 0 1
orfl9.2263 orfl9.2263 0 0 0 0 0 0 1 1
orfl9.69 orfl9.69 0 0 0 0 1 0 0 1
orfl9.1286 orfl9.1286 0 1 0 0 0 0 0 1
orfl9.1287 orfl9.1287 0 0 0 0 1 0 0 1
orfl9.1285 orfl9.1285 0 0 0 0 1 0 0 1
orfl9.801 TBF1 0 0 1 0 0 0 0 1
orfl9.1945 AURI 0 0 0 0 1 0 0 1
orfl9.250 SLC1 0 0 0 0 1 0 0 1
orfl9.1743 ACS1 0 0 1 0 0 0 0 1
orfl9.5672 MEP2 0 0 1 0 0 0 0 1
orfl9.377 PHR3 0 0 0 0 1 0 0 1
orfl9.2002 orfl9.2002 0 1 0 0 0 0 0 1
orfl9.2736 HFL2 0 0 1 0 0 0 0 1
orfl9.2739 orfl9.2739 0 0 1 0 0 0 0 1
orfl9.4746 JIPS 0 0 0 0 1 0 0 1
orfl9.3010.1 ECM33 0 0 0 0 1 0 0 1
orfl9.4955 orf19.4955 0 0 0 0 0 1 0 1
orfl9.4951 orfl9.4951 0 0 0 0 1 0 0 1
orfl9.3252 DAL81 0 0 1 0 0 0 0 1
orfl9.6309 MSSI1 0 0 0 0 0 0 1 1
orfl9.3285 orfl9.3285 0 0 1 0 0 0 0 1
orfl9.2651 CAM1-1 0 0 0 0 1 0 0 1
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orfl9.3281 orfl9.3281 0 0 0 0 1 0 0 1
orfl9.3775 SSK2 0 0 1 0 0 0 0 1
orfl9.3553 RPF2 0 0 1 0 0 0 0 1
orfl9.4420 orfl9.4420 0 0 1 0 0 0 0 1
orfl9.7452 orfl9.7452 0 0 0 0 0 1 0 1
orfl9.3593 RPT6 0 0 1 0 0 0 0 1
orfl9.5440 RPT2 0 0 0 0 0 0 1 1
orfl9.7529 EPLI 1 0 0 0 0 0 0 1
orfl9.5653 ATP2 0 0 1 0 0 0 0 1
orfl9.3512 orfl9.3512 0 0 1 0 0 0 0 1
orfl9.4261 TIF5 0 0 0 0 0 1 0 1
orfl9.4395 orfl9.4395 0 0 0 0 1 0 0 1
orfl9.4391 orfl9.4391 0 0 0 1 0 0 0 1
orfl9.4399 orfl9.4399 0 0 0 0 1 0 0 1
orfl9.4398 orfl9.4398 0 0 1 0 0 0 0 1
orfl9.4883 orfl9.4883 0 0 0 0 1 0 0 1
orfl9.4880 orfl9.4880 0 0 0 0 0 1 0 1
orfl9.1279 CDS1 0 0 0 0 1 0 0 1
orfl9.3356 ESPI 0 1 0 0 0 0 0 1
orfl9.3605 PEX17 0 1 0 0 0 0 0 1
orfl9.2868 orfl9.2868 0 0 1 0 0 0 0 1
orfl9.4372 orfl9.4372 0 0 0 0 1 0 0 1
orfl9.2867 orfl9.2867 0 0 0 0 1 0 0 1
orfl9.723 BCR1 0 0 1 0 0 0 0 1
orfl9.4088 orfl9.4088 0 1 0 0 0 0 0 1
orfl9.4081 orfl9.4081 0 0 1 0 0 0 0 1
orfl9.2335 orfl9.2335 0 0 0 0 1 0 0 1
orfl9.707 APG7 0 0 0 1 0 0 0 1
orfl9.1275 GATI 0 0 0 0 1 0 0 1
orfl9.1604 orfl9.1604 0 0 1 0 0 0 0 1
orfl9.1600 orfl9.1600 0 0 0 0 1 0 0 1
orfl9.1609 orfl9.1609 0 0 0 0 1 0 0 1
orfl9.4174 orf19.4174 0 0 1 0 0 0 0 1
orfl9.4172 orfl9.4172 0 0 1 0 0 0 0 1
orfl9.4171 orfl9.4171 0 0 1 0 0 0 0 1
orfl9.4274 PUTI 0 0 0 0 1 0 0 1
orfl9.2552 orfl9.2552 0 0 0 0 0 0 1 1
orfl9.5498 EFHI 0 0 0 0 1 0 0 1
orfl9.1084 CDC39 0 0 0 0 0 1 0 1
orfl9.3623 SMC2 0 0 1 0 0 0 0 1
orfl9.1116 orfl9.1116 0 0 1 0 0 0 0 1
orfl9.5531 CDC37 0 0 0 0 0 1 0 1
orfl9.6556 orfl9.6556 0 0 0 0 1 0 0 1
orfl9.6126 KGD2 0 0 1 0 0 0 0 1
orfl9.1272 orfl9.1272 0 0 0 0 1 0 0 1
orfl9.1059 HHF1 0 0 0 1 0 0 0 1
orfl9.3468 ALGIl 0 0 0 0 1 0 0 1
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orfl9.6559 orfl9.6559 1 0 0 0 0 0 0 1
orfl9.6558 orfl9.6558 1 0 0 0 0 0 0 1
orfl9.10 ALK8 0 0 1 0 0 0 0 1
orfl9.612 orfl9.612 0 0 0 0 1 0 0 1
orfl9.6673 HEXI 0 0 0 0 1 0 0 1
orfl9.1343 orfl9.1343 0 0 0 0 1 0 0 1
orfl9.6031 VPS27 1 0 0 0 0 0 0 1
orfl9.6670 CAC2 0 0 0 0 1 0 0 1
orfl9.6005 HGT5 0 0 0 0 1 0 0 1
orfl9.3668 HGT2 0 0 0 0 1 0 0 1
orfl9.291 orfl9.291 1 0 0 0 0 0 0 1
orfl9.5601 orfl9.5601 0 0 0 0 1 0 0 1
orfl9.5358 orfl9.5358 0 0 0 0 1 0 0 1
orfl9.2135 TSM1 0 0 0 1 0 0 0 1
orfl9.6482 orfl9.6482 0 0 0 0 0 1 0 1
orfl9.6488 orfl9.6488 0 0 1 0 0 0 0 1
orfl9.5353 orfl9.5353 1 0 0 0 0 0 0 1
orfl9.470 orfl9.470 0 0 1 0 0 0 0 1
orfl9.477 orfl9.477 0 0 1 0 0 0 0 1
orfl9.1613 ILV2 0 0 1 0 0 0 0 1
orfl9.3461 orfl9.3461 0 0 0 0 0 1 0 1
orfl9.5771 PBP2 0 0 1 0 0 0 0 1
orfl9.6739 orfl9.6739 0 0 0 0 1 0 0 1
orfl9.2257 orfl9.2257 0 0 1 0 0 0 0 1
orfl9.6481 YPS7 0 0 1 0 0 0 0 1
orfl9.2252 orfl9.2252 0 0 0 0 1 0 0 1
orfl9.51 orf19.51 0 0 0 1 0 0 0 1
orfl9.7193 orfl9.7193 0 1 0 0 0 0 0 1
orfl9.6934 orfl9.6934 0 0 1 0 0 0 0 1
orfl9.2038 orfl9.2038 0 0 1 0 0 0 0 1
orfl9.879 orfl9.879 0 0 1 0 0 0 0 1
orfl9.7511 orfl9.7511 0 0 1 0 0 0 0 1
orfl9.7043 orfl9.7043 0 0 0 0 1 0 0 1
orfl9.6022 orfl9.6022 0 1 0 0 0 0 0 1
orfl9.6018 LRO1 0 0 0 0 1 0 0 1
orfl9.5926 ARGil 0 0 0 0 1 0 0 1
orfl9.6027 orfl9.6027 0 1 0 0 0 0 0 1
orfl9.2133 LIP4 0 0 0 1 0 0 0 1
orfl9.6025 orfl9.6025 0 0 0 1 0 0 0 1
orfl9.6024 orfl9.6024 0 1 0 0 0 0 0 1
orfl9.5172 LIP9 0 0 0 0 0 0 1 1
orfl9.2746 orfl9.2746 0 0 1 0 0 0 0 1
orfl9.4966 orf19.4966 0 0 0 0 1 0 0 1
orfl9.3680 SEP7 0 1 0 0 0 0 0 1
orfl9.4064 GPI7 0 0 0 0 1 0 0 1
orfl9.3728 orfl9.3728 0 0 1 0 0 0 0 1
orfl9.4415 orfl9.4415 0 0 1 0 0 0 0 1
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orfl9.3722 orfl9.3722 0 0 1 0 0 0 0 1
orfl9.3726 orfl9.3726 0 0 1 0 0 0 0 1
orfl9.6496 TRS33 0 0 0 0 1 0 0 1
orfl9.1836 APN2 0 0 0 0 1 0 0 1
orfl9.7468 orfl9.7468 0 0 0 0 1 0 0 1
orfl9.2106 orfl9.2106 1 0 0 0 0 0 0 1
orfl9.7460 orfl9.7460 0 0 1 0 0 0 0 1
orf19.2488 FALl 0 0 0 0 1 0 0 1
orfl9.7463 orfl9.7463 0 0 1 0 0 0 0 1
orfl9.5919 MEAl 0 0 0 0 0 0 1 1
orfl9.3501 orfl9.3501 0 0 0 0 1 0 0 1
orfl9.1479 orfl9.1479 0 1 0 0 0 0 0 1
orfl9.1476 orfl9.1476 0 0 1 0 0 0 0 1
orfl9.1525 orf19.1525 0 0 0 0 0 1 0 1
orfl9.6533 MSK1 0 0 0 0 0 1 0 1
orfl9.3423 TIF3 0 0 0 0 1 0 0 1
orfl9.2818 orfl9.2818 0 0 1 0 0 0 0 1
orfl9.4347 orfl9.4347 1 0 0 0 0 0 0 1
orfl9.4340 orfl9.4340 1 0 0 0 0 0 0 1
orfl9.4341 orfl9.4341 0 1 0 0 0 0 0 1
orf19.434 PRD1 0 0 0 0 1 0 0 1
orfl9.647.3 orfl9.647.3 0 0 0 0 1 0 0 1
orfl9.4741 orfl9.4741 0 0 0 0 1 0 0 1
orfl9.4981 orfl9.4981 0 0 0 0 1 0 0 1
orfl9.2922 orf19.2922 0 0 1 0 0 0 0 1
orfl9.2921 orfl9.2921 0 0 1 0 0 0 0 1
orfl9.1617 orfl9.1617 0 0 0 0 1 0 0 1
orfl9.1611 orf19.1611 0 1 0 0 0 0 0 1
orfl9.1619 orfl9.1619 0 0 0 0 1 0 0 1
orf19.4182 orfl9.4182 0 0 1 0 0 0 0 1
orfl9.4187 orfl9.4187 0 0 1 0 0 0 0 1
orfl9.4185 orfl9.4185 0 0 1 0 0 0 0 1
orfl9.4189 orfl9.4189 0 0 0 0 1 0 0 1
orf19.1753 PUS7 0 0 0 0 1 0 0 1
orfl9.4682 HGT17 0 0 0 0 1 0 0 1
orfl9.1358 GCN4 0 0 0 0 1 0 0 1
orfl9.4533 orfl9.4533 0 0 0 0 1 0 0 1
orf19.579 FOLI 0 0 1 0 0 0 0 1
orfl9.4482 IFI3 1 0 0 0 0 0 0 1
orfl9.4573 ZCF26 0 0 0 0 1 0 0 1
orfl9.511 orfl9.511 0 0 1 0 0 0 0 1
orf19.512 orfl9.512 0 0 0 0 0 0 1 1
orfl9.3954 orfl9.3954 0 0 0 0 0 1 0 1
orfl9.3628 RSPS 0 0 1 0 0 0 0 1
orfl9.3374 ECEl 0 0 1 0 0 0 0 1
orfl9.3337 orfl9.3337 0 0 0 0 1 0 0 1
orfl9.5083 DRG1 0 0 0 0 1 0 0 1
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orfl9.5767 orfl9.5767 0 0 0 0 1 0 0 1
orfl9.761 TC089 1 0 0 0 0 0 0 1
orfl9.609 orfl9.609 0 1 0 0 0 0 0 1
orfl9.6985 TEAl 0 1 0 0 0 0 0 1
orfl9.852 SAP98 0 0 1 0 0 0 0 1
orfl9.7442 orfl9.7442 0 0 0 0 0 1 0 1
orfl9.3122 ARR3 0 0 0 0 1 0 0 1
orfl9.391 UPC2 1 0 0 0 0 0 0 1
orfl9.7499.1 orfl9.7499.1 0 0 0 0 1 0 0 1
orfl9.5587 orfl9.5587 0 0 0 0 1 0 0 1
orfl9.5586 orfl9.5586 0 0 0 0 0 1 0 1
orfl9.5589 orfl9.5589 0 0 0 0 1 0 0 1
orfl9.4416 VPS13 0 0 0 0 1 0 0 1
orfl9.505 SRV2 0 0 0 0 1 0 0 1
orfl9.5617 orfl9.5617 0 0 0 0 1 0 0 1
orfl9.3298 CCH1 0 0 0 0 1 0 0 1
orfl9.1827 orfl9.1827 0 0 0 0 1 0 0 1
orfl9.1823 orfl9.1823 0 0 0 0 0 0 1 1
orfl9.5830 orfl9.5830 0 0 1 0 0 0 0 1
orfl9.261 orfl9.261 0 0 0 0 1 0 0 1
orfl9.2247 orfl9.2247 0 0 0 1 0 0 0 1
orfl9.2246 orfl9.2246 0 0 0 0 1 0 0 1
orfl9.6230 orfl9.6230 0 0 0 0 1 0 0 1
orfl9.6585 orfl9.6585 1 0 0 0 0 0 0 1
orfl9.6586 orf19.6586 0 0 0 0 0 1 0 1
orfl9.6587 orfl9.6587 0 1 0 0 0 0 0 1
orfl9.7083 DCC1 0 0 0 0 1 0 0 1
orfl9.6909 orfl9.6909 0 1 0 0 0 0 0 1
orfl9.2787 PRYl 0 1 0 0 0 0 0 1
orfl9.4969 KEMI 0 0 0 0 1 0 0 1
orfl9.864 orfl9.864 0 0 1 0 0 0 0 1
orfl9.5548 LYS14 0 0 0 0 1 0 0 1
orfl9.7057 orfl9.7057 0 0 0 0 1 0 0 1
orfl9.2024 orfl9.2024 0 0 0 0 0 1 0 1
orfl9.3050 AGEl 0 0 0 0 1 0 0 1
orfl9.3630 RRP8 0 1 0 0 0 0 0 1
orfl9.2834 RPD3 0 0 0 0 0 1 0 1
orfl9.4407 orfl9.4407 0 0 0 0 1 0 0 1
orfl9.3758 orfl9.3758 0 1 0 0 0 0 0 1
orfl9.2110 orfl9.2110 0 0 1 0 0 0 0 1
orfl9.2115 orfl9.2115 0 0 1 0 0 0 0 1
orfl9.3196 orfl9.3196 0 1 0 0 0 0 0 1
orfl9.6550 orfl9.6550 0 0 0 0 1 0 0 1
orfl9.3573 PEX6 0 0 0 0 0 1 0 1
orfl9.3409 SEC12 0 0 0 0 1 0 0 1
orfl9.4757 NARI 0 0 0 0 0 1 0 1
orfl9.4571 orfl9.4571 0 0 1 0 0 0 0 1
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orfl9.3102 CTA6 1 0 0 0 0 0 0 _
orfl9.3376 orfl9.3376 0 0 0 0 1 0 0 1
orfl9.3371 JAB1 0 0 1 0 0 0 0 1
orfl9.3373 orfl9.3373 0 0 1 0 0 0 0 1
orfl9.4357 orfl9.4357 0 0 0 0 1 0 0 1
orfl9.5897 orfl9.5897 0 0 0 0 1 0 0 1
orfl9.2805 PEX8 0 1 0 0 0 0 0 1
orfl9.2804 orfl9.2804 0 0 1 0 0 0 0 1
orfl9.451 SOKI 1 0 0 0 0 0 0 1
orfl9.3405 ZCF18 0 0 0 0 1 0 0 1
orfl9.139 TRAl 0 1 0 0 0 0 0 1
orfl9.3818 GOAl 0 0 0 0 1 0 0 1
orfl9.1592 orfl9.1592 0 0 0 0 0 1 0 1
orfl9.4756 orfl9.4756 0 0 0 0 0 1 0 1
orfl9.4751 orfl9.4751 0 0 0 1 0 0 0 1
orfl9.4998 ROBI 1 0 0 0 0 0 0 1
orfl9.2236 FHLI 0 0 0 0 0 0 1 1
orfl9.3227 FTH2 0 0 0 0 0 1 0 1
orfl9.4995 orfl9.4995 0 0 0 0 0 1 0 1
orfl9.2930 orfl9.2930 0 1 0 0 0 0 0 1
orfl9.5121 OPT5 0 0 0 0 1 0 0 1
orfl9.2938 orfl9.2938 0 0 0 0 1 0 0 1
orfl9.3506 DBR1 0 0 0 0 1 0 0 1
orfl9.1626 orfl9.1626 0 0 1 0 0 0 0 1
orfl9.4195 orfl9.4195 0 0 0 0 0 0 1 1
orfl9.3990 orfl9.3990 0 0 0 0 0 1 0 1
orfl9.7173 orfl9.7173 0 0 0 1 0 0 0 1
orfl9.808 orfl9.808 0 0 1 0 0 0 0 1
orfl9.2534 PIN4 0 1 0 0 0 0 0 1
orfl9.87 GPX1 0 0 0 0 1 0 0 1
orfl9.5291 orfl9.5291 0 0 0 0 0 1 0 1
orfl9.4048 DESI 0 1 0 0 0 0 0 1
orfl9.1363 orfl9.1363 0 0 0 0 1 0 0 1
orfl9.4072 IFF6 0 0 0 0 1 0 0 1
orfl9.4361 IFF3 0 0 0 1 0 0 0 1
orfl9.5634 FRPI 0 0 1 0 0 0 0 1
orfl9.6522 orfl9.6522 0 0 0 0 1 0 0 1
orfl9.2654 RMS1 0 0 0 0 0 1 0 1
orfl9.3557 GPI19 0 0 0 1 0 0 0 1
orfl9.1050 orfl9.1050 1 0 0 0 0 0 0 1
orfl9.832 GPI13 0 0 1 0 0 0 0 1
orfl9.5026 orfl9.5026 0 1 0 0 0 0 0 1
orfl9.5755 orfl9.5755 0 0 0 0 1 0 0 1
orfl9.5757 orfl9.5757 0 0 0 0 0 0 1 1
orfl9.1804 orfl9.1804 0 0 0 0 0 1 0 1
orfl9.1902 NOC4 0 0 0 0 0 1 0 1
orfl9.2579 orfl9.2579 0 0 1 0 0 0 0 1
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orfl9.992 LKH 1 0 0 0 0 1 0 0 1
orfl9.676 orfl9.676 0 0 0 0 0 1 0 1
orfl9.6138 orfl9.6138 0 0 1 0 0 0 0 1
orfl9.3973 orfl9.3973 0 1 0 0 0 0 0 1
orfl9.1032 SKOl 0 0 0 1 0 0 0 1
orfl9.2361 SPT1O 0 0 1 0 0 0 0 1
orfl9.5808 orfl9.5808 0 0 1 0 0 0 0 1
orfl9.494 orfl9.494 0 0 0 0 0 1 0 1
orfl9.3150 GRE2 0 0 1 0 0 0 0 1
orfl9.499 orfl9.499 0 0 1 0 0 0 0 1
orfl9.702 orfl9.702 0 0 0 0 1 0 0 1
orfl9.254 orfl9.254 0 0 1 0 0 0 0 1
orfl9.35 orfl9.35 0 0 1 0 0 0 0 1
orfl9.2231 orfl9.2231 0 0 0 0 0 1 0 1
orfl9.7564 DPB2 0 0 0 0 1 0 0 1
orfl9.5930 orfl9.5930 0 0 0 0 1 0 0 1
orfl9.5931 ARVI 0 0 0 0 0 1 0 1
orfl9.5932 orfl9.5932 0 0 0 0 1 0 0 1
orfl9.4610 orfl9.4610 0 0 0 0 1 0 0 1
orfl9.6912 orfl9.6912 0 0 1 0 0 0 0 1
orfl9.2582 orfl9.2582 0 0 0 0 0 0 1 1
orfl9.7063 orfl9.7063 0 0 1 0 0 0 0 1
orfl9.7067 orfl9.7067 0 0 0 0 1 0 0 1
orfl9.7088 orfl9.7088 1 0 0 0 0 0 0 1
orfl9.5484 SERI 0 0 0 0 1 0 0 1
orfl9.2563 orfl9.2563 0 0 1 0 0 0 0 1
orfl9.210 orfl9.210 0 0 0 0 1 0 0 1
orfl9.7086 orfl9.7086 0 0 0 0 1 0 0 1
orfl9.3823 ZDS1 0 0 0 0 1 0 0 1
orfl9.5640 PEX5 0 0 1 0 0 0 0 1
orfl9.925 orfl9.925 0 0 1 0 0 0 0 1
orfl9.2005 REGI 0 0 1 0 0 0 0 1
orfl9.5001 CUP2 0 0 0 1 0 0 0 1
orfl9.2169 orfl9.2169 0 0 1 0 0 0 0 1
orfl9.59 REIl 1 0 0 0 0 0 0 1
orfl9.1450 orfl9.1450 1 0 0 0 0 0 0 1
orfl9.4222 SST2 0 0 0 0 1 0 0 1
orfl9.3152 AMO2 0 0 1 0 0 0 0 1
orfl9.4690 orfl9.4690 0 0 1 0 0 0 0 1
orfl9.4691 orfl9.4691 0 0 0 0 1 0 0 1
orfl9.4508 orfl9.4508 0 0 1 0 0 0 0 1
orfl9.4509 orfl9.4509 0 0 1 0 0 0 0 1
orfl9.4502 orfl9.4502 0 0 1 0 0 0 0 1
orfl9.3364 orfl9.3364 0 0 1 0 0 0 0 1
orfl9.4326 orfl9.4326 0 1 0 0 0 0 0 1
orfl9.940 BUD2 0 0 1 0 0 0 0 1
orfl9.2838 orfl9.2838 0 0 0 0 0 0 1 1
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orfl9.4299 MSWI 0 0 0 0 1 0 0 1
orfl9.4592 HSX11 1 0 0 0 0 0 0 1
orfl9.5758 SAL6 0 0 0 0 0 0 1 1
orfl9.1961 orfl9.1961 0 0 1 0 0 0 0 1
orfl9.20 RTS1 0 0 0 0 1 0 0 1
orfl9.5170 ENA21 0 0 0 0 1 0 0 1
orfl9.4214 orfl9.4214 0 0 0 0 0 0 1 1
orfl9.24 RTA2 0 0 1 0 0 0 0 1
orfl9.2012 NOT3 0 0 1 0 0 0 0 1
orfl9.6011 SIN3 0 0 0 0 1 0 0 1
orfl9.3734 GEF2 0 0 1 0 0 0 0 1
orfl9.2903 AGOl 0 0 1 0 0 0 0 1
orfl9.1634 orfl9.1634 0 0 1 0 0 0 0 1
orfl9.2908 orfl9.2908 0 0 0 0 1 0 0 1
orf19.1632 orfl9.1632 0 0 1 0 0 0 0 1
orfl9.2998 TSR2 1 0 0 0 0 0 0 1
orfl9.6321 PGA48 0 0 0 0 0 0 1 1
orfl9.3638 PGA46 0 0 0 0 1 0 0 1
orfl9.2906 PGA41 0 0 0 0 1 0 0 1
orfl9.2910 PGA43 0 0 0 0 1 0 0 1
orfl9.3765 RAX2 0 0 0 0 0 1 0 1
orfl9.3980 orfl9.3980 0 0 0 0 1 0 0 1
orfl9.2917.1 orfl9.2917.1 0 0 1 0 0 0 0 1
orfl9.5005 OSM2 0 0 0 0 1 0 0 1
orfl9.1123 orfl9.1123 0 0 0 0 0 1 0 1
orfl9.4784 CRP1 0 0 0 0 1 0 0 1
orfl9.272 FAA21 0 0 0 0 1 0 0 1
orfl9.5288 IFE2 0 0 0 0 0 0 1 1
orfl9.1026 orfl9.1026 1 0 0 0 0 0 0 1
orfl9.5747 orfl9.5747 0 0 0 0 1 0 0 1
orf19.5034 orfl9.5034 0 1 0 0 0 0 0 1
orfl9.5037 HRQ2 0 0 0 0 1 0 0 1
orfl9.5748 orfl9.5748 0 0 0 0 1 0 0 1
orfl9.1891 APRI 1 0 0 0 0 0 0 1
orfl9.5162 BCKI 0 0 0 0 1 0 0 1
orfl9.4924 orfl9.4924 0 0 0 0 0 1 0 1
orfl9.666 orfl9.666 0 0 0 0 1 0 0 1
orfl9.1413 YFH1 0 0 0 0 1 0 0 1
orfl9.6691 orfl9.6691 0 0 0 0 0 1 0 1
orfl9.6693 orfl9.6693 0 0 1 0 0 0 0 1
orfl9.2507 ARP9 0 0 1 0 0 0 0 1
orf19.5623 ARP4 0 0 0 0 1 0 0 1
orfl9.2641 ARPI 0 0 0 0 1 0 0 1
orfl9.6456 orfl9.6456 0 0 0 0 0 1 0 1
orfl9.6457 orfl9.6457 0 0 0 0 1 0 0 1
orfl9.5322 orfl9.5322 1 0 0 0 0 0 0 1
orfl9.2154 HXK1 1 0 0 0 0 0 0 1
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orfl9.5817 orfl9.5817 0 0 1 0 0 0 0 1
orfl9.1324 RAD2 0 0 1 0 0 0 0 1
orfl9.5061 ADE5,7 0 0 0 0 1 0 0 1
orfl9.4275 RAD9 0 0 0 0 1 0 0 1
orfl9.2228 orfl9.2228 0 0 0 0 0 0 1 1
orfl9.29 orfl9.29 0 0 1 0 0 0 0 1
orfl9.2227 orfl9.2227 0 0 1 0 0 0 0 1
orfl9.22 orfl9.22 0 0 0 0 1 0 0 1
orfl9.21 orfl9.21 0 0 0 0 1 0 0 1
orfl9.1935 orfl9.1935 0 0 1 0 0 0 0 1
orfl9.1933 orfl9.1933 0 0 0 0 1 0 0 1
orfl9.5253 orfl9.5253 0 0 0 0 0 1 0 1
orfl9.5921 orfl9.5921 0 0 0 0 1 0 0 1
orfl9.645.1 VMA13 0 0 0 0 1 0 0 1
orfl9.6033 CMP 0 0 0 0 0 0 1 1
orfl9.804 orfl9.804 0 0 0 0 0 0 1 1
orfl9.7074 orfl9.7074 0 1 0 0 0 0 0 1
orfl9.7073 orfl9.7073 0 0 0 0 1 0 0 1
orfl9.7079 orfl9.7079 0 0 1 0 0 0 0 1
orfl9.6679 orfl9.6679 0 0 0 1 0 0 0 1
orfl9.2138 ILSI 0 0 0 1 0 0 0 1
orfl9.1802 orfl9.1802 0 0 1 0 0 0 0 1
orfl9.6852 orfl9.6852 0 0 0 0 1 0 0 1
orfl9.3086 orfl9.3086 0 0 1 0 0 0 0 1
orfl9.3083 orfl9.3083 0 0 0 0 0 0 1 1
orfl9.3080 orfl9.3080 0 0 1 0 0 0 0 1
orfl9.7095 orfl9.7095 0 0 0 0 1 0 0 1
orfl9.2574 orfl9.2574 0 0 1 0 0 0 0 1
orfl9.7096 orfl9.7096 0 1 0 0 0 0 0 1
orfl9.2832 INN1 0 0 0 0 0 1 0 1
orfl9.3777 orfl9.3777 0 0 0 0 0 1 0 1
orfl9.937 orfl9.937 0 0 0 0 0 0 1 1
orfl9.2684 orfl9.2684 0 0 0 1 0 0 0 1
orfl9.3177 orfl9.3177 0 0 0 0 1 0 0 1
orfl9.3175 orfl9.3175 1 0 0 0 0 0 0 1
orfl9.3178 orfl9.3178 0 0 1 0 0 0 0 1
orfl9.3211 RCF3 0 0 0 0 1 0 0 1
orfl9.3798 orfl9.3798 0 0 1 0 0 0 0 1
orfl9.3796 DCR1 0 0 0 0 1 0 0 1
orfl9.3797 orfl9.3797 0 0 0 0 1 0 0 1
orfl9.4686 orfl9.4686 0 0 0 0 0 1 0 1
orfl9.2365 POL2 0 0 1 0 0 0 0 1
orfl9.4511 orfl9.4511 0 0 1 0 0 0 0 1
orfl9.6628 orfl9.6628 0 0 0 0 1 0 0 1
orfl9.2779 orfl9.2779 0 0 0 0 0 1 0 1
orfl9.22.1 orfl9.22.1 0 0 0 0 1 0 0 1
orfl9.7300 orfl9.7300 0 0 0 0 1 0 0 1
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orfl9.2471 GIM5 1 0 0 0 0 0 0 1
orfl9.56 ARG2 0 0 0 0 1 0 0 1
orfl9.2827 orfl9.2827 0 1 0 0 0 0 0 1
orfl9.2822 orfl9.2822 0 0 0 0 0 0 1 1
orfl9.4332 orfl9.4332 0 0 0 0 0 1 0 1
orfl9.5776 TOMI 0 0 0 0 0 1 0 1
orf19.2828 orfl9.2828 0 0 0 0 1 0 0 1
orfl9.2474 PRC3 0 0 0 0 1 0 0 1
orfl9.4203 orfl9.4203 0 0 0 0 0 0 1 1
orfl9.5630 APA2 0 0 0 0 1 0 0 1
orfl9.3552 orfl9.3552 0 0 1 0 0 0 0 1
orfl9.4028 orfl9.4028 0 0 0 0 1 0 0 1
orfl9.913.2 orfl9.913.2 0 0 0 0 0 1 0 1
orfl9.2917 orfl9.2917 0 0 0 0 0 1 0 1
orfl9.2914 orfl9.2914 0 0 1 0 0 0 0 1
orf19.4870 DBP3 0 0 0 0 1 0 0 1
orfl9.1661 DBP5 0 0 0 0 1 0 0 1
orfl9.738 MYO5 0 0 1 0 0 0 0 1
orfl9.2767 PGA59 0 0 0 0 0 0 1 1
orfl9.2685 PGA54 0 0 1 0 0 0 0 1
orfl9.5191 FGR6-1 0 0 0 0 0 0 1 1
orfl9.5137 orfl9.5137 0 0 0 1 0 0 0 1
orfl9.5139 orfl9.5139 1 0 0 0 0 0 0 1
orfl9.100 orfl9.100 0 0 0 0 1 0 0 1
orfl9.3228 orfl9.3228 0 0 1 0 0 0 0 1
orfl9.5595 SHE3 0 0 0 0 0 0 1 1
orfl9.3699 TEP 0 0 0 0 1 0 0 1
orfl9.3886 orfl9.3886 0 0 0 0 0 1 0 1
orfl9.7059 orfl9.7059 0 0 0 0 1 0 0 1
orfl9.1030 orfl9.1030 0 0 0 0 1 0 0 1
orfl9.5009 orfl9.5009 0 0 0 0 1 0 0 1
orfl9.1223 DBF2 0 0 1 0 0 0 0 1
orfl9.653 orfl9.653 0 1 0 0 0 0 0 1
orfl9.120 orfl9.120 0 1 0 0 0 0 0 1
orfl9.1659 ALG8 0 0 0 0 0 1 0 1
orfl9.1221 ALG2 0 0 0 0 0 1 0 1
orfl9.4410 ALGI 0 0 0 0 1 0 0 1
orfl9.2187 ALG7 0 0 1 0 0 0 0 1
orfl9.6687 orfl9.6687 0 0 1 0 0 0 0 1
orf19.1238 TUB4 0 0 1 0 0 0 0 1
orfl9.2215 GLEl 0 0 0 0 0 0 1 1
orfl9.1323 orfl9.1323 0 0 0 0 1 0 0 1
orfl9.6114 orfl9.6114 0 0 1 0 0 0 0 1
orfl9.4015 CAGI 0 0 0 0 1 0 0 1
orfl9.5644 orfl9.5644 1 0 0 0 0 0 0 1
orfl9.6119 orfl9.6119 0 0 1 0 0 0 0 1
orfl9.5488 orfl9.5488 0 0 0 0 1 0 0 1
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orfl9.5489 orfl9.5489 0 0 0 0 1 0 0 1
orfl9.807 CHS5 0 0 1 0 0 0 0 1
orfl9.5155 CHS6 0 0 1 0 0 0 0 1
orfl9.5865 orfl9.5865 0 0 1 0 0 0 0 1
orfl9.5869 orfl9.5869 0 0 1 0 0 0 0 1
orfl9.4322 DAP2 0 0 0 0 1 0 0 1
orfl9.2210 orfl9.2210 0 0 1 0 0 0 0 1
orfl9.4054 CTA24 0 0 0 0 0 1 0 1
orfl9.2213 orfl9.2213 1 0 0 0 0 0 0 1
orfl9.5269 orfl9.5269 0 0 0 0 1 0 0 1
orfl9.5262 orfl9.5262 0 0 0 0 1 0 0 1
orfl9.4630 CPA1 0 0 0 0 1 0 0 1
orfl9.6686 ENP2 0 0 0 0 0 0 1 1
orfl9.349 orfl9.349 0 0 0 0 1 0 0 1
orfl9.341 orfl9.341 0 0 0 0 1 0 0 1
orfl9.831 orfl9.831 0 0 1 0 0 0 0 1
orfl9.346 orfl9.346 0 1 0 0 0 0 0 1
orfl9.797 BAT21 0 0 0 1 0 0 0 1
orfl9.6065 orfl9.6065 0 0 0 0 1 0 0 1
orfl9.2367 orfl9.2367 0 1 0 0 0 0 0 1
orfl9.2362 orfl9.2362 0 0 0 0 1 0 0 1
orfl9.5050 MTO1 0 0 1 0 0 0 0 1
orfl9.1814 orfl9.1814 0 0 1 0 0 0 0 1
orfl9.3091 orfl9.3091 0 0 1 0 0 0 0 1
orfl9.2549 orfl9.2549 0 0 0 0 0 1 0 1
orfl9.6014 RRS1 0 0 0 0 1 0 0 1
orfl9.4884 WORI 1 0 0 0 0 0 0 1
orfl9.2143 orfl9.2143 0 0 0 1 0 0 0 1
orfl9.1445 ESC4 1 0 0 0 0 0 0 1
orfl9.3780 orfl9.3780 0 0 0 0 1 0 0 1
orfl9.3783 orfl9.3783 0 0 1 0 0 0 0 1
orfl9.3787 orfl9.3787 0 0 0 0 0 1 0 1
orfl9.2454 PH087 1 0 0 0 0 0 0 1
orfl9.2791 BBC1 0 1 0 0 0 0 0 1
orfl9.4520 orfl9.4520 0 1 0 0 0 0 0 1
orfl9.4521 orfl9.4521 0 0 1 0 0 0 0 1
orfl9.4834 orfl9.4834 0 0 0 0 1 0 0 1
orfl9.4529 orfl9.4529 0 0 0 0 1 0 0 1
orfl9.2991 HOLl 0 0 0 0 1 0 0 1
orfl9.3304 orf19.3304 0 1 0 0 0 0 0 1
orfl9.658 GIN1 0 0 0 0 0 1 0 1
orfl9.3431 orfl9.3431 0 0 0 0 1 0 0 1
orfl9.3430 orfl9.3430 0 1 0 0 0 0 0 1
orfl9.2580 HST2 1 0 0 0 0 0 0 1
orfl9.4761 HST1 0 0 0 0 1 0 0 1
orfl9.4789 orfl9.4789 1 0 0 0 0 0 0 1
orfl9.5526 SEC20 0 0 0 0 0 0 1 1
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orfl9.4732 SEC24 0 0 0 0 1 0 0 1
orfl9.3547 orfl9.3547 0 0 1 0 0 0 0 1
orfl9.3545 orfl9.3545 0 0 1 0 0 0 0 1
orfl9.3543 orfl9.3543 0 0 0 1 0 0 0 1
orfl9.2968 orfl9.2968 0 0 0 0 1 0 0 1
orfl9.4014 orfl9.4014 1 0 0 0 0 0 0 1
orfl9.2963 orfl9.2963 0 1 0 0 0 0 0 1
orfl9.6512 EXO70 0 0 1 0 0 0 0 1
orfl9.4013 orfl9.4013 0 0 0 0 1 0 0 1
orfl9.1491 orfl9.1491 0 0 1 0 0 0 0 1
orfl9.6796 orfl9.6796 1 0 0 0 0 0 0 1
orfl9.1497 ZCF6 0 0 1 0 0 0 0 1
orfl9.943 FET33 0 0 1 0 0 0 0 1
orfl9.4656 orfl9.4656 1 0 0 0 0 0 0 1
orfl9.4657 orfl9.4657 0 0 1 0 0 0 0 1
orfl9.4306 orfl9.4306 0 0 0 0 1 0 0 1
orfl9.4076 METlO 0 0 0 0 0 1 0 1
orfl9.4679 AGP2 0 0 1 0 0 0 0 1
orfl9.6243 VPS34 0 0 0 0 1 0 0 1
orfl9.156 FGR51 0 0 1 0 0 0 0 1
orfl9.1143 orfl9.1143 0 0 0 0 1 0 0 1
orfl9.5163 SF1I 0 0 1 0 0 0 0 1
orfl9.795 VPS36 0 0 1 0 0 0 0 1
orfl9.7574 orfl9.7574 0 0 0 0 1 0 0 1
orfl9.4755 KEX2 0 0 0 0 1 0 0 1
orfl9.4934 OP4 0 0 0 0 0 0 1 1
orfl9.3746 IFC1 0 0 1 0 0 0 0 1
orfl9.3749 IFC3 0 0 0 0 0 0 1 1
orfl9.1524 SPR3 0 0 1 0 0 0 0 1
orfl9.5019 orfl9.5019 1 0 0 0 0 0 0 1
orfl9.5959 NOP14 0 0 0 0 1 0 0 1
orfl9.1008 orfl9.1008 0 0 1 0 0 0 0 1
orfl9.1009 orfl9.1009 0 0 0 1 0 0 0 1
orfl9.3370 DOT4 0 0 1 0 0 0 0 1
orfl9.5557 MNN4-4 0 0 0 0 0 1 0 1
orfl9.5783 orfl9.5783 0 0 1 0 0 0 0 1
orfl9.133 orfl9.133 0 0 0 0 0 0 1 1
orfl9.77.1 orfl9.77.1 0 1 0 0 0 0 0 1
orfl9.5780 orf19.5780 1 0 0 0 0 0 0 1
orfl9.137 orfl9.137 0 0 0 0 1 0 0 1
orfl9.643 orfl9.643 0 0 1 0 0 0 0 1
orfl9.1942 SGEI 0 0 0 0 0 0 1 1
orfl9.6477 orfl9.6477 0 0 0 0 1 0 0 1
orfl9.1310 orfI9.1310 0 0 0 0 1 0 0 1
orfl9.5306 orfl9.5306 0 0 1 0 0 0 0 1
orfl9.5499 orfl9.5499 0 0 0 0 1 0 0 1
orfl9.5495 orfl9.5495 0 0 0 0 1 0 0 1
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orfl9.4082 DDR48 0 0 1 0 0 0 0 1
orfl9.3756 CHRI 0 1 0 0 0 0 0 1
orfl9.5879 orfl9.5879 0 0 1 0 0 0 0 1
orfl9.6789 orfl9.6789 0 0 0 0 1 0 0 1
orfl9.6786 orfl9.6786 0 0 0 0 1 0 0 1
orfl9.1958 orfl9.1958 0 1 0 0 0 0 0 1
orfl9.6275 orfl9.6275 0 0 0 0 1 0 0 1
orfl9.5270 orfl9.5270 0 0 0 0 1 0 0 1
orfl9.1290 XKS1 0 0 1 0 0 0 0 1
orfl9.2911 SEC3 0 0 0 0 0 1 0 1
orfl9.1842 orfl9.1842 0 0 0 0 0 1 0 1
orfl9.352 orfl9.352 0 0 0 0 1 0 0 1
orfl9.2681 RBT7 0 0 0 0 1 0 0 1
orfl9.2598 VMA4 0 0 0 0 1 0 0 1
orfl9.6307 orfl9.6307 0 0 1 0 0 0 0 1
orfl9.6305 orfl9.6305 0 0 1 0 0 0 0 1
orfl9.6654 orfl9.6654 0 0 0 0 0 1 0 1
orfl9.6308 orfl9.6308 0 0 0 0 0 0 1 1
orfl9.4773 AOX2 1 0 0 0 0 0 0 1
orfl9.6803 HUTI 0 0 0 0 0 1 0 1
orfl9.2558 orfl9.2558 0 1 0 0 0 0 0 1
orfl9.1333 SNG3 0 0 0 0 1 0 0 1
orfl9.6899 orf19.6899 0 0 0 0 1 0 0 1
orfl9.1756 GPD1 0 0 0 0 1 0 0 1
orfl9.6893 orfl9.6893 0 0 1 0 0 0 0 1
orfl9.6897 orfl9.6897 0 0 1 0 0 0 0 1
orfl9.5292 AXL2 0 0 0 0 1 0 0 1
orfl9.915 orfl9.915 0 0 0 1 0 0 0 1
orfl9.3156 orfl9.3156 0 0 1 0 0 0 0 1
orfl9.6249 HAKI 0 0 0 0 1 0 0 1
orfl9.4820 orfl9.4820 0 0 0 0 1 0 0 1
orfl9.4825 orfl9.4825 0 0 0 0 1 0 0 1
orfl9.4532 orfl9.4532 1 0 0 0 0 0 0 1
orfl9.3269 GSL2 0 0 0 1 0 0 0 1
orfl9.2495 GSL1 0 0 0 1 0 0 0 1
orfl9.2795 orfl9.2795 1 0 0 0 0 0 0 1
orfl9.2307 orfl9.2307 0 0 0 0 0 0 1 1
orfl9.4785 PTC1 0 0 0 0 0 1 0 1
orfl9.2538 PTC2 0 0 0 0 0 1 0 1
orfl9.6313 MNT4 0 0 0 0 0 1 0 1
orfl9.3446 orfl9.3446 0 0 0 0 1 0 0 1
orfl9.1796 orfl9.1796 0 0 0 0 1 0 0 1
orfl9.1799 GAP5 0 0 1 0 0 0 0 1
orfl9.3449 orfl9.3449 0 0 0 1 0 0 0 1
orfl9.94 orfl9.94 0 0 0 0 1 0 0 1
orfl9.4799 orfl9.4799 1 0 0 0 0 0 0 1
orfl9.4791 orfl9.4791 1 0 0 0 0 0 0 1
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orfl9.2808 ZCF16 0 0 0 0 1 0 0 1
orfl9.4220 orfl9.4220 0 0 1 0 0 0 0 1
orfl9.6972 SMI1B 0 0 0 0 0 1 0 1
orfl9.4001 orfl9.4001 0 0 0 0 1 0 0 1
orf19.4000 GRF1O 0 0 0 0 0 0 1 1
orfl9.2977 orfl9.2977 0 0 0 1 0 0 0 1
orfl9.2971 orfl9.2971 0 0 0 0 1 0 0 1
orfl9.3404 orfl9.3404 0 0 0 0 1 0 0 1
orfl9.4099 ECM17 0 0 0 0 1 0 0 1
orfl9.1782.1 orfl9.1782.1 0 0 0 0 1 0 0 1
orfl9.4788 ARGS 6 1 0 0 0 0 0 0 1
orfl9.4316 orfl9.4316 0 0 0 0 1 0 0 1
orfl9.4642 orfl9.4642 0 0 1 0 0 0 0 1
orfl9.5059 GCSI 0 0 0 0 1 0 0 1
orfl9.2615 MDL1 0 0 0 0 1 0 0 1
orfl9.1778 orfl9.1778 0 0 1 0 0 0 0 1
orfl9.5967 FGR44 0 1 0 0 0 0 0 1
orfl9.4769 IPTI 0 0 0 0 1 0 0 1
orfl9.1771 orfl9.1771 0 1 0 0 0 0 0 1
orfl9.1777 orfl9.1777 0 0 1 0 0 0 0 1
orfl9.3209 FGR42 1 0 0 0 0 0 0 1
orfl9.6534.2 orfl9.6534.2 0 0 0 0 1 0 0 1
orfl9.1968.1 orfl9.1968.1 0 0 0 0 0 0 1 1
orfl9.5066 orfl9.5066 0 0 0 0 1 0 0 1
orfl9.3770 ARG8 0 0 1 0 0 0 0 1
orfl9.1683 PPH21 0 1 0 0 0 0 0 1
orfl9.5610 ARG3 1 0 0 0 0 0 0 1
orfl9.6877 PNG2 0 1 0 0 0 0 0 1
orfl9.652 orfl9.652 0 0 1 0 0 0 0 1
orfl9.6469 orfl9.6469 0 0 0 0 1 0 0 1
orfl9.1303 orfl9.1303 0 0 1 0 0 0 0 1
orfl9.1302 orfl9.1302 0 0 0 0 1 0 0 1
orfl9.1300 orfl9.1300 0 0 0 0 1 0 0 1
orfl9.1306 orfl9.1306 0 0 0 0 1 0 0 1
orfl9.3264 CCEI 0 0 1 0 0 0 0 1
orfl9.4952 orfl9.4952 0 0 0 0 0 1 0 1
orfl9.5465 orfl9.5465 0 0 0 0 0 1 0 1
orfl9.4899 GCA1 0 0 0 1 0 0 0 1
orfl9.999 GCA2 0 0 0 0 1 0 0 1
orfl9.5688 orfl9.5688 0 0 0 0 0 1 0 1
orfl9.217 orfI9.217 0 0 1 0 0 0 0 1
orfl9.581 orfl9.581 0 0 1 0 0 0 0 1
orf19.580 orfl9.580 0 0 1 0 0 0 0 1
orfl9.587 orfl9.587 0 0 1 0 0 0 0 1
orfl9.6790 orfl9.6790 0 0 0 0 1 0 0 1
orf19.6269 orfl9.6269 0 0 0 0 1 0 0 1
orfl9.5203 orfl9.5203 0 0 0 0 1 0 0 __I
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orfl9.1633 UTP4 0 0 0 0 1 0 0 1
orfl9.17 SCP1 0 0 1 0 0 0 0 1
orfl9.2099 orfl9.2099 1 0 0 0 0 0 0 1
orfl9.2090 orfl9.2090 0 0 1 0 0 0 0 1
orfl9.2091 orfl9.2091 0 0 1 0 0 0 0 1
orfl9.5958 CDR2 0 0 0 1 0 0 0 1
orfl9.7223 orfl9.7223 0 1 0 0 0 0 0 1
orfl9.7539.1 orfl9.7539.1 0 0 1 0 0 0 0 1
orfl9.5518 orfl9.5518 1 0 0 0 0 0 0 1
orfl9.6864 orfl9.6864 0 0 1 0 0 0 0 1
orfl9.6316 orfl9.6316 0 0 0 0 0 0 1 1
orfl9.5516 orfl9.5516 0 0 0 0 1 0 0 1
orfl9.6869 orfl9.6869 0 0 1 0 0 0 0 1
orfl9.3000 ORCI 0 0 0 0 1 0 0 1
orfl9.6888 orfl9.6888 0 0 1 0 0 0 0 1
orfl9.1932 CFL4 0 0 1 0 0 0 0 1
orfl9.1263 CFL1 0 0 1 0 0 0 0 1
orfl9.3140 orfl9.3140 0 0 1 0 0 0 0 1
orfl9.6449 orfl9.6449 0 0 0 0 0 1 0 1
orfl9.7130 orf19.7130 1 0 0 0 0 0 0 1
orfl9.7131 orfl9.7131 1 0 0 0 0 0 0 1
orfl9.4307 orfl9.4307 0 0 0 0 1 0 0 1
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Supplementary Table 4. Clustered recurrent, persistently mutated genes and their
enrichments.
A. Shown are persistently mutated genes that are recurrent in three or more time courses.
ORF GENE Cluster PTl PT7 PT9 PT14 PT15 PT43 PT59
orfl9.5592 orfl9.5592 1 1 1 0 1 1 1 0
orfl9.5596 orfl9.5596 1 0 1 0 1 1 1 1
orfl9.5597 POLS 1 0 1 0 1 1 1 1
orfl9.6277 orfl9.6277 1 1 1 0 1 1 1 0
orfl9.1769 orfl9.1769 1 0 1 0 1 0 1 1
orfl9.7204 orfl9.7204 1 0 1 0 1 0 1 1
orfl9.3473 orfl9.3473 1 0 1 0 1 0 1 1
orfl9.2646 ZCF13 1 0 0 0 1 1 1 1
orfl9.4288 CTA7 1 0 0 0 1 1 1 1
orfl9.4245 orfl9.4245 1 0 0 0 1 0 1 1
orfl9.1690 TOSI 1 0 0 0 1 1 1 0
orfl9.7561 DEF 1 0 0 0 1 1 1 0
orfl9.1356 orfl9.1356 1 0 0 0 1 1 1 0
orfl9.1607 ALR1 1 0 1 0 1 0 1 0
orfl9.6544 LPI9 1 0 0 0 1 1 1 0
orfl9.4553 orfl9.4553 1 0 1 0 1 1 0 0
orfl9.4080 orfl9.4080 1 0 0 0 1 1 1 0
orfl9.7194 orfl9.7194 1 0 0 0 1 0 1 1
orfl9.4064 GPI7 1 1 0 0 1 1 0 0
orfl9.5621 orfl9.5621 1 1 0 0 1 1 0 0
orfl9.6592 orfl9.6592 1 0 0 0 1 1 1 0
orfl9.5058 SMIl 1 0 0 0 1 1 1 0
orfl9.5003 orfl9.5003 1 0 1 0 1 0 1 0
orfl9.3437 orfl9.3437 1 0 1 0 1 1 0 0
orfl9.1706 MET18 1 0 0 0 1 1 1 0
orfl9.1144 orfl9.1144 1 1 0 0 1 1 0 0
orfl9.7342 AXL1 1 0 0 0 1 1 1 0
orfl9.4316 orfl9.4316 1 1 0 0 1 1 0 0
orfl9.745 VAC8 1 0 0 0 1 0 1 1
orfl9.5045 orfl9.5045 2 0 1 1 0 1 1 1
orfl9.169 CHO2 2 0 1 1 0 1 1 1
orfl9.4346 orfl9.4346 2 0 1 1 0 1 1 1
orfl9.2168 orfl9.2168 2 0 1 1 0 1 1 0
orfl9.5038 orfl9.5038 2 0 1 1 0 1 1 0
orfl9.649 orfl9.649 2 0 1 1 0 0 1 1
orfl9.4643 orfl9.4643 2 0 1 1 0 1 1 0
orfl9.1766 orfl9.1766 2 0 1 1 0 1 0 0
orfl9.4243 orfl9.4243 2 0 1 1 0 1 0 0
orfl9.3906 orfl9.3906 2 0 1 1 0 1 0 0
orfl9.2901 NUP60 2 0 0 1 0 1 1 0
orfl9.1748 orfl9.1748 2 0 1 1 0 1 0 0
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orfl9.2510 orfl9.2510 2 0 0 1 0 1 1 0
orfl9.1624.1 orfl9.1624.1 2 0 1 1 0 0 1 0
orfl9.4191.1 orfl9.4191.1 2 0 1 1 0 1 0 0
orfl9.3380 HWP2 2 0 0 1 0 1 1 0
orfl9.5918 orfl9.5918 2 0 1 1 0 1 0 0
orfl9.1083 orfl9.1083 2 0 1 0 0 1 1 0
orfl9.6499 orfl9.6499 2 0 0 1 0 1 1 0
orfl9.7036 orfl9.7036 2 0 1 0 0 1 1 0
orfl9.1608 orfl9.1608 2 0 1 1 0 1 0 0
orfl9.5915 DUR35 2 0 0 1 0 1 1 0
orfl9.4412 orfl9.4412 2 0 1 1 0 1 0 0
orfl9.1622 YCG1 2 0 1 0 0 1 1 0
orfl9.3613 orfl9.3613 2 0 1 0 0 1 1 0
orfl9.267 orfl9.267 2 0 1 1 0 0 1 0
orfl9.4570 orfl9.4570 2 0 1 1 0 1 0 0
orfl9.5854.1 orfl9.5854.1 2 0 0 1 0 1 1 0
orfl9.4404 PGA49 2 0 0 1 0 1 1 0
orfl9.4225 LEU3 2 0 0 1 0 1 1 0
orfl9.1772 orfl9.1772 2 0 1 1 0 1 0 0
orfl9.5924 ZCF31 2 0 0 1 0 1 1 0
orfl9.7277 orfl9.7277 2 0 1 0 0 1 1 0
orfl9.2826 orfl9.2826 2 0 0 1 0 1 1 0
orfl9.2547 orfl9.2547 2 0 1 1 0 0 1 0
orfl9.1779 MP65 2 0 0 1 0 1 1 0
orfl9.3937 orfl9.3937 2 0 0 1 0 1 1 0
orfl9.6260 orfl9.6260 2 0 1 0 0 1 1 0
orfl9.1616 FGR23 3 0 1 1 1 1 0 1
orfl9.2850 orfl9.2850 3 0 1 1 1 1 0 1
orfl9.2629 orfl9.2629 3 0 0 1 0 1 1 1
orfl9.4655 OPT6 3 0 1 1 0 1 0 1
orfl9.2747 RGT1 3 0 0 1 1 1 0 1
orfl9.255 ZCF1 3 0 1 1 1 1 0 0
orfl9.1808 orfl9.1808 3 0 1 1 0 1 0 1
orfl9.4239 orfl9.4239 3 0 0 1 1 1 0 1
orfl9.366 orfl9.366 3 0 1 1 1 0 0 1
orfl9.5510 orfl9.5510 3 0 1 0 0 1 1 1
orfl9.4510 IFA4 3 0 1 1 0 0 0 1
orfl9.115 orfl9.115 3 0 1 0 0 1 0 1
orfl9.371 orfl9.371 3 0 0 1 1 0 0 1
orfl9.3463 orfl9.3463 3 0 0 0 1 1 0 1
orfl9.3916 orfl9.3916 3 0 0 1 0 1 0 1
orfl9.3190 HAL9 3 0 1 1 0 0 0 1
orfl9.4901 orfl9.4901 3 0 0 0 0 1 1 1
orfl9.4280 orfl9.4280 3 0 1 0 0 1 0 1
orfl9.6280 orfl9.6280 3 0 1 0 1 0 0 1
orfl9.3100 orfl9.3100 3 0 1 0 0 1 0 1
orfl9.92 orfl9.92 3 0 0 0 0 1 1 1
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orfl9.3429 FGR47 3 0 0 0 1 1 0 1
orfl9.3986 PPRI 3 0 1 0 0 1 0 1
orfl9.4918 orfl9.4918 3 0 0 0 1 1 0 1
orfl9.4715 orfl9.4715 3 0 0 1 0 1 0 1
orfl9.4369 orfl9.4369 3 0 0 1 0 1 0 1
orfl9.5141 orfl9.5141 3 0 0 1 0 1 0 1
orfl9.6921 orfl9.6921 3 0 0 0 1 1 0 1
orfl9.4348 orfl9.4348 3 0 0 1 0 1 0 1
orfl9.1296 orfl9.12% 3 0 1 1 1 0 0 0
orfl9.5505 HIS7 3 0 1 0 0 1 0 1
orfl9.2879 IFFS 3 0 0 1 0 1 0 1
orfl9.6999 orf19.6999 3 0 0 0 0 1 1 1
orfl9.3773 CDL1 3 0 1 1 1 0 0 0
orf19.3098 orf19.3098 3 0 0 1 0 1 0 1
orfl9.2797 orfl9.2797 3 0 0 0 1 1 0 1
orfl9.1551 orfl9.1551 3 0 1 1 1 0 0 0
orf19.102 orfl9.102 3 0 0 0 0 1 1 1
orfl9.4697 MDN1 4 1 1 1 0 1 0 1
orfl9.4658 orfl9.4658 4 1 1 1 1 0 0 1
orf19.4958 ECM25 4 1 1 0 1 1 0 1
orfl9.4498 orfl9.4498 4 1 1 0 1 0 1 0
orfl9.4068 orfl9.4068 4 1 1 1 1 0 0 0
orfl9.5710 orf19.5710 4 1 1 0 0 1 0 1
orfl9.2647 ZCF14 4 1 0 0 0 1 1 1
orfl9.4557 orfl9.4557 4 1 1 0 0 1 0 1
orfl9.4649 ZCF27 4 1 1 1 0 1 0 0
orf19.5065 orfl9.5065 4 1 1 0 0 1 1 0
orfl9.4961 STP2 4 1 1 0 1 0 0 0
orfl9.3239 CTF18 4 1 1 1 0 0 0 0
orfl9.2433 orfl9.2433 4 1 1 0 0 1 0 0
orfl9.1531 orfl9.1531 4 1 1 1 0 0 0 0
orfl9.5705 NAM2 4 1 0 0 0 1 0 1
orfl9.1492 PRP39 4 1 1 1 0 0 0 0
orfl9.3997 ADHI 4 1 0 0 0 0 1 1
orfl9.894 orfl9.894 4 1 1 1 0 0 0 0
orfl9.6979 orfl9.6979 4 1 1 0 0 0 1 0
orfl9.1500 orfl9.1500 4 1 1 0 0 0 0 1
orfl9.4459 orfl9.4459 4 1 0 0 0 1 0 1
orfl9.6480 orfl9.6480 4 1 1 0 0 1 0 0
orfl9.427 orfl9.427 4 1 1 0 0 1 0 0
orfl9.4257 INTl 4 1 0 0 0 0 1 1
orfl9.3203 RCY1 4 1 1 0 0 1 0 0
orfl9.1841 orfl9.1841 4 1 1 0 0 0 0 1
orfl9.4394 orfl9.4394 4 1 1 0 0 1 0 0
orfl9.6694 orfl9.6694 4 1 1 1 0 0 0 0
orfl9.7193 orfl9.7193 4 1 1 0 1 0 0 0
orfl9.4965 orfl9.4965 4 1 0 0 0 0 1 1
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orfl9.3615 orfl9.3615 4 1 1 1 0 0 0 0
orfl9.5752 orfl9.5752 4 1 1 0 0 0 0 1
orfl9.6919 orfl9.6919 4 1 1 0 0 0 0 1
orfl9.3439 orfl9.3439 4 1 0 0 0 1 0 1
orfl9.5949 FAS2 4 1 1 0 0 0 1 0
orfl9.6344 RBK1 4 1 1 0 0 0 1 0
orfl9.3188 TACI 5 1 1 1 0 1 1 0
orfl9.7032 orf19.7032 5 1 0 1 0 1 1 1
orfl9.1298 NUP84 5 1 0 1 0 1 1 0
orfl9.2761 orfl9.2761 5 1 0 1 0 1 0 1
orfl9.3706 orfl9.3706 5 1 0 1 0 1 1 0
orfl9.4337 orfl9.4337 5 1 0 1 0 1 0 1
orfl9.2652 TEF4 5 1 0 1 0 1 1 0
orfl9.3629 DSE1 5 1 0 1 0 1 0 0
orfl9.76 SPB1 5 1 0 0 0 1 1 0
orfl9.5504 orfl9.5504 5 1 0 0 0 1 1 0
orfl9.1532 SAM37 5 1 0 1 0 0 1 0
orfl9.1400 orfl9.1400 5 1 0 1 0 1 0 0
orfl9.1096 orfl9.1096 5 1 0 0 0 1 1 0
orfl9.290 KRE5 5 1 0 1 0 1 0 0
orfl9.2266 orfl9.2266 5 1 0 0 0 1 1 0
orfl9.1798 TSC2 5 1 0 1 0 1 0 0
orfl9.4145 ZCF20 5 1 0 1 0 1 0 0
orfl9.4315 orfl9.4315 5 1 0 1 0 1 0 0
orfl9.4325 orfl9.4325 5 1 0 1 0 0 1 0
orfl9.2907 PGA42 5 1 0 1 0 1 0 0
orfl9.4683 MLP1 5 1 0 1 0 1 0 0
orfl9.6294 MYOl 5 1 0 1 0 1 0 0
orfl9.5134 orfl9.5134 5 1 0 1 0 0 1 0
orfl9.3166 orfl9.3166 5 1 0 1 0 1 0 0
orfl9.1305 orfl9.1305 5 1 0 1 0 1 0 0
orfl9.746 orfl9.746 5 1 0 1 0 0 1 0
orfl9.2404 orfl9.2404 6 1 0 1 1 0 1 1
orfl9.1596 FGR28 6 0 0 1 1 1 1 1
orfl9.7029 orfl9.7029 6 1 0 1 1 1 1 0
orfl9.2650 orfl9.2650 6 0 0 1 1 1 1 1
orfl9.1606 orfl9.1606 6 0 1 1 1 1 1 0
orfl9.5297 orfl9.5297 6 1 0 1 1 0 1 1
orfl9.230 orfl9.230 6 1 0 1 1 1 1 0
orfl9.4673 BMT9 6 0 1 1 1 0 1 0
orfl9.7472 IFF4 6 0 0 1 1 1 1 0
orfl9.6862 orfl9.6862 6 0 0 1 1 1 1 0
orfl9.2400 orfl9.2400 6 0 0 1 0 0 1 1
orfl9.175 orfl9.175 6 0 0 1 0 0 1 1
orfl9.1111 orfl9.1111 6 0 0 1 1 0 1 0
orfl9.1795 PUF3 6 0 0 1 1 0 1 0
orfl9.5976 orfl9.5976 6 1 0 0 1 0 1 0
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orfl9.7027 orfl9.7027 6 0 0 1 1 0 1 0
orfl9.7023 orfl9.7023 6 1 0 0 1 0 1 0
orfl9.2724 orfl9.2724 6 0 0 1 1 0 1 0
orfl9.194 orfl9.194 6 0 0 1 0 0 1 1
orfl9.1113 orfl9.1113 6 0 0 1 1 0 1 0
orfl9.262 SMC3 6 0 0 1 1 0 1 0
orfl9.1106 orfl9.1106 6 0 0 1 1 0 1 0
orfl9.3170 orfl9.3170 6 0 0 1 1 0 1 0
orfl9.3178 orfl9.3178 6 1 0 1 1 0 0 0
orfl9.2847.1 orfl9.2847.1 6 0 0 1 1 0 1 0
orfl9.8 orfl9.8 6 0 0 1 1 0 1 0
orfl9.229 orfl9.229 6 0 0 1 1 0 1 0
orfl9.3148 orfl9.3148 6 0 0 1 1 0 1 0
orfl9.1768 orfl9.1768 7 0 0 1 1 1 0 0
orfl9.3910 orfl9.3910 7 0 0 1 1 1 0 0
orfl9.1359 orfl9.1359 7 0 0 1 1 1 0 0
orfl9.1555 SAC3 7 0 0 1 1 1 0 0
orfl9.1662 orfl9.1662 7 0 0 1 1 1 0 0
orfl9.2182 BLM3 7 0 0 1 1 1 0 0
orfl9.3603 orfl9.3603 7 0 0 1 1 1 0 0
orfl9.1327 RBT1 7 0 0 1 1 1 0 0
orfl9.736 SRB8 0 1 1 1 1 1 1 1
B. Shown are the GO enrichments for each cluster, as well as each gene. Benjamini-Hochberg
correction and Bonferroni correction are supplied in combination with the nominal P-value.
Cluster 1
rank p GO N K n k BHP Bonferroni
GO:0005515 - protein
1 0.0179 binding 6250 121 29 3 0.125 0.125
2 0.3453 GO:0005634 - nucleus 6250 640 29 4 0.800 2.417
GO:0005739 -
3 0.3662 mitochondrion 6250 464 29 3 0.800 2.563
GO:0005575 -
4 0.5442 cellular component 6250 2120 29 10 0.800 3.810
GO:0003674 -
5 0.6748 molecular function 6250 2743 29 12 0.800 4.724
6 0.6964 GO:0005737 - cytoplasm 6250 753 29 3 0.800 4.875
GO:0008150 -
7 0.8003 biological process 6250 2080 29 8 0.800 5.602
Cluster 2
rank p GO N K n k BHP Bonferroni
GO:0008150 -
1 0.0494 biologicalprocess 6250 2080 38 18 0.177 0.297
GO:0005575 -
2 0.0589 cellular component 6250 2120 38 18 0.177 0.354
GO:0009986 - cell
3 0.1180 surface 6250 198 38 3 0.236 0.708
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GO:0003674 -
4 0.1772 molecular function 6250 2743 38 20 0.266 1.063
5 0.4899 GO:0005737 - cytoplasm 6250 753 38 5 0.555 2.940
6 0.5552 GO:0005634 - nucleus 6250 640 38 4 0.555 3.331
Cluster 3
rank p GO N K n k BHP Bonferroni
GO:0003674 -
1 0.0129 molecular function 6250 2743 38 24 0.064 0.064
GO:0005575 -
2 0.0292 cellular component 6250 2120 38 19 0.073 0.146
GO:0008150 -
3 0.1620 biological process 6250 2080 38 16 0.270 0.810
GO:0030447 -
4 0.2234 filamentous growth 6250 269 38 3 0.279 1.117
GO:0005739 -
5 0.5436 mitochondrion 6250 464 38 3 0.544 2.718
Cluster 4
rank p GO N K n k BHP Bonferroni
GO:0005739 -
1 0.0150 mitochondrion 6250 464 36 7 0.120 0.120
GO:0005515 - protein
2 0.0318 binding 6250 121 36 3 0.127 0.254
GO:0003700 -
transcription factor
3 0.0744 activity 6250 171 36 3 0.199 0.596
GO:0003674 -
4 0.1813 molecular function 6250 2743 36 19 0.363 1.451
GO:0008150 -
5 0.2905 biological process 6250 2080 36 14 0.408 2.324
6 0.3064 GO:0005634 - nucleus 6250 640 36 5 0.408 2.451
7 0.4409 GO:0005737 - cytoplasm 6250 753 36 5 0.452 3.528
GO:0005575 -
8 0.4521 cellular component 6250 2120 36 13 0.452 3.616
Cluster 5
rank p GO N K n k BHP Bonferroni
GO:0008150 -
1 0.2179 biological_process 6250 2080 26 11 0.506 0.872
GO:0003674 -
2 0.3311 molecular function 6250 2743 26 13 0.506 1.325
GO:0005575 -
3 0.3812 cellular component 6250 2120 26 10 0.506 1.525
4 0.5063 GO:0005634 - nucleus 6250 640 26 3 0.506 2.025
Cluster 6
rank p GO N K n k BHP Bonferroni
GO:0003674 -
1 0.0545 molecular function 6250 2743 28 17 0.218 0.218
2 0.1889 GO:0008150 - 6250 2080 28 12 0.279 0.756
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biologicalprocess
GO:0005575 -
3 0.2095 cellular component 6250 2120 28 12 0.279 0.838
4 0.6729 GO:0005737 - cytoplasm 6250 753 28 3 0.673 2.692
Cluster 7
rank p GO N K n k BHP Bonferroni
GO:0008150 -
1 0.0873 biological_process 6250 2080 8 5 0.262 0.349
GO:0003674 -
2 0.2394 molecular function 6250 2743 8 5 0.359 0.958
GO:0005575 -
3 0.5462 cellular component 6250 2120 8 3 0.546 2.185
Unclusterd
rank .p GO N K n k BHP Bonferroni
All Clusters
rank p GO N K n k BHP Bonferroni
GO:0003704 - specific
RNA polymerase II
transcription factor
1 0.0006 activity 6250 45 204 7 0.023 0.023
GO:0003674 -
2 0.0022 molecular function 6250 2743 204 110 0.024 0.087
GO:0005654 -
3 0.0022 nucleoplasm 6250 29 204 5 0.024 0.088
GO:0007120 - axial
4 0.0024 cellular bud site selection 6250 18 204 4 0.024 0.094
GO:0008150 -
5 0.0100 biological_process 6250 2080 204 84 0.077 0.399
GO:0005575 -
6 0.0115 cellular component 6250 2120 204 85 0.077 0.460
GO:0000747 -
conjugation with cellular
7 0.0138 fusion 6250 29 204 4 0.079 0.552
GO:0000142 - cellular
8 0.0166 bud neck contractile ring 6250 17 204 3 0.083 0.665
GO:0007064 - mitotic
9 0.0259 sister chromatid cohesion 6250 20 204 3 0.115 1.037
GO:0009277 - fungal-
10 0.0368 type cell wall 6250 96 204 7 0.147 1.470
GO:0005198 - structural
11 0.0505 molecule activity 6250 43 204 4 0.180 2.020
GO:0006406 - mRNA
12 0.0580 export from nucleus 6250 45 204 4 0.180 2.321
GO:0009986 - cell
13 0.0585 surface 6250 198 204 11 0.180 2.342
GO:0005643 - nuclear
14 0.0730 pore 6250 30 204 3 0.209 2.919
GO:0030446 - hyphal
15 0.0839 cell wall 6250 51 204 4 0.224 3.357
250
GO:0005515 - protein
16 0.0999 binding 6250 121 204 7 0.250 3.998
GO:0045944 - positive
regulation of
transcription from RNA
17 0.1314 polymerase II promoter 6250 60 204 4 0.309 5.258
GO:0006364 - rRNA
18 0.1493 processing 6250 63 204 4 0.332 5.973
GO:0009060 - aerobic
19 0.1745 respiration 6250 67 204 4 0.367 6.980
GO:0016563 -
transcription activator
20 0.2316 activity 6250 51 204 3 0.463 9.263
GO:0030447 -
21 0.2627 filamentous growth 6250 269 204 11 0.480 10.506
GO:0043565 - sequence-
22 0.2669 specific DNA binding 6250 55 204 3 0.480 10.674
GO:0005576 -
23 0.2758 extracellular region 6250 56 204 3 0.480 11.032
GO:0003700 -
transcription factor
24 0.3247 activity 6250 171 204 7 0.541 12.986
GO:0000324 - fungal-
25 0.3388 type vacuole 6250 63 204 3 0.542 13.553
GO:0009405 -
26 0.4108 pathogenesis 6250 187 204 7 0.632 16.431
27 0.4318 GO:0005634 - nucleus 6250 640 204 22 0.639 17.272
GO:0005739 -
28 0.4474 mitochondrion 6250 464 204 16 0.639 17.896
GO:0005935 - cellular
29 0.4962 bud neck 6250 81 204 3 0.684 19.847
GO:0031505 - fungal-
type cell wall
30 0.5446 organization 6250 87 204 3 0.700 21.784
GO:0006355 - regulation
of transcription, DNA-
31 0.5482 dependent 6250 119 204 4 0.700 21.928
GO:0005759 -
32 0.5601 mitochondrial matrix 6250 89 204 3 0.700 22.405
GO:0030448 - hyphal
33 0.6774 growth 6250 174 204 5 0.798 27.094
GO:0005625 - soluble
34 0.7027 fraction 6250 110 204 3 0.798 28.109
GO:0005783 -
35 0.7152 endoplasmic reticulum 6250 182 204 5 0.798 28.607
36 0.7182 GO:0005730 - nucleolus 6250 148 204 4 0.798 28.729
GO:0042493 - response
37 0.7969 to drug 6250 343 204 9 0.862 31.876
GO:0016020 -
38 0.8585 membrane 6250 145 204 3 0.891 34.340
39 0.8683 GO:0005737 - cytoplasm 6250 753 204 20 0.891 34.730
GO:0005886 - plasma
40 0.9983 membrane 6250 416 204 5 0.998 39.932
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C. Shown are persistently mutated genes that are recurrent in three or more time courses that co-
occur with increases to MIC. Clustering was determined via NMF of the Pearson correlations of
each row-vector.
ORF Genes Cluster PT1 PT7 PT9 PT14 PT15 PT43 PT59
orfl9.7029 orfl9.7029 1 1 0 1 1 1 1 0
orfl9.1606 orfl9.1606 1 0 1 1 1 1 1 0
orfl9.5592 orfl9.5592 1 1 1 0 1 1 1 0
orfl9.6277 orfl9.6277 1 1 1 0 1 1 1 0
orfl9.4673 BMT9 1 0 1 1 1 0 1 0
orfl9.2646 ZCF13 1 0 0 0 1 1 1 1
orfl9.5297 orfl9.5297 1 0 0 1 1 0 1 1
orfl9.7472 IFF4 1 0 0 1 1 1 1 0
orfl9.5504 orfl9.5504 1 1 0 0 0 1 1 0
orfl9.7561 DEFI 1 0 0 0 1 1 1 0
orfl9.1356 orfl9.1356 1 0 0 0 1 1 1 0
orfl9.1111 orfl9.1111 1 0 0 1 1 0 1 0
orfl9.1795 PUF3 1 0 0 1 1 0 1 0
orfl9.1607 ALRl 1 0 1 0 1 0 1 0
orfl9.7023 orfl9.7023 1 1 0 0 1 0 1 0
orfl9.2724 orfl9.2724 1 0 0 1 1 0 1 0
orfl9.6544 LPI9 1 0 0 0 1 1 1 0
orfl9.2266 orfl9.2266 1 1 0 0 0 1 1 0
orfl9.4080 orfl9.4080 1 0 0 0 1 1 1 0
orfl9.1113 orfl9.1113 1 0 0 1 1 0 1 0
orfl9.262 SMC3 1 0 0 1 1 0 1 0
orfl9.1106 orfl9.1106 1 0 0 1 1 0 1 0
orfl9.5621 orfl9.5621 1 1 0 0 1 1 0 0
orfl9.6592 orfl9.6592 1 0 0 0 1 1 1 0
orfl9.5058 SMIl 1 0 0 0 1 1 1 0
orfl9.5003 orfl9.5003 1 0 1 0 1 0 1 0
orfl9.229 orfl9.229 1 0 0 1 1 0 1 0
orfl9.7342 AXL1 1 0 0 0 1 1 1 0
orfl9.746 orfl9.746 1 1 0 1 0 0 1 0
orfl9.745 VAC8 1 0 0 0 1 0 1 1
orfl9.5710 orfl9.5710 2 1 1 0 0 1 0 1
orfl9.4557 orfl9.4557 2 1 1 0 0 1 0 1
orfl9.2168 orfl9.2168 2 0 1 1 0 1 1 0
orfl9.5038 orfl9.5038 2 0 1 1 0 1 1 0
orfl9.4649 ZCF27 2 1 1 1 0 1 0 0
orfl9.4643 orfl9.4643 2 0 1 1 0 1 1 0
orfl9.1766 orfl9.1766 2 0 1 1 0 1 0 0
orfl9.4961 STP2 2 1 1 0 1 0 0 0
orfl9.4243 orfl9.4243 2 0 1 1 0 1 0 0
orfl9.4068 orfl9.4068 2 1 1 1 0 0 0 0
orfl9.3239 CTF18 2 1 1 1 0 0 0 0
orfl9.3906 orfl9.3906 2 0 1 1 0 1 0 0
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orfl9.2433 orfl9.2433 2 1 1 0 0 1 0 0
orfl9.1748 orfl9.1748 2 0 1 1 0 1 0 0
orfl9.1624.1 orfl9.1624.1 2 0 1 1 0 0 1 0
orfl9.4191.1 orfl9.4191.1 2 0 1 1 0 1 0 0
orfl9.894 orfl9.894 2 1 1 1 0 0 0 0
orfl9.6979 orfl9.6979 2 1 1 0 0 0 1 0
orfl9.1500 orfl9.1500 2 1 1 0 0 0 0 1
orfl9.5918 orfl9.5918 2 0 1 1 0 1 0 0
orfl9.1083 orfl9.1083 2 0 1 0 0 1 1 0
orfl9.7036 orfl9.7036 2 0 1 0 0 1 1 0
orfl9.4394 orfl9.4394 2 1 1 0 0 1 0 0
orfl9.3613 orfl9.3613 2 0 1 0 0 1 1 0
orfl9.1608 orfl9.1608 2 0 1 1 0 1 0 0
orfl9.6694 orfl9.6694 2 1 1 1 0 0 0 0
orfl9.4412 orfl9.4412 2 0 1 1 0 1 0 0
orfl9.1622 YCG1 2 0 1 0 0 1 1 0
orfl9.267 orfl9.267 2 0 1 1 0 0 1 0
orfl9.4570 orfl9.4570 2 0 1 1 0 1 0 0
orfl9.255 ZCF1 2 0 1 1 0 1 0 0
orfl9.6919 orfl9.6919 2 1 1 0 0 0 0 1
orfl9.1772 orfl9.1772 2 0 1 1 0 1 0 0
orfl9.7277 orfl9.7277 2 0 1 0 0 1 1 0
orfl9.2547 orfl9.2547 2 0 1 1 0 0 1 0
orfl9.1551 orfl9.1551 2 0 1 1 1 0 0 0
orfl9.5065 orfl9.5065 2 0 1 0 0 1 1 0
orfl9.5949 FAS2 2 1 1 0 0 0 1 0
orfl9.6260 orfl9.6260 2 0 1 0 0 1 1 0
orfl9.736 SRB8 3 0 1 1 1 1 1 1
orfl9.5045 orfl9.5045 3 0 1 1 0 1 1 1
orfl9.5596 orfl9.5596 3 0 1 0 1 1 1 1
orfl9.169 CHO2 3 0 1 1 0 1 1 1
orfl9.4346 orfl9.4346 3 0 1 1 0 1 1 1
orfl9.1769 orfl9.1769 3 0 1 0 1 0 1 1
orfl9.2404 orfl9.2404 3 1 0 1 0 0 1 1
orfl9.2629 orfl9.2629 3 0 0 1 0 1 1 1
orfl9.4697 MDN1 3 0 1 1 0 1 0 1
orfl9.1596 FGR28 3 0 0 1 0 1 1 1
orfl9.1616 FGR23 3 0 1 1 0 1 0 1
orfl9.3473 orfl9.3473 3 0 1 0 1 0 1 1
orfl9.2850 orfl9.2850 3 0 1 1 0 1 0 1
orfl9.2650 orfl9.2650 3 0 0 1 0 1 1 1
orfl9.7032 orfl9.7032 3 0 0 1 0 1 1 1
orfl9.4655 OPT6 3 0 1 1 0 1 0 1
orfl9.2747 RGT1 3 0 0 1 1 1 0 1
orfl9.1808 orfl9.1808 3 0 1 1 0 1 0 1
orfl9.5597 POL5 3 0 1 0 0 1 1 1
orfl9.649 orfl9.649 3 0 1 1 0 0 1 1
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orfl9.366 orfl9.366 3 0 1 1 1 0 0 1
orfl9.5510 orfl9.5510 3 0 1 0 0 1 1 1
orfl9.4510 IFA4 3 0 1 1 0 0 0 1
orfl9.115 orfl9.115 3 0 1 0 0 1 0 1
orfl9.371 orfl9.371 3 0 0 1 1 0 0 1
orfl9.2400 orfl9.2400 3 0 0 1 0 0 1 1
orfl9.3916 orfl9.3916 3 0 0 1 0 1 0 1
orfl9.7204 orfl9.7204 3 0 1 0 0 0 1 1
orfl9.3190 HAL9 3 0 1 1 0 0 0 1
orfl9.4901 orfl9.4901 3 0 0 0 0 1 1 1
orfl9.175 orfl9.175 3 0 0 1 0 0 1 1
orfl9.4280 orfl9.4280 3 0 1 0 0 1 0 1
orfl9.3997 ADHI 3 1 0 0 0 0 1 1
orfl9.6280 orfl9.6280 3 0 1 0 1 0 0 1
orfl9.3100 orfl9.3100 3 0 1 0 0 1 0 1
orfl9.92 orfl9.92 3 0 0 0 0 1 1 1
orfl9.3986 PPR1 3 0 1 0 0 1 0 1
orfl9.4918 orfl9.4918 3 0 0 0 1 1 0 1
orfl9.4257 INTl 3 1 0 0 0 0 1 1
orfl9.4715 orfl9.4715 3 0 0 1 0 1 0 1
orfl9.4369 orfl9.4369 3 0 0 1 0 1 0 1
orfl9.5141 orfl9.5141 3 0 0 1 0 1 0 1
orfl9.194 orfl9.194 3 0 0 1 0 0 1 1
orfl9.2647 ZCF14 3 0 0 0 0 1 1 1
orfl9.4348 orfl9.4348 3 0 0 1 0 1 0 1
orfl9.4965 orfl9.4965 3 1 0 0 0 0 1 1
orfl9.5505 HIS7 3 0 1 0 0 1 0 1
orfl9.4288 CTA7 3 0 0 0 0 1 1 1
orfl9.2879 IFF5 3 0 0 1 0 1 0 1
orfl9.6999 orfl9.6999 3 0 0 0 0 1 1 1
orfl9.2761 orfl9.2761 3 0 0 1 0 1 0 1
orfl9.3098 orfl9.3098 3 0 0 1 0 1 0 1
orfl9.4239 orfl9.4239 3 0 0 1 0 1 0 1
orfl9.4658 orfl9.4658 3 0 1 1 0 0 0 1
orfl9.4958 ECM25 3 0 1 0 0 1 0 1
orfl9.2797 orfl9.2797 3 0 0 0 1 1 0 1
orfl9.102 orfl9.102 3 0 0 0 0 1 1 1
orfl9.3188 TACI 4 1 1 1 0 1 1 0
orfl9.1298 NUP84 4 1 0 1 0 1 1 0
orfl9.4337 orfl9.4337 4 1 0 1 0 1 0 1
orfl9.230 orfl9.230 4 1 0 1 0 1 1 0
orfl9.2652 TEF4 4 1 0 1 0 1 1 0
orfl9.3629 DSE1 4 1 0 1 0 1 0 0
orfl9.2901 NUP60 4 0 0 1 0 1 1 0
orfl9.2510 orfl9.2510 4 0 0 1 0 1 1 0
orfl9.1555 SAC3 4 0 0 1 1 1 0 0
orfl9.3380 HWP2 4 0 0 1 0 1 1 0
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orfl9.1400 orfl9.1400 4 1 0 1 0 1 0 0
orfl9.3706 orfl9.3706 4 0 0 1 0 1 1 0
orfl9.290 KRE5 4 1 0 1 0 1 0 0
orfl9.6499 orfl9.6499 4 0 0 1 0 1 1 0
orfl9.3603 orfl9.3603 4 0 0 1 1 1 0 0
orfl9.1798 TSC2 4 1 0 1 0 1 0 0
orfl9.5915 DUR35 4 0 0 1 0 1 1 0
orfl9.4145 ZCF20 4 1 0 1 0 1 0 0
orfl9.5854.1 orfl9.5854.1 4 0 0 1 0 1 1 0
orfl9.4404 PGA49 4 0 0 1 0 1 1 0
orfl9.4225 LEU3 4 0 0 1 0 1 1 0
orfl9.5924 ZCF31 4 0 0 1 0 1 1 0
orfl9.2826 orfl9.2826 4 0 0 1 0 1 1 0
orfl9.3166 orfl9.3166 4 1 0 1 0 1 0 0
orfl9.1327 RBT1 4 0 0 1 1 1 0 0
orfl9.1779 MP65 4 0 0 1 0 1 1 0
orfl9.3937 orfl9.3937 4 0 0 1 0 1 1 0
orfl9.6862 orfl9.6862 4 0 0 1 0 1 1 0
orfl9.4683 MLP1 4 1 0 1 0 1 0 0
D. Shown are the GO enrichments for each cluster for the MIC-coupled persistent recurrent
mutation list. Benjamini-Hochberg corrected and Bonferroni corrected p-values are supplied in
combination with the nominal P-value.
Cluster 1
rank p GO N K n k BHP Bonferonni
1 0.164 GO:0008150 - biologicalprocess 6250 2080 30 13 0.324 0.819
2 0.188 GO:0005634 - nucleus 6250 640 30 5 0.324 0.938
3 0.194 GO:0003674 - molecular function 6250 2743 30 16 0.324 0.972
4 0.299 GO:0005575 - cellular component 6250 2120 30 12 0.374 1.497
5 0.387 GO:0005739 - mitochondrion 6250 464 30 3 0.387 1.935
Cluster 2
rank p GO N K n k BHP Bonferonni
1 0.001 GO:0008150 - biologicalprocess 6250 2080 39 23 0.005 0.005
2 0.008 GO:0005575 - cellular component 6250 2120 39 21 0.024 0.048
3 0.020 GO:0003674 - molecular function 6250 2743 39 24 0.039 0.118
4 0.328 GO:0005739 - mitochondrion 6250 464 39 4 0.492 1.969
5 0.514 GO:0005737 - cytoplasm 6250 753 39 5 0.576 3.083
6 0.576 GO:0005634 - nucleus 6250 640 39 4 0.576 3.458
Cluster 3
rank p GO N K n k BHP Bonferonni
1 0.078 GO:0005625 - soluble fraction 6250 110 57 3 0.292 0.941
GO:0006355 - regulation of
2 0.094 transcription, DNA-dependent 6250 119 57 3 0.292 1.128
3 0.097 GO:0030447 - filamentous growth 6250 269 57 5 0.292 1.167
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4 0.106 GO:0009986 - cell surface 6250 198 57 4 0.292 1.267
5 0.122 GO:0005575 - cellular component 6250 2120 57 24 0.292 1.461
GO:0003700 - transcription factor
6 0.204 activity 6250 171 57 3 0.408 2.449
7 0.252 GO:0003674 - molecular function 6250 2743 57 28 0.432 3.023
8 0.328 GO:0008150 - biologicalprocess 6250 2080 57 21 0.493 3.941
9 0.620 GO:0005739 - mitochondrion 6250 464 57 4 0.827 7.442
10 0.741 GO:0005886 - plasma membrane 6250 416 57 3 0.849 8.897
11 0.833 GO:0005737 - cytoplasm 6250 753 57 5 0.849 9.999
12 0.849 GO:0005634 - nucleus 6250 640 57 4 0.849 10.193
Cluster 4
rank p GO N K n k BHP Bonferonni
1 0.001 GO:0009277 - fungal-type cell wall 6250 96 29 4 0.006 0.009
GO:0006406 - mRNA export from
2 0.001 nucleus 6250 45 29 3 0.006 0.011
3 0.012 GO:0009986 - cell surface 6250 198 29 4 0.042 0.125
4 0.054 GO:0009405 - pathogenesis 6250 187 29 3 0.136 0.545
5 0.072 GO:0042493 - response to drug 6250 343 29 4 0.143 0.717
6 0.170 GO:0005634 - nucleus 6250 640 29 5 0.283 1.695
7 0.469 GO:0005737 - cytoplasm 6250 753 29 4 0.670 4.690
8 0.675 GO:0003674 - molecular function 6250 2743 29 12 0.843 6.748
9 0.984 GO:0008150 - biological process 6250 2080 29 5 0.996 9.839
10 0.996 GO:0005575 - cellular component 6250 2120 29 4 0.996 9.963
All
Genes
rank p GO N K n k BHP Bonferonni
GO:0003704 - specific RNA
polymerase 11 transcription factor
1 0.000 activity 6250 45 155 7 0.004 0.004
GO:0007120 - axial cellular bud site
2 0.009 selection 6250 18 155 3 0.141 0.316
GO:0007064 - mitotic sister
3 0.013 chromatid cohesion 6250 20 155 3 0.141 0.425
GO:0005198 - structural molecule
4 0.021 activity 6250 43 155 4 0.141 0.721
GO:0006406 - mRNA export from
5 0.025 nucleus 6250 45 155 4 0.141 0.838
6 0.030 GO:0003674 - molecular function 6250 2743 155 80 0.141 1.033
7 0.031 GO:0009277 - fungal-type cell wall 6250 96 155 6 0.141 1.069
8 0.034 GO:0005654 - nucleoplasm 6250 29 155 3 0.141 1.160
9 0.037 GO:0005643 - nuclear pore 6250 30 155 3 0.141 1.266
10 0.045 GO:0008150 - biologicalprocess 6250 2080 155 62 0.153 1.527
11 0.057 GO:0009986 - cell surface 6250 198 155 9 0.172 1.938
GO:0045944 - positive regulation of
transcription from RNA polymerase
12 0.061 1 promoter 6250 60 155 4 0.172 2.070
13 0.079 GO:0005515 - protein binding 6250 121 155 6 0.199 2.703
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14 0.084 GO:0009060-aerobic respiration 6250 67 155 4 0.199 2.857
15 0.088 GO:0005575-cellular component 6250 2120 155 61 0.199 2.983
16 0.132 GO:0030446-hyphalcellwall 6250 51 155 3 0.264 4.489
GO:00 16563 - transcription activator
17 0.132 activity 6250 51 155 3 0.264 4.489
GO:0043565 - sequence-specific
18 0.155 DNA binding 6250 55 155 3 0.293 5.278
19 0.205 GO:0006364 - rRNA processing 6250 63 155 3 0.367 6.968
20 0.223 GO:0030447 - filamentous growth 6250 269 155 9 0.380 7.593
GO:0003700 - transcription factor
21 0.250 activity 6250 171 155 6 0.405 8.504
22 0.319 GO:0009405-pathogenesis 6250 187 155 6 0.461 10.842
23 0.321 GO:0005634-nucleus 6250 640 155 18 0.461 10.926
24 0.326 GO:0005935 - cellular bud neck 6250 81 155 3 0.461 11.073
GO:0006355 - regulation of
25 0.342 transcription, DNA-dependent 6250 119 155 4 0.462 11.612
26 0.365 GO:0005739-mitochondrion 6250 464 155 13 0.462 12.402
GO:003 1505 - fungal-type cell wall
27 0.367 organization 6250 87 155 3 0.462 12.467
28 0.473 GO:0005783 - endoplasmic reticulum 6250 182 155 5 0.574 16.085
29 0.517 GO:0005625-soluble fraction 6250 110 155 3 0.606 17.577
30 0.623 GO:0042493-responsetodrug 6250 343 155 8 0.693 21.188
31 0.632 GO:0030448-hyphalgrowth 6250 174 155 4 0.693 21.482
32 0.703 GO:0016020-membrane 6250 145 155 3 0.747 23.915
33 0.783 GO:0005737-cytoplasm 6250 753 155 16 0.807 26.619
34 0.981 GO:0005886-plasmamembrane 6250 416 155 5 0.981 33.338
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Supplementary Table 5. Filamentation summary of each strain. Shown are the strain IDs and
their filamentation intensity as described in the methods section of Chapter 2.
Strain Filamentation
1 0
2 1
3 1
4 1
5 2
6 0
7 3
8 2
9 1
11 2
12 5
13 0
14 3
15 1
16 0
17 2
412 1
2307 2
1002 5
3795 6
580 3
2440 3
2501 4
945 0
1619 0
3107 0
3119 0
5106 0
5108 0
1649 0
3034 0
3917 0
4617 6
4639 7
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